香港浸會大學
HONG KONG BAPTIST UNIVERSITY

School of 中醫藥學院
Chinese Medicine

OUR RESEARCH

SCHOOL OF CHINESE MEDICINE

AY2016 - AY2021

TABLE OF CONTENTS

OUR RESEARCH
AY2016-AY2021

MESSAGES

Prof Alexander Ping-kong WAI

Aspiring to be a leading research-led liberal arts university in Asia, Hong Kong Baptist University (HKBU) is committed to academic excellence in teaching, research and service, and to the development of the whole person in all these endeavours. A pioneer of Chinese medicine education and research in Hong Kong, the University was the first higher education institution in Hong Kong to offer Chinese medicine programmes funded by the University Grants Committee, and one of HKBU's key research areas is "health, Chinese medicine and drug research".

Since its founding in 1999, the School of Chinese Medicine (SCM) has gone from strength to strength. In addition to attaining remarkable achievements in Chinese medicine education and the provision of healthcare, its novel research has led to scientific breakthroughs and generated significant solutions for pressing challenges in the healthcare system in Hong Kong and beyond. As HKBU has been selected by the Government to operate Hong Kong's first Chinese Medicine Hospital (CMH), the University will strive to take Chinese medicine education, research and services to new heights to facilitate the CMH's key role as the "flagship" and "change driver" of Chinese medicine.

The COVID-19 swept through the globe in the past three years. Firm and united, HKBU has been at the forefront of fighting the pandemic by using Chinese medicine for prevention and treatment, and providing holistic care for rehabilitation. The fast response and unremitted efforts made by our Chinese medicine team have demonstrated the School's sustained commitment to providing best medical care to patients and safeguarding the wellbeing of the community.

This brochure records the research attainments of SCM from 2016 to 2021. With solid foundation laid, I am confident that the School is on the road to even greater scientific breakthroughs and knowledge expansion — for the benefits of our society and the world at large.

Professor Alexander Ping-kong WAI
President and Vice-Chancellor
Hong Kong Baptist University

Prof **Rick WK WONG**

To move towards the aspiration of becoming a leading research-led liberal arts university in the world, Hong Kong Baptist University continues to step up its efforts in conducting world-leading research through focusing on its niche research areas to extend the frontiers of knowledge across disciplines to address global challenges. Our School of Chinese Medicine (SCM) has been standing at the forefront of medical science, emerging as a pioneer and leader in Chinese medicine education, research, and healthcare that integrating into the overall research development strategy of the University.

Leveraging on its state-of-the-art research facilities and vibrant environment for intellectual interactions, the School has accomplished countless scientific inventions and discoveries as well as granted with considerable research awards from various funding bodies, including the award of Theme-based Research Scheme 2020/2021, one of the most prestigious and competitive grants of the Research Grants Council, to carry out an aptamer research project, and the funding from the InnoHK initiative under the Innovation and Technology Commission for the establishment of "Centre for Chinese Herbal Medicine Drug Development" at the Hong Kong Science Park to enhance the creation of novel Chinese medicine drugs in Hong Kong.

Keen on expanding research impact for the public good, the School has devoted tremendous efforts to transferring its research findings from the academic to technologies. The illustrious patents and products exhibit the growing strength of SCM in translational medicine research. It has also developed research collaborations with strategic partners around the world to spark innovative ideas and further encourage the exchange of knowledge for bigger impact.

In this edition of "Our Research School of Chinese Medicine AY2016-2021", we are pleased to showcase the School's sterling contributions to research excellence and scientific explorations on multiple fronts. It is with pride that our researchers have attained remarkable accomplishments with flying colours. I look forward to the School's continued success and significant impact on the development and internationalisation of Chinese medicine in the future!

Professor Rick WK WONG
Interim Provost and Acting Vice-President
(Research and Development)
Hong Kong Baptist University

Prof LYU Aiping

Chinese medicine, with its wisdom amassed over the millennia and clinical efficacy proven in treating diseases, has become a new focus of attention for scientists all over the world. Committed to both inheritance and innovation in Chinese medicine, the School of Chinese Medicine (SCM) makes full use of cutting-edge technologies to conduct innovative research in traditional Chinese medicine with an aim to discover new knowledge and create pioneering technologies for translation and application to benefit a wider community, as well as to contribute to the modernisation and internationalisation of Chinese medicine.

Riding on the University's strategy to foster interdisciplinary and theme-based research, SCM collaborates with academics across a broad range of disciplines to explore and discover novel solutions for grand challenges at two of the University-wide interdisciplinary research laboratories: Computational Medicine Laboratory and System Health Laboratory. Drawing on diverse expertise within the School, SCM has devoted resources to establishing 12 research centres and institutes to focus on multi-disciplinary and integrative research on three major areas: (1) precision medicine and phenomics; (2) translational medicine and innovative drug discovery; and (3) authentication and testing of Chinese medicines.

Embracing the opportunities afforded by Hong Kong's first Chinese Medicine Hospital, which will be managed and operated by the University, SCM will continue to build its global profile through research partnerships and cross-disciplinary collaborations in different areas, and utilise novel clinical trial facilities to enable research and development of more effective Chinese medicinal drugs and therapies for various diseases. This, in turn, will enhance Hong Kong's standards in Chinese medicine clinical research and improve the competitiveness of Hong Kong's Chinese medicine pharmaceutical products regionally and internationally.

The concerted efforts of our academic and research experts have resulted in a proven track record of success in conducting research of far-reaching impact and publishing findings in internationally esteemed journals, as well as winning external competitive grants and patents. While we are proud to present our research endeavours and major accomplishments in this brochure, we look forward to working with world-class researchers to further advance research underpinned by Chinese medicine for the benefits of the global community.

Professor LYU Aiping
Dean of Chinese Medicine
Hong Kong Baptist University

OUR RESEARCH
AY2016-AY2021

RESEARCH STRENGTH

RESEARCH HIGHLIGHTS

The Chinese medicine discipline is within the ambits of “Health and Drug Discovery” and “Data Analytics and Artificial Intelligence in X”, which are two of the three strategic research clusters of Hong Kong Baptist University. Established in 1999, the School of Chinese Medicine (SCM) is committed to achieving excellence in its core research areas, thereby contributing to the overall success of the University as well as the modernisation, standardisation and internationalisation of Chinese medicine.

Our research is driven by our strong desire to tackle real-world health challenges, whilst contributing to a better understanding of the mechanisms of human diseases from a clinical and research perspective, thereby advancing precision medicine and devising innovative therapeutic solutions.

Major Research Areas of SCM

Precision medicine and phenomics

Translational medicine and innovative drug discovery

Authentication and testing of Chinese medicines

In the results of the Research Assessment Exercise 2020 announced by the University Grants Committee, over 45% of our research activities were rated “internationally excellent” (3 stars) and “world leading” (4 stars).

Some Significant Achievements

- Our aptamer research project led by Professor Lyu Aiping, Dean and Chair Professor of SCM, **won HK$50M in the 10th round of the Theme-based Research Scheme (TRS)** of the Research Grants Council. Not only is this our first TRS project with the University as the Project Coordinator, we were also awarded the highest amount among the seven TRS projects awarded in this round.

- Our research in herbal medicine drugs is highly acclaimed. Professor Bian Zhaoxiang, Director and Chair Professor of Clinical Division, School of Chinese Medicine, received **an award of HK$255M under the Health@InnoHK Programme** of the Innovation and Technology Commission for the establishment of "Centre for Chinese Herbal Medicine Drug Development Limited" at the Hong Kong Science Park.

- Our research team led by Professor Zhang Ge, Associate Dean (Research) and Professor of SCM, and Professor Lyu Aiping, Dean and Chair Professor of SCM, has successfully developed a novel aptamer, i.e. a single-stranded piece of DNA, for the treatment of osteogenesis imperfecta (OI) with the aid of artificial intelligence (AI) technology. It is the **first time a drug in Hong Kong has been granted orphan drug designation by the US Food and Drug Administration (FDA)**. The designation will bring a series of benefits to the subsequent research and development of the drug, such as tax credits when conducting qualified clinical trials. The research team expects that clinical trials can be conducted in three years' time, at the earliest.

REPRESENTATIVE PUBLICATIONS

RESEARCH AND REPORTING METHODS **Annals of Internal Medicine**

CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration

Chung-wah Cheng, MPH; Tai-xiang Wu, MPH; Hong-cai Shang, MD, PhD; You-ping Li, MPH; Douglas G. Altman, PhD; David Moher, PhD; and Zhao-xiang Bian, MD, PhD; for the CONSORT-CHM Formulas 2017 Group*

Chinese herbal medicine (CHM) formulas are the major components of traditional Chinese medicine (TCM) interventions. The general reporting quality of randomized controlled trials (RCTs) of CHM formulas is disappointing, although CONSORT (Consolidated Standards of Reporting Trials) Statement extensions for herbal medicinal interventions and acupuncture interventions are available. A group of TCM clinical experts, methodologists, epidemiologists, and editors has developed this CONSORT Extension for CHM Formulas (CONSORT-CHM Formulas 2017) through a comprehensive process, including publication of the draft version, solicitation of comments, revision, and finalization.

The CONSORT 2010 Statement was extended by introducing the idea of TCM *Pattern* and the features of CHM formulas. One new checklist subitem, keywords, was added to facilitate indexing and data searching. Seven of the 25 CONSORT checklist items, namely title and abstract, background and objectives, participants, interventions, outcomes, generalizability, and interpretation, are now elaborated, and the explanation of harms specific to CHM formulas is revised. Illustrative examples and explanations are also provided. The group hopes that CONSORT-CHM Formulas 2017 can improve the reporting quality of RCTs of CHM formulas.

Ann Intern Med. 2017;167:112-121. doi:10.7326/M16-2977 **Annals.org**

For author affiliations, see end of text.

This article was published at Annals.org on 27 June 2017.

* For a list of contributors to the CONSORT Extension for Chinese Herbal Medicine Formulas (CONSORT-CHM Formulas 2017), see **Appendix 1** (available at Annals.org).

Traditional Chinese medicine (TCM), one of the oldest medical systems in the world, is based on its own unique principles and comprehensive theory. Today, it plays an indispensable role in the Chinese health care system, and its impact worldwide is increasing (1). Since the first randomized controlled trial (RCT) of a Chinese herbal medicine (CHM) formula was published in 1982 (2), tens of thousands of clinical reports have been published (3). However, the quality of reporting is not optimal (4–6). Inadequate reporting not only compromises the values of the CHM but also may affect reviewers' and readers' judgments about the efficacy and safety of TCM in general, inviting skepticism and criticism (6). As a result, clinical practice and patient care suffer.

The CONSORT (Consolidated Standards of Reporting Trials) Statement and its extensions have substantially improved the reporting quality of RCTs (7). CONSORT extensions for herbal medicinal interventions (8) and acupuncture interventions (9) have been developed, but neither can be used for reporting clinical trials of CHM formulas, which are the most common interventions in TCM practice. These CONSORT extensions do not adequately take into account the unique characteristics of TCM—theory, principles, formulas, and Chinese medicinal substances (**Boxes 1** to **4**). Therefore, a new extension has been developed to guide the reporting of trials using CHM formulas.

See also:

Editorial comment 133

Web-Only
Chinese translations

METHODS FOR THE DEVELOPMENT OF CONSORT-CHM FORMULAS 2017

The development of CONSORT-CHM Formulas (formerly known as CONSORT for TCM) has been a comprehensive process. The first draft of CONSORT-CHM Formulas, including a 22-item checklist and a flow diagram, was published in Chinese (16) and English (17) in 2007 for open solicitation of comments. Afterward, the draft was disseminated in workshops and academic conferences by executive members of the working group to attract further discussion. Articles on the significance of the CHM formula extension (18), study design rationale (19), CHM formula composition (20), outcome measures (21), adverse effects (22), and further development (23) were published in Chinese or English.

On the basis of the comments and suggestions received, as well as the 2010 version of CONSORT Statement (24), executive members of the working group discussed and revised this extension in Chengdu, China, in late 2012. A consensus meeting, including executive members of working groups, 12 TCM clinical trial experts from China, and 2 herbal medicine experts from Korea, was held in Beijing in June 2013. After the meeting, a further revision was made by executive members and circulated to the working group members. The executive working group finalized the recommendation at the end of 2016.

HIGHLIGHTS OF CONSORT-CHM FORMULAS 2017

CONSORT-CHM Formulas 2017 includes the key concepts of *Pattern* and the features of CHM formulas. With regard to the checklist, compared with CONSORT 2010, CONSORT-CHM Formulas includes 1 new sub-

Extracted from

Cheng, Chung-Wah *et al.* CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. *Ann Intern Med.* 167, 112-121, DOI: 10.7326/M16-2977 (2017). Impact Factor: 19.384

nature COMMUNICATIONS

ARTICLE

DOI: 10.1038/s41467-017-01565-6 OPEN

A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer

Fangfei Li[1], Jun Lu[1], Jin Liu[2], Chao Liang[1,2], Maolin Wang[3], Luyao Wang[1,2], Defang Li[2], Houzong Yao[1], Qiulong Zhang[1], Jia Wen[4], Zong-Kang Zhang[5], Jie Li[5], Quanxia Lv[1], Xiaojuan He[2], Baosheng Guo[2], Daogang Guan[3], Yuanyuan Yu[2], Lei Dang[1], Xiaohao Wu[2], Yongshu Li[2], Guofen Chen[6], Feng Jiang[1], Shiguo Sun[4], Bao-Ting Zhang[5], Aiping Lu[1,2,3] & Ge Zhang[1,2,3]

Paclitaxel (PTX) is among the most commonly used first-line drugs for cancer chemotherapy. However, its poor water solubility and indiscriminate distribution in normal tissues remain clinical challenges. Here we design and synthesize a highly water-soluble nucleolin aptamer-paclitaxel conjugate (NucA-PTX) that selectively delivers PTX to the tumor site. By connecting a tumor-targeting nucleolin aptamer (NucA) to the active hydroxyl group at 2′ position of PTX via a cathepsin B sensitive dipeptide bond, NucA-PTX remains stable and inactive in the circulation. NucA facilitates the uptake of the conjugated PTX specifically in tumor cells. Once inside cells, the dipeptide bond linker of NucA-PTX is cleaved by cathepsin B and then the conjugated PTX is released for action. The NucA modification assists the selective accumulation of the conjugated PTX in ovarian tumor tissue rather than normal tissues, and subsequently resulting in notably improved antitumor activity and reduced toxicity.

[1] Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China. [2] Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China. [3] Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China. [4] College of Science, Northwest Agriculture and Forestry University, Yangling, 712100 Shaanxi, P.R. China. [5] School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China. [6] Department of Orthopaedics and Traumatology, Nanfang Hospital, Guangzhou 510515, China. Fangfei Li, Jun Lu, Jin Liu, Chao Liang, Maolin Wang and Luyao Wang contributed equally to this work. Correspondence and requests for materials should be addressed to B.-T.Z. (email: zhangbaoting@cuhk.edu.hk) or to A.L. (email: aipinglu@hkbu.edu.hk) or to G.Z. (email: zhangge@hkbu.edu.hk)

Extracted from

Li, Fangfei *et al.* A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. *Nat Commun.* 2017 Nov 9;8(1):1390. doi: 10.1038/s41467-017-01565-6. Impact Factor: 12.353

REPRESENTATIVE PUBLICATIONS

ORIGINAL ARTICLE

Journal of Cachexia, Sarcopenia and Muscle 2018; **9**: 613–626
Published online 7 March 2018 in Wiley Online Library (wileyonlinelibrary.com) **DOI:** 10.1002/jcsm.12281

A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration

Zong-Kang Zhang[1†], Jie Li[1†], Daogang Guan[2†], Chao Liang[3†], Zhenjian Zhuo[1], Jin Liu[3], Aiping Lu[2*], Ge Zhang[3*] & Bao-Ting Zhang[1*]

[1]*School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China,* [2]*Institute of Integrated Bioinformedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China,* [3]*Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China*

Abstract

Background Skeletal muscle atrophy induced by either aging (sarcopenia) or mechanical unloading is associated with serious health consequences. Long non-coding RNAs (lncRNAs) are implicated as important regulators in numerous physiological and pathological processes.

Methods Microarray analysis was performed to identify the differentially expressed lncRNAs in skeletal muscle between adult and aged mice. The most decreased lncRNA in aged skeletal muscle was identified. The C2C12 mouse myoblast cells were used to assess the biological function of the lncRNA *in vitro*. The target microRNA of lncRNA and the target protein of microRNA were predicted by bioinformatics analysis and validated *in vitro*. Furthermore, the biology function of the lncRNA *in vivo* was investigated by local overexpression or knockdown the lncRNA in skeletal muscle. The therapeutic effect of the lncRNA overexpression in age-related or mechanical unloading-induced muscle atrophy was also evaluated.

Results We identified a novel lncRNA (muscle anabolic regulator 1, MAR1) which was highly expressed in mice skeletal muscle and positively correlated with muscle differentiation and growth *in vitro* and *in vivo*. We predicted and validated that microRNA-487b (miR-487b) was a direct target of MAR1. We also predicted and validated that Wnt5a, an important regulator during myogenesis, was a target of miR-487b in C2C12 cells. Our findings further demonstrated that enforced MAR1 expression in myoblasts led to derepression of Wnt5a. Moreover, MAR1 promoted skeletal muscle mass/strength and Wnt5a protein level in mice. Enforced MAR1 expression in mice attenuated muscle atrophy induced by either aging or unloading.

Conclusions The newly identified lncRNA MAR1 acts as a miR-487b sponge to regulate Wnt5a protein, resulting in promoting muscle differentiation and regeneration. MAR1 could be a novel therapeutic target for treating muscle atrophy induced by either aging or mechanical unloading.

Keywords Long non-coding RNA; miR-487b; Wnt5a; Muscle differentiation; Muscle regeneration

Received: 14 June 2017; Revised: 6 November 2017; Accepted: 7 December 2017
**Correspondence to: Bao-Ting Zhang, School of Chinese Medicine, Faculty of Medicine,The Chinese University of Hong Kong, Hong Kong SAR, China. Tel: 852-3943-4285; Fax: 852-3942-0941. Email: zhangbaoting@cuhk.edu.hk*
Ge Zhang, Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China. Tel: 852-3411-2457; Fax: 852-3411-2461. Email: zhangge@hkbu.edu.hk
Aiping Lu, Institute of Integrated Bioinformedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China. Tel: 852-3411-2457; Fax: 852-3411-2461. Email: aipinglu@hkbu.edu.hk
†These authors contributed equally to this work.

Extracted from

Zhang, Zong-Kang *et al.* A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. *J Cachexia Sarcopenia Muscle* 9(3), 613-626, DOI: 10.1002/jcsm.12281 (2018). Impact Factor: 10.754

nature COMMUNICATIONS

ARTICLE

There are amendments to this paper

https://doi.org/10.1038/s41467-019-12163-z OPEN

HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis

Chao Liang[1,2,3,8,9], Jie Li[4,8], Cheng Lu[1,2,3,5,8], Duoli Xie[1,2,3], Jin Liu[1,2,3], Chuanxin Zhong[1,2,3], Xiaohao Wu[1,2,3], Rongchen Dai[1,2,3], Huarui Zhang[1,2,3], Daogang Guan[1,2,3], Baosheng Guo[1,2,3], Bing He[1,2,3], Fangfei Li[1,2,3], Xiaojuan He[1,2,3,5], Wandong Zhang[6], Bao-Ting Zhang[4,9], Ge Zhang[1,2,3,9] & Aiping Lu[1,2,3,7,9]

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive bone erosion. Leflunomide is originally developed to suppress inflammation via its metabolite A77 1726 to attenuate bone erosion. However, distinctive responsiveness to Leflunomide is observed among RA individuals. Here we show that Leflunomide exerts immunosuppression but limited efficacy in RA individuals distinguished by higher serum C-reactive protein (CRP^{Higher}, CRP^{H}), whereas the others with satisfactory responsiveness to Leflunomide show lower CRP (CRP^{Lower}, CRP^{L}). CRP inhibition decreases bone erosion in arthritic rats. Besides the immunomodulation via A77 1726, Leflunomide itself induces AHR-ARNT interaction to inhibit hepatic CRP production and attenuate bone erosion in CRP^{L} arthritic rats. Nevertheless, high CRP in CRP^{H} rats upregulates HIF1α, which competes with AHR for ARNT association and interferes Leflunomide-AHR-CRP signaling. Hepatocyte-specific *HIF1α* deletion or a HIF1α inhibitor Acriflavine re-activates Leflunomide-AHR-CRP signaling to inhibit bone erosion. This study presents a precision medicine-based therapeutic strategy for RA.

[1] Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077 Hong Kong SAR, China. [2] Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, 999077 Hong Kong SAR, China. [3] Institute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, 518000 Shenzhen, China. [4] Faculty of Medicine, School of Chinese Medicine, Chinese University of Hong Kong, 999077 Hong Kong SAR, China. [5] Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, 100700 Beijing, China. [6] The First Affiliated Hospital of Anhui University of Chinese Medicine, 230031 Hefei, China. [7] Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital/Shanghai University of TCM, 200032 Shanghai, China. [8] These authors contributed equally: Chao Liang, Jie Li, Cheng Lu. [9] These authors jointly supervised this work: Chao Liang, Bao-Ting Zhang, Ge Zhang, Aiping Lu. Correspondence and requests for materials should be addressed to G.Z. (email: zhangge@hkbu.edu.hk)

Extracted from

Liang, Chao *et al.* HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. *Nature Commun.* 10(1), 4579, DOI: 10.1038/s41467-019-12163-z (2019). Impact Factor: 12.121

REPRESENTATIVE PUBLICATIONS

ACS NANO

www.acsnano.org

ARTICLE

A Self-Assembled α-Synuclein Nanoscavenger for Parkinson's Disease

Jingyi Liu,[#] Chao Liu,[#] Jinfeng Zhang,[#] Yunming Zhang, Keyin Liu, Ju-Xian Song, Sravan Gopalkrishnashetty Sreenivasmurthy, Ziying Wang, Yesi Shi, Chengchao Chu, Yang Zhang, Caisheng Wu, Xianhua Deng, Xingyang Liu, Jing Song, Rongqiang Zhuang, Shuqiong Huang, Pengfei Zhang, Min Li,* Lei Wen,* Yun wu Zhang, and Gang Liu*

Cite This: *ACS Nano* 2020, 14, 1533−1549

Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

ABSTRACT: **Although emerging evidence suggests that the pathogenesis of Parkinson's disease (PD) is closely related to the aggregation of alpha-synuclein (α-syn) in the midbrain, the clearance of α-syn remains an unmet clinical need. Here, we develop a simple and efficient strategy for fabricating the α-syn nanoscavenger for PD *via* a reprecipitation self-assembly procedure. The curcumin analogue-based nanoscavenger (Nano-CA) is engineered to be capable of a controlled-release property to stimulate nuclear translocation of the major autophagy regulator, transcription factor EB (TFEB), triggering both autophagy and calcium-dependent exosome secretion for the clearance of α-syn. Pretreatment of NanoCA protects cell lines and primary neurons from MPP^+-induced neurotoxicity. More importantly, a rapid arousal intranasal delivery system (RA-IDDS) was designed and applied for the brain-targeted delivery of NanoCA, which affords robust neuroprotection against behavioral deficits and promotes clearance of monomer, oligomer, and aggregates of α-syn in the midbrain of an MPTP mouse model of PD. Our findings provide a clinically translatable therapeutic strategy aimed at neuroprotection and disease modification in PD.**



KEYWORDS: *Parkinson's disease, α-synuclein, curcumin analogue, TFEB, autophagy, exosome secretion, intranasal administration*

Parkinson's disease (PD) is characterized by a gradual loss of dopaminergic neurons in the substantia nigra (SN) and the accumulation of α-synuclein (α-syn) named Lewy bodies.[1,2] As the second most prevalent neurodegenerative disease (ND), PD affects approximately 2−3% of the population ≥65 years of age.[3] It has been estimated that 10 million people worldwide suffer from PD.[4] As the population ages, this number has risen sharply and the growth rate is expected to increase by more than 50% by 2030.[5] Currently, first-line medications for PD improve symptoms by enhancing brain dopamine function.[6] However, as the disease progresses, these drugs become less effective and can lead to serious complications.[7] Despite tremendous efforts that have been made, no clinical treatments have successfully halted or slowed the disease progression.[8,9]

Emerging evidence suggests that the accumulation of α-syn in the midbrain plays a pivotal role in PD pathogenesis, which may be closely related to the overwhelming or impaired cell degradation system.[10,11] Recently, the basic helic-loop-helix transcription factor EB (TFEB) has been highlighted as a major regulator of several cellular clearance pathways, including lysosomal proliferation,[12] autophagy degradation,[13] and lysosomal exocytosis.[14] Under physiological conditions, dephosphorylated TFEB enters the nucleus and activates the transcription of target genes.[12] Under pathological conditions, TFEB is rare in the nucleus but colocalizes with α-syn in Lewy bodies of dopamine substantia nigra neurons in post-mortem human brains.[15] This cytoplasmic retention of TFEB leads to the impairment of degradation pathways, contributing to the accumulation of misfolded proteins.[16] Based on these observations, adeno-associated virus (AAV)-mediated TFEB overexpression was established, and its preventive effect on dopaminergic neuron loss was demonstrated by inhibiting the mechanistic target of rapamycin (mTOR) signaling pathway.[15] Moreover, the overexpression of micro-RNA *MIR128*, a negative regulator of TFEB, exacerbated the α-syn toxicity

Received: August 14, 2019
Accepted: February 6, 2020
Published: February 6, 2020

https://dx.doi.org/10.1021/acsnano.9b06453
ACS Nano 2020, 14, 1533−1549

Extracted from

Reprinted with permission from Liu, Jingyi *et al.* A Self-Assembled α-Synuclein Nanoscavenger for Parkinson's Disease. *ACS Nano.* 2020 Feb 25;14(2):1533-1549. DOI: 10.1021/acsnano.9b06453. Epub 2020 Feb 10. PMID: 32027482. Copyright 2020 American Chemical Society. Impact Factor: 15.881

ADVANCED SCIENCE Open Access
www.advancedscience.com

A Loop-Based and AGO-Incorporated Virtual Screening Model Targeting AGO-Mediated miRNA–mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice

Zhenjian Zhuo, Youyang Wan, Daogang Guan, Shuaijian Ni, Luyao Wang, Zongkang Zhang, Jin Liu, Chao Liang, Yuanyuan Yu, Aiping Lu, Ge Zhang,* and Bao-Ting Zhang**

Several virtual screening models are proposed to screen small molecules only targeting primary miRNAs without selectivity. Few attempts have been made to develop virtual screening strategies for discovering small molecules targeting mature miRNAs. Mature miRNAs and their specific target mRNA can form unique functional loops during argonaute (AGO)-mediated miRNA–mRNA interactions, which may serve as potential targets for small-molecule drug discovery. Thus, a loop-based and AGO-incorporated virtual screening model is constructed for targeting the loops. The previously published studies have found that miR-214 can target ATF4 to inhibit osteoblastic bone formation, whereas miR-214 can target TRAF3 to promote osteoclast activity. By using the virtual model, the top ten candidate small molecules targeting miR-214-ATF4 mRNA interactions and top ten candidate small molecules targeting miR-214-TRAF3 mRNA interactions are selected, respectively. Based on both in vitro and in vivo data, one small molecule can target miR-214-ATF4 mRNA to promote ATF4 protein expression and enhance osteogenic potential, whereas one small molecule can target miR-214-TRAF3 mRNA to promote TRAF3 protein expression and inhibit osteoclast activity. These data indicate that the loop-based and AGO-incorporated virtual screening model can help to obtain small molecules specifically targeting miRNA–mRNA interactions to rescue bone phenotype in genetically modified mice.

1. Introduction

MicroRNAs (miRNAs) are endogenous, single-stranded and non-coding RNAs, which regulate hundreds of genes and play key roles in a number of physiological and pathological processes, such as proliferation, differentiation, and apoptosis.[1] Recently, an innovative approach Inforna has been reported, which enables the rational design of small molecules targeting RNA.[2] Using the Inforna, a small molecule specially binding to primary microRNA-96 with high affinity was identified.[2c] However, this strategy to target primary miRNAs lacks selectivity because one miRNA might regulate various target mRNAs, thus regulate various biological processes. Based on the Inforna, it is desirable for drug discovery to develop a selective small molecule strategy that could specifically target the interaction between miRNA and its target mRNA to rescue the inhibition of mRNA translation.

It is known that miRNAs guide the miRNA-induced silencing complexes

Dr. Z. Zhuo, Dr. Z. Zhang, Prof. B.-T. Zhang
School of Chinese Medicine
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong SAR, China
E-mail: zhangbaoting@cuhk.edu.hk
Dr. Z. Zhuo
Aptacure Therapeutics Limited
Kowloon, Hong Kong SAR, China

The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/advs.201903451

DOI: 10.1002/advs.201903451

Y. Wan, Dr. D. Guan, Dr. S. Ni, L. Wang, Dr. J. Liu, Dr. C. Liang, Dr. Y. Yu, Prof. A. Lu, Prof. G. Zhang
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases
School of Chinese Medicine
Hong Kong Baptist University
Hong Kong SAR, China
E-mail: aipinglu@hkbu.edu.hk zhangge@hkbu.edu.hk
Y. Wan, Dr. D. Guan, Dr. S. Ni, L. Wang, Dr. J. Liu, Dr. C. Liang, Dr. Y. Yu, Prof. A. Lu, Prof. G. Zhang
Institute of Integrated Bioinformedicine and Translational Science
School of Chinese Medicine
Hong Kong Baptist University
Hong Kong SAR, China
Dr. S. Ni, L. Wang, Dr. Y. Yu, Prof. A. Lu
Guangdong-Hong Kong-Macao Greater Bay
Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery
Hong Kong 999077, China

Extracted from

Zhuo, Zhenjian *et al.* A Loop-Based and AGO-Incorporated Virtual Screening Model Targeting AGO-Mediated miRNA-mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice. *Adv Sci.* 7(13), 1903451, DOI: 10.1002/advs.201903451 (2020). Impact Factor: 16.806

REPRESENTATIVE PUBLICATIONS

AUTOPHAGY
2021, VOL. 17, NO. 5, 1112–1130
https://doi.org/10.1080/15548627.2020.1760623

Taylor & Francis
Taylor & Francis Group

RESEARCH PAPER

Check for updates

NRBF2 is a RAB7 effector required for autophagosome maturation and mediates the association of APP-CTFs with active form of RAB7 for degradation

Cui-Zan Cai[a,#], Chuanbin Yang [b*,#], Xu-Xu Zhuang[a], Ning-Ning Yuan[a], Ming-Yue Wu[a], Jie-Qiong Tan[c], Ju-Xian Song [b,d], King-Ho Cheung[b], Huanxing Su[a], Yi-Tao Wang[a], Bei-Sha Tang[e], Christian Behrends [f], Siva Sundara Kumar Durairajan [b,g], Zhenyu Yue [h], Min Li [b*], and Jia-Hong Lu [a*]

[a]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China; [b]Mr. And Mrs. Ko Chi Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; [c]Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China; [d]Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China; [e]Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China; [f]Munich Cluster for Systems Neurology (Synergy), Ludwig-Maximilians-Universität München, München, Germany; [g]Division of Mycobiology and Neurodegenerative Disease Research, Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India; [h]Department of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

ABSTRACT

NRBF2 is a component of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex. Our previous study has revealed its role in regulating ATG14-associated PtdIns3K activity for autophagosome initiation. In this study, we revealed an unknown mechanism by which NRBF2 modulates autophagosome maturation and APP-C-terminal fragment (CTF) degradation. Our data showed that NRBF2 localized at autolysosomes, and loss of NRBF2 impaired autophagosome maturation. Mechanistically, NRBF2 colocalizes with RAB7 and is required for generation of GTP-bound RAB7 by interacting with RAB7 GEF CCZ1-MON1A and maintaining the GEF activity. Specifically, NRBF2 regulates CCZ1-MON1A interaction with PI3KC3/VPS34 and CCZ1-associated PI3KC3 kinase activity, which are required for CCZ1-MON1A GEF activity. Finally, we showed that NRBF2 is involved in APP-CTF degradation and amyloid beta peptide production by maintaining the interaction between APP and the CCZ1-MON1A-RAB7 module to facilitate the maturation of APP-containing vesicles. Overall, our study revealed a pivotal role of NRBF2 as a new RAB7 effector in modulating autophagosome maturation, providing insight into the molecular mechanism of NRBF2-PtdIns3K in regulating RAB7 activity for macroautophagy/autophagy maturation and Alzheimer disease-associated protein degradation..

KEYWORDS

Autophagy; CCZ1-MON1A; maturation; NRBF2; PI3KC3/VPS34; RAB7; trafficking

Abbreviations: 3xTg AD, triple transgenic mouse for Alzheimer disease; Aβ, amyloid beta peptide; $A\beta_{1-40}$, amyloid beta peptide 1–40; $A\beta_{1-42}$, amyloid beta peptide 1–42; AD, Alzheimer disease; APP, amyloid beta precursor protein; APP-CTFs, APP C-terminal fragments; ATG, autophagy related; ATG5, autophagy related 5; ATG7, autophagy related 7; ATG14, autophagy related 14; CCD, coiled-coil domain; CCZ1, CCZ1 homolog, vacuolar protein trafficking and biogenesis associated; CHX, cycloheximide; CQ, chloroquine; DAPI, 4′,6-diamidino-2-phenylindole; dCCD, delete CCD; dMIT, delete MIT; FYCO1, FYVE and coiled-coil domain autophagy adaptor 1; FYVE, Fab1, YGL023, Vps27, and EEA1; GAP, GTPase-activating protein; GDP, guanine diphosphate; GEF, guanine nucleotide exchange factor; GTP, guanine triphosphate; GTPase, guanosine triphosphatase; HOPS, homotypic fusion and vacuole protein sorting; ILVs, endosomal intralumenal vesicles; KD, knockdown; KO, knockout; LAMP1, lysosomal associated membrane protein 1; MAP1LC3/LC3, microtubule associated protein 1 light chain 3; MLVs, multilamellar vesicles; MON1A, MON1 homolog A, secretory trafficking associated; NRBF2, nuclear receptor binding factor 2; PtdIns3K, class III phosphatidylinositol 3-kinase; PtdIns3P, phosphatidylinositol-3-phosphate; RILP, Rab interacting lysosomal protein; SNARE, soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor; SQSTM1/p62, sequestosome 1; UVRAG, UV radiation resistance associated; VPS, vacuolar protein sorting; WT, wild type.

Introduction

Macroautophagy (henceforth to be referred to as autophagy) is a conserved pathway that is involved in the degradation of cytoplasmic materials including long-lived proteins, protein aggregates, cellular organelles (e.g., mitochondria), and infectious agents via lysosomes [1–5]. Autophagy involves the formation of cup-shaped double-membrane structures called phagophores, followed by extension and closure to form

*CONTACT Chuanbin Yang nkyangchb@gmail.com Mr. And Mrs. Ko Chi Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Min Li limin@hkbu.edu.hk Mr. And Mrs. Ko Chi Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Jia-Hong Lu jiahonglu@um.edu.mo State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China
#These authors contributed equally

Supplemental data for this article can be accessed here.

Extracted from

Cai, Cui-Zan *et al.* NRBF2 is a RAB7 effector required for autophagosome maturation and mediates the association of APP-CTFs with active form of RAB7 for degradation. *Autophagy* 17(5), 1112-1130, DOI: 10.1080/15548627.2020.1760623 (2020). Impact Factor: 16.016

Protein Cell 2021, 12(5):374–393
https://doi.org/10.1007/s13238-020-00748-0

Protein & Cell

REVIEW

Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma

Wei Jia[1,2]✉, **Cynthia Rajani**[3], **Hongxi Xu**[4], **Xiaojiao Zheng**[1]✉

[1] Center for Translational Medicine and Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China
[2] Hong Kong Tranditional Chinese Medicine Phenome Research Center, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong 999077, Hong Kong, China
[3] University of Hawaii Cancer Center, Honolulu, HI 96813, USA
[4] School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
✉ Correspondence: weijia1@hkbu.edu.hk (W. Jia), joyzheng99@sjtu.edu.cn

Received February 14, 2020 Accepted June 15, 2020

ABSTRACT

Colorectal cancer (CRC) and hepatocellular carcinoma (HCC) are the second and third most common causes of death by cancer, respectively. The etiologies of the two cancers are either infectious insult or due to chronic use of alcohol, smoking, diet, obesity and diabetes. Pathological changes in the composition of the gut microbiota that lead to intestinal inflammation are a common factor for both HCC and CRC. However, the gut microbiota of the cancer patient evolves with disease pathogenesis in unique ways that are affected by etiologies and environmental factors. In this review, we examine the changes that occur in the composition of the gut microbiota across the stages of the HCC and CRC. Based on the idea that the gut microbiota are an additional "lifeline" and contribute to the tumor microenvironment, we can observe from previously published literature how the microbiota can cause a shift in the balance from normal → inflammation → diminished inflammation from early to later disease stages. This pattern leads to the hypothesis that tumor survival depends on a less pro-inflammatory tumor microenvironment. The differences observed in the gut microbiota composition between different disease etiologies as well as between HCC and CRC suggest that the tumor microenvironment is unique for each case.

KEYWORDS gut microbiota, colorectal cancer, hepatocellular carcinoma

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third most common cause of death by cancer with a high mortality rate (Patel et al., 2012). Approximately 50% of HCC are induced by hepatitis B (HBV) infection and 20% by hepatitis C (HCV) infection. Viral infection acts as a first hit to produce liver inflammation that can develop into cirrhosis over time, and approximately 70%–90% of HCC cases occur in conjunction with cirrhosis (Guo et al., 2018). CRC is the second most common cause of death from cancer and has high incidence in Western countries. The incidence is currently increasing in Asian countries, and environmental factors such as diet have a large impact (Park et al., 2018). Excessive consumption of red meat and high fat influences the composition of the gut microbiota which in turn, can produce metabolites that contribute to intestinal inflammation resulting in the initial carcinogenic milieu for CRC (Feng et al., 2015). Pathological changes in the gut microbiota, referred to as "gut dysbiosis", that lead to inflammation in the intestine is a common feature of both CRC and HCC. However, primary CRC and HCC develop as distinctive tumors in the intestine and liver, respectively. The connection between gut microbiota composition and both CRC and HCC has been well studied in animal models (Xie et al., 2016b; Wong et al., 2017). There are three categories of gut dysbiosis: 1) loss of beneficial, commensal bacteria, 2) enhanced abundance of pathobionts, and 3) loss of overall microbial diversity. These categories often occur concurrently (Petersen and Round, 2014).

Extracted from

Jia, Wei *et al.* Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. *Protein Cell* 12(5), 374-393, DOI: 10.1007/s13238-020-00748-0 (2020). Impact Factor: 14.870

REPRESENTATIVE PUBLICATIONS

nature COMMUNICATIONS

ARTICLE

https://doi.org/10.1038/s41467-021-21744-w OPEN

Check for updates

Hyocholic acid species as novel biomarkers for metabolic disorders

Xiaojiao Zheng[1,8], Tianlu Chen[1,8], Aihua Zhao[1,8], Zhangchi Ning[2,3,8], Junliang Kuang[1], Shouli Wang[1], Yijun You[1], Yuqian Bao[4], Xiaojing Ma[4], Haoyong Yu[4], Jian Zhou[4], Miao Jiang[5], Mengci Li[1], Jieyi Wang[1], Xiaohui Ma[6], Shuiping Zhou[6], Yitao Li[2], Kun Ge[1], Cynthia Rajani[7], Guoxiang Xie[7], Cheng Hu[4], Yike Guo[2], Aiping Lu[2]✉, Weiping Jia[1,4]✉ & Wei Jia[1,2,7]✉

Hyocholic acid (HCA) is a major bile acid (BA) species in the BA pool of pigs, a species known for its exceptional resistance to spontaneous development of diabetic phenotypes. HCA and its derivatives are also present in human blood and urine. We investigate whether human HCA profiles can predict the development of metabolic disorders. We find in the first cohort ($n = 1107$) that both obesity and diabetes are associated with lower serum concentrations of HCA species. A separate cohort study ($n = 91$) validates this finding and further reveals that individuals with pre-diabetes are associated with lower levels of HCA species in feces. Serum HCA levels increase in the patients after gastric bypass surgery ($n = 38$) and can predict the remission of diabetes two years after surgery. The results are replicated in two independent, prospective cohorts ($n = 132$ and $n = 207$), where serum HCA species are found to be strong predictors for metabolic disorders in 5 and 10 years, respectively. These findings underscore the association of HCA species with diabetes, and demonstrate the feasibility of using HCA profiles to assess the future risk of developing metabolic abnormalities.

[1] Center for Translational Medicine and Shanghai Key Laboratory of Diabetes Mellitus and Shanghai Key Laboratory of Sleep Disordered Breathing, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. [2] School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China. [3] Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. [4] Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai, China. [5] Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China. [6] Department of Pharmacology and Toxicology, Tasly Pharmaceutical Co. Ltd, Tianjin, China. [7] University of Hawaii Cancer Center, Honolulu, HI, USA. [8] These authors contributed equally: Xiaojiao Zheng, Tianlu Chen, Aihua Zhao, Zhangchi Ning. ✉email: aipinglu@hkbu.edu.hk; wpjia@sjtu.edu.cn; weijia1@hkbu.edu.hk

Extracted from

Zheng, Xiaojiao *et al.* Hyocholic acid species as novel biomarkers for metabolic disorders. *Nat Commun.* 12(1), 1487, DOI: 10.1038/s41467-021-21744-w (2021). Impact Factor: 14.919

IVYSPRING INTERNATIONAL PUBLISHER

Theranostics

2021; 11(11): 5585-5604. doi: 10.7150/thno.54477

Research Paper

Targeting long noncoding RNA PMIF facilitates osteoprogenitor cells migrating to bone formation surface to promote bone formation during aging

Dijie Li[1,2,4,5*], Jin Liu[2,3*], Chaofei Yang[1,4,5*], Ye Tian[1,4,5*], Chong Yin[1,4,5], Lifang Hu[1,4,5], Zhihao Chen[1,4,5], Fan Zhao[1,4,5], Ru Zhang[1,4,5], Aiping Lu[2,3]✉, Ge Zhang[2,3]✉ and Airong Qian[1,4,5]✉

1. Lab for Bone Metabolism, Xi'an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, China.
2. Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinses Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
3. Shenzhen Institute for Research and Continuing Education (IRACE), Hong Kong Baptist University, Shenzhen, China.
4. Research Center for Special Medicine and Health Systems Engineering, School of Life Sciences, Northwestern Polytechnical University, Xi'an, China.
5. NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi'an, China.

*Co-first authors.

✉ Corresponding authors: E-mail: qianair@nwpu.edu.cn (Airong Qian); zhangge@hkbu.edu.hk (Ge Zhang); aipinglu@hkbu.edu.hk (Aiping Lu).

Received: 2020.10.14; Accepted: 2021.02.17; Published: 2021.03.20

Abstract

Rationale: The migration of mesenchymal osteoprogenitor cells (OPCs) to bone formation surface is the initial step of osteoblastogenesis before they undergo osteoblast differentiation and maturation for governing bone formation. However, whether the migration capacity of OPCs is compromised during aging and how it contributes to the aging-related bone formation reduction remain unexplored. In the present study, we identified a migration inhibitory factor (*i.e.*, long noncoding RNA PMIF) and examined whether targeting lnc-PMIF could facilitate osteoprogenitor cells migrating to bone formation surface to promote bone formation during aging.

Methods: Primary OPCs from young (6-momth-old) and aged (18-momth-old) C57BL/6 mice and stable lnc-PMIF knockdown/overexpression cell lines were used for *in vitro* and *in vivo* cell migration assay (*i.e.*, wound healing assay, transwell assay and cell intratibial injection assay). RNA pulldown-MS/WB and RIP-qPCR were performed to identify the RNA binding proteins (RBPs) of lnc-PMIF. Truncations of lnc-PMIF and the identified RBP were engaged to determine the interaction motif between them by RNA pulldown-WB and EMSA. By cell-based therapy approach and by pharmacological approach, small interfering RNA (siRNA)-mediated lnc-PMIF knockdown were used in aged mice. The cell migration ability was evaluated by transwell assay and cell intratibial injection assay. The bone formation was evaluated by microCT analysis and bone morphometry analysis.

Results: We reported that the decreased bone formation was accompanied by the reduced migration capacity of the bone marrow mesenchymal stem cells (BMSCs, the unique source of OPCs in bone marrow) in aged mice. We further identified that the long non-coding RNA PMIF (postulated migration inhibitory factor) (*i.e.*, lnc-PMIF) was highly expressed in BMSCs from aged mice and responsible for the reduced migration capacity of aged OPCs to bone formation surface. Mechanistically, we found that lnc-PMIF could bind to human antigen R (HuR) for interrupting the HuR-β-actin mRNA interaction, therefore inhibit the expression of β-actin for suppressing the migration of aged OPCs. We also authenticated a functionally conserved human lncRNA ortholog of the murine lnc-PMIF. By cell-based therapy approach, we demonstrated that replenishing the aged BMSCs with small interfering RNA (siRNA)-mediated lnc-PMIF knockdown could promote bone formation in aged mice. By pharmacological approach, we showed that targeted delivery of lnc-PMIF siRNA approaching the OPCs around the bone formation surface could also promote bone formation in aged mice.

Conclusion: Toward translational medicine, this study hints that targeting lnc-PMIF to facilitate aged OPCs migrating to bone formation surface could be a brand-new anabolic strategy for aging-related osteoporosis.

Key words: long non-coding RNA; osteoprogenitor cells; cell migration; bone formation; aging

Extracted from

Li, Dijie *et al.* Targeting long noncoding RNA PMIF facilitates osteoprogenitor cells migrating to bone formation surface to promote bone formation during aging. *Theranostics* 11(11), 5585-5604, DOI: 10.7150/thno.54477 (2021). Impact Factor: 11.556

RESEARCH
CENTRES AND INSTITUTES

Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research (CCIR)

Director | Professor Lyu Aiping

In 2009, the School established CCIR to investigate the causes of and novel therapeutic strategies for cancer and inflammatory diseases by integrating Chinese medicine and modern scientific technology, with the aim of making breakthroughs in research and contributing to health and well-being.

The Centre's efforts are currently focused on the following three major areas:

I. Basic science research, focusing on:

- (i) Molecular cancer biology and carcinogenesis of colorectal cancer, ovarian cancer, melanoma and liver cancer.
- (ii) Metastatic cancer biology of the aforementioned cancers.
- (iii) Chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel diseases.

II. Translational science/medicine research, devoted to treating cancer and inflammatory diseases by means of:

- (i) Chinese medicine.
- (ii) Targeted therapies, including among others immunotherapy.
- (iii) Development of different drug delivery methods.

III. Clinical research, focusing on:

- (i) The design of clinical trials to evaluate the therapeutic efficacy of Chinese pharmaceutical products.
- (ii) The carrying out of epidemiological and clinical studies to evaluate the therapeutic efficacy of herbal medicines alone or in combination with chemotherapy and radiotherapy.
- (iii) The establishment of a tissue sample library for the common cancerous and inflammatory diseases in Hong Kong.

Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ)

Director | Professor Zhang Ge

Associate Director | Professor Lyu Aiping

TMBJ was established in September 2012 to create a collaboration platform for scientists of the School to work in synergy with those of the Faculty of Science to efficiently and effectively translate basic scientific findings into clinical applications that would benefit patients suffering from bone and joint diseases. With its rich academic resources comprising both expertise and infrastructure, TMBJ collaborates with the industry to conduct cutting-edge research leading to the development of innovative biological reagents, therapeutic agents, bio-imaging modalities and advanced biomaterials for the diagnosis, prevention and treatment of bone and joint diseases for clinical trials and commercialisation.

TMBJ aims to bring scientific knowledge and research findings "from the bench to the bedside", and improve the quality of life for patients suffering from bone and joint diseases all over the world.

Hong Kong Chinese Medicine Clinical Study Centre (CMCS)

Director | Professor Bian Zhaoxiang

Associate Director | Professor Lyu Aiping

Established in June 2014, CMCS is the only centre which focuses on Chinese medicine clinical trial in Hong Kong. The mission of CMCS is to create a dynamic centre that enables its academic faculty to develop, demonstrate and implement innovative models of clinical research in integrative and Chinese medicine in Hong Kong, mainland China and all over the world.

Currently, CMCS focuses on two main research directions:

i. To provide multidisciplinary health professions a synergistic collaboration platform to perform high-quality Chinese Medicine Clinical trials across a wide range of therapeutic areas, and to integrate pharmacological, biological & clinical research.

ii. To develop 2-4 new drugs for gastrointestinal, orthopedics, metabolism, oncology and dementia based on an efficacy-driven Chinese Medicine discovery platform.

The scope of our research centre includes:

i. Clinical trial design and implementation.
ii. Standardisation strategies for TCM.
iii. New drug discovery and screening.
iv. Clinical practice guidelines development.

Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research (CPDR)

Director | Professor Li Min

Associate Director | Professor Bian Zhaoxiang

Established in October 2014, CPDR is a centre for translational and clinical research in Parkinson's disease and other neurodegenerative diseases which aims to develop new drugs for preventing and treating neurodegenerative diseases including Parkinson's disease using Chinese medicines.

CPDR adopts Chinese medicine perspectives and findings from long-standing clinical practice as the fundamental basis for pharmacological studies of neurodegenerative diseases, including Parkinson's disease and their etiology and pathogenesis. It endeavours to discover more effective and non-toxic or less toxic drugs through integrating the application of molecular/cell biology and pharmacology techniques to benefit patients suffering from Parkinson's disease and other neurodegenerative diseases. Through collaborations with top global and national/world-class institutes in China and the world, CPDR aims to become an excellent platform to integrate Western and Chinese medicine and transform basic research into clinical applications, and serve as an innovative research and development base for training professionals.

RESEARCH
CENTRES AND INSTITUTES

Consun Chinese Medicines Research Centre for Renal Diseases (CCRD)

Director | Professor Yu Zhiling

Established in February 2015, CCRD aims to boost research and development of Chinese medicines for the prevention and treatment of renal diseases, and ultimately benefit patients suffering from different kinds of renal and related diseases.

In addition to serving as a platform for innovative research on and development of preventative and therapeutic approaches for renal diseases, CCRD is committed to the nurturing of researchers and professionals, and dissemination and transfer of knowledge of new preventive and therapeutic approaches for renal diseases.

Research Centre for Standardisation of Chinese Medicines (CSCM)

Director | Professor Chen Hubiao

Director (2014 - Aug 2022) | Professor Zhao Zhongzhen

Established in March 2015, CSCM aims to develop innovative QC of and standardisation methods for Chinese medicines, promote the standardisation of Chinese medicines, formulate standards using developed methods through collaboration with governments, and provide services to industries using standardized methods.

The researchers of CSCM provide expertise in scientific elucidation of macroscopic identification of commonly used Chinese materia medica, focus on the standardisation of processed Chinese materia medica and processing methods, conduct comparative studies of chemistry and bioactivities of multi-sourced medicines, investigate into the active ingredients of Chinese medicines, and contribute to the studies of innovative methods for quality analysis of Chinese medicine decoction and polysaccharide-rich Chinese medicines. CSCM is committed to contributing to the standardisation and globalisation of Chinese medicines.

Institute of Integrated Bioinformedicine and Translational Science (IBTS)

Director | Professor Lyu Aiping

Associate Director | Professor Zhang Ge



IBTS, established in 2015, is committed to the promotion of precision medicine and translational medicine to enhance health management for the people in Hong Kong, mainland China and all over the world.

It seeks to establish a collaborative platform to facilitate multidisciplinary research to achieve better healthcare. Through integrating the academic, clinical and industrial resources, IBTS aims to build a partnership network for collecting and managing clinical, biological and environmental big data, which enable the researchers to develop models, networks, and approaches for providing predictive, preventive and personalised healthcare services.

Institute for Precision Medicine and Innovative Drug (PMID)

Director | Professor Zhang Ge

Associate Director | Professor Lyu Aiping

Established in April 2016, the Institute focuses on precision medicine and innovative drug discovery and develops the next generation of aptamer drug and next generation targeted aptamer-drug conjugate. The Institute aims to play indispensable roles in the life safety of human beings, and to become a leading research institute in the world.

The objectives of the institute are listed as follow:

i. Establish the research and development platform for next generation of aptamer drug alternative to antibody drug.

ii. Establish the research and development platform for next generation targeted aptamer-drug conjugate.

iii. Train the doctor and post-doctoral research fellow of precision medicine and innovative drug discovery, hold senior academic meeting (Academician Forum), and promote the development of precision medicine and innovative drug discovery; and attract and cultivate the enterprises settling.

RESEARCH
CENTRES AND INSTITUTES

Hong Kong Traditional Chinese Medicine Phenome Research Centre (HKPR)

Director | Professor Jia Wei

Associate Director | Professor Zhang Ge, Bian Zhaoxiang

The Centre was established in April 2017. HKPR allows performing Chinese medicine phenomics studies at a population level. The acquisition of the high-throughput mass spectrometric bioanalysis platform in the Centre will support and expand the bench-to-bedside and bedside-to-bench studies on Chinese medicine, drug discovery, development and delivery.

HKPR will serve as a state-of-the-art platform to:

i. Modernize TCM and advance TCM diagnosis.

ii. Facilitate preventive treatment.

iii. Promote translational medicine and drug discovery, which will open up new avenue for disease treatments.

Centre for Chinese Herbal Medicine Drug Development Limited (CDD)

Director | Professor Bian Zhaoxiang

Funded by Innovation and Technology Commission (ITC) of the Hong Kong Government, Centre for Chinese Herbal Medicine Drug Development Limited (CDD) was established in September 2020 to accelerate the development of Chinese Herbal Medicine (CHM)-based drugs, and serve as a strategic platform to promote collaborations among local and international researchers, institutions and industry. The centre aims to achieve the goal by enhancing the quality for pre-clinical and clinical CHM research and transforming the results into pharmaceutical products for international markets. In particular, the centre develops treatments and cures for diseases such as ulcerative colitis and chronic constipation. It also supports the incubation of new CHM-based pharmaceutical start-ups that will target the global market, and nurtures talent for CHM research in Hong Kong.

i. To develop a CHM drug development platform. Each component of the platform could either work together as the pipeline for CHM-based new drug development or work separately for a specific CHM formula related preclinical or clinical studies.

ii. To develop CHM-based new pharmaceutical drugs based on the requirements of the NMPA in China, the Chinese Medicine Council of Hong Kong and the US FDA, targeting the market needs, with the CHM formulas that are supported by evidence-based pre-clinical and clinical researches.

iii. To nurture talents for CHM research in Hong Kong.

EQUATOR (Enhancing the QUAlity and Transparency Of health Research) China Centre (EQCC)

Director | Professor Bian Zhaoxiang

The EQUATOR China Centre, established in October 2019, aims to improve the reliability and value of published health research literature by promoting transparent and accurate reporting and wider use of robust reporting guidelines. It is the first coordinated attempt to tackle the problems of inadequate reporting systematically in China. Therefore, it is beneficial to galvanize and expand the existing medical research strength of the School of Chinese Medicine, as well as to enhance the leadership of Hong Kong Baptist University in the Good Publication of health research and Chinese medicines.

HKBU and IncreasePharm Joint Centre for Nucleic Acid Drug Discovery (NADD)

Director | Professor Zhang Ge

Projects in NADD emphasize on industrial transformation of nucleic acid research work with large-scale nucleic acid preparation ability to fill up the gaps between new drug industry and academic research. Findings in NADD will be applied in clinical practice, which will benefit the community and mankind.

Established in Jun 2020, NADD will serve as a state-of-the-art platform to:

(i) Standardize nucleic acid drug development and advance nucleic acid-based diagnosis.

(ii) Facilitate preventive treatment.

(iii) Promote translational medicine and drug discovery, which will open up new avenue for disease treatments.

Hong Kong Baptist University Joint Centre for Pain Research (JCPR)

Director | Professor Lyu Aiping

Associate Director | Professor Zhang Ge, Bian Zhaoxiang

Established in September 2018, JCPR aims to conduct joint projects and high-quality pain-related research, in collaboration with the State University of New York at Stony Brook (SBU) and the Shanghai University of Traditional Chinese Medicine (SUTCM). The Centre will serve as an integrated platform not only to support and expand our bench-to-bedside and bedside-to-bench studies on pain-related diseases, but also to promote public education and knowledge of pain and its management.

The mission of the Centre is to develop new biomaterials for diagnosis, prevention and treatment of pain, select policy topics and write joint position papers for publication, and also advise local governments on the subject.

RESEARCH COLLABORATIONS & SPONSORSHIPS

Chan Hon Yin Couple Charity Trust

2021 Philanthropic Support

HKBU has received a generous donation of HK$15 million from the Chan Hon Yin Couple Charity Trust in support of the University's clinical Chinese medicine research. The Trust has been a staunch supporter of the HKBU School of Chinese Medicine's development for over 20 years. They have so far donated a total of more than HK$50 million in support of a variety of the University's initiatives.

2021

Simon Suen Foundation

2021 Philanthropic Support

HKBU has received a generous donation pledge of HK$25 million from the Simon Suen Foundation designated for the University's artificial intelligence and clinical Chinese medicine research, in particular the use of intelligent wearable devices to collect important data for related research projects.

2021

2021

Lippo Group

2021 Philanthropic Support

HKBU has received a generous donation of HK$2 million from Dr Stephen Riady, President of the Lippo Group, in support of the University's strategic development of Chinese medicine and its preparatory work for the operation of Hong Kong's first Chinese Medicine Hospital.

Tan Siu Lin Foundation

2020 & 2021 Philanthropic Support

HKBU has received HK$2 million in donations from Dr Tan Siu-lin. Two donations, each of HK$1 million, were made in 2020 and 2021 respectively through the Tan Siu Lin Foundation in support of the development of the School of Chinese Medicine.

2020 & 21

Guangdong Provincial Hospital of Chinese Medicine, University of Macau, Macau University of Science and Technology and Guangzhou Youcare Biopharmaceutics Company Limited

2020 Academic and Industrial Collaboration

SCM has joined hands with Guangdong Provincial Hospital of Chinese Medicine, University of Macau and Macau University of Science and Technology along with Guangzhou Youcare Biopharmaceutics Company Limited to establish the Guangdong-Hong Kong-Macao Joint Laboratory for Chinese Medicine and Immunological Disease Research. This collaborative platform combining clinical, basic and industrial research was over three years in the making before being officially recognised by the Department of Science and Technology of Guangdong Province at the Plaque Presentation Ceremony held on 25 November 2020. By capitalising on the expanded talent pool and the well-developed infrastructure of all partners, the Joint Laboratory aims to conduct interdisciplinary and innovative research on the prevention and treatment of autoimmune and allergic diseases as well as immune regulation of malignant tumours with Chinese medicine.

2020

University of Technology Sydney

2020 Academic Collaboration

Dr Linda Zhong, Assistant Professor of the School of Chinese Medicine, has been admitted as a Fellow of the International Complementary and Integrative Medicine (CIM) Research Leadership Program in recognition of her excellence in the clinical study of Chinese medicine and integrative medicine. The programme was launched by the Australian Research Centre in Complementary and Integrative Medicine, which is part of the Faculty of Health at the University of Technology Sydney.

Tan Siu Lin Foundation

2019 Philanthropic Support

HKBU received a generous donation of HK$1 million from the Tan Siu Lin Foundation, in support of the development of the HKBU School of Chinese Medicine.

2019

Sun Yat-sen University

2019 Academic Collaboration

HKBU and Guangzhou-based Sun Yat-sen University (SYSU) have established a joint PhD programme partnership between the HKBU School of Chinese Medicine and the SYSU School of Pharmaceutical Sciences. Outstanding SYSU master's students admitted onto this programme will carry out research under the co-supervision of HKBU and SYSU advisors.

2019

Vincent and Lily Woo Foundation and Cornell University

2018 Industrial and Academic Collaboration

HKBU received a generous donation of HK$2.3 million from the Vincent and Lily Woo Foundation in support of a collaborative research project by the HKBU School of Chinese Medicine and Cornell University. The project was entitled "East Meets West: A Revolutionised Nanotechnology Approach to Modernise the Delivery of Chinese Medicine for Vast Improved Cancer Therapeutic Efficacy".

2018

Laboratory JaneClare Limited

2017 Industrial Collaboration

HKBU received a generous donation of HK$5 million from Laboratory JaneClare Limited for the establishment of JaneClare Transdermal TCM Therapy Laboratory, in support of product and talent development for the SCM.

2017

Mr Lai Kin-hak and Mr Tang Fung of Capital Estate Limited

2017 Philanthropic Support

The University received a generous donation of HK$2 million from Mr Lai Kin-hak and Mr Tang Fung of Capital Estate Limited, in support of the SCM's research project entitled "Combinational Drug Discovery from Chinese Medicines for the Treatment of Rheumatoid Arthritis".

2017

2017

Xiao Pen Jing Kou Wei Tang Hotel Management Pty Limited

2017 Philanthropic Support

SCM received a donation of HK$200,000 from Xiao Pen Jing Kou Wei Tang Hotel Management Pty Limited to develop a database for seasonal food therapy. The establishment of the database will lay a solid foundation for future development of a mobile phone application for Chinese medicine food therapy.

Harvard University

2017 Academic Collaboration

The University joined hands with the Harvard Medical School (HMS) of Harvard University in the US to hold a two-day symposium entitled "Traditional Chinese and Western medicine: what can we learn from each other" on the HMS campus on 20-21 June 2017. This first event of its kind between the two schools brought together scientists and clinicians of Western and Chinese medicine not only to share knowledge but also to spark discussions and explore potential research collaborations.

2017



2017

Northwestern Polytechnical University, Tsinghua University, Zhejiang University, the Academy of Military Medical Sciences, and the Institute of Zoology of the Chinese Academy of Sciences

2017 Academic Collaboration

The School of Chinese Medicine conducted a space life science study on board China's first cargo spacecraft, Tianzhou-1, which was launched in 2017. HKBU was the only higher education institution from outside of Mainland to conduct a scientific research project onboard Tianzhou-1.

2017

Logan Property Holdings Company Limited

2017 Philanthropic Support

The University received a generous donation of HK$5 million from Logan Charitable Foundation in support of the School of Chinese Medicine's research project entitled "Efficacy and Mechanism Study of Artemisinin Derivatives for Inflammatory Bowel Diseases".

2017

Nanjing University of Chinese Medicine

2017 Academic Collaboration

HKBU and Nanjing University of Chinese Medicine signed a co-operation framework agreement on 16 January 2017. Both sides seek to further strengthen their close partnership of over 15 years through this cooperation which aims at promoting Chinese medicine culture and creating synergy in the development of Chinese medicine education, medical services and research. Under the agreement, the two universities will jointly nurture more undergraduate students and postgraduate students, enhance the exchange and visits of teachers and researchers, establish a Chinese medicine clinical and research base, and foster academic exchange.

Lung Cheong Group

2017 Philanthropic Support

HKBU received a generous donation of HK$500,000 from Dr Leung Lun, Chairman of Lung Cheong Group and Member of the Entrepreneur Committee of the HKBU Foundation. The fund will support the development of the SCM. This donation brought the total contributions by Dr Leung to SCM past the HK$1 million mark.

2017

2016

Chinese University of Hong Kong and PuraPharm Corporation Ltd

2016 Academic and Industrial Collaboration

The University signed a cooperation agreement with the Chinese University of Hong Kong (CUHK) and PuraPharm Corporation Ltd (PuraPharm) on 10 November 2016 to develop new drugs for treating functional gastrointestinal disorders. The collaboration was the first new Chinese medicine project in Hong Kong with an integrative medical research approach. Based on the two universities' research into irritable bowel syndrome – diarrhoea type (IBS-D) – and their profound knowledge of Chinese medicine, a treatment called Ren Shu Chang Le Granules was developed using technology provided by the manufacturer.

The Chinese Manufacturers' Association of Hong Kong

2016 Philanthropic Support

The University received a HK$4 million donation from The Chinese Manufacturers' Association of Hong Kong in support of the Scheme of Study Tour and Exchange for Undergraduates and Junior Chinese Medicine Practitioners of the School of Chinese Medicine (SCM). In recognition of the generous support of the Association, the University named one of the teaching and research facilities at the Jockey Club School of Chinese Medicine Building located on the Baptist University Road Campus "The Chinese Manufacturers' Association of Hong Kong Chinese Medicine Education Centre".

2016

2016

Nagoya City University

2016 Academic Collaboration

SCM signed an academic exchange agreement with the Graduate School of Pharmaceutical Sciences, Nagoya City University, Japan in February 2016 to foster collaboration in a number of areas, including the exchange of faculty members, research fellows and students and the launch of joint research projects with a view to boosting international exchange and collaboration.

New World Strategic Investment Limited

2016 Philanthropic Support

The School of Chinese Medicine (SCM) received a donation of HK$500,000 from Ms Flora Chan, Executive Director, New World Strategic Investment Limited as a start-up fund for a wearable acupoint diagnostic and treatment device.

INTERNATIONAL COLLABORATIONS

List of International Collaborations AY2016 - AY2021

Collaborator	Institute	Regional District	Country
Douglas Altman	Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, University of Oxford	Oxford	UK
Jeffrey A. Banas	Dows Institute for Dental Research and Pediatric Dentistry, University of Iowa	Iowa	USA
Rudolf Bauer	Institute of Pharmaceutical Sciences, University of Graz	Graz	Austria
Heather Boon	Leslie Dan Faculty of Pharmacy, University of Toronto	Toronto	Canada
Michael B. Brenner	Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School	Massachusetts	USA
George Priya Doss C	School of Biosciences and Technology, VIT University	Vellore	India
Yihai Cao	Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet	Stockholm	Sweden
Chiranjib Chakraborty	Department of Bioinformatics, Galgotias University	Greater Noida	India
Gong Chen	Department of Biology, The Pennsylvania State University	Pennsylvania	USA
Yegao Chen	Department of Chemistry, Yunnan Normal University	Kunming	China
Chih-Chang Chu	College of Human Ecology, Cornell University	New York	USA
Baomin Fan	YMU-HKBU Joint Laboratory of Traditional Natural Medicine, Yunnan Minzu University	Kunming	China
Harry H.S. Fong	Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, University of Illinois at Chicago	Illinois	USA
J. Kevin Foskett	Department of Physiology, University of Pennsylvania	Pennsylvania	USA
Scott G. Franzblau	Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, University of Illinois at Chicago	Illinois	USA
Peter Friedl	Department of Cell Biology, RIMLS, Radboud University Medical Center; David H. Koch Center for Applied Research of Genitourinary Cancers, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center	Texas	USA
Antony Galione	Department of Pharmacology, University of Oxford	Oxford	UK
Xin Ge	Chemical Engineering, Bioengineering and Biochemistry, University of California Riverside	California	USA
Zhendan He	School of Pharmacy, Shenzhen University	Shenzhen	China
Victor W. Hsu	Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School	Massachusetts	USA
Yingjie Hu	Tropical Medicine Institute, Guangzhou University of Chinese Medicine	Guangzhou	China
Zhaofeng Huang	Zhongshan School of Medicine, Sun Yat-sen University	Guangzhou	China
Mien-Chie Hung	Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center	Texas	USA
Josef Jampilek	Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University	Bratislava	Slovakia
Wendy WY Keung	Dr. Li Dak-Sum Research Centre, The University of Hong Kong – Karolinska Institutet Collaboration in Regenerative Medicine	Hong Kong / Stockholm	China / Sweden
Edward Keystone	The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital/ University Health Network, University of Toronto	Toronto	Canada
Konstantinos Konstantopoulos	Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, Johns Hopkins University	Maryland	USA
Rejji Kuruvilla	Department of Biology, Johns Hopkins University	Maryland	USA
Zou Lan	Enzhi (Guangzhou) Medical Technology Co., Ltd.	Guangzhou	China
Yiping Li	Zhongshan School of Medicine, Sun Yat-sen University	Guangzhou	China
Youping Li	Chinese Evidence-based Medicine Centre, Sichuan University	Chengdu	China

List of International Collaborations AY2016 - AY2021

Collaborator	Institute	Regional District	Country
Frank M. Longo	Department of Neurology and Neurological Sciences, Stanford University	California	USA
Jia-hong Lu	State Key Lab of Quality Research in Chinese Medicine; Institute of Chinese Medical Sciences, University of Macau	Macau	China
Daqing Ma	Department of Surgery & Cancer, Imperial College London	London	UK
Diego Luis Medina	Telethon Institute of Genetics and Medicine	Pozzuoli	Italy
David Moher	Ottawa Hospital Research Institute, University of Ottawa	Ottawa	Canada
Jeremy Nicholson	MRC-NIHR National Phenome Centre, Imperial College London	London	UK
Lutai Pan	Guiyang College of Traditional Chinese Medicine	Guiyang	China
Weidong Pan	Guizhou Medical University	Guiyang	China
Lijun Rong	Department of Microbiology & Immunology, College of Medicine, the University of Illinois at Chicago	Illinois	USA
Mart Saarma	Institute of Biotechnology, University of Helsinki	Helsinki	Finland
Jeffrey E. Segall	Department of Anatomy and Structural Biology, and Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine	New York	USA
Hongcai Shang	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine	Beijing	China
Djaja D. Soejarto	Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, the University of Illinois at Chicago	Illinois	USA
Ghee T. Tan	College of Pharmacy, University of Hawaii at Hilo	Hawaii	USA
Hongqi Wang	Guangzhou TCM University	Guangzhou	China
Yitao Wang	Institute of Chinese Medical Sciences, University of Macau	Macau	China
Taixiang Wu	Chinese Cochrane Centre, Sichuan University	Chengdu	China
Hongxi Xu	Shanghai University of Traditional Chinese Medicine	Shanghai	China
Jun Yang	NPFPC Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research	Shanghai	China
Yunlong Yang	Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University	Shanghai	China
Albert S. Yeung	Harvard Medical School	Massachusetts	USA
Sun Ok Yoon	The Ohio State University of College of Medicine	Ohio	USA
Jian Zhang	Department of Medical Oncology, Fudan University Cancer Institute, Fudan University Shanghai Cancer Center (FUSCC)	Shanghai	China
Yuan Zhang	The 2nd People Hospital of Shenzhen	Shenzhen	China
Jean J. Zhao	Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School	Massachusetts	USA
Hong Zhou	ANZAC Research Institute, University of Sydney	Sydney	Australia
范吉平	中國中醫藥出版社	Beijing	China
徐黎明	四川新綠色藥業科技發展有限公司	Chengdu	China
譚曉濱	深圳市星路海文化傳播有限公司	Shenzhen	China
--	廣州海博特醫藥科技有限公司	Guangzhou	China
--	無限極 (中國) 有限公司	Guangzhou	China
--	深圳市老年醫學研究所	Shenzhen	China
--	昆藥集團股份有限公司	Kunming	China

MAP OF

INTERNATIONAL COLLABORATIONS




NETHERLANDS
NORWAY
FINLAND
SWEDEN
SLOVAKIA
AUSTRIA
SOUTH KOREA
Trondheim
Leiden
Helsinki
Stockholm
Bratislava
Graz
Seoul
Daejeon
UNITED KINGDOM
JAPAN
London
Oxford
Cambridge
Saitama
NORTH PACIFIC OCEAN
INDIAN OCEAN
North Rhine-Westphalia
Hamburg
Rostock
GERMANY
Vellore
Greater Noida
Pozzuoli
Naples
Pavia
Chennai
ITALY
INDIA
Nedlands
Sydney
AUSTRALIA


Lanzhou
Chengdu
Guiyang
Kunming
Zhuhai
Macao
Shenzhen
CHINA
Beijing
Dalian
Shanghai
Wuhan
Nanchang
Changsha
Guangzhou

Research Grants

NUMBER OF MAJOR EXTERNAL COMPETITIVE RESEARCH GRANTS AWARDED



TOTAL AMOUNT OF MAJOR EXTERNAL COMPETITIVE RESEARCH GRANTS AWARDED



Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen; **TRS:** Theme-based Research Scheme; **HKJC:** Hong Kong Jockey Club Charities Trust

Patents

NUMBER OF PATENTS GRANTED



NUMBER OF PATENTS FILED



Publications

NUMBER OF RESEARCH PAPERS AND BOOKS PUBLISHED



ACADEMIC ACTIVITIES

MAJOR CONFERENCES

AY2020/21

18 December 2020

GP-TCM Research Association Virtual Conference 2020: Chinese Medicines: from Anti-viral Effects to Future Global Development

從中醫藥抗病毒功效到未來全球發展」線上研討會

2021 — 2020 — 2019

30 March 2021

The 5th Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine Award Ceremony-cum-Award Winners' Lecture

第五屆張安德中醫藥國際貢獻獎頒發典禮暨得獎學人講座

AY2019/20

Owing to the social unrest and pandemic situation in 2019 and 2020 respectively, the international/regional forums/talks/ meetings were cancelled or postponed.

AY2020/21

AY2018/19

28 July 2019

The 3rd International Forum on the Development of Hong Kong Chinese Medicine Hospital

第三屆香港中醫醫院發展國際論壇

2019

29 - 30 June 2019

The 5th Forum (Hong Kong) on the Development of Chinese Medicine cum The Eleventh Annual Meeting of Global University Network of Traditional Medicine

第五屆中醫中藥發展(香港)論壇暨第十一屆全球傳統醫學大學聯盟年會

AY2018/19

AY2018/19

28 April 2019

2019 Chinese Medicine Forum
2019 香港中醫藥論壇

AY2018/19

16 March 2019

2019 Hong Kong Summit on Quality Control of Valuable Chinese Medicines
2019 香港名貴中藥質量控制產學研峰會

2019

18 March 2019

Institute of Creativity Seminar - International Symposium on Cell Biology: Advance in Cell Biology and Disease Mechanism
創意研究院「細胞生物學與疾病機制的發展」國際研討會

AY2018/19

AY2018/19

9 December 2018

Symposium of Hong Kong Zhongjing Academic Heritage and Innovation
香港仲景學術傳承與創新研討會

2018

25-26 August 2018

The 4th International Summit on Innovative Drug Discovery in Chinese Medicine: Network Pharmacology and Big Data Analysis
第四屆國際中藥創新藥物研發高峰論壇

AY2017/18

AY2017/18

29 July 2018

The Second International Forum on the Development of Hong Kong Chinese Medicine Hospital: Integrative Chinese and Western Medicine

第二屆香港中醫醫院發展國際論壇:中西醫協作

2018

19 August 2018

The 11th Professional Lecture Series on Chinese Medicine Classics and Clinical Practice

第十一屆香港中醫經典與臨床應用學術研討會

3 June 2018

The 4th Forum (Hong Kong) on the Development of Chinese Medicine

第四屆中醫中藥發展(香港)論壇

AY2017/18

AY2017/18

AY2017/18

13 May 2018

The 10th Professional Lecture Series on Chinese Medical Classics and Clinical Practice

第十屆香港中醫經典與臨床應用學術研討會

2018

24 March 2018

The 2018 Hong Kong Summit on Quality Control of Valuable Chinese Medicines

2018香港名貴中藥質量控制產學研峰會

AY2017/18

AY2017/18

23 March 2018

The 4th Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine Ceremony-cum-Award Winner's Lecture

第四屆張安德中醫藥國際貢獻獎頒獎典禮暨得獎學人講座

2018

14 January 2018

Forum on Hong Kong Chinese Medicine Specialty Development-cum-Forum on Prevention and Treatment of Influenza in Chinese Medicine

香港中醫專科發展論壇暨中醫防治流感論壇

AY2017/18

AY2017/18

21 October 2017

The 7th Honorary Professorship Conferment Ceremony-cum-Seminar

中醫藥學院第七屆榮譽教授頒授典禮暨研討會

2017

24-25 August 2017

Forum on Quality Research and Standardisation of Chinese Medicines 2017

中藥質量研究及標準化論壇 2017

16-17 July 2017

The 3rd Forum on the Development of TCM (Hong Kong) & Academic Conference on Bone and Joint Diseases

第三屆中醫中藥發展(香港)論壇暨骨與關節疾病學術大會

AY2016/17

AY2016/17

5-8 June 2017

The International Organisation for Standardisation/Technical Committee 249 on Traditional Chinese Medicine (ISO/TC 249)

第八屆國際標準化組織中醫藥技術委員會(ISO/TC 249)全體大會

2017

11-12 March 2017

Conference on "Frontiers of Integrative Medicine – Clinical Challenges and Future Directions"

「結合醫學前沿—臨床挑戰與路向」會議

18 February 2017

First Forum of Materia Medica Culture-cum-15th Meeting of the Materia Medica Study Group

首屆本草文化論壇暨第十五次本草讀書會

AY2016/17

ACADEMIC ACTIVITIES
GUEST SPEAKERS

Name	Affiliation	Topic
AY2020 - 2021		
Prof. Yan Shi-Yun	Shanghai University of Traditional Chinese Medicine, China	Pursuit of Harmony - TCM Theory Under the Perspective of Traditional Philosophy
Prof. Wang Yi-Tao	State Key Laboratory of Quality Research in Chinese Medicines, University of Macau, Macau	Systemic Investigation of Quality Research in Chinese Medicine
Prof. Yang Zifeng	Guangzhou Institute of Respiratory Health, Guangzhou Medical University, China	The pathway for medical translation of TCM against SARS-CoV-2 based on integration of Chinese and Western medicine
Prof. Rudolf Bauer	University of Graz, Austria	What is needed for the acceptance of Chinese medicine in the fight against COVID-19 in European countries
Prof. Thomas Efferth	Johannes Gutenberg University Mainz, Germany	Artemisinin derivatives to combat viral diseases
Prof. Liu Jianping	Beijing University of Chinese Medicine, China	Anti-COVID-19 with Traditional Chinese Medicine: research evidence in China
Prof. Shaw Pang-Chui	The Chinese University of Hong Kong, Hong Kong	Evidence-based study on traditional prescriptions for the inhibition of influenza virus

Name	Affiliation	Topic
AY2019 - 2020		
徐啟河博士	倫敦國王學院	「腎虛」與「補腎」的中西醫藥結合研究 — 讓中醫藥智慧照亮腎臟病學的明天

Name	Affiliation	Topic
AY2018 - 2019		
Prof. Chen Dacan	Guangdong Provincial Hospital of Chinese Medicine	Adhering to the integration of Chinese and Western medicine and constructing a modern hospital of Chinese medicine: A case presentation from Guangdong Provincial Hospital of Chinese Medicine
Dr. Cheung Wai Lun	Chinese Medicine Hospital Project Office, Food and Health Bureau, Hong Kong	Principle Design Concept for the Chinese Medicine Hospital
Dr. Gary Deng	Bendheim Integrative Medicine Center at Memorial Sloan Kettering Cancer Center, United States	How to Integrate TCM at a Comprehensive Cancer Center in the U.S.: Challenges and Solutions
Prof. Jiang Weimin	Department of Internal Medicine of Nanjing University of Traditional Chinese Medicine, China	Exploration and Practice on the Inheritance and Development of Traditional Chinese Medicine
Dr. Lai King Kwong	Planning Office for Chinese Medicine Hospital, Hong Kong Baptist University	Opportunities for Hong Kong Chinese Medicine Hospital under One Country, Two Systems
Prof. Tang Xudong	China Academy of Chinese Medical Sciences, China	Reflections on the Cultural Construction of TCM Hospital
Prof. Justin Wu	CUHK Medical Centre, Hong Kong	Integrative Chinese and Western Medicine: From Theory to Practicality
Prof. Xu Qingshi	Bao'an Authenic TCM Therapy Hospital and the Establishment of the Hospital	Shenzhen Bao'an Authentic TCM Therapy Hospital Setting Standards and Construction Experience
Prof. Zhang Xiaoyang	Peking Union Medical College Hospital, China	The Current Situation and Opportunities of Chinese Medicine in PUMCH
Prof. Zhu Mingjun	First Affiliated Hospital of Henan University of Chinese Medicine	Strengthening the Construction of Disciplines and Promoting the Development of Hospitals
周光飚博士	中國科學院	肺癌的分子機理與中醫藥防治
Prof. Lee Eui Ju	College of Korean Medicine, Kyung Hee University, Korea	Korean Medication Clinical Practice Guidelines of Dizziness

Name	Affiliation	Topic
AY2018 - 2019		
Prof. Lu Liming	Guangzhou University of Chinese Medicine, China	Construction of Integrative Evidence Chain for Acupuncture Clinical Research
Prof. Sadamoto Kiyomi	Yokohama University of Pharmacy, Japan	Issue of Pharmacy Education Moving Towards Practical in Japan
Dr. Te Kian Keong	Universiti Tunku Abdul Rahman, Malaysia	Recent Development of Traditional & Complementary Medicine Education in Malaysia
Prof. Yen Hung-Rong	China Medical University, Taiwan	Traditional Chinese Medicine for Cancer Patients in Taiwan
Prof. Zhang Li	Shanghai University of Traditional Chinese Medicine, China	Safety and Anti-Fatigue Effect of Korean Red Ginseng: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial
Prof. Chen Xiaoye	China Academy of Chinese Medical Sciences - Institute of Basic Theory of Chinese Medicine, China	Landscapes: "Realm" of Life
Prof. Jiang Quan	China Academy of Chinese Medical Sciences - Guanganmen Hospital, China	Classic Prescription Practices in Rheumatic Diseases
Prof. Jiang Yiping	Jiangxi University of Traditional Chinese Medicine, China	A Thinking on Liver Disease Transmits to Spleen
Prof. Shang Hongcai	Beijing University of Chinese Medicine - Dongzhimen Hospital, China	The Function and Mechanism of Integrated Regulation of Traditional Chinese Medicine
Prof. Song Chunsheng	Graduate School of China Academy of Chinese Medical Sciences, China	Training Practice of Intellectuals with Western Medicine Learning TCM and Integrated Medicine
Prof. Sun Xiaobo	Chinese Academy of Medical Sciences - Institute of Medicinal Plant Development, China	Strategy and Thinking for High Quality Development of Chinese Medicine Industry
Prof. Xu Hao	China Academy of Chinese Medical Sciences - Xiyuan Hospital, China	Construction and Transformation of the Innovative Theory of TCM Etiology and Pathogenesis of Coronary Heart Disease
Prof. Yang Jinsheng	Exchange Center for Taiwan, Hong Kong and Macao, National Administration of Traditional Chinese Medicine	Standardized Research Mode of TCM Technology
Prof. Huang Jiandong	The University of Hong Kong, Hong Kong	Engineering bacteria to form biological structures and to attack cancer
Prof. Hui Ka-Kit	UCLA Center for East-West Medicine, United States David Geffen School of Medicine at UCLA, United States	Important Role of Chinese Medicine in Global Healthcare
Prof. Chen Yao-long	Lanzhou University, China	RIGHT : Reporting Checklist for Practice Guideline
Prof. Shan Yibing	D. E. Shaw Research (DESRES), United States	A structural model of megadalton Ras-Raf signalosome
朱 恩博士	香港註冊中醫學會	頸椎間盤突出症的中醫治療經驗分享
姜 苗醫師	北京中醫藥大學	32 例晚期惡性腫瘤的中醫綜合康復淺析
邵 輝博士	--	蒲公英提取物質 T-1 促孕臨床效果與其機理研究—反復失敗高齡患者備孕的治療策略
蘇 晶博士	香港大學中醫藥學院	回歸經典，重道明術 經典經方防治更年期抑鬱症
陳永光教授	香港註冊中醫學會	中醫治療重症肌無力的辨治思路
袁 冰教授	香港註冊中醫學會	香港醫藥現行監管法規對中醫藥發展的束縛
陳飛松醫師	--	淺述脾胃升降理論在老年腫瘤治療中的重要價值
郝東方醫師	香港大學中醫藥學院	肩部筋傷的整體治療
彭增福博士	--	足跟疼痛的激痛點針刺療法
王建國醫師	--	中藥配方顆粒研究與臨床應用

ACADEMIC ACTIVITIES
GUEST SPEAKERS

Name	Affiliation	Topic
AY2018 - 2019		
符文澍教授	香港中文大學中醫學院	中醫藥在延緩皮膚衰老中的應用
王英杰醫師	--	老年癡呆症探討
吉鳳霞醫師	仁愛堂 - 香港中文大學中醫診所暨教研中心	烏蛇榮皮湯治療慢性濕疹的體會
涂家生教授	中國藥科大學	藥用輔料及藥用輔料的標準的現狀及未來
Prof. Kong Jian	Harvard Medical School, United States	Applying the power of the mind to enhance acupuncture treatment effect
邵鵬柱教授	香港中文大學	Development of Molecular Techniques to Quick Authenticate Shark Fin
李紹平教授	澳門大學中藥質量研究國家重點實驗室	冬蟲夏草研究
陳立鑽所長	浙江天台中藥研究所	鐵皮石斛的道地性研究
周祥山教授	膠類中藥國家工程技術研究中心	阿膠全產業鏈質量控制
靳洪濤教授	中國醫學科學院新藥安全性評價中心	Protective Effect of Colla Corii Asini against Lung Injuries Induced by Intratracheal Instillation of Artificial Fine Particles in Rats
Prof. Bao Zhirong	Memorial Sloan Kettering Cancer Center, New York, United States	Single-cell analysis of complex tissues : live-imaging, single-cell seq, and synthesis
Prof. Jiang Xuejun	Memorial Sloan Kettering Cancer Center, New York, United States	Ferroptosis, Mechanisms and Role in Disease
Prof. Li Yue-Ming	Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States	Regulation of gamma-Secretase : from small molecules to modulatory proteins
Prof. Lin Yu-Chun Frank	Institute of Molecular Medicine, Department of Medical Science, National Tsing Hua University, Taiwan	Sonogenetic modulation of cellular activities using an engineered auditory-sensing protein
Prof. Lin Zhixiu	School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong	BD is a Promising Anti-Pancreatic Cancer Adjuvant: Results from Preclinical Investigations
Prof. Tsou Meng-fu Bryan	Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States	Centrosome, Cilia and Cell Fitness
Prof. Wang Won-Jing	Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taiwan	The control of cilia initiation
Prof. Wong Ka-Leung	Department of Chemistry, Hong Kong Baptist University, Hong Kong	Lanthanide for biomedical applications
Prof. Yu Siu-Bun Sidney	School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong	Von TRAPP, and the sound of lipid
Prof. Zhou Pengbo	Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States	Dissecting the functional complexity of cellular proteins by Protein Knockout
Prof. Rejji Kuruvilla	The Johns Hopkins University, United States	Sympathetic Neuron Development and Neurotrophic Mechanisms
Prof. Kelvin Chan	Liverpool John Moores University, United Kingdom University of Western Sydney, Australia	QA-QC standards are key issues for global acceptance of TCM
Prof. Joseph M. Betz	NIH Office of Dietary Supplements, United States	Botanical Products in the U.S. Scientific and Regulatory Perspectives
Prof. Jeremy Nicholson	Murdoch University, Australia Imperial College London, United Kingdom	Molecular Phenomics Approaches in Personalized and Public Healthcare
Dr. Kenichi Shimada	Harvard Medical School, United States	Understanding Landscape of Chemically Induced Cell Death Phenotypes
Prof. Yu Li	Tsinghua University, China	Mirgrasome and Migracytosis

Name	Affiliation	Topic
AY2018 - 2019		
Prof. Zhang Hong	Institute of Biophysics of Chinese Academy of Sciences, China	Autophagy: Lessons from C. elegans
Prof. Hao Quan	The University of Hong Kong, Hong Kong	Structural Study of Sirtuin Family Proteins
Dr. Louis Liu	University of Toronto, Canada	Achieving Success in IBS Management: Think Beyond the Gut
Dr. Liu Ying	University of Illinois at Chicago, United States	Self-assembled Polymeric Nanoparticles – from Competitive Kinetics to Biomedical Applications
Dr. Mark Sayles	Purdue University, United States	Dissecting Neural Circuits for Spatial Hearing: Systems-identification Approaches
Miss Rachel Wu	Purdue University, United States	In Vivo Direct Reprogramming Restores Local Circuit Connectivity After Focal Stroke
張　藝教授	成都中醫藥大學	民族醫藥學術傳承與創新研究的思路和方法
王劍鋒博士	河南中醫藥大學	張仲景學術研究現狀與展望
石　軍醫師	香港大學中醫藥學院	厥陰病探微
林志秀教授	香港中文大學中醫學院	黃蓮解毒湯和濕疹：從臨床到實驗研究
徐宏喜教授	上海中醫藥大學	人參藥理作用及臨床療效研究
陳建萍博士	香港大學中醫藥學院	當中醫遇上了乳腺癌 - 仲景學術思想給予的啟發
張保亭教授	香港中文大學中醫學院	基於分子機制的中藥小分子開發策略干預肌肉骨骼系統疾病
張保獻先生	中國中醫科學院中藥研究所	中藥及其相關大健康產業現狀分析
郭岳峰博士	香港仲景堂中醫綜合診療中心	中醫治療肺癌的心得和病案分析
謝　瑩博士	澳門科技大學藥學院	水飛薊賓的葯代動力學研究進展
Prof. Jeffrey E. Segall	Albert Einstein College of Mediciney, United States	Studies on Cancer Invasion and Metastasis
Dr. Joy Wolfram	University of North Florida, United States	Synthetic and Biological Nanotherapeutics
周岱翰教授	國醫大師 廣州中醫藥大學第一附屬醫院主任醫師	中醫壽命學對防治惡性腫瘤的貢獻
張忠德教授	廣東省名中醫 廣東省中醫院副院長、主任醫師	嶺南甄氏雜病流派防治久咳頑咳經驗
嚴蔚冰先生	國家級非物質文化遺產項目易筋經傳承人 上海中醫藥大學	易筋經在中醫臨床的應用
Dr. Trish Groves	The BMJ, United Kingdom	How to write a paper that editors will want to publish
Prof. Chen Gong	The Pennsylvania State University, United States	Reconstruct Destructed Brain Circuits Through In Vivo Astrocyte-to-neuron Conversion
Prof. Xu Jun	Sun Yat-Sen University, China	Finding Pharmaceutical Agents by Assembling Chemotypes

Name	Affiliation	Topic
AY2017 - 2018		
Prof. Cao Zhiwei	School of Life Sciences and Technology, Tongji University, China	TCM computational biology and application
Prof. Chen Shilin	Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, China	Herbgenomics: the development and future of TCM-omics
Prof. Thomas Efferth	Johannes Gutenberg University Mainz, Germany	Deciphering the multi-specificity of cytotoxic phytochemicals by network pharmacology
Prof. Michael Heinrich	University College London, United Kingdom	Understanding TCM preparations - challenges and opportunities for developing medicines

ACADEMIC ACTIVITIES
GUEST SPEAKERS

Name	Affiliation	Topic
AY2017 - 2018		
Prof. Peter Hylands	King's College London, United Kingdom	Metabolomics in Traditional Chinese Medicine research: a new case study
Prof. Huang Yu	Institute of Vascular Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong	Therapeutic targeting of injured vascular endothelium
Prof. Li Shao	Tsinghua University, China	Unveiling the biological basis of traditional Chinese medicine by network pharmacology
Prof. Lin Na	Research Center of Chinese Medica Theory, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, China	The multi-field study on the clinical rational prescription of triptolide
Prof. Sun Xiaobo	Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, China	Clinical big data delivers new routes to drug discovery in Chinese medicine
Prof. Wang Yitao	Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau	Delivery systems for active ingredients hom Chinese medicine: targeting and modulating cellular microenvironment
Prof. Wang Yonghua	School of Life Sciences, Northwest A&F University, China	Systems pharmacology for drug discovery from TCM
Prof. Xu Hongxi	School of Pharmacy, Shanghai University of Traditional Chinese Medicine, China	Identification and mechanism study of novel anticancer compounds isolated from Garcinia plants
Prof. Yang Ning-Sun	The Agricultural Biotechnology Research Center (ABRC) of Academia Sinica, Taiwan	Use of specific immune cells and their signaling systems for R&D of candidate anti-tumor metastasis phytochemicals
Dr. Zhu Guidong	Sparx Therapeutics, Inc., United States	Big data-aided target mining in new drug discovery
周岱翰教授	廣州中醫藥大學 國醫大師	《傷寒雜病論》辨治癌症與經方治療肝癌舉隅
談勇教授	南京中醫藥大學第一臨床醫學院	早發性卵巢功能低下性不孕症的治療與體會
唐旭東教授	中國中醫科學院西苑醫院	消化系統疾病中醫經典與臨床之思考與實踐
黃仕沛教授	廣州市越秀區中醫院	讀傷寒，用經方，聯繫臨床，還仲景本原
張曉陽教授	北京協和醫科大學	中醫風病理論與臨床應用
Prof. Yuan Chun-Su	University of Chicago, United States	Botanical Cancer Chemoprevention: Role of Enter Microbiome and Biological Signatures
Dr. Cheung Wai Lun	Chinese Medicine Hospital Project Office, Food and Health Bureau, Hong Kong	Integrative Medicine - Challenges and Opportunities of Chinese Medicine Hospital
Prof. Dai Jingzhang	TCM-Klinik Bad Kötzting, Germany	Clinical observation of combination acupuncture Back shu points mainly and Chinese herbal medicine on the treatment of fibromyalgia symptom in 136 cases
Prof. Ko Seong-Gyu	Kyung Hee University, Korea	Clinical study to evaluate the safety of an herbal medicine SH003 in patients with solid cancer
Prof. Liu Luming	Academy of Integrative Medicine, Fudan University, China	The Application of Traditional Chinese Medicine in Treating Pancreatic Cancer - Opportunity and Challenge
Dr. Lu Weidong	Harvard Medical School, United States	Oncology Acupuncture Practice and Research at an Harvard Teaching Hospital
Prof. Shen Jiangang	School of Chinese Medicine, University of Hong Kong, Hong Kong	Targeting Neural Stem Cells for Neurogenesis for Post-stroke Brain Repair: Opportunity and Challenge for Chinese Herbal Medicine
Dr. Su Shanyu	China Medical University, China	Merging of traditional Chinese medicine into integrated medical care for Cancer patients - an example of breast cancer patient care in China Medical University Hospital
Dr. Tse Man Li	Hong Kong Poison Information Centre, Hospital Authority, Hong Kong	Managing the risk in Integrative use of herb and drug

Name	Affiliation	Topic
AY2017 - 2018		
Prof. Mohammad Amjad Kamal	King Abdulaziz University, Saudi Arabia	Enzymoics: From Amido Phosphoribosyltransferase to Cholinesterases
Prof. Jia Wei	University of Hawaii Cancer Center, United States	Bile Acid – Microbiome Crosstalk in Metabolic Disorders
徐慶鋒局長	廣東省中醫藥管理局	共建健康大灣區 助力“一帶一路”建設 傳承創新發展中醫藥事業
吳一昌先生	臺灣中華海峽兩岸牛樟芝產業發展協會	臺灣道地藥材如何透過“一帶一路”的政策走向世界—以牛樟芝為例
石崇榮醫師	澳門中醫藥學會 (AIPPMCM)	澳門中醫藥在“一帶一路”的發展與機遇
楊金生教授	國家中醫藥管理局對台港澳中醫藥交流合作中心	以針帶藥，促進中醫藥走進“一帶一路”
沈劍剛教授	香港大學中醫藥學院	神經幹細胞靶向腦修復策略及其在中醫藥的應用
危劍安教授	中國中醫科學院廣安門醫院	中醫藥治療老年常見病的臨床感悟
林志秀教授	中大醫學院中西醫結合醫學研究所	常見皮膚損害和治療用藥心得
吳潔教授	中國中醫科學院廣安門醫院血液科	中醫藥在惡性淋巴瘤治療中的應用與思考
郭元琦教授	博愛醫院沙田中醫中心	腹針治療頸椎病頸痛的功效
馬桂琴教授	中國中醫科學院廣安門醫院風濕免疫科	中醫藥防治風濕病的特色與優勢
趙勇教授	中國中醫科學院望京醫院骨傷科	軟組織張力性疼痛的鍼針療法
號周科教授	深圳市中醫院腦病與心理病科	臨床狀態醫學—新的醫療模式
王三虎教授	西安市中醫院	肺癌的經方治療
曾慶明教授	羅湖區中醫院	從六經辨治眩暈的體會
杜寧教授	上海市傷骨科研究所	中醫手法治療疾病的物質基礎
Prof. Wang Yong	Shanghai Institutes for Biological Sciences, China	Natural Product Synthetic Biology: From Bacteria to Plant
邵鵬柱教授	香港中文大學生命科學學院	DNA技術在貴重藥材鑒定中的應用
周祥山博士	膠類中藥國家工程技術研究中心	阿膠歷史、藥材資源及科技創新
曹暉博士	中藥現代化國家工程技術研究中心	冬蟲夏草的資源調查
韓全斌博士	香港鐵皮石斛檢定中心	鐵皮石斛多糖標誌物的發現和應用
Prof. Gerhard Franz	Herbal Medicine Committee, German Pharmacopoeia University of Regensburg, German	Internationalisation of Traditional Chinese Medicine: A Global Challenge
Dr. Tan Jieqiong	Central South University, China	ATP13A2 Regulates HDAC6 Activity to Control Autophagosome-Lysosome Fusion
勞力行教授	香港大學中醫藥學院	香港中醫專科發展進展報告
羅翌醫師	香港大學中醫藥學院	國家治療流感指引
陳虹醫生	衛生署衛生防護中心感染控制處	社區中醫門診的流感應變措施及感染防控措施
朱偉星醫生	家庭醫學專科醫生	西醫門診流感應變措施及治療經驗分享
張保亭教授	香港中文大學中醫學院	中醫治療流感的科研實證總論
梁挺雄教授	香港中文大學中醫學院	香港中醫專科發展論壇暨中醫防治流感論壇總結
Dr. Li Jin	HitGen Limited, China	DNA Encoded Library Technology & Applications in Drug Discovery
Dr. Abigail Sloan Devlin	Harvard Medical School, United States	Bioactive small molecules metabolized by human gut bacteria
Prof. Cai Zongwei	Department of Chemistry, Hong Kong Baptist University, Hong Kong	LC-MS-based metabolomics revealed correlations between rheumatoid arthritis and gut microbiota

ACADEMIC ACTIVITIES
GUEST SPEAKERS

Name	Affiliation	Topic
AY2017 - 2018		
Prof. Yu Jun	The Chinese University of Hong Kong, Hong Kong	Gut microbial dysbiosis and colon carcinogenesis: basic and translational
Dr. Hani Said El-nezami	The University of Hong Kong, Hong Kong	Liver cancer a potential target for gut derived probiotic intervention
Dr. Quan Jingjing	Griffith University, Australia	Molecular Mechanisms of Bone Invasion by Oral Squamous Cell Carcinoma
Prof. Josef Jampilek	Comenius University in Bratislava, Slovakia	Design and Antimicrobial Activity of Ring-Substituted Hydroxynaphthalenecarboxamides and their Aza-Analogues
曹洪欣教授	中國中醫科學院	中醫對突發傳染性疾病的作用
劉平教授	上海中醫藥大學 上海市教育委員會上海高校中醫內科學E-研究院	臨床病證病機相應不同功效方劑干預肝硬化的效應機制
Prof. So Kwok-fai	The University of Hong Kong, Hong Kong Jinan Univesity, China	Neuroprotective Effect of Wolfberry on the Retina
王國強教授	國家衛生和計劃生育委員會 國家中醫藥管理局	新實施的中國首部中醫藥法對中醫藥發展的影響

Name	Affiliation	Topic
AY2016 - 2017		
王一濤教授	澳門大學中華醫藥研究院	中藥質量研究的探索與思考
王小瑩教授	天津中醫藥大學中藥學院	基礎–臨床相結合的中藥複方現代研究
王崢濤教授	上海中醫藥大學中藥研究所	中藥科學標準研究制定的策略與實踐
李萍教授	中國藥科大學	等效成分群導向的中藥質量標準體系構建及應用
林文雄教授	福建農林大學	連作影響藥用植物產量與品質的機理及其調控技術
林志秀教授	香港中文大學中醫學院	以毒攻毒？有毒中藥鴉膽子中的抗胰腺癌活性成份
果德安教授	中國科學院上海藥物研究所	中藥質量標準研究科學問題與技術關鍵
唐于平教授	陝西中醫藥大學藥學院	基於選擇性敲除策略的中藥效應物質辨識技術及在質量評價中的應用
徐宏喜教授	上海中醫藥大學中藥學院	中藥品質及療效研究與思考
屠鵬飛教授	北京大學	基於活性成分中藥質量控制新技術及其應用
張藝博士	成都中醫藥大學民俗醫藥學院	整合核磁共振代謝組學和生物信息學的藏藥質量控制
陳道峰教授	復旦大學	清熱解毒中藥的藥效物質與質量控制
程永現教授	深圳大學醫學部藥學院	中藥“偏性物質”相對論與個性化質量標準的呼喚
楊秀偉教授	北京大學藥學院	以紅參為載體的基於體內過程的有效成分和有效效應物質的發現策略及質量標準制定
詹華強教授	香港科技大學中藥研發中心	開心散的組方藥對優化—化學質控及抗抑鬱作用機理
齊煉文教授	中國藥科大學	參皂苷結構解析和調節糖脂代謝的機制研究
劉中秋教授	廣州中醫藥大學中藥學院	中藥活性成分肝腸處置的分子調控機制
劉碧珊教授	香港中文大學中醫中藥研究所	從分辨白花蛇舌草和水線草的啟示—新發現化學標記的抗癌潛力
Dr. Wang Jigang	National University of Singapore, Singapore	Studies of Drug Mechanism and Autophagy Using Chemical Proteomics Approaches
Prof. Jiang Xuejun	Medical School, Cornell University, United States	Autophagy, the Mechanisms and Role in Cancer

Name	Affiliation	Topic
AY2016 - 2017		
李佳博士	遼寧中醫藥大學	基于 TGF-beta 信號通路對中醫腎與關節軟骨系統聯系機制的探究
王擁軍教授	上海中醫藥大學附屬龍華醫院	上海市女性膝骨關節炎現況調查與證型分析
朱洪民博士	香港中醫學會	肩袖損傷
吳夏勃教授	中國中醫科學院望京醫院	點穴療法治療小兒痙攣性腦癱技術要領
李西海教授	福建中醫藥大學	Electro-acupuncture serum inhibits TNF-α-mediated inflammation of chondrocyte by the Ras-Raf-MEK1/2-ERK1/2 signaling pathway
俞劍虹醫師	中山大學附屬第八醫院	腰椎滑脫治療手法的力學分析
范筱醫師	福建中醫藥大學	活血通督湯對脊髓損傷後BDNF/TrkB 信號表達的影響
孫銀娣醫師	陝西省西安市紅會醫院中醫骨科康復診療中心	“頸八針”在頸背部軟組織疼痛中的應用研究
孫衛東醫師	中國中醫科學院望京醫院	中西結合治療拇外翻截骨端穩定愈合的原理
桑志成教授	中國中醫科學院望京醫院	中醫藥治療骨科常見病點滴體會
徐浩博士	上海中醫藥大學附屬龍華醫院	The Synovial Lymphatic System Plays a Critical Role in the Pathogenesis of Osteoarthritis
張立教授	北京大學第三院	頸椎椎板成形術的發展曆程
張鄭瑤博士	大連理工大學	The Research Progress of Velvet Antler extractive in Treatments of Bone Diseases
梁倩倩醫師	上海中醫藥大學附屬龍華醫院	蠲痹湯調控淋巴系統治療炎症性關節炎的基礎研究
陳仲強教授	北京大學國際醫院	脊柱截骨技術在脊柱外科的臨床應用與實踐
黃傑醫師	香港中醫藥管理委員會	從《內經》三陽脈衰淺析骨關節炎
楊卓明醫師	香港中醫骨傷學會	人老腿先衰之腰盆膝關系分析
楊金生教授	國家中醫藥管理局對臺港澳中醫藥交流合作中心、中國針灸學會	針灸治療肩周疼痛的指南與運動康復
楊偉毅教授	廣東省中醫院	UKA 手術適應症及術式選擇的關鍵點暨膝骨關節病的精准治療
溫建民教授	中國中醫科學院望京醫院	基于“陷者升其位”蹠痛症的診療方案臨床研究
鄧洋洋教授	遼寧中醫藥大學	基于 Hedgehog 信號通路探討“腎虛血瘀”骨代謝失常的分子機制
鄭秋堅教授	廣東省人民醫院	PRP 在骨科的應用
盧致鵬教授	澳門新華中醫內科協會	桂枝芍藥湯加減方治療類風濕關節炎 60 例臨床觀察與聚類分析論述
謝慶祥醫師	廣東省東莞中醫院	足副舟骨的診斷和治療
韓燕鴻醫師	廣東省中醫院	慢性踝關節不穩定的中西醫治療
羅素蘭醫師	北京羅有明骨傷醫院	羅氏正筋八法
譚官峰教授	深圳市寶安中醫院	傳統手法閉合複位+小夾板固定治療上肢骨折
蘇同生博士	陝西省中醫醫院	熱敏灸技術治療慢性膝骨關節病方法研究
Prof. Mo Huanbiao	Byrdine F. Lewis School of Nursing and Health Professions, Georgia State University, United States	Tocotrienol and the Mevalonate Pathway in Adipogenesis
程京院士	中國工程院、清華大學醫學院生物醫學工程系及醫學系統生物學研究中心	中西醫並重的疾病測調診治
唐農教授	廣西中醫藥大學	談談人體內陽外陰的本體結構對扶陽學派核心思想的直接解讀
Prof. Michael Rychlik	Technical University of Munich, Germany	Using Stable Isotopes in Quantitation and Assessing Activity of Trace Compounds in Foods

ACADEMIC ACTIVITIES
GUEST SPEAKERS

Name	Affiliation	Topic
AY2016 - 2017		
Dr. Chow H. Lee	University of Northern British Columbia, Canada	Exploring Mushrooms Native to British Columbia for Medicinal Properties
姚新生教授	暨南大學	關於中藥複方製劑現代化及國際化的思考
Dr. Josef Jampilek	Comenius University in Bratislava, Slovakia	Strategies Focused on Overcoming Bacterial Resistance
Dr. Robert Bryson-Richardson	Monash University, Australia	Disease mechanisms and therapies for aggregate myopathies
Dr. Jiang Feng	HKBU (Haimen) Institute of Science and Technology (IST), China	Synthesis and biological evaluation of novel oligopeptide (AspSerSer)6-HSD-016 conjugate as 11β-HSD1 inhibitor for treatment of obesity
胡新天教授	中國科學院昆明動物研究所	慢性應激與抑鬱症關係-基於獼猴的研究
Dr. Peng Shaoliang	National University of Defense Technology, China	Biomedical Big Data Science on Tianhe Supercomputers
張其成教授	北京中醫藥大學國學院	中醫文化的魅力

RESEARCH FACILITIES

Cellular & Molecular Biology Lab

The lab provides techniques, equipment and protocols to investigate musculoskeletal disorders at cellular and molecular levels.

The laboratory can realize recognizing, analyzing and manipulating cells as well as biomolecular with efficiency, sensitiveness and high throughput. So far, the lab has established the following techniques:

Cell Techniques

It includes cell separation, cell culture, cell fusion, cell activity analysis, cell immunophenotyping analysis, cell circle analysis and so on.

Nucleic Acid Techniques

It includes DNA / RNA extraction, gene splicing, gene transduction, gene transfection, gene clone, gene expression, nucleic acid aptamer screening and so on.

Protein Macromolecular Techniques

It includes protein extraction, protein purification, protein separation, protein quantitative / qualitative analysis, protein-protein interaction analysis, nucleic acid aptamer-protein analysis interaction and so on.

Histopathology & Bio-imaging Lab

The lab provides techniques, equipment and protocols for bio-imaging and non-destructive 3-D imaging evaluation as well as histopathological examination and histomorphometric analysis for musculoskeletal research and for developing innovative drugs in bone and joint diseases. So far, the lab has established the following techniques.









Biophotonic-based Fluorescence Imaging Techniques

Lumina XR Series III could sensitively image bioluminescent / fluorescent reporters and differentially evaluate their distribution in various organs within the same animal. It is employed to examine drug delivery by in vivo bio-imaging analysis.

Histopathological Examination & Histomorphometric Analysis & Gene Expression Analysis in Specific Cells

Non-decalcified histological processing for bone tissue and static / dynamic bone histomorphometric analysis could be performed in the lab. Techniques of wide special stains for bone and cartilage, such as the VonKossa, tartrate-resistant acid phosphatase (TRAP), alkaline phosphatase, Gömöritrichrome, safranin O and toluidine blue stains are provided in the lab. Further, laser-captured micro-dissection in combination with Q-PCR analysis for gene expression in specific cells is also established in the lab.

RESEARCH FACILITIES

Synthesis & Pharmaceutics & Chemical Analysis Lab

The lab focuses on improving human health by safely and effectively translating new drug into clinical trials using synthetic technology, targeted nano-pharmaceutical technology and quality analysis.



Drug Synthesis

Synthesizing conjugates of certain nucleic acid aptamers (possessing high specificity and affinity to specificity cell type) and natural products to develop smart drug molecules with both cell-selectivity and intracellular bioactivity for achieving efficacy and safety.

Drug Delivery

Linking certain nucleic acid aptamers (possessing high specificity and affinity to specificity cell type) with lipid- / polymer-based cargo system to develop targeted delivery system for translating the molecular understandings toward RNA interference-based therapeutics in bone and joint diseases.

Drug Analysis

Providing expert analysis in all facets of pharmaceutical analysis (including stability, related substances, impurities and active assays, etc.) to establish specification for active pharmaceutic ingredient (API) and formulation according to the instructions provided by FDA or CFDA.

Bioinformatics & Drug Design Lab

The lab provides an integrated bioinformatics analysis and drug design platform focusing on the following five aspects: constructing an comprehensive and large biomedical data warehouse; data mining techniques for extraction of useful results from large amounts of biological data; undertaking assay of omics, including proteomics and metabolomics; dealing with methods for storing, retrieving and analyzing biological data, such as nucleic acid and protein sequences, structures, functions, pathways and genetic interactions; computer-aided drug design (CADD) technology from the availability of bioinformatics applications.



Biomedical Database

We construct biomedical data warehouse by collecting and integrating databases of different biomedical domains. By now, these biomedical databases including SinoMed, PubMed, OMIM, GO, NCI pathway interaction database, MeSH, PubChem, TCMDB, PDB, ChEMBL, PharmaGKB, TTD, DrugBank, UniProt, UMLS and KEGG.



Data Mining

Based on the biomedical database, typical text mining tasks include text categorization, text clustering, concept / entity extraction, sentiment analysis and document summarization are performed to derive high-quality information from these texts.

Assay of Proteomics & Metabolomics

The lab provides a comprehensive analysis platform for protein and metabolite. Two widely used and powerful methods, including Gas chromatography (GC) and High performance liquid chromatography (HPLC) are used for separation in the lab. Furthermore, Mass spectrometry (MS) is applied to identify and to quantify metabolites after separation by GC, HPLC. Also several statistical programs are available for analysis of MS data.

RESEARCH FACILITIES

Bioinformatics & Drug Design Lab

Bioinformatics Analysis

By applying computationally intensive techniques, we develop new algorithms and statistics with which to assess relationships among members of large data sets, to increase the understanding of biological processes. Also commercial software, such as ingenuity pathway analysis (IPA) is often used for casual network analysis, comparison analysis, upstream regulator analysis, mechanistic networks and pathway analysis.

Computer-Aided Drug Design

With understanding the structure of small molecules, proteins and nucleic acids, we apply computer-aided drug design (CADD) technology to discover or design active compounds to cure the diseases. To further understand the mechanism of effects of drug / drug combination on biological network, we also develop structure- based technology to identify targets of compounds from drug / drug combination.



Experimental Animal Center (EAC)

The centre is located at the ground floor of Jockey Club School of Chinese Medicine Building. EAC is committed to ensuring the humane care and use of all animals associated with its research and teaching programs. EAC currently equips 6 laboratory animal breeding rooms that offer independent air condition system with high efficiency air filter and full air exchange rate, and that are in compliance with the international standards and regulations for breeding environment and laboratory room of murine. EAC provides services and resources needed by investigators to accomplish the animal research of bone-related disease and assist in providing training in laboratory animal care and use to technical personnel, students and faculty.

INDUSTRIALIZATION AND ENTREPRENEURSHIP



Aptacure Therapeutics Limited

Supported by the Incubation Programme of Hong Kong Science Park, Aptacure Therapeutics Limited is a biotechnology company aiming to develop innovative aptamer drugs to meet unmet medical need (https://www.aptacure.com). Funded by the HKSAR Government's Innovation and Technology Commission (UIM/298 and UIM/328), the core technologies and products of the Aptacure are originated from a synergetic research platform named "Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery (HKAP)" https://www.hkaptamer.com/.

The Aptacure was successfully selected on the list of the 2020 Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area and won the Potential Enterprise Award. Currently, the Aptacure is cooperating with the members of HKAP including Prof. Lyu Aiping and Prof. Zhang Ge by focusing on developing core technologies, including the technologies for aptamer drug discovery, the long-lasting modification technologies of aptamers, and the high-affinity modification technologies of aptamers to their targets. At present, Aptacure is cooperating with the members of HKAP by focusing on developing three innovative aptamer drugs, including aptamer drug targeting sclerostin (Apc001), aptamer drug targeting DKK-1 (Apc002), and aptamer drug targeting CTGF (Apc003). Apc001 was granted Orphan Drug Designation (FDA number: DRU-2019-6966, DRU-2022-9087), and Rare Pediatric Disease Designation (FDA number: RPD-2022-667) from US FDA for the treatment of osteogenesis imperfecta.

Rare Pediatric Disease Designation from FDA (RPD-2022-667)

U.S. FOOD & DRUG ADMINISTRATION

Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Bioinformedicine Service
15711 Spieckels Place
San Diego, CA 92127-6112

Re: Designation request # RPD-2022-667
Dated: August 21, 2022
Received: August 22, 2022

This letter responds to your request on behalf of Aptacure Therapeutics Limited for rare pediatric disease designation of sclerostin inhibitor Apc001OA DNA, (Cm-Om-Om-Om-G-T-G-T-G-G-G-T-T-C -G-T-C-G-T-T-A-G-C -TT-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm(T—>3'-dT), 5'-ester with (2S)-2-(tert-butoxycarbonyl)-1-((hydroxyphosphoryl)oxy)-8,17,26,31-tetraoxo-10,13,19,22-tetrasoa7,16,25,30-tetraazooctatetracontan-48-oic acid) for "treatment of Osteogenesis Imperfecta (OI)."

We hereby grant your request and designate sclerostin inhibitor (DNA, (Cm-Gm-Om-Gm-G-T-G-T-G-G-G-T-T-C -G-T-C-G-T-T-A-G-C -TT-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm(T—>3'-dT), 5'-ester with (2S)-2-(tert-butoxycarbonyl)-1-((hydroxyphosphoryl)oxy)-8,17,26,31-tetraoxo-10,13,19,22-tetrasoa7,16,25,30-tetraazooctatetracontan-48-oic acid) for *treatment of osteogenesis imperfecta (OI)* as a drug for a "rare pediatric disease," as defined in section 528(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360ff(a)(1)). We determined that OI meets the definition of a rare pediatric disease based on the information you submitted.

Based on information you provided, there is sufficient information to demonstrate that susceptibility to fractures of the long bones and vertebral compressions, variable deformity of long bones, ribs and spine, substantial growth deficiency, and an increased mortality risk are serious or life-threatening manifestations of OI that primarily affect children. OI also meets the definition of "rare disease or condition" at section 526 of the FD&C Act. Therefore, your drug is eligible for rare pediatric disease designation for treatment of OI.



Aptacure Therapeutics Limited 3

...is submitted on or after October 7, 2012 and approved after September 30, 2016.

The final answer to whether your marketing application qualifies as a "rare pediatric disease product application" as defined by statute will come in the form of an award or non award of a rare pediatric disease priority review voucher at the time of marketing approval, should you request such a voucher in your marketing application.

If you are interested in receiving such a voucher, you must include a voucher request in your original marketing application to FDA for the rare pediatric disease product. This voucher request should include a copy of this designation letter to show that your drug is for a "rare pediatric disease" and explain how your application meets the remaining eligibility criteria in section 529(a)(4) of the FD&C Act (21 U.S.C. 360ff(a)(4)). Please notify us (1) when you submit a marketing application that includes a voucher request, and (2) if, upon approval of your marketing application, you receive a voucher. Please also provide a copy of any voucher transfer notification that you provide to the appropriate FDA review division. We encourage early communication with the relevant review division as to your interest in receiving a priority review voucher to allow discussion of the issues.

Please notify us whenever there is a change in the contact information provided in your designation request, or there is a change in ownership of the designated product. Cite the designation request number in all your correspondence.

Should you have any questions specifically about the disease being a "serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years," please contact Cindy Twomi, PhD, MPH, OPT at 301-796-8224.

Should you have any other questions about this rare pediatric disease designation, please contact Catherine Park, OOPD at 240-402-4296 or alternatively at 301-796-8660.

Congratulations on obtaining your rare pediatric disease designation.

Sincerely yours,

Donna J. [illegible]
Green -S

Doreen Green, M.D., F.C.P.
Director
Office of Pediatric Therapeutics

Sandra [illegible]
Retzky -S

Sandra S. Retzky, D.O., J.D., M.P.H.

Orphan Drug Designation from FDA (DRU-2019-6966)

U.S. FOOD & DRUG ADMINISTRATION

Office of Orphan Products Development
Food and Drug Administration
WO32-3295
10903 New Hampshire Avenue
Silver Spring, MD 20993

Bioinformedicine Service
15711 Spieckels Place
San Diego, CA 92127

Re: Designation request #ORU-2019-6966
Dated: May 28, 2019
Received: May 28, 2019

This letter responds to your request submitted on behalf of Eagle Biotechnology Limited for orphan-drug designation of DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm(T—>3'-dT), 5'-ester with [[5-(phosphonooxy) pentyl] amino] carbonyl)-oxy)-1, 2-ethanediyl, sodium salt for "treatment of osteogenesis imperfecta."

Pursuant to section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb), your orphan-drug designation request of DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm(T—>3'-dT), 5'-ester with [[5-(phosphonooxy) pentyl] amino] carbonyl)-oxy)-1, 2-ethanediyl, sodium salt is granted for *treatment of osteogenesis imperfecta*. Please be advised that it is the active moiety or principal molecular structural features of the drug[1] and not the formulation of the drug that is designated.

If your drug receives marketing approval for an indication broader than what is designated, it may not be entitled to exclusive marketing rights under section 527 (21 U.S.C. 360cc). Therefore, prior to submission of your marketing application, we request that you compare the drug's orphan designation with the proposed marketing indication and submit additional information to amend the orphan-drug designation if warranted. 21 CFR 316.20.

[1] The term "drug" in this letter includes drug and biological products.



Eagle Biotechnology Limited 2

If the same drug is approved for the same indication before you obtain marketing approval of your drug, you will have to demonstrate that your drug is clinically superior to the already approved same drug in order to obtain orphan-drug exclusivity. Failure to demonstrate clinical superiority over the already approved same drug will result in your drug not receiving orphan-drug exclusivity. 21 CFR 316.34(a).

You must submit to the Office of Orphan Products Development a brief progress report of drug development within 14 months after this date and annually thereafter until marketing approval. 21 CFR 316.30.

Please notify this Office within 30 days of submitting a marketing application for the drug's designated use. Once your marketing application is approved, please contact Ms. Norris Asare at 301-796-7329 or alternatively at 301-796-8660 to assess eligibility for orphan-drug exclusivity.

If you have questions regarding the development of your designated product, please feel free to contact Erica K. McNeilly, RPh at 301-796-8679 or alternatively at 301-796-8660. Congratulations on obtaining your orphan-drug designation.

Sincerely,

[signature]

Janet W. Maynard, M.D., M.H.S
Director
Office of Orphan Products Development

Human Metabolomics Institute, Inc.



Human Metabolomics Institute, Inc. (HMI) is a biomedical enterprise founded by Prof. Jia Wei, a world-leading expert in translational metabolomics research. HMI is dedicated to developing and providing innovative mass spectrometry-based molecular diagnostic solutions for precision medicine and personalized health management. The company, with offices and laboratories located in Shenzhen and Shanghai, has extensive knowledge and expertise in the development of proprietary and integrated technologies of in-vitro diagnostics, targeted metabolic phenotyping, human metabolic database, machine learning and artificial intelligence to advance the early and accurate detection of human disease phenotypes. HMI has a strong executive leadership team specializing in the cutting-edge translational metabolomics research as well as business operation and management. The company is aimed to become the global leader in clinical metabolomics to transform how diseases are predicted, prevented and managed.

HMI: https://hmibiotech.com/sc/

Our research group



Our Services

Customers & Published Papers

Cell Metabolism, 2020,31,1-15 (**IF=22.41**)
Immunity, 2019, 50,1-16 (**IF=19.73**)
Gut, 2019, doi:10.1136/gutjnl-2018-317609 (**IF=17.02**)
Advanced Acience, 2020, doi.org/10.1002/advs.202000681 (**IF=15.84**)
Hepatology, 2020, doi:10.1002/hep.31280 (**IF=14.97**)
Signal Transduction and Targeted Therapy, 2020,5:177-90 (**IF=13.49**)
Microbiome, 2020, 8:74 (**IF=11.61**)
Microbiome, 2020, 8: 133 (**IF=11.61**)
The EMBO Journal,2020,39:e103304 (IF=**9.89**)
Cell Mol Gastroenter, 2020, dio.org/10.1016/j.jcmgh.2020.10.006 (**IF=9.8**)
Arthritis Rheumatol, 2020, doi:10.1002/art.41419 (**IF=9.59**)
Theranostics ,2019; 9(3):900-919 (**IF=8.71**)
Theranostics 2019; 9(10): 2999-3013 (**IF=8.71**)
Clin Gastroenterol Hepatol, 2020, doi:10.1016/j.cgh.2020.06.067 (**IF=8.55**)

INDUSTRIALIZATION AND ENTREPRENEURSHIP

HK Authentication Centre of Valuable Chinese Medicines

With solely licensed patent technologies by HKBU, as well as a financial support from HKSAR government via Technology Start-up Support Scheme for Universities, Hong Kong Authentication Centre of Valuable Chinese Medicines Limited (HKACVCM) was launched and founded by Prof. Han Quanbin Simon as the HKBU spin-off high-tech start-up company with mission to end up the market mess and to facilitate the upgrading of industry with support of innovative technologies, which are with significant advantages over conventional methods in terms of cost and efficiency. HKACVCM newly graduated from a 4-year Incu-Bio program operated by Hong Kong Science and Technology Park.

By offering a new business model which enables HKACVCM as a third-party quality control platform to build the confidence of consumers on the tested products, HKACVCM has a growing client network including government departments, whole sellers and retailers, with an extending service spectrum from authentication of valuable Chinese medicines (based on 20+ patents) to routine safety tests and tailor-made manufacturing protocol modification.

In the future, HKACVCM will continue to research in the authentication of valuable Chinese medicine and provide more, better services to the industry.

HKACVCM: http://www.hkacdoc.com/

業務範圍與現有客戶 Business & Clients

HKBU獨家授權專利新技術提供第三方認證服務

Third-party authentication service using HKBU solely licensed patent technologies

鐵皮石斛、冬蟲夏草、燕窩、東阿阿膠…

使用HOKLAS认证实验设施，完成中藥材顯微鑒定與安全性檢測服務 MI & Safety test using HOKLAS Lab

包括近500種藥材的性狀纖維鑒別、農殘、二氧化硫、重金屬以及黃麴黴毒素的檢測

中藥品質控制評價與產品開發服務

Tailor made QC service

根據客戶需求量身定制產品品質評價方案與實驗研究。

Dendrobium Skincare Products of S&L

Silver Medal in the "Geneva International Exhibition of Inventions"


DIPLÔME

Inventions Geneva

SALON INTERNATIONAL DES INVENTIONS

GENÈVE

Après examen, le Jury a décidé

de remettre à: Professor ZHANG Hongjie

pour l'invention: Skin Whitening, Anti-aging and Skin Care Product

MÉDAILLE D'ARGENT SILVER MEDAL SILBERMEDAILLE

Genève, le 28 mars 2022

Le Président du Jury: David Tyl

Le Président du Salon: Jean-Luc Vincent

Excellence Award in High-value Patent Portfolio Layout Competition

Gihon Biotech Limited

Gihon Biotech

Gihon Biotech Limited, established in 2016, is a green biopharmaceutical company founded by Prof. Zhang Hongjie and launched to develop skin and health care products enriched in natural ingredients. With advanced health-aging biotechnology, Gihon aims to provide high quality products for improving the life quality of humans.

Gihon has a professional R&D team comprising with experts from HKBU including Professors, post-doctoral fellows and PhD students. Our experienced R&D consultants have been working in the fields of plant medicine and natural products for more than 25 years. Our specialty ingredients are specialized in the formulation of products for skin protection and skin whitening whilst they are also applicable to the preparation of antiaging, antimicrobial and anti-inflammatory supplements.

Gihon is located at the Hong Kong Science Park, and is a company graduated from Incu-Bio Program, HKSTP. As a green start-up company, Gihon Biotech had been granted the TSSSU funding for three consecutive years since 2017 and the TSSSU plus funding in 2023.

Gihon has discovered a specific class of natural compounds in the *Dendrobium* plants used in Chinese herbal medicine. According to our studies, the compounds can achieve skin whitening and protection as well as anti-ageing effects by inhibiting the formation of melanin and eliminating harmful free radicals and reactive oxygen species. The related patents have been granted in the US, China, Taiwan, Japan, Singapore and Malaysia.

Based on the investigations, we have launched a series of skincare products with the brand name "Shine & Laud".

Contact Information:
Email: info@gihonbiotech.com
Website: gihonbiotech.com / hksnl.com
Address: M03, Unit 527, 5/F, Biotech Centre 2, No.11 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong
Tel. no.: (852) 3687 4422



INDUSTRIALIZATION AND ENTREPRENEURSHIP

EC Bot Limited

EC Bot, founded by Dr. Zhang Shiping, is revolutionizing the Chinese medicine tele-healthcare industry with its cutting-edge technological solutions for e-health promotion, tele-consultation and health product delivery. Its core technologies stem from innovations in smartphone tongue imaging and smart health instruments. It aims to develop its patented smartphone tongue imaging technologies into a medical device for tele-health and tele-medicine applications. In one of its application scenarios, EC Bot provides automatic health assessment and personalized remedial soup recommendations. Currently, the company is working with the local community and health food industry to promote individualized dieting and other healthy lifestyle practices.

EC Bot: https://www.ecbot5a.com/
Smart TCM Remedial Food Therapy Platform: https://www.ecfoodie.com
Tongue Diagnosis: https://www.i-heals.com/



OUR RESEARCH
AY2016-AY2021

AWARDS

FACULTY STAFF AWARDS

Awarded Staff	Title	Title of the Award / Honours	Events / Awarding Organisations	Location
2020-2021				
Han Quanbin	Associate Professor	Gold Medal "Quality control markers for use in herbs authentication"	2021 Geneva International Exhibition of Inventions	Switzerland
Zhong Lidan	Assistant Professor	Qi Huang Young Scholar	The State Administration of Traditional Chinese Medicine	China
Lyu Aiping	Dean & Chair Professor	First prize	The 2020 National Award for Outstanding Contribution to Innovation in Standardisation by the State Administration for Market Regulation	China

Awarded Staff	Title	Title of the Award / Honours	Events / Awarding Organisations	Location
2019-2020				
Han Quanbin and his research team	Associate Professor	Excellence Award (the third prize)	The 2nd Guangdong-Hong Kong-Macao Greater Bay Area (GBA) High-Value Patent Portfolio Contest 2020	China
Han Quanbin and his research team	Associate Professor	Top 50 Patents	The 2nd Guangdong-Hong Kong-Macao Greater Bay Area (GBA) High-Value Patent Portfolio Contest 2020	China
Zhao Zhongzhen and his research team	Chair Professor	Second Prize of the International Award for Contribution to Chinese Medicine – Achievement Award in Medical Science	The World Federation of Chinese Medicine Societies	China
Yu Zhiling and his research team	Professor	Best Research Articles in the Journal in 2018/2019 "A TCM formula comprising Sophorae Flos and Lonicerae Japonicae Flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment"	Pharmacological Research	--
Tong Chun Kit, Benjamin	Research Assistant Professor	Best Poster Award	The 9th International Symposium on Autophagy	Taiwan
Liu Jin	Research Assistant Professor	2019 ASBMR Young Investigator Award "Unraveling the mystery behind bone-cartilage crosstalk: Osteoclast derived exosomal microRNAs deprive the resistance of cartilage to matrix degeneration, angiogenesis and innervation in osteoarthritis"	American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting	United States of America

Awarded Staff	Title	Title of the Award / Honours	Events / Awarding Organisations	Location
2018-2019				
Iyaswamy Ashok	Postdoctoral Research Fellow	Young Investigator Award – 2nd Runner Up "Theranostic Cyanine F-SLOH Attenuates Amyloid-β and Tau Pathology in Experimental Alzheimer Disease Models"	The International Alzheimer's Disease Conference 2019	Hong Kong
Tong Chun Kit, Benjamin	Research Assistant Professor	Young Investigator Award	The 14th International Symposium on Healthy Aging	Hong Kong
Bian Zhaoxiang and his research team	Chair Professor	2nd prize in the International Award for Contribution to Chinese Medicine — Achievement Award in Medical Science "Study on Key Problems of Chinese Herbal Formula MaZiRenWan (MZRW) for Functional Constipation"	The World Federation of Chinese Medicine Societies	China
Zhang Hongjie and his research team	Professor	Silver Asia International Innovation Invention Award "Innovative use of the Chinese medicine "Dendrobium" in skin-protecting agents"	The Hong Kong Federation of Innovative Technologies and Manufacturing Industries	Hong Kong
Zhang Hongjie and his research team	Professor	Bronze medal "Skin whitening, anti-aging and skin care agent"	The First Asia Exhibition of Inventions Hong Kong	Hong Kong
Han Quanbin and his research team	Associate Professor	Gold medal "Quality control markers for use in herb authentication"	The First Asia Exhibition of Inventions Hong Kong	Hong Kong
Yu Zhiling	Professor	科學技術獎二等獎 "201802-12ZY-23 中藥五味子飲片生產質量關鍵技術體系構建及推廣應用"	中華中醫藥學會	China
Wu Xiaohao	Senior Research Assistant	Webster Jee Travel Award "A novel Cathepsin K inhibitor specifically approaching bone resorption surfaces to suppress osteoclastic bone resorption"	The 9th International Conference on Osteoporosis and Bone Research (ICOBR2018)	China
Liang Chao	Research Assistant Professor	Best Paper Award "HIF1α inhibition facilitates Leflunomide suppressing CRP to attenuate progressive bone erosion in distinctive rheumatoid arthritis"	The 9th International Conference on Osteoporosis and Bone Research (ICOBR2018)	China
Wu Xiaohao	Senior Research Assistant	Young Investigator Travel Grant Award "A novel Cathepsin K inhibitor specifically approaching bone resorption surfaces to suppress osteoclastic bone resorption"	American Society of Bone and Mineral Research (ASBMR) 2018 Annual Meeting	Canada

FACULTY STAFF AWARDS

Awarded Staff	Title	Title of the Award / Honours	Events / Awarding Organisations	Location
2017-2018				
Lyu Aiping	Dean & Chair Professor	Chief Executive's Commendation for Community Service	Government of the Hong Kong Special Administrative Region	Hong Kong
Zhao Zhongzhen	Chair Professor	Honorary Curator of Li Shenzhen Commemorative Museum	China Association of Chinese Medicine	China
Zhang Ge Liang Chao	Professor Research Assistant Professor	First Prize of the Beijing Science and Technology Award 2017 "Mechanism of post-translational modification in protein homeostasis control"	The People's Government of Beijing Municipality	China
Bian Zhaoxiang	Chair Professor	Gold Medal with Congratulations of Jury "Treatment for Irritable Bowel Syndrome (IBS) Diseases"	The 46th International Exhibition of Inventions of Geneva	Switzerland
Wong Hoi Leong Xavier	Research Assistant Professor	March 2018 Go Everywhere with Bio-Techne Travel Grant	Bio-Techne's Go Everywhere Travel Grant Program	United States of America
Han Quanbin and his research team	Associate Professor	Silver medal of the Hong Kong Innovative Invention Award	Hong Kong Federation of Innovative Technologies and Manufacturing Industries (FITMI)	Hong Kong
Fu Xiuqiong	Postdoctoral Research Fellow	Third Prize of Young Investigator Awards: Best Oral Presentation	The 10th Pong Ding Yuen International Symposium on Traditional Chinese Medicine	China
Yue Kin Man	Associate Professor	Best Chapter Award	Open-access e-Book publication IAmLearning: Mobilizing and Supporting Educator Practice (https://iamlearning.pressbooks.com/)	--
Su Tao	Postdoctoral Research Fellow	Excellent Research Papaer Award	China Association of Chinese Medicine	China
Zhang Xuan	Postdoctoral Research Fellow	Frontrunner 5000-Top Articles in Outstanding S&T Journals of China	Institute of Scientific and Technical Information of China (ISTIC)	China
Lyu Aiping	Dean & Chair Professor	Award for his outstanding accomplishment and contribution to Chinese medicine research	Hong Kong Chinese Medicine Industry Association	Hong Kong
Yang Chuanbin	Postdoctoral Research Fellow	Best Poster Award	The 1st National Congress of Autophagy	China

Awarded Staff	Title	Title of the Award / Honours	Events / Awarding Organisations	Location
2016-2017				
Yang Zhijun and his CRI research team	Associate Professor	Best Ten Project Award for Innovation	Science Committee and Science & Technology Bureau of Changshu City, Jiangsu Province, China	China
Yu Yuanyuan	Postdoctoral Research Fellow	Travel Award "An innovative gain-loss cell-SELEX strategy for development of a nucleic acid aptamer against PD-L1 for immunotherapy of triple negative breast cancer"	The fourth Oxford symposium on aptamers, Aptamers 2017	United Kingdom
Liang Chao	Postdoctoral Research Fellow	2017 Webster Jee Young Investigator Award "From precision medicine to drug discovery: inhibition of osteoblastic Smurf1 promotes bone formation in distinctive individuals with age-related osteoporosis"	2017 International Chinese Musculoskeletal Research Society-Orthopaedic Research Society (ICMRS-ORS) Membership Meeting	United States of America
Xu Xinya	Postdoctoral Research Fellow	Best Poster Award	Hong Kong Scholars Annual Symposium 2017	Hong Kong
Yu Zhiling	Professor	Best Abstract Award	The 2nd Annual Meeting of the Specialty Committee of Chinese Herbal Medicine Decoction Pieces Qualification of the World Federation of Chinese Medicine Societies	China
Zhong Lidan	Postdoctoral Research Fellow	Best Oral Presentation Award	2016 International Society for complementary Medicine Research Symposium	Canada
Liang Chao	Postdoctoral Research Fellow	Best Paper Award "Inhibition of osteoblastic Smurf1 promotes bone formation in distinctive individuals with age-related osteoporosis"	The 8th International Conference on Osteoporosis and Bone Research	China
Wang Luyao	Senior Research Assistant	Webster Jee Travel Award "Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma"	The 8th International Conference on Osteoporosis and Bone Research	China
Wu Xiaohao	Senior Research Assistant	Webster Jee Travel Award "Alterations of Gut Microbiome in Rheuma toid Arthritis"	The 8th International Conference on Osteoporosis and Bone Research	China
Yu Zhiling	Professor	Best Abstract Award	Branch of Chinese Herbal Medicine Processing of the China Association of Chinese Medicine	China

RESEARCH POSTGRADUATE STUDENT AWARDS

Awarded Student	Programme	Title of the Award / Honours	Events / Awarding Organisations	Location
2020-2021				
Lam Chu Shing	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award	The 17th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Wang Xiaoqi	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award	The 17th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Li Sze Man Amy	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award	The 17th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Yang Wei	PhD	基礎研究(含藥學)三等獎	2021年度熱心腸獎學金	China
Chen Yingjie	PhD	Candidate Award	The 12th China (Shenzhen) Innovation & Entrepreneurship Competition	China

Awarded Student	Programme	Title of the Award / Honours	Events / Awarding Organisations	Location
2019-2020				
Tsang Nga Yi	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award	The 16th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Wu Jiaying	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award	The 16th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Zhang Quanwei	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award	The 16th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Tsang Nga Yi (with Ma Xinyue (BPharm) & Tian Xueying (BPharm))	PhD	Second Prize in the category of Life Science Innovation Projects	The 6th Hong Kong University Student Innovation and Entrepreneurship Competition under the "Challenge Cup" National Competition	Hong Kong
Yuen Chun Sum	MPhil	2019-2020 Sir Edward Youde Memorial Fellowship for postgraduate research students	Sir Edward Youde Memorial Fund	Hong Kong
Wang Zhichun (with Yeung Tsz-ching (BCM), Lau Kwan-yi (MCM), Song Zixuan (BCM) & Lee Gong-kuen (Econ))	PhD	First Runner-up Prize	A.I. Future Tense InnoTech Solutions Pitching competition	Hong Kong
Liu Yuxi	PhD	Best Research Article "A two-herb formula alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment"	World Federation of Chinese Medicine Societies	China
Wu Jiaxi	PhD	Best Poster Presentation Award "Altered ER-mitochondria contacts induce mitochondrial calcium overloading and impair mitophagy in AD models"	2019 China Conference on Autophagy	China

Awarded Student	Programme	Title of the Award / Honours	Events / Awarding Organisations	Location
2018-2019				
Tsang Nga Yi Lam Chu Shing	PhD MPhil	Second Prize	Innovation Nanshan 2019 Entrepreneurship Star Contest Hong Kong Final	Hong Kong
Xie Wenjian	PhD (Joint SZU)	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award "Novel miliusanes identified from the antitumor plant Miliusa sinensis"	The 15th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Chou Jiyao	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award "Synergistic anti-melanoma effects of MK-8776 and Atrctylenolide I"	The 15th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Chen Qilei	PhD	Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award "Discovery of anti-arthritic agents from Saussurea laniceps using magnetic ligand fishing with progressive bio-screening"	The 15th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Chen Minting	PhD	Travel Grant "Synergistic Anti-tumor Potency of Artesunate and Wogonin in Hepatocellular Carcinoma"	The Consortium for Globalization of Chinese Medicine	China
Tsang Nga Yi Lam Chu Shing (with Tsoi Hong-kit (BPharm))	PhD MPhil	Second Prize in the category of Entrepreneurship Proposal Projects	The 5th Hong Kong University Student Innovation and Entrepreneurship Competition under the "Challenge Cup" National Competition	Hong Kong
Xie Wenjian	PhD (Joint SZU)	Merit Award in the category of Life Science Innovation Projects	The 5th Hong Kong University Student Innovation and Entrepreneurship Competition under the "Challenge Cup" National Competition	Hong Kong
Dang Lei	PhD	Travel Grant Award	The 39th KCR Annual Scientific Meeting and the 13th International Symposium	Korea
Pan Wenhui Xia Yixuan	PhD PhD	Bronze Award	The China College Students' Entrepreneurship Competition organised by Zhejiang University	China
Sreenivasa Murthy Sravan G S	PhD	Third Place Presentation Award "Chinese medicinal compounds activate transcription factor EB and promote the degradation of α-synuclein in Parkinson's disease models"	2018 Postgraduate Symposium on Chinese Medicinal Sciences	Macau

RESEARCH POSTGRADUATE STUDENT AWARDS

Awarded Student	Programme	Title of the Award / Honours	Events / Awarding Organisations	Location
2017-2018				
Chou Jiyao	PhD	Outstanding Thesis Award	The 14th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Liu Yuxi	PhD	Outstanding Thesis Award	The 14th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Wong Tin Long	PhD	Outstanding Oral Presentation	The 14th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Zhai Lixiang	PhD	Second Prize (Poster Presentation)	The International Symposium for Graduate Students on Pharmaceutical Sciences 2018 cum 1st Guangdong-Hong Kong-Macau Greater Bay Area Biomedical Sciences Forum	China
Pan Wenhui Xia Yixuan (with Ting Shuk-ching (BPharm))	PhD PhD	Second prize in the category of Business Plan Projects "V-skin" which is a WeChat mini programme aimed at spreading Chinese medicine culture and promoting the use of Chinese medicine in skincare	"Challenge Cup" National Competition – Hong Kong Regional Final – Hong Kong University Student Innovation and Entrepreneurship Competitiont	Hong Kong
Li Wanfei Chik Wai I (with Yip Man-hui (BPharm))	PhD PhD	Third prize in the category of Life Science Innovation Projects "Fight Against Athlete's Foot Disease Using Chinese Medicine"	"Challenge Cup" National Competition – Hong Kong Regional Final – Hong Kong University Student Innovation and Entrepreneurship Competition	Hong Kong
Zhu Peili	PhD	Second Prize of Young Investigator Awards: Best Oral Presentation	10th Pong Ding Yuen International Symposium on Traditional Chinese Medicine	Hong Kong
Lu Jun	PhD	First prize	15th "Challenge Cup" National College Students' Extracurricular Academic Science and Technology Works Contest	China
Dang Lei	PhD	Third prize	15th "Challenge Cup" National College Students' Extracurricular Academic Science and Technology Works Contest	China
Lu Jun	PhD	Dragon Culture Traditional Chinese Medicine Scholarships	Dragon Culture Charity Fund	Hong Kong

Awarded Student	Programme	Title of the Award / Honours	Events / Awarding Organisations	Location
2016-2017				
Parcus Robert	MPhil	Outstanding Oral Presentation Award "New Approaches for Tongue Image Collection, Analysis and Applications"	The 13th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Li Ting	PhD	Outstanding Poster Award	The 13th International Postgraduate Symposium on Chinese Medicine	Hong Kong
Parcus Robert (with George Chow, Tim Wong and Declan Kan (BCM))	MPhil	Runner-up prize in the student category "Western and Eastern Health (WE Health)"	AIA Blockchain Challenge	Hong Kong
Lu Jun	PhD	Second prize in the category of innovation in life sciences "Develop a Highly Water Soluble Nucleolin Aptamer Paclitaxel Conjugate with a Cathepsin Labile Linker for Tumor Specific Targeting in Ovarian Cancer"	Hong Kong University Student Innovation and Entrepreneurship Competition under the "Challenge Cup" National Competition	Hong Kong
Dang Lei Shaikh Atik Badshah	PhD PhD	Third prize in the category of innovation in life sciences "Osteoblastic PLEKHO1 contributes to articular inflammation and bone repair failure in rheumatoid arthritis"	Hong Kong University Student Innovation and Entrepreneurship Competition under the "Challenge Cup" National Competition	Hong Kong
Pan Wenhui Xia Yixuan	PhD PhD	Second prize in the category of start-up projects "Avantgarde Formulation of Skin-lightening and Skin-protecting Products with Natural Ingredients"	Hong Kong University Student Innovation and Entrepreneurship Competition under the "Challenge Cup" National Competition	Hong Kong
Lin Congcong	PhD	Dragon Culture Traditional Chinese Medicine Scholarships	Dragon Culture Charity Fund	Hong Kong
Liang Li	PhD	Dragon Culture Traditional Chinese Medicine Scholarships	Dragon Culture Charity Fund	Hong Kong

OUR RESEARCH
AY2016-AY2021

RESEARCH EXPERTISE

ACADEMIC STAFF

Prof LYU Aiping

aipinglu@hkbu.edu.hk

- Dean, School of Chinese Medicine
- Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine
- Director, Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research
- Director, Institute of Integrated Bioinformedicine and Translational Science
- Director, Hong Kong Baptist University Joint Centre for Pain Research

Field of expertise

Chinese Medicine, Clinical Pharmacology and Arthritis and related New Drug Discovery

Prof LI Min

limin@hkbu.edu.hk

- Associate Dean (Teaching and Learning), School of Chinese Medicine
- Professor, Teaching and Research Division
- Director, Mr. and Mrs. Ko Chi Ming Centre for Parkinson's Disease Research
- Director, Bachelor of Chinese Medicine & Bachelor of Science (Hons) in Biomedical Science Programme
- Director, Master of Chinese Medicine Programme

Field of expertise

Chinese Medicine, Pharmacology of Chinese Medicine, Neurodegenerative Diseases and Cardio-cerebrovascular Diseases

Prof ZHANG Ge

zhangge@hkbu.edu.hk

- Associate Dean (Research), School of Chinese Medicine
- Director, Technology Development Division
- Professor, Teaching and Research Division
- Director, Institute for Precision Medicine and Innovative Drug
- Director, Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases
- Director, Master of Science in Drug Discovery (Modernization of Chinese Medicine) Programme

Field of expertise

Basic Science and Clinical Translational Medicine in Orthopedics and Traumatology

Prof JIA Wei

weijia1@hkbu.edu.hk

- Associate Dean (International Collaboration), School of Chinese Medicine
- Cheung On Tak Endowed Professor in Chinese Medicine
- Chair Professor, Teaching and Research Division
- Director, Hong Kong Traditional Chinese Medicine Phenome Research Centre

Field of expertise

Metabolomics, Microbiome, Bioinformatics and Molecular Biology

Prof BIAN Zhaoxiang

bzxiang@hkbu.edu.hk



- Associate Vice-President (Chinese Medicine Development), HKBU
- Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies
- Director and Chair Professor, Clinical Division
- Director, Hong Kong Chinese Medicine Clinical Study Centre
- Associate Director, Institute of Creativity
- Director, Master of Science in Personal Health Management (Chinese Medicine) Programme

Field of expertise

Basic and Clinical Research of Gastrointestinal Disease with Chinese Medicine

Prof ZHANG Hongjie

zhanghj@hkbu.edu.hk

- Director and Professor, Teaching and Research Division

Field of expertise

Phytochemistry and Drug Discovery from Natural Resources

Prof ZHAO Zhongzhen

zzzhao@hkbu.edu.hk

- Professor Emeritus, Teaching and Research Division
- Director, Research Centre for Standardisation of Chinese Medicines (2014 – Aug 2022)

Field of expertise

Medicinal Plant, Chinese Materia Medica, Chinese Medicinal Formulae, History of Chinese Medicine and Authentication of Chinese Materia Medica

Prof CHEN Hubiao

hbchen@hkbu.edu.hk

- Professor, Teaching and Research Division
- Director, Research Centre for Standardisation of Chinese Medicines
- Director, Bachelor of Pharmacy (Hons) in Chinese Medicine Programme

Field of expertise

Medicinal Botany and Resource Science of Chinese Medicinal Materials

Prof HAN Quanbin, Simon

simonhan@hkbu.edu.hk

- Associate Director (Research), Research Centre for Standardisation of Chinese Medicines
- Professor, Teaching and Research Division

Field of expertise

Natural Product Chemistry, Chemical Analysis of Herbal Medicines and Natural Polysaccharides

Prof YANG Zhijun

yzhijun@hkbu.edu.hk

- Professor, Teaching and Research Division
- Associate Director, Master of Science in Personal Health Management (Chinese Medicine) Programme

Field of expertise

Pharmaceutical Formulation in Chinese Materia Medica and Drug Delivery System

Prof YU Zhiling

zlyu@hkbu.edu.hk

- Professor, Teaching and Research Division
- Director, Consun Chinese Medicines Research Centre for Renal Diseases
- Director, Master of Pharmaceutical Sciences in Chinese Medicine Programme

Field of expertise

Pharmacology of Chinese Medicine

DR KWAN Hiu Yee

hykwan@hkbu.edu.hk

- Associate Director and Assistant Professor, Teaching and Research Division

Field of expertise

Nutritional Science and Therapeutic Mechanisms of Chinese Herbal Medicines in Colorectal Cancer, Obesity and Nonalcoholic Fatty Liver Disease

DR CHEUNG King Ho

kingho@hkbu.edu.hk

- Associate Professor, Teaching and Research Division

Field of expertise

Ion Channel, Electrophysiology, Epithelial Transport and Alzheimer's Disease

Dr CHONG Wai Po

chongwp@hkbu.edu.hk

- Associate Professor, Teaching and Research Division

Field of expertise

Immunology and Autoimmunity

DR KO Ka Shun, Joshua

jksko@hkbu.edu.hk

- Associate Professor, Teaching and Research Division

Field of expertise

Pharmacology, Toxicology, Chemotherapy and Gastroenterology

Dr YUE Kin Man, Kevin

kkmyue@hkbu.edu.hk

- Associate Professor, Teaching and Research Division

Field of expertise

Diabetes and Biomedical Sciences

Dr ZHANG Shiping

spzhang@hkbu.edu.hk

- Associate Professor, Teaching and Research Division

Field of expertise

Acupuncture and Neuroscience

Dr LI Fangfei

fangfeili@hkbu.edu.hk

- Assistant Professor, Teaching and Research Division

Field of expertise

Biochemistry, Molecular Pharmacology, Targeted Drug Delivery for Anticancer and Antimicrobial Therapies

DR LIU Jin

liujin@hkbu.edu.hk

- Assistant Professor, Teaching and Research Division

Field of expertise

Bone and Cartilage Biology, Translational Medicine in Bone and Joint Diseases

Dr WONG Hoi Leong, Xavier

xavierwong@hkbu.edu.hk

- Assistant Professor, Teaching and Research Division

Field of expertise

Developmental Biology, Stem Cell and Tissue Regeneration and Gastrointestinal Diseases

DR XU Jun

davidxujun@hkbu.edu.hk

- Assistant Professor, Teaching and Research Division

Field of expertise

Pharmacognosy, Processing of Chinese Medicinal Materials, Interaction between Herbal Medicines and Gut Microbiota

DR YU Yuanyuan

yuyuanyuan@hkbu.edu.hk

- Assistant Professor, Teaching and Research Division

Field of expertise

Optimization of the Aptamer Selection Methodologies, Aptamer-based Translational Medicine and Drug Discovery, and Aptamer Structural Biology

DR ZHONG Lidan

ldzhong@hkbu.edu.hk

- Visiting Associate Professor, Teaching and Research Division

Field of expertise

Clinical research on Gastroenterology, Gynecology, and Rheumatology with Chinese Medicine and Integrative Medicine, Evidence-Based Approaches and Epidemiological Research with Chinese Medicine and Integrative Medicine

DR LAM Yan Yan

yanlam2021@hkbu.edu.hk

- Assistant Professor, Centre for Chinese Herbal Medicine Drug Development Limited

Field of expertise

Nutrition, gut microbiome, metabolic health and gastrointestinal disorders

DR TAN Hor Yue, Hoey

hyhtan@hkbu.edu.hk

- Assistant Professor, Centre for Chinese Herbal Medicine Drug Development Limited

Field of expertise

Immune targeted drug discovery from natural products and cellular interactions and molecular mechanisms in the inflammatory microenvironment



RESEARCH ASSISTANT PROFESSORS

DR CHEUNG Chat Pan, Kenneth

kcpcheung@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Immunology, Cell Metabolism and Metabolic Syndrome

DR DENG Zhiqiang

zhiqiangdeng@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Selective Autophagy and Autophagy Receptors in Neurodegenerative Diseases, and Neuroprotective Mechanism by Traditional Chinese Medicine

DR FU Xiuqiong

makyfu@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Anticancer Properties of Chinese Medicines and Novel Pathogenic Factors of Cancers

DR IYASWAMY Ashok

iashok@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Dissecting Molecular Mechanisms of Alzheimer's Disease and New Drug Discovery from Traditional Chinese Medicine for Alzheimer's Disease Therapy



Dr LI Lifeng

cherrylfli@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Natural Polysaccharide Chemistry and Application

DR LIAO Boya

liaoboya@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Ischemic stroke, Metabolism and Molecular Biology



Dr MA Yuan

mayuan@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Pharmaceutical Sciences in Chinese Medicine

DR TONG Chun Kit Benjamin

cktong@hkbu.edu.hk

- Research Assistant Professor, Teaching and Research Division

Field of expertise

Calcium Signaling and Neuronal Pathophysiology in Neurodegenerative Disease

DR ZHANG Xuan

zhangxuan@hkbu.edu.hk

- Research Assistant Professor, Clinical Division

Field of expertise

Chinese Medicine and Reporting Guideline of Health Research, and Clinical Research of Gastrointestinal Disease with Chinese Medicine

DR ZHU Lin

zhulin@hkbu.edu.hk



- Research Assistant Professor, Centre for Chinese Herbal Medicine Drug Development Limited

Field of expertise

Toxicology, Natural product chemistry, Biochemistry



OUR RESEARCH
AY2016-AY2021

APPENDICES

- LIST OF MAJOR EXTERNAL RESEARCH GRANTS AWARDED
- LIST OF PATENTS
- LIST OF PUBLICATIONS

MAJOR EXTERNAL RESEARCH GRANTS AWARDED

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2020-2021			
CMDF	Liu Yulong	大腸癌化療相關消化道毒副反應中醫藥治療臨床路徑制訂	HK$1,926,900
	Chua Ka Kit	柏金遜症患者對中西醫結合治療的調查分析及中醫病機相關性研究	HK$734,441
	Zhang Xuan	中醫藥臨床試驗報告規範的應用研究	HK$1,164,000
	Chua Ka Kit	從微電影推廣香港中醫行業	HK$750,000
GRF / ECS	Yu Zhiling	Does upregulating RNF125 expression with luteolin overcome vemurafenib resistance in melanoma? (Ref. No.: 12100221)	HK$1,175,432
	Cheung King Ho	Unravelling the pathogenic role of lysosomal TPC2 Ca2+ channel in Alzheimer's disease (Ref. No.: 12100321)	HK$1,174,474
	Zhang Hongjie	To develop patentiflorin A analogs as a broad spectrum of viral inhibitors against SARS-CoV-2 (Ref. No.: 12103021)	HK$1,170,982
	Zhang Ge	A next generation of sclerostin inhibitor with bone anabolic potential and without increasing cardiovascular risk for osteogenesis imperfecta: How does sclerostin loop3-specific aptamer work? (Ref. No.: 12100921)	HK$1,159,228
	Bian Zhaoxiang	Investigating the regulatory role of phenethylamine for serotonin production in the pathogenesis of diarrhea-predominant Irritable Bowel Syndrome (Ref. No.: 12102721)	HK$1,148,982
HA	Zhong Lidan	Treating acute low back pain with acupuncture - comparison of the efficacy between distal points and local points	HK$320,000
	Zhong Lidan	Comparison study of the effectiveness between syndrome differentiation treatment and fixed Formula treatment on Peri-menopausal Syndrome (PMS)	HK$320,000
HMRF	Fu Xiuqiong	Ranunculi Ternati Radix inhibits STAT3 signaling through upregulating miR-351 to exert anticancer effects (Ref. No.: 18192731)	HK$100,000
	Wong Hoi Leong Xavier	Investigating the role of ADAM9 in the regulation of body weight and food intake (Ref. No.: 8193626)	HK$1,500,000
	Kwan Hiu Yee	WNT974 and artesunate exhibit synergy in inhibiting colorectal cancer growth by increasing KRAS protein degradation (Ref. No.: 08193596)	HK$1,151,520
	Zhang Xuan	Research on improving the quality of multicentre clinical trials: development of the reporting guideline (Ref. No.: 18192671)	HK$499,000
ITF	Chen Hubiao	Quality evaluation and production development of wild ginseng stem cell wall-broken powder (Ref. No.: PRP/036/20FX)	HK$294,000
	Chen Hubiao	Construction and Application Demonstration of Traditional Chinese Medicine Anti-Tumor Active Ingredients Screening Platform Based on Key Technology of Organ Chip (Ref. No.: MHP/023/20)	HK$680,000
	Yu Zhiling	Pharmacological studies of ginsenoside Rg3 in treating selective BRAF(V600E) inhibitor-resistant cancers (Ref. No.: ITS/092/20)	HK$1,399,780
	Zhong Lidan	The Pathway of Chinese Medicine on Artificial Intelligence, Tele-Medicine and E-commerce: An Exploratory Study	HK$294,095

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2020-2021			
GDSTC	Ma Yuan	模塊化固相合成長循環AS1411-氟尿苷-紫杉醇偶合物(ApDC)用於腫瘤微環境ROS激活的乳腺癌協同治療	CNY 100,000
	Yu Zhiling	基於白介素1介導的炎症信號通路研究黑豆餾油抗特應性皮炎的作用機制	CNY 100,000
	Kwan Hiu Yee	探索hERG/HIF-1信號通路對超重和肥胖mCRC患者產生抗VEGF治療耐藥性的作用及機制研究	CNY 100,000
	Wong Hoi Leong Xavier	探究靶向MT1-MMP作為治疗肥胖症新方法的潛力	CNY 100,000
NSFC	Chen Hubiao	基於多成分多靶點雙向垂釣研究綿頭雪蓮治療類風濕性關節炎的活性物質及作用機制	CNY 550,000
	Zhao Ling	膽汁酸轉化梭菌通過5-羥色胺通路加劇腸易激綜合症腹瀉症狀的機制研究	CNY 240,000
	Yu Zhiling	基於miR-142-3p/FAM98A通路研究槐花散抗結直腸癌的機制研究	CNY 550,000
SZSTI	Yu Zhiling	逆轉腫瘤耐藥天然產物的篩選及機理研究	CNY 2,000,000
	Kwan Hiu Yee	基於不同部位脂肪組織來源外泌體的蛋白質整體研究其對肥胖症的影響	CNY 200,000

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2019-2020			
Theme-based Research Scheme	Lyu Aiping	Aptamer: Molecular Insight & Translational Theranostics (Ref. No.: T12-201/20-R)	HK$50,000,000
Hong Kong Jockey Club Charities Trust	Bian Zhaoxiang	Chinese Herb-drug Interaction: Knowledge Generation, Application and Public Education	HK$12,650,000
CMDF	Yue Kin Man Kevin	中小學生中醫藥推廣計劃 (Ref. No.: 19B1-2/009A)	HK$588,700
	Peng Bo	香港居民對中醫藥及流感認知與運用相關的調查 (Ref. No.: 19B2/032A)	HK$705,400
	Li Min	香港中醫師培訓課程–新冠肺炎的中醫治療及感染控制 (Ref. No.: 19SB1-1/001A)	HK$1,321,160
	Zhang Xuan	基於中醫運氣理論的新型冠狀病毒肺炎發病及防治研究 (Ref. No.: 19SB2/003A)	HK$328,960
	Zhang Xuan	推拿臨床試驗報告規範：CONSORT聲明的擴展 (Ref. No.: 19B2/044A_R1)	HK$397,000
	Zhong Lidan	制定中醫藥治療優勢病症的循證臨床實踐指南 (Ref. No.: 19B2/057A)	HK$1,035,256

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

MAJOR EXTERNAL RESEARCH GRANTS AWARDED

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2019-2020			
CMDF	Li Min	中藥複方辨證治療柏金遜症先導性實用臨床試驗 (Ref. No.: 20B2/002A)	HK$1,404,760
GRF / ECS	Wong Hoi Leong Xavier	To investigate the role of klotho shedding in the ageing process (Ref. No.: 12102020)	HK$1,195,542
	Yu Yuanyuan	Targeting sclerostin loop3 to promote bone formation with low cardiovascular risk in animal models (Ref. No.: 12102120)	HK$1,132,623
	Bian Zhaoxiang	Gut dysbiosis disrupts stem cell functions via NGF/TrkA signaling pathway in diarrhea-predominant irritable bowel syndrome (Ref. No.: 12102620)	HK$1,195,542
HA	Bian Zhaoxiang	Observation Study for Special Chinese Medicine Programme for Discharged COVID-19 Patients (Ref. No.: 8110079158)	HK$1,471,764
HMRF	Bian Zhaoxiang	Mechanistic investigation of herbal formula JCM16021 in attenuation of bowel symptoms for irritable bowel syndrome through modulating clostridia-driven bile acid metabolic disturbance (Ref. No.: 17182661)	HK$1,190,000
	Li Min	Evaluating the anti-Alzheimer's efficacy of Caudatin, isolated from Chinese medicine herb Qingyangshen, on AD mice model (Ref. No.: 17182541)	HK$1,487,800
	Cheung King Ho	The anti-asthmatic effects of Houttuynia cordata (Yu Xing Cao) essential oil – a mechanistic study (Ref. No.: 17182591)	HK$1,463,600
	Han Quanbin	Interaction between Chinese medicines and antibiotics in tumor suppression in terms of gut microbiota: dendrobii polysaccharide, a case study (Ref. No.: 17182681)	HK$1,474,760
	Yang Chuanbin / Iyaswamy Ashok	Neuroprotective effects Chinese medicine Corynoxine in experimental Alzheimer's disease via autophagy induction (Ref. No.: 17182551)	HK$1,495,800
	Tong Chun Kit Benjamin	A pilot study on evaluating tau clearance by a Chinese medicinal compound tetrandrine (Ref. No.: 17182561)	HK$100,000
HMRF COVID-19	Zhang Hongjie	Development of resveratrol and its congeners as preventive and therapeutic agents for control of COVID-19 (Ref. No.: COVID190214)	HK$2,890,000
ITF	Yu Zhiling	Research and development of functional foods based on Ganoderma cultivated in Hong Kong (Ref. No.: PRP/034/19FX)	HK$1,200,000
	Xu Jun	A reliable method for inspecting sulfur-fumigated Chinese medicinal materials (Ref. No.: PRP/003/20FX)	HK$353,950
GDSTC	Cheung King Ho	粉防己碱衍生物T6缓解阿尔茨海默病的分子机制研究	CNY 100,000
	Wong Hoi Leong Xavier	肠道微生物与肠道干细胞在肠易激综合征发病机制中的相互作用	CNY 100,000
	Fu Xiuqiong	基于EGFR/STAT3信号通路探索白术及其有效成分抗黑色素瘤的机制 (Ref. No.: 2020A1515010579)	CNY 100,000

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2019-2020			
NSFC	Bian Zhaoxiang	療效導向下中醫辨証論治能力提升數字化關鍵技術及平台構建 [国家重点研发项目2019YFC1710400]	CNY 12,950,000
	Liang Chao	Translational medicine and precision medicine in bone and joint diseases [NSFC Excellent Young Scientists Fund (Hong Kong and Macau)]	CNY 1,300,000

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2018-2019			
GRF / ECS	Xu Jun	Exploring the glycosyl structural specificity of multiple components involved in the gut microbiota-targeted anti-obesity effect of ginseng (Ref. No.: 12100219)	HK$633,006
	Lyu Aiping	A Novel Nucleolin Aptamer-Maytansine Conjugate for Chemo-resistant Ovarian Cancer (Ref. No.: 12100719)	HK$733,805
	Wong Hoi Leong Xavier	Investigating the role of MT1-MMP in the regulation of insulin sensitivity and the therapeutic potential of MT1-MMP inhibition in Type 2 diabetes mellitus (Ref. No.: 12101019)	HK$1,037,200
	Yu Zhiling	Does atractylenolide I synergize the anti-melanoma effects of MK-8776 by inhibiting cyclin-dependent kinase 2 signaling? (Ref. No.: 12101519)	HK$938,066
	Zhang Hongjie	Ent-Kaurene Analogs for Control of Colorectal Carcinoma Progression and Metastasis (Ref. No.: 12102219)	HK$1,115,935
	Liu Jin	Unraveling a novel mechanism of bone-cartilage crosstalk: the osteoclast-derived exosomal microRNAs promote cartilage degradation, osteochondral angiogenesis and innervation in early osteoarthritis (Ref. No.: 12103519)	HK$1,004,456
	Zhao Zhongzhen	Investigating the scientific basis behind the ancient processing method of heshouwu by hepatotoxicity assessment and chemical characterization (Ref. No.: 12103919)	HK$618,277
	Gu Zhizhan	KIF9 in Glioblastoma Progression and Immunotherapy (Ref. No.: 22103319)	HK$1,029,400
HMRF	Chen Hubiao	Identification of natural COX-2 selective inhibitors from medicinal plant (saussurea laniceps) for the both safe and effective treatment of arthritis (Ref no: 16170251)	HK$994,120
	Wong Hoi Leong Xavier	Exploring the regulatory role of MT1-MMP for body weight and the therapeutic potential of MT1-MMP inhibition in obesity (Ref no: 06170056)	HK$1,500,000
ITF	Yang Zhijun	Development of Inhalable Nano-suspension of Salmeterol and Fluticasone (Ref. No.: ITS/348/18FX)	HK$1,486,147
	Liang Chao	Effects Of A Novel Smurf1 Inhibitor Loaded In Alginate Hydrogel On Local Bone Formation In Distinctive Age-related Osteoporosis During Spinal Fusion (Ref. No.: GHX/013/18SZ)	HK$918,200
	Kwan Hiu Yee	Development of Zanthoxylum piperitum mature pericarp as health product to control body weight (Ref. No.: PRP-015-19FX)	HK$631,000

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

MAJOR EXTERNAL RESEARCH GRANTS AWARDED

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2018-2019			
GDSTC	Kwan Hiu Yee	基于STAT3信號通路探索咖啡酸抑制高脂飲食相關前列腺癌生長和轉移的機制	CNY 100,000
	Wang Chao	基于單分子熒光成像定位技術的基因轉錄組合調控下噪聲發生的分子機制研究	CNY 100,000
NSFC	Bian Zhaoxiang	中藥複方JCM-16021 促進腸道菌群的短鏈脂肪酸生成改善腸屏障功能的機制研究	CNY 550,000

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2017-2018			
GRF / ECS	Li Min	Study of Chinese Medicine Protopine on Attenuating Tau Pathology in Alzheimer's Disease: the Roles of Histone Deacetylase 6 (Ref no: 12100618)	HK$1,148,400
	Han Simon Quanbin	Astragalus polysaccharide RAP enters Peyer's patches to initiate immune response through M cell transcytosis via TLR2/4 mediated pathway (Ref no: 12100818)	HK$930,795
	Zhang Ge	From precision medicine to drug discovery: osteoblast-specific inhibition of Smurf1 activity promotes bone formation in distinctive rats with age-related osteoporosis (Ref no: 12100918)	HK$971,481
	Li Fangfei	Osteosarcoma-specific delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in a patient-derived xenograft model (Ref no: 12101018)	HK$882,090
	He Xiaojuan	The role of osteoblastic CKIP-1 in regulating joint inflammation during rheumatoid arthritis (Ref no: 12101118)	HK$781,650
	Tsang Siu-wai	Modulation of membrane type 1-matrix metalloproteinase by 3,5,4′-trihydroxybibenzyl, an aromatic dihydrostilbene, against perpetual pancreatic stellate cell activation in pancreatogenic diabetes (Ref no: 12101718)	HK$807,926
	Lyu Aiping	Toward the next generation of smart anti-tumor drugs: a highly water-soluble nucleolin aptamer-paclitaxel conjugate with a serum-stable linker for tumor-specific targeting in ovarian cancer (Ref no: 12102518)	HK$697,734
	Yu Zhiling	Does parthenolide overcome vemurafenib resistance by inhibiting heat shock protein 90 in melanoma? (Ref no: 12102918)	HK$960,903
	Zhang Hongjie	To Develop Arylnaphthalene Lignans as Potent Inhibitors Against HIV through Chemical Synthesis (Ref no: 12103618)	HK$688,817
	Zhu Hailong	A mechanistic study on the role of combinatorial gene regulation in controlling gene expression noise through direct observation on the transcriptional activities in single cells (Ref no: 12201818)	HK$490,400

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2017-2018			
HMRF	Li Min	Investigation of anti-alzheimer's activity of protopine derivative for clearing Tau through modulation of HDAC6-Hsp90 interplay and for improving memory via stimulation of RAS-GRF1/ERK pathway (Ref no: 15163481)	HK$1,159,200
	Yu Zhiling	Regulation of microRNA biogenesis by BRAF-MEK targeted therapy: molecular mechanisms and role in drug resistance (Ref no: 15163441)	HK$898,600
	Cheung King Ho	Correcting presenilin-1 mutation-mediated autophagy deficit in familial Alzheimer's disease by Chinese medicine tetrandrine (Ref no: 15163421)	HK$1,175,304
	Zhong Lidan	Electro-acupuncture combined auricular acupressure for central obesity: a single blinded randomized sham-controlled clinical trial (Ref no:15163331)	HK$581,048
ITF	Bian Zhaoxiang	Efficacy of JCM-16021 for Irritable Bowel Syndrome: from Basic Mechanism to the Clinical Efficacy Approval in a Randomized Placebo Controlled Large Scale Trial (Ref no: ITS/148/14FP)	HK$4,997,712
	Yu Zhiling	Preclinical Study of the Category I Antitumor New Drug EN-002 Inhibiting the Novel Targets - DNA Replication Initiation Proteins (Ref no: GHX/002/17GD)	HK$489,999
	Zhang Hongjie	Synthesis of Acetal Analogs of 11-Oxo-flexicaulin A for Control of Cancer Progression and Metastasis (Ref no: ITS/254/16)	HK$1,099,492
NSFC	Wang Maolin	靶向 miRNA-mRNA 解除 mRNA 抑制的小分子化合物發現新策略	CNY 217,000
	Zhu Hailong	通過超高分辨率熒光成像技術研究細胞基因轉錄噪聲組合調控的分子機制	CNY 590,000
	Wong Hoi Leong Xavier	MT1-MMP調控腫瘤相關巨噬細胞促淋巴管生成的機制研究	CNY 220,000
	Lu Jun	基于靶向核仁素的適配子-雷公藤甲素偶合物的製備及其抗乳腺癌的作用研究	CNY 210,000
	Fu Xiuqiong	基于Hsp90信號通路探索菊花及其有效成分小白菊內酯抗黑色素瘤的作用機制	CNY 230,000
	Zhao Chen	中醫臨床試驗證據個體適用性評價方法的建立	CNY 210,000
	Lyu Aiping	基于消退素調控炎症相關通路探討片仔癀治療肝癌的作用機制	CNY 570,000
	Yu Zhiling	基于miR-34b/MET/β-catenin 通路探討四君子湯與達卡吧嗪合用抗黑色素瘤的機制	CNY 570,000
SZSTI	Yang Chuanbin	新型TFEB激活劑通過調節自噬-溶酶體通路對帕金森病模型的保護作用及其分子機制研究	CNY 300,000
	Chen Hubiao	構建天然COX-2抑制劑分離新平臺用於靶向篩選中藥薯蕷抗炎活性成分的研究	CNY 300,000
	Yu Zhiling	基於JNK2信號通路研究豨薟草的長期肺毒性機制	CNY 500,000
	Lu Jun	基於靶向核仁素的適配子-雷公藤甲素偶合物的製備及其抗乳腺癌的作用研究	CNY 300,000

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

MAJOR EXTERNAL RESEARCH GRANTS AWARDED

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2016-2017			
GRF / ECS	Zhang Ge	The role of osteoclastic miR-214-3p in early osteoarthritis development (Ref no: 12101117)	HK$871,855
	Li Min	Study of a novel TFEB activator on attenuating Tau pathology in Alzheimer's disease (Ref no: 12101417)	HK$1,255,050
	Zhao Zhongzhen	A special perspective to evaluate the toxicity and quality of Yimucao decoction pieces by probing the chemical distribution and change in its different tissues and medicinal parts (Ref no: 12102217)	HK$600,000
	Zhang Hongjie	To Elucidate the Anti-Ebola Potency of the Active Leads Discovered Based on the Diversified Plants in Lingnan Region of China (Ref no: 12103917)	HK$795,982
	Kwan Hiu-yee	Contribution of palmitic acid-TLR4 axis in high fat diet-associated colorectal cancer cell proliferation (Ref no: 22103017)	HK$674,648
HA	Bian Zhaoxiang	The Chinese and Western Medicine Collaborative Studies on Palliative Cancer Patients with Constipation	HK$500,000
	Zhong Lidan	The efficacy and safety of acupuncture for alleviating chemotherapy-induced peripheral neuropathy in colorectal cancer patients: study protocol for a pilot single-blinded, randomized sham-controlled trial	HK$300,000
HMRF	Li Min	Investigation on the anti-Parkinson's disease activity of BIGWISE - a Tianma Gouteng Yin-derived molecular formulation (Ref no: 14150811)	HK$1,119,920
	Han Simon Quanbin	Application of polysaccharide as chemical marker in quality control of saccharide-dominant Chinese medicines: Cordyceps sinensis, a case study (Ref no: 14150521)	HK$1,200,000
	Tsang Siu Wai	Use of ephemeranthoquinone, a naturally ocurring phenanthraquinone, in the treatment of pancreatic fibrosis in chronic pancreatitis (Ref no: 14150471)	HK$779,700
	Yu Zhiling	Elucidating the involvement of IL-17-IL-6-STAT3 axis in the anti-melanoma effects of a herbal formula comprising Flos Sophorae and Flos Loincerae (Ref no: 14150571)	HK$827,480
ITF	Zhang Hongjie	Synthesis of Acetal Analogs of 11-oxo-flexicaulin A for Control of Cancer Progression and Metastasis (Ref no: ITS/254/16)	HK$1,099,492
	Zhang Ge	Targeting Sclerostin to Reverse Established Osteoporosis: Aptamer Characterization and Evaluation for Drug Discover (Ref: UIM/298)	HK$499,997
	Yu Zhiling	Research on the Second Development of Yi-Shen-Hua-Shi Granules (Ref: UIM/290)	HK$2,750,000
	Yu Zhiling	Study on the Pharmacological Effects and Mechanism of Action of Young Yum Pill (Ref: UIT/135)	HK$270,000

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

Funding Scheme / Funding Body	Principal Investigator	Project Title	Approved Amount
2016-2017			
NSFC	Li Min	原阿片碱(Protopine)通過特異性抑制HDAC6用於治療阿爾茲海默病的實驗研究	CNY 550,000
	Liang Chao	從精准醫學到藥物發現:查耳酮衍生物抑制Smurf1活性，對特定老年骨質疏鬆小鼠亞群脊柱融合術中局部骨形成的影響研究	CNY 200,000
	Liu Jin	破骨細胞內microRNA-214-3p 介導骨關節炎早期軟骨下骨骨重塑失常的分子機制研究	CNY 200,000
	Li Fangfei	核酸適配子功能化的脂質聚合物腫瘤靶向遞送CRISPR/Cas9用於基因編輯VEGFA治療骨肉瘤	CNY 200,000
	Yang Chuanbin	基於自噬溶酶體通路研究一種小分子化合物用於治療帕金森氏病的實驗研究	CNY 201,000
	Su Tao	基於RNA-Seq轉錄組技術探討豨薟草炮製減毒機理	CNY 200,000
	Zhang Xuan	基於数据挖掘與運氣學說的香港地區氣象疫病監測預警系統研究	CNY 170,000
SZSTI	Han Simon Quanbin	馬兜鈴酸快速檢測用納米金花試紙條的研製	CNY 200,000
	Yi Tao	創建新型功能化磁性納米粒配體分離平臺聯用LC-NMR/MS技術靶向篩選綿頭雪蓮花中COX-2抑制劑的研究	CNY 300,000
	Bian Zhaoxiang	基20170327協同抗肝癌組合藥物研究	CNY 2,000,000

Notes

CMDF: Chinese Medicine Development Fund; **GRF/ECS:** General Research Fund / Early Career Scheme; **HA:** Funding Schemes under Hospital Authority; **HMRF:** Health and Medical Research Fund; **ITF:** Innovation and Technology Fund; **GDSTC:** Funding Schemes under The Department of Science and Technology of Guangdong Province; **NSFC:** Funding Schemes under National Natural Science Foundation of China; **SZSTI:** Funding Schemes under Science, Technology and Innovation Commission of Shenzhen

PATENTS GRANTED

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2020-2021				
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	I 732967	2021-07-11	Taiwan
Method and Compounds for Inhibiting the MCM Complex and Their Application in Cancer Treatment	Bai Liping Wang Jingrong Jiang Zhihong Liang Chun Wang Ziyi Yu Zhiling	CA2873283	2021-05-04	Canada
TFEB Activator C1 Ameliorates App and Tau Pathology and Rescues Cognitive Deficits in Neurodegenerative Diseases	Li Min Malampati Sandeep Song Juxian	US 10,987,319	2021-04-27	United States of America
Anti-Cancer Composition Consisting of Halofuginone and Sesquiterpene Lactone Compounds of Artemisia Apiacea and Use Thereof	Bian Zhaoxiang Yang Dajian Gong Rui Hong Chen Guoqing Lyu Aiping	US 10,973,823	2021-04-13	United States of America
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	11201904092V	2021-03-04	Singapore
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	Li Min Zeng Yu Liu Liangfeng Song Juxian	EP3113767B1	2020-12-09	European Procedure
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	Li Min Zeng Yu Liu Liangfeng Song Juxian	EP3113767	2020-12-09	France
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	Li Min Zeng Yu Liu Liangfeng Song Juxian	EP3113767	2020-12-09	Germany
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	Li Min Zeng Yu Liu Liangfeng Song Juxian	EP3113767	2020-12-09	United Kingdom

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2019-2020				
Method of Using Dihydro-resveratrol for Treating Acute Pancreatitis and Associated Pulmonary Injury	Bian Zhaoxiang Chan Sun Chi Albert Tsang Siu Wai Lyu Aiping Zhang Hongjie	HK 1230076 B	2020-08-07	Hong Kong
Tongue picture acquisition methods, device and system	Zhang Shi Ping Parcus Robert	CN106859595B	2020-05-05	China
Method for Inhibiting Growth of Esophageal Tumorin Subject in Need Thereof and Application of Flavonol Compound in Preparation of Medicine for Treating Esophageal Tumor	Lin Chengyuan Yang Zhijun Bian Zhaoxiang Chan Sun Chi Albert Mu Huaixue Lyu Aiping Wang Jinjin	CN107693529B	2020-04-24	China
Composition of Halofuginone and Artemisia Apiacea Sesquiterpene Lactone Compounds for Resisting Cancer and Application of Composition	Bian Zhaoxiang Yang Dajian Gong Rui Hong Chen Guoqing Lyu Aiping	CN105497091B	2020-01-24	China
Method of use of diterpenoid derivatives as anticancer agents	Zhang Tongxin Tsang Siu Wai Guo Lei Liu Kanglun Wong Man Shing Ricky Zhang Hongjie	US 10,493,056	2019-12-03	United States of America
Inhibit the Application in the Method and Lignan Compound of the Intracorporal Cancer of the Esophagus Growth of Master in Need as Preparation Treatment Esophageal Cancer Medicine	Lin Chengyuan Bian Zhaoxiang Chan Sun Chi Albert Mu Huaixue Xu Hongxi Yang Dajian Chen Shilin Lyu Aiping	HK1229716	2019-11-22	Hong Kong
Anticancer Maytansinoids with Two Fused Macrocyclic Rings	Soejarto Djaja D. Zhang Hongjie Fong H.S. Harry	HK 1221722 B	2019-11-08	Hong Kong
Long-Acting Controlled-Release Liposome Gel Composition	Yang Zhijun Bian Zhaoxiang Wong Blenda Chi Kwan Chen Xiaoyu Lyu Aiping	HK 1208626	2019-11-08	Hong Kong
Method of Using Dihydro-resveratrol for Treating Acute Pancreatitis and Associated Pulmonary Injury	Bian Zhaoxiang Chan Sun Chi Albert Tsang Siu Wai Lyu Aiping Zhang Hongjie	CN106256349B	2019-10-18	China

PATENTS GRANTED

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2018-2019				
Identification of Cyclic Peptide Agonists of Galanin Receptor 2 and 3 Guided By Spexin Solution Structure	Lin Chengyuan Bian Zhaoxiang Huang Tao	US 10,376,555	2019-08-13	United States of America
Quality Control marker and its use in Cordyceps species authentication	Han Quanbin	US 10,359,407	2019-07-23	United States of America
Method of Using of Dihydro-Resveratrol or its Stilbenoid Derivatives and/or Chemical Variants as Antimicrobial Agents	Tsang Siu Wai Zhang Hongjie	US 10,351,500	2019-07-16	United States of America
Miliusanes As Antiviral Agents	Zhang Hongjie	US 10,323,012	2019-06-18	United States of America
The Method and Compound of Inhibition MCM Albumen Composition and Its Application in Treating Cancer	Bai Liping Wang Jingrong Jiang Zhihong Liang Chun Wang Ziyi Yu Zhiling	CN104736157B	2019-06-11	China
Inhibit the Application in the Method and Lignan Compound of the Intracorporal Cancer of the Esophagus Growth of Master in Need as Preparation Treatment Esophageal Cancer Medicine	Lin Chengyuan Bian Zhaoxiang Chan Sun Chi Albert Huaixue Mu Xu Hongxi Yang Dajian Chen Shilin Lyu Aiping	CN106265610B	2019-04-02	China
Slow and controlled released liposomal gel composition comprising hypoglycemic active ingredient and method of preparing thereof	Yang Zhijun Bian Zhaoxiang Wong Blenda Chi Kwan Chen Xiaoyu Lyu Aiping	CN104840415B	2019-03-15	China
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	US10,188,590	2019-01-29	United States of America
Anti-cancer and Anti-obesity Cyclic Peptide Agents	Zhang Hongjie	EP 2909227	2018-12-12	European Procedure
Anti-cancer and Anti-obesity Cyclic Peptide Agents	Zhang Hongjie	EP 2909227	2018-12-12	Germany
Anti-cancer and Anti-obesity Cyclic Peptide Agents	Zhang Hongjie	EP 2909227	2018-12-12	United Kingdom
Use of a Flavanol Glycoside for Suppressing Activation of Stellate Cells	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Tsang Siu Wai Yang Dajian Chen Yegao Chen Shilin Lyu Aiping Zhang Hongjie	HK1202058B	2018-10-05	Hong Kong

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2017-2018				
Quality control marker and its use in herbs authentication	Xu Jun Chen Hubiao Han Quanbin	HK1204362	2018-08-31	Hong Kong
Quality Control Marker and Its Use in Herbs Authentication	Xu Jun Chen Hubiao Han Quanbin	J/3077	2018-08-07	Macao
Method for the Preparation of Iodoalkanes	Fan Baomin Lin Chengyuan Bian Zhaoxiang Zhou Yongyun Chen Jingchao	US 10,040,740	2018-08-07	United States of America
Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatment of tumorous pathologies	Tsang Siu Wai Zhang Hongjie	US 10,017,442	2018-07-10	United States of America
Slow and controlled released liposomal gel composition comprising hypoglycemic active ingredient and method of preparing thereof	Yang Zhijun Bian Zhaoxiang Wong Blenda Chi Kwan Chen Xiaoyu Lyu Aiping	9,980,906	2018-05-29	United States of America
Cycloheptapeptide Agents for Treatment of Cancer and Obesity Diseases	Zhang Hongjie	US 9,963,485	2018-05-08	United States of America
A Chinese Medicinal Formulation for Treating Inflammatory Bowel Disease and the Preparation Thereof	Bian Zhaoxiang Chan Sun Chi Albert Tsang Siu Wai Lyu Aiping Wu Che Yuen Justin Ip Siu Po	HK1206618	2018-05-04	Hong Kong
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	US 9,956,152	2018-05-01	United States of America
Anti-cancer and Anti-obesity Cyclic Peptide Agents	Zhang Hongjie	CN104640873B	2018-04-27	China
Use of a Flavanol Glycoside for Suppressing Activation of Stellate Cells	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Tsang Siu Wai Yang Dajian Chen Yegao Chen Shilin Lyu Aiping Zhang Hongjie	CN104173390A	2018-04-06	China
Composition Comprising Rhizoma Coptidis, Cortex Phellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases	Li Min Chen Leilei Durairajan Siva Sundara Kumar Liu Liangfeng Song Juxian	HK1200119B	2018-03-29	Hong Kong
Quality Control Marker and Its Use in Herbs Authentication	Xu Jun Chen Hubiao Han Quanbin	CN104280469A	2018-03-23	China

PATENTS GRANTED

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2017-2018				
Long-Acting Gel Composition Comprising Blood Sugar Reducing Active Component and Capable of Controlling and Releasing Liposome, and preparation Method Thereof	Yang Zhijun Bian Zhaoxiang Wong Blenda Chi Kwan Chen Xiaoyu Lyu Aiping	JP 6305555	2018-03-16	Japan
New Triptolide Derivatives, Their Preparation Method and Uses	Lu Jun Lu Cheng Liu Biao Wang Cheng Lyu Aiping Zhang Ge	1217708	2018-03-16	Hong Kong
Herbal Composition for Skin-Whitening and Anti-Skin-Aging, Method of Preparation and the Use thereof	Yu Hua Yu Zhiling	CN104013566A	2018-03-06	China
Method of Using Dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions	Tsang Siu Wai Chen Yegao Zhang Hongjie	US 9,877,931	2018-01-30	United States of America
Compound for Inhibiting Syk Activity	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Chen Kaixian Chen Shilin Fu Wenwei Yang Dajian Lyu Aiping Lv Yue	US 9,868,716	2018-01-16	United States of America
Aryl Naphthalide Lignans As anti-HIV Agents	Rong Lijun Fong H.S. Harry Zhang Hongjie Soejarto Djaja D. Rumschlag-Booms Emily	HK1196608B	2018-01-05	Hong Kong
Anticancer Miliusane Derivatives	Zhang Hongjie	US 9,822,071	2017-11-21	United States of America
Composition Comprising Rhizoma Coptidis, Cortex Phellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases	Li Min Chen Leilei Durairajan Siva Sundara Kumar Liu Liangfeng Song Juxian	J/002740	2017-11-14	Macao
Triptolide Derivatives and Preparation Method and Use Thereof	Lu Jun Lu Cheng Liu Biao Wang Cheng Lyu Aiping Zhang Ge	US 9,809,822	2017-11-07	United States of America

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2017-2018				
Method of use of diterpenoid derivatives as anticancer agents	Zhang Tongxin Tsang Siu Wai Guo Lei Liu Kanglun Wong Man Shing Ricky Zhang Hongjie	US 9,795,589	2017-10-24	United States of America
A Chinese Medicinal Formulation for Treating Inflammatory Bowel Disease and the Preparation Thereof	Bian Zhaoxiang Chan Sun Chi Albert Tsang Siu Wai Lyu Aiping Wu Che Yuen Justin Ip Siu Po	CN104436088B	2017-10-13	China
Palladium/Silver Co-Catalyzed Tandem Reactions Synthesis of Phenylacetophenone Derivatives by Oxabenzonorbornadienes with Terminal Alkynes and Their Anti-Tumor or Anti-Cancer Activities	Fan Baomin Lin Chengyuan Bian Zhaoxiang Chan Sun Chi Albert Mu Huaixue Zhou Yongyun Chen Jingchao Lyu Aiping	US 9,783,519	2017-10-10	United States of America
Lignans Isolated from Lasia spinosa (L.) Thwait	Lin Chengyuan Bian Zhaoxiang Chan Sun Chi Albert Mu Huaixue Xu Hongxi Chen Shilin Yang Dajian Lyu Aiping	US 9,775,857	2017-10-03	United States of America

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2016-2017				
Method of Using Dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions	Tsang Siu Wai Chen Yegao Zhang Hongjie	US 9,738,581	2017-08-22	United States of America
Composition Comprising Rhizoma Coptidis, Cortex Phellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases	Li Min Chen Leilei Durairajan Siva Sundara Kumar Liu Liangfeng Song Juxian	CN104225023B	2017-07-25	China
Anticancer Miliusane Derivatives	Zhang Hongjie	US 9,695,141	2017-07-04	United States of America

PATENTS GRANTED

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2016-2017				
New Triptolide Derivatives, Their Preparation Method and Uses	Lu Jun Lu Cheng Liu Biao Wang Cheng Lyu Aiping Zhang Ge	CN105121455B	2017-06-16	China
Anti-Esophageal Cancer Compound and Method of Use thereof	Lin Chengyuan Yang Zhijun Bian Zhaoxiang Chan Sun Chi Albert Mu Huaixue Lyu Aiping Wang Jinjin	US 9,655,913 B2	2017-05-23	United States of America
Synthesis of Autophagy Inducing Compound and the Uses thereof	Li Min Zhang Hongjie Liu Liangfeng Song Juxian	US 9,604,987	2017-03-28	United States of America
Aryl Naphthalide Lignans As anti-HIV Agents	Rong Lijun Fong H.S. Harry Zhang Hongjie Soejarto Djaja D. Rumschlag-Booms Emily	CN103857674B	2017-02-15	China
Ethyl Acetate Extract of Salvia Miltiorrhiza, and Preparation Method and Application Thereof	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Yang Dajian Chen Shilin Huang Linfang Wang Dongmei Liu Ailin	CN103860644A	2017-02-08	China
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	Li Min Zeng Yu Malampati Sandeep Zhang Hongjie Yang Chuanbin Song Juxian	US 9,540,299	2017-01-10	United States of America
Melanogenesis Effect of Saponins of Gynostemma Pentaphyllum	Hsiao Wen Luan Wendy Tsang Ting Fung	US 9,539,275	2017-01-10	United States of America
Folium isatidis and sophora flavescens external medicament, preparation and application thereof	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Yang Dajian Chen Shilin Chen Guoqing Lyu Aiping Zhang Yi	CN103565915B	2017-01-04	China

Patent Title	Inventor (s)	Patent No.	Date of Patent	Jurisdiction
2016-2017				
Abrotani herba and folium isatidis combined medicament, preparation method and application thereof	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Yang Dajian Chen Shilin Chen Guoqing Lyu Aiping Zhang Yi	CN103566058B	2017-01-04	China
Method of Using Dihydro-resveratrol for Treating Acute Pancreatitis and Associated Pulmonary Injury	Bian Zhaoxiang Chan Sun Chi Albert Tsang Siu Wai Lyu Aiping Zhang Hongjie	US 9,526,706	2016-12-27	United States of America
Herbal Composition for Skin-Whitening and Anti-Skin-Aging, Method of Preparation and the Use thereof	Yu Hua Yu Zhiling	US 9,511,013	2016-12-06	United States of America
One Kind of Honey-Roasted Coltsfoot Processing Methods	Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Chen Shilin Yang Dajian Huang Linfang Li Wentao	CN103877137B	2016-11-23	China
Anti-cancer and Anti-obesity Cyclic Peptide Agents	Zhang Hongjie	US 9,499,586	2016-11-22	United States of America
Medical Use of Compound from Garcinia Esculenta	Lin Chengyuan Tan Hongsheng Ding Zhi-Jie Bian Zhaoxiang Chan Sun Chi Albert Xu Hongxi Chen Kaixian Chen Shilin Yang Dajian Lao Yuanzhi Lyu Aiping Zhang Hong	US 9,468,623	2016-10-18	United States of America

PATENTS FILED

Patent Title	Inventor (s)	Application No.	Filing Date	Jurisdiction
2020-2021				
Peptide Markers for Authenticating Ejiao and Related Gelatins	Li Lifeng Wu Wenjie Han Quanbin	PCT/CN2021/110107	2021-08-02	International Procedure
Peptide Markers for Authentication of Ejiao and Related Gelatins by LC-QTOF-MS/MS	Li Lifeng Wu Wenjie Han Quanbin	PCT/CN2021/110054	2021-08-02	International Procedure
Peptide Markers for Authenticating Ejiao and Related Gelatins	Lifeng LI Wenjie WU Quanbin HAN	US 17/443,963	2021-07-29	United States of America
Peptide Markers for Authentication of Edible Bird's Nest and Related Products	Lifeng LI Wenjie WU Quanbin HAN	US 17/443,968	2021-07-29	United States of America
Peptide-Drug Conjugates	Lin Chengyuan Guo Xuanming Bian Zhaoxiang Huang Tao	US 17/304,472	2021-06-22	United States of America
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	Li Min Zeng Yu Liu Liangfeng Song Juxian	CN 202110429206.6	2021-04-21	China
Tuberculatin Analogs as Antiviral Agents	Zhang Hongjie	US 63/199,329	2020-12-21	United States of America

Patent Title	Inventor (s)	Application No.	Filing Date	Jurisdiction
2019-2020				
Synthetic patentiflorin A analogs as antiviral agents	Tsang Nga Yi Zhang Hongjie Li Wanfei	US 16/947,935	2020-08-25	United States of America
Synthetic patentiflorin A analogs as antiviral agents	Tsang Nga Yi Zhang Hongjie Li Wanfei	PCT/CN2020/111463	2020-08-26	International Procedure
Bradykinin potentiating peptide-paclitaxel conjugate directed at ectopically expressed angiotensin-converting enzyme in triple-negative breast cancer	Lin Chengyuan Guo Xuanming Bian Zhaoxiang Huang Tao	63/043,112	2020-06-23	United States of America
Chromophore-labeled oligosaccharide markers and methods of use thereof	Wong Tin Long Han Quanbin	PCT/CN2020/089893	2020-05-13	International Procedure
Chromophore-labeled oligosaccharide markers and methods of use thereof	Wong Tin Long Li Lifeng Han Quanbin	US 16/871,188	2020-05-11	United States of America
Skin-protection composition containing Dendrobium-based ingredients	Bian Zhaoxiang Chan Sun Chi Albert Tsang Siu Wai Lyu Aiping Zhang Hongjie	HK 19132414.4	2019-11-19	Hong Kong

Patent Title	Inventor (s)	Application No.	Filing Date	Jurisdiction
2018-2019				
Method of using of dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants as antimicrobial agents	Tsang Siu Wai Zhang Hongjie	CN 201910596632.1	2019-07-03	China
The Method and Compound of Inhibition MCM Albumen Composition and Its Application in Treating Cancer	Bai Liping Wang Jingrong Jiang Zhihong Liang Chun Wang Ziyi Yu Zhiling	CN 201910489605.4	2019-06-06	China
Anti-Cancer Composition Comprising of Halofuginone and Sesquiterpene Lactone Compounds of Artemisia Apiacea and the Use Thereof	Bian Zhaoxiang Yang Dajian Gong Rui Hong Chen Guoqing Lyu Aiping	19123501.9	2019-05-08	Hong Kong
Uses and Development of Neurodefend for Treating neurodegenerative Diseases	Li Min Durairajan Siva Sundara Kumar Iyaswamy Ashok Krishnamoorthi Senthilkumar Sreenivasamurthy Sravan G.S. Zhang Huan	CN 201910197461.5	2019-03-15	China
Compound is preparing the Purposes in the Drug for Treating Colorectal Cancer	Tsang Siu Wai Zhang Hongjie	CN 201811558798.6	2018-12-19	China
Uses and Development of Neurodefend for Treating neurodegenerative Diseases	Li Min Durairajan Siva Sundara Kumar Iyaswamy Ashok Krishnamoorthi Senthilkumar Sreenivasamurthy Sravan G.S. Zhang Huan	16/219,976	2018-12-14	United States of America
Close Tumor as Antivirotic is Killed	Zhang Hongjie	CN 201811306320.4	2018-11-05	China

PATENTS FILED

Patent Title	Inventor (s)	Application No.	Filing Date	Jurisdiction
2017-2018				
Identification of Cyclic Peptide Agonists of Galanin Receptor 2 and 3 Guided By Spexin Solution Structure	Lin Chengyuan Bian Zhaoxiang Huang Tao	CN 201880022729.5	2018-03-23	China
Identification of Cyclic Peptide Agonists of Galanin Receptor 2 and 3 Guided By Spexin Solution Structure	Lin Chengyuan Bian Zhaoxiang Huang Tao	EP 18780453.9	2018-03-23	European Procedure (Patents)
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	CN 201780069402.9	2017-10-26	China
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	JP 2019-524017	2017-10-26	Japan
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	PI 2019002612	2017-10-26	Malaysia
Skin-protection composition containing Dendrobium-based ingredients	Tsang Siu Wai Zhu Yu Zhang Hongjie	1901002883	2017-10-26	Thailand
Anticancer Miliusane Lactams	Zhang Hongjie	CN 201780089677.9	2017-09-30	China

Patent Title	Inventor (s)	Application No.	Filing Date	Jurisdiction
2016-2017				
Anti-Cancer Composition Comprising of Halofuginone and Sesquiterpene Lactone Compounds of Artemisia Apiacea and the Use Thereof	Bian Zhaoxiang Yang Dajian Gong Rui Hong Chen Guoqing Lyu Aiping	16883244.2	2016-09-27	European Procedure (Patents)

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
The Effect of Tai Chi for Improving Sleep Quality: A Systematic Review and Meta-analysis. *J Affect Disord.* 2020 Sep 1;274:1102-1112. doi: 10.1016/j.jad.2020.05.076.	Li H, Chen J, Xu G, Duan Y, Huang D, Tang C, Liu J.	4.839	5.515
Pristimerin induces apoptosis and inhibits proliferation, migration in H1299 Lung Cancer Cells. *J Cancer.* 2020 Sep 2;11(21):6348-6355. doi: 10.7150/jca.44431.	Li J, Guo Q, Lei X, Zhang L, Su C, Liu Y, Zhou W, Chen H, Wang H, Wang F, Yan Y, Zhang J.	4.207	4.277
Adaptogenic flower buds exert cancer preventive effects by enhancing the SCFA-producers, strengthening the epithelial tight junction complex and immune responses. *Pharmacol Res.* 2020 Sep;159:104809. doi: 10.1016/j.phrs.2020.104809.	Xia W, Khan I, Li XA, Huang G, Yu Z, Leong WK, Han R, Ho LT, Hsiao WL.	7.658	7.377
GLUT3 induced by AMPK/CREB1 axis is key for withstanding energy stress and augments the efficacy of current colorectal cancer therapies. *Signal Transduct Target Ther.* 2020 Sep 2;5(1):177. doi: 10.1038/s41392-020-00220-9.	Dai W, Xu Y, Mo S, Li Q, Yu J, Wang R, Ma Y, Ni Y, Xiang W, Han L, Zhang L, Cai S, Qin J, Chen WL, Jia W, Cai G.	18.187	21.177
Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically. *Gut Microbes.* 2020 Sep 2;11(5):1450-1474. doi: 10.1080/19490976.2020.1763770.	Ma J, Hong Y, Zheng N, Xie G, Lyu Y, Gu Y, Xi C, Chen L, Wu G, Li Y, Tao X, Zhong J, Huang Z, Wu W, Yuan L, Lin M, Lu X, Zhang W, Jia W, Sheng L, Li H.	10.245	12.117
Scopy: an integrated negative design python library for desirable HTS/VS database design. *Brief Bioinform.* 2020 Sep 7:bbaa194. doi: 10.1093/bib/bbaa194.	Yang ZY, Yang ZJ, Lu AP, Hou TJ, Cao DS.	11.622	10.288
Disorders of Calcium and Phosphorus Metabolism and the Proteomics/Metabolomics-Based Research. *Front Cell Dev Biol.* 2020 Sep 10;8:576110. doi: 10.3389/fcell.2020.576110.	Sun M, Wu X, Yu Y, Wang L, Xie D, Zhang Z, Chen L, Lu A, Zhang G, Li F.	6.684	7.219
Multigenerational Impacts of Benzo[a]pyrene on Bone Modeling and Remodeling in Medaka (Oryzias latipes). *Environ Sci Technol.* 2020 Sep 14. doi: 10.1021/acs.est.0c02416.	Mo J, Au DW, Wan MT, Shi J, Zhang G, Winkler C, Kong RY, Seemann F.	9.028	9.922
A new bisepoxylignan dendranlignan A isolated from Chrysanthemum Flower inhibits the production of inflammatory mediators via the TLR4 pathway in LPS-induced H9c2 cardiomyocytes. *Arch Biochem Biophys.* 2020 Sep 15;690:108506. doi: 10.1016/j.abb.2020.108506.	Zeng M, Li M, Chen Y, Zhang J, Cao Y, Zhang B, Feng W, Zheng X, Yu Z.	4.013	4.076
DRAM1 plays a tumor suppressor role in NSCLC cells by promoting lysosomal degradation of EGFR. *Cell Death Dis.* 2020 Sep 17;11(9):768. doi: 10.1038/s41419-020-02979-9.	Geng J, Zhang R, Yuan X, Xu H, Zhu Z, Wang X, Wang Y, Xu G, Guo W, Wu J, Qin ZH.	8.469	8.713
Identifying Transcription Factor Combinations to Modulate Circadian Rhythms by Leveraging Virtual Knockouts on Transcription Networks. *iScience.* 2020 Sep 25;23(9):101490. doi: 10.1016/j.isci.2020.101490.	Chowdhury D, Wang C, Lu A, Zhu H.	5.458	5.458
Improving Docking-Based Virtual Screening Ability by Integrating Multiple Energy Auxiliary Terms from Molecular Docking Scoring. *J Chem Inf Model.* 2020 Sep 28;60(9):4216-4230. doi: 10.1021/acs.jcim.9b00977.	Ye WL, Shen C, Xiong GL, Ding JJ, Lu AP, Hou TJ, Cao DS.	4.956	5.390
Reporting quality of systematic reviews with moxibustion. *Chin Med.* 2020 Sep 29;15:104. doi: 10.1186/s13020-020-00385-z.	Tian R, Zhang X, Li SY, Aixinjueluo QY, Lam WC, Bian ZX.	5.455	4.426
A study on the mechanism of bruceine D in the treatment of non-small cell lung cancer H1299 cells. *World J Tradit Chin Med.* 2020 Sep; 6(4):500-507. doi: 10.4103/wjtcm.wjtcm_42_20.	Shen X, Su C, Yan Y, Zhang L, Guo Q, Chen H, Zhumabieke S, Danabek Y, Li J, Liu Y, Makabel B, Zhang J.	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
One-step deep eutectic solvent strategy for efficient analysis of aflatoxins in edible oils. *J Sci Food Agric.* 2020 Oct;100(13):4840-4848. doi: 10.1002/jsfa.10544.	He T, Zhou T, Wan H, Han Q, Ma Y, Tan T, Wan Y.	3.639	3.803
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction. *Eur J Med Chem.* 2020 Oct 1;203:112570. doi: 10.1016/j.ejmech.2020.112570.	Zhao Y, Zhang LX, Jiang T, Long J, Ma ZY, Lu AP, Cheng Y, Cao DS.	6.514	6.099
Prevalence of sleep disturbances during COVID-19 outbreak in an urban Chinese population: a cross-sectional study. *Sleep Med.* 2020 Oct;74:18-24. doi: 10.1016/j.sleep.2020.07.009.	Yu BY, Yeung WF, Lam JC, Yuen SC, Lam SC, Chung VC, Chung KF, Lee PH, Ho FY, Ho JY.	3.492	4.609
Targeting cell cycle by β-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer. *Chem Biol Interact.* 2020 Oct 1;330:109229. doi: 10.1016/j.cbi.2020.109229.	Ahmad I, Fakhri S, Khan H, Jeandet P, Aschner M, Yu ZL.	5.194	4.611
A Novel Network Pharmacology Strategy to Decode Mechanism of Lang Chuang Wan in Treating Systemic Lupus Erythematosus. *Front Pharmacol.* 2020 Oct 2;11:512877. doi: 10.3389/fphar.2020.512877.	Gao Y, Wang KX, Wang P, Li X, Chen JJ, Zhou BY, Tian JS, Guan DG, Qin XM, Lu AP.	5.811	6.006
Hong Kong Chinese medicine clinical practice guideline for insomnia. *Eur J Integr Med.* 2020 Oct; 39:101193. doi: 10.1016/j.eujim.2020.101193.	Zhong LD, Shi NN, Sun YG, Ng BFL, Bian ZX, Lu AP.	1.314	1.491
Microbial metabolomics and network analysis reveal fungistatic effect of basil (Ocimum basilicum) oil on Candida albicans. *J Ethnopharmacol.* 2020 Oct 5;260:113002. doi: 10.1016/j.jep.2020.113002.	Miao Q, Zhao L, Wang Y, Hao F, Sun P, He P, Liu Y, Huang J, Liu X, Liu X, Deng G, Li H, Li L, Tang Y, Wang L, Feng M, Jia W.	4.360	4.489
A traditional Chinese medicine formula inhibits tumor growth in mice and regulates the miR-34b/c-Met/β-catenin pathway. *J Ethnopharmacol.* 2020 Oct 5;260:113065. doi: 10.1016/j.jep.2020.113065.	Wang YP, Fu XQ, Yin CL, Chou JY, Liu YX, Bai JX, Chen YJ, Wu Y, Wu JY, Wang XQ, Liu B, Yu ZL.	4.360	4.489
Potential Advantages of Bioactive Compounds Extracted From Traditional Chinese Medicine to Inhibit Bone Destructions in Rheumatoid Arthritis. *Front Pharmacol.* 2020 Oct 7;11:561962. doi: 10.3389/fphar.2020.561962.	Shi Y, Shu H, Wang X, Zhao H, Lu C, Lu A, He X.	5.811	6.006
Current advances in ligand-based target prediction. *Wiley Interdiscip Rev Comput Mol Sci.* 2020 Oct. doi: 10.1002/wcms.1504.	Yang SQ, Ye Q, Ding JJ, Yin MZ, Lu AP, Chen X, Hou TJ, Cao DS.	25.113	16.743
A combinatorial target screening strategy for deorphaning macromolecular targets of natural product. *Eur J Med Chem.* 2020 Oct 15;204:112644. doi: 10.1016/j.ejmech.2020.112644.	Wei H, Guan YD, Zhang LX, Liu S, Lu AP, Cheng Y, Cao DS.	6.514	6.099
PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. *Syst Rev.* 2020 Oct 25;9(1):247. doi: 10.1186/s13643-020-01502-7.	Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX.	2.522	5.039
Connective Tissue Growth Factor: From Molecular Understandings to Drug Discovery. *Front Cell Dev Biol.* 2020 Oct 29;8:593269. doi: 10.3389/fcell.2020.593269.	Chen Z, Zhang N, Chu HY, Yu Y, Zhang ZK, Zhang G, Zhang BT.	6.684	7.219
pH-Responsive Fluorescence Enhanced Nanogel for Targeted Delivery of AUR and CDDP Against Breast Cancer. *Int J Nanomedicine.* 2020 Oct 29;15:8369-8382. doi: 10.2147/IJN.S274842.	Cao Z, Li W, Liu R, Li C, Song Y, Liu G, Chen Y, Lu C, Lu A, Liu Y.	6.400	6.761
Yuan-Hu Zhi Tong Prescription Mitigates Tau Pathology and Alleviates Memory Deficiency in the Preclinical Models of Alzheimer's Disease. *Front Pharmacol.* 2020 Oct 30;11:584770. doi: 10.3389/fphar.2020.584770.	Iyaswamy A, Krishnamoorthi SK, Liu YW, Song JX, Kammala AK, Sreenivasmurthy SG, Malampati S, Tong BCK, Selvarasu K, Cheung KH, Lu JH, Tan JQ, Huang CY, Durairajan SSK, Li M.	5.811	6.006

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Silencing of miR-138-5p sensitizes bone anabolic action to mechanical stimuli. *Theranostics.* 2020 Oct 30;10(26):12263-12278. doi: 10.7150/thno.53009.	Chen Z, Zhao F, Liang C, Hu L, Li D, Zhang Y, Yin C, Chen L, Wang L, Lin X, Su P, Ma J, Yang C, Tian Y, Zhang W, Li Y, Peng S, Chen W, Zhang G, Qian A.	11.556	11.629
A novel inulin-type fructan from Asparagus cochinchinensis and its beneficial impact on human intestinal microbiota. *Carbohydr Polym.* 2020 Nov 1;247:116761. doi: 10.1016/j.carbpol.2020.116761.	Sun Q, Zhu L, Li Y, Cui Y, Jiang S, Tao N, Chen H, Zhao Z, Xu J, Dong C.	9.381	8.678
Evidence-based Chinese Medicine Clinical Practice Guideline for Stroke in Hong Kong. *Chin Med.* 2020 Nov 3;15(1):116. doi: 10.1186/s13020-020-00397-9.	Zhong LLD, Kun W, Shi N, Ziea TC, Ng BFL, Gao Y, Bian Z, Lu A.	5.455	4.426
Anti-Adipogenic Effect of Theabrownin Is Mediated by Bile Acid Alternative Synthesis via Gut Microbiota Remodeling. *Metabolites.* 2020 Nov 23;10(11):475. doi: 10.3390/metabo10110475.	Kuang J, Zheng X, Huang F, Wang S, Li M, Zhao M, Sang C, Ge K, Li Y, Li J, Rajani C, Ma X, Zhou S, Zhao A, Jia W.	4.932	4.980
Electromoxibustion for knee osteoarthritis in older adults: A pilot randomized controlled trial. *Complement Ther Clin Pract.* 2020 Nov;41:101254. doi: 10.1016/j.ctcp.2020.101254.	Cheung T, Ho YS, Yuen CS, Lam CS, So BCL, Chen SC, Leung DYP, Suen LKP, So LTY, Ho ACH, Yeung WF.	2.446	2.825
Resveratrol Stimulates the Na+-Ca2+ Exchanger on the Plasma Membrane to Reduce Cytosolic Ca2+ in Rat Aortic Smooth Muscle Cells. *J Cardiovasc Pharmacol.* 2020 Nov;76(5):610-616. doi: 10.1097/FJC.0000000000000897.	Yan F, Lu J, Zhang Y, Li X, Chan WH, Zhao Q, Kwan HY, Liu H, Yao X.	3.105	2.835
Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. *Acta Pharmacol Sin.* 2020 Nov 5. doi: 10.1038/s41401-020-00553-9.	Zhu L, Zhang CY, Li DP, Chen HB, Ma J, Gao H, Ye Y, Wang JY, Fu PP, Lin G.	6.150	6.124
Efficacy based ginger fingerprinting reveals potential antiproliferative analytes for triple negative breast cancer. *Sci Rep.* 2020 Nov 5;10(1):19182. doi: 10.1038/s41598-020-75707-0.	Zhao L, Rupji M, Choudhary I, Osan R, Kapoor S, Zhang HJ, Yang C, Aneja R.	4.380	5.134
Twenty-four-week oral dosing toxicities of Herba Siegesbeckiae in rats. *BMC Complement Med Ther.* 2020 Nov 11;20(1):341. doi: 10.1186/s12906-020-03137-6.	Wu JY, Chan YC, Guo H, Chen YJ, Liu YX, Yi H, Yu ZL.	3.659	3.767
Network Pharmacology-Based Strategy for the Investigation of the Anti-Obesity Effects of an Ethanolic Extract of Zanthoxylum bungeanum Maxim. *Front Pharmacol.* 2020 Nov 13;11:572387. doi: 10.3389/fphar.2020.572387.	Wang Y, Yang SH, Zhong K, Jiang T, Zhang M, Kwan HY, Su T.	5.811	6.006
ChemFLuo: a web-server for structure analysis and identification of fluorescent compounds. *Brief Bioinform.* 2020 Nov 17:bbaa282. doi: 10.1093/bib/bbaa282.	Yang ZY, Dong J, Yang ZJ, Yin M, Jiang HL, Lu AP, Chen X, Hou TJ, Cao DS.	11.622	10.288
Rubinoboletus ballouii polysaccharides exhibited immunostimulatory activities through toll-like receptor-4 via NF-κB pathway. *Phytother Res.* 2021 Apr;35(4):2108-2118. doi: 10.1002/ptr.6958.	Li LF, Yue GG, Chan BC, Zeng Q, Han QB, Leung PC, Fung KP, Liu JK, Lau CB.	5.882	5.289
Berberine Suppresses Colonic Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis Through Inhibition of Cytosolic Phospholipase A2 Activity. *Front Pharmacol.* 2020 Nov 19;11:576496. doi: 10.3389/fphar.2020.576496.	Zhai L, Huang T, Xiao HT, Wu PG, Lin CY, Ning ZW, Zhao L, Kwan HYA, Hu XJ, Wong HLX, Li XQ, Bian ZX.	5.811	6.006
Roles of MicroRNAs in Bone Destruction of Rheumatoid Arthritis. *Front Cell Dev Biol.* 2020 Nov 19;8:600867. doi: 10.3389/fcell.2020.600867.	Zhao H, Lu A, He X.	6.684	7.219
Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin. *Br J Pharmacol.* 2021 Feb;178(3):582-599. doi: 10.1111/bph.15298.	Li Z, Zhang J, Zhang Y, Zhou L, Zhao J, Lyu Y, Poon LH, Lin Z, To KKW, Yan X, Zuo Z.	8.740	7.956
A scoping review of cohort studies assessing traditional Chinese medicine interventions. *BMC Complement Med Ther.* 2020 Nov 23;20(1):361. doi: 10.1186/s12906-020-03150-9.	Duan Y, Xu Z, Deng J, Lin Y, Zheng Y, Chen J, Tang X, Zhang X, Tang C, Miao J, Bian Z.	3.659	2.986

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1. *Front Pharmacol.* 2020 Nov 30;11:512598. doi: 10.3389/fphar.2020.512598.	Pan CF, Zhang X, Wang JW, Yang T, Zhong LLD, Shen KP.	5.811	6.006
Effects of sulfur fumigation and heating desulfurization on quality of medicinal herbs evaluated by metabolomics and glycomics: Codonopsis Radix, a pilot study. *J Pharm Biomed Anal.* 2020 Nov 30;191:113581. doi: 10.1016/j.jpba.2020.113581.	Xu F, Kong M, Xu JD, Xu J, Jiang Y, Li SL.	3.935	3.564
Targeting the alternative bile acid synthetic pathway for metabolic diseases. *Protein Cell.* 2020 Nov 30. doi: 10.1007/s13238-020-00804-9.	Jia W, Wei M, Rajani C, Zheng X.	14.870	11.279
Modified Zhibai Dihuang pill, a traditional Chinese medicine formula, on steroid withdrawal in systemic lupus erythematosus: A systematic review and meta-analysis. *J Integr Med.* 2020 Nov;18(6):478-491. doi: 10.1016/j.joim.2020.08.007.	Dai L, Chan KK, Mao JC, Tian Y, Gu JH, Zhou J, Zhong LLD.	3.034	3.045
Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. *Environ Pollut.* 2020 Dec;267:115542. doi: 10.1016/j.envpol.2020.115542.	He Y, Zhu L, Ma J, Wong L, Zhao Z, Ye Y, Fu PP, Lin G.	8.071	8.350
A Novel Strategy for Decoding and Validating the Combination Principles of Huanglian Jiedu Decoction From Multi-Scale Perspective. *Front Pharmacol.* 2020 Dec 4;11:567088. doi: 10.3389/fphar.2020.567088.	Wang KX, Gao Y, Gong WX, Ye XF, Fan LY, Wang C, Gao XF, Gao L, Du GH, Qin XM, Lu AP, Guan DG.	5.811	6.006
Modified Huang-Lian-Jie-Du-Tang and its combination with memantine for Alzheimer disease: an in vivo study (abridged secondary publication). *Hong Kong Med J.* 2020 Dec;26 Suppl 7(6):33-36.	Durairajan SSK, Li M, Chung SK, Han QB, Iyaswamy A, Sreenivasmurthy SG, Malampati S, Kammala AK.	2.070	2.189
Peptide-based fluorescent chemical sensors for the specific detection of Cu2+ and S2-. *Inorg Chim Acta.* 2020 Dec 1; 513:119943. doi: 10.1016/j.ica.2020.119943.	Hao CW, Guo XM, Lai Q, Li YX, Fan BM, Zeng GZ, He ZX, Wu J.	2.545	2.235
Secreted PDZD2 exerts an insulinotropic effect on INS-1E cells by a PKA-dependent mechanism. *Mol Cell Endocrinol.* 2020 Dec 1;518:111026. doi: 10.1016/j.mce.2020.111026.	Fai So DH, Yan Chan JC, Tsui MG, Wai Tsang PS, Yao KM.	4.102	4.226
MALDI-MS Imaging Analysis of Noninflammatory Type III Rotaxane Dendrimers. *J Am Soc Mass Spectrom.* 2020 Dec 2;31(12):2488-2494. doi: 10.1021/jasms.0c00198.	Wang T, Cai Z, Chen Y, Lee WK, Kwan CS, Li M, Chan ASC, Chen ZF, Cheung AKL, Leung KC.	3.109	3.323
The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe? *Front Cell Dev Biol.* 2020 Dec 3;8:621428. doi: 10.3389/fcell.2020.621428.	Xu JL, Yuan L, Tang YC, Xu ZY, Xu HD, Cheng XD, Qin JJ.	6.684	7.219
Deciphering Antitumor Mechanism of Pien Tze Huang in Mice of Hepatocellular Carcinoma Based on Proteomics. *J Immunol Res.* 2020 Dec 3;2020:4876251. doi: 10.1155/2020/4876251.	Fan D, Liu C, Li L, Lu C, Zhao N, Shu J, He X, Lu A.	4.818	4.849
Diphyllin Improves High-Fat Diet-Induced Obesity in Mice Through Brown and Beige Adipocytes. *Front Endocrinol (Lausanne).* 2020 Dec 10;11:592818. doi: 10.3389/fendo.2020.592818.	Duan YN, Ge X, Jiang HW, Zhang HJ, Zhao Y, Li JL, Zhang W, Li JY.	5.555	5.456
Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. *Cell Metab.* 2020 Dec 17:S1550-4131(20)30652-5. doi: 10.1016/j.cmet.2020.11.017.	Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M, Wang S, Bao Y, Li H, Hu C, Dong B, Li D, Wu J, Xia J, Wang X, Lan K, Rajani C, Xie G, Lu A, Jia W, Jiang C, Jia W.	27.287	30.768
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. *Semin Cancer Biol.* 2020 Dec 25:S1044-579X(20)30275-3. doi: 10.1016/j.semcancer.2020.12.015.	Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, Ashraf GM.	15.707	14.564

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Kindlin-2 regulates skeletal homeostasis by modulating PTH1R in mice. *Signal Transduct Target Ther.* 2020 Dec 26;5(1):297. doi: 10.1038/s41392-020-00328-y.	Fu X, Zhou B, Yan Q, Tao C, Qin L, Wu X, Lin S, Chen S, Lai Y, Zou X, Shao Z, Wang M, Chen D, Jin W, Song Y, Cao H, Zhang G, Xiao G.	18.187	21.177
ALKAL1 gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway. *J Cancer.* 2021 Jan 1;12(1):150-162. doi: 10.7150/jca.46447.	Chen S, Wang B, Fu X, Liang Y, Chai X, Ye Z, Li R, He Y, Kong G, Lian J, Li X, Chen T, Zhang X, Qiu X, Tang X, Zhou K, Lin B, Zeng J.	4.207	4.277
Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: A mechanism review. *Biomed Pharmacother.* 2021 Jan;133:110968. doi: 10.1016/j.biopha.2020.110968.	Wang ZY, Liu J, Zhu Z, Su CF, Sreenivasmurthy SG, Iyaswamy A, Lu JH, Chen G, Song JX, Li M.	6.530	5.980
Transcription factor EB: an emerging drug target for neurodegenerative disorders. *Drug Discov Today.* 2021 Jan;26(1):164-172. doi: 10.1016/j.drudis.2020.10.013.	Song JX, Liu J, Jiang Y, Wang ZY, Li M.	7.851	8.458
Quantitative structure-toxicity relationship model for acute toxicity of organophosphates via multiple administration routes in rats and mice. *J Hazard Mater.* 2021 Jan 5;401:123724. doi: 10.1016/j.jhazmat.2020.123724.	Wang LL, Ding JJ, Pan L, Fu L, Tian JH, Cao DS, Jiang H, Ding XQ.	10.588	10.129
Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews. *World J Clin Cases.* 2021 Jan 6;9(1):102-117. doi: 10.12998/wjcc.v9.i1.102.	Dai L, Zhou WJ, Zhong LLD, Tang XD, Ji G.	1.337	1.742
Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials. *BMC Complement Med Ther.* 2021 Jan 6;21(1):11. doi: 10.1186/s12906-020-03176-z.	Wang Y, Liu B, Fu X, Tong T, Yu Z.	3.659	2.986
The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: a network meta-analysis. *BMC Gastroenterol.* 2021 Jan 7;21(1):23. doi: 10.1186/s12876-020-01593-5.	Hu Z, Li M, Yao L, Wang Y, Wang E, Yuan J, Wang F, Yang K, Bian Z, Zhong LLD.	3.067	3.441
QSAR-assisted-MMPA to expand chemical transformation space for lead optimization. *Brief Bioinform*. 2021 Jan 9:bbaa374. doi: 10.1093/bib/bbaa374.	Fu L, Yang ZY, Yang ZJ, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS.	11.622	10.288
BioMedR: an R/CRAN package for integrated data analysis pipeline in biomedical study. *Brief Bioinform.* 2021 Jan 18;22(1):474-484. doi: 10.1093/bib/bbz150.	Dong J, Zhu MF, Yun YH, Lu AP, Hou TJ, Cao DS.	11.622	10.288
Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study. *Front Oncol.* 2021 Jan 20;10:600298. doi: 10.3389/fonc.2020.600298.	Kwan HY, Xu Q, Gong R, Bian Z, Chu CC.	6.244	6.264
The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review. *Front Pharmacol.* 2021 Jan 25;11:578318. doi: 10.3389/fphar.2020.578318.	Chen L, Luo Z, Wang M, Cheng J, Li F, Lu H, He Q, You Y, Zhou X, Kwan HY, Zhao X, Zhou L.	5.811	6.006
Plant-derived isoquinoline alkaloids that target ergosterol biosynthesis discovered by using a novel antifungal screening tool. *Biomed Pharmacother.* 2021 Feb 9;137:111348. doi: 10.1016/j.biopha.2021.111348.	Wong-Deyrup SW, Song X, Ng TW, Liu XB, Zeng JG, Qing ZX, Deyrup ST, He ZD, Zhang HJ.	6.530	5.980
Benchmarking the mechanisms of frequent hitters: limitation of PAINS alerts. *Drug Discov Today.* 2021 Jun;26(6):1353-1358. doi: 10.1016/j.drudis.2021.02.003.	Yang ZY, Yang ZJ, He JH, Lu AP, Liu S, Hou TJ, Cao DS.	7.851	8.458
The Distinctive Serum Metabolomes of Gastric, Esophageal and Colorectal Cancers. *Cancers (Basel).* 2021 Feb 10;13(4):720. doi: 10.3390/cancers13040720.	Ren Z, Rajani C, Jia W.	6.639	6.999

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Therapeutic Effects of (5R)-5-Hydroxytriptolide on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via lncRNA WAKMAR2/miR-4478/E2F1/p53 Axis. *Front Immunol.* 2021 Feb 16;12:605616. doi: 10.3389/fimmu.2021.605616.	Zhou X, Xie D, Huang J, Lu A, Wang R, Jin Y, Zhang R, Chang C, Xu L, Xu L, Fan J, Liang C, He D.	7.561	7.624
A two-herb formula inhibits hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes. *Sci Rep.* 2021 Feb 16;11(1):3850. doi: 10.1038/s41598-021-83435-2.	Chen YJ, Liu YX, Wu JY, Li CY, Tang MM, Bai L, Fu XQ, Li JK, Chou JY, Yin CL, Wang YP, Bai JX, Wu Y, Wang XQ, Yu ZL.	4.380	5.134
Evaluation of Beneficial and Adverse Effects of a Diet Supplemented with Schisandrae Fructus Seed Ethanol Extract on Lipid and Glucose Metabolism in Normal and Hypercholesterolemic/Hyperglycemic Mice. *Evid Based Complement Alternat Med.* 2021 Feb 20;2021:8858962. doi: 10.1155/2021/8858962.	Wang XY, Song XL, Zhang Y, Luo G, Tai HC, Lin ZH, Zhu PL, Sun N, Chu ZS, Yu ZL, Pan SY, Tang JF, Ko KM.	2.630	2.846
Systems Pharmacology-Based Strategy to Explore the Pharmacological Mechanisms of Citrus Peel (Chenpi) for Treating Complicated Diseases. *Am J Chin Med.* 2021 Feb 20:1-21. doi: 10.1142/S0192415X2150018X.	Zhou W, Chen Z, Lu A, Liu Z.	4.667	4.135
Rectifying Attenuated Store-Operated Calcium Entry as a Therapeutic Approach for Alzheimer's Disease. *Curr Alzheimer Res.* 2020 Feb 22;17(12):1072-1087. doi: 10.2174/1567205018666210119150613.	Huang AS, Tong BCK, Wu AJ, Chen X, Sreenivasmurthy SG, Zhu Z, Liu J, Su C, Li M, Cheung KH.	3.498	4.083
Electroacupuncture ameliorates beta-amyloid pathology and cognitive impairment in Alzheimer disease via a novel mechanism involving activation of TFEB (transcription factor EB). *Autophagy.* 2021 Feb 23:1-15. doi: 10.1080/15548627.2021.1886720.	Zheng X, Lin W, Jiang Y, Lu K, Wei W, Huo Q, Cui S, Yang X, Li M, Xu N, Tang C, Song JX.	16.016	16.586
Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. *Front Med (Lausanne).* 2021 Feb 23;8:637652. doi: 10.3389/fmed.2021.637652.	Sang C, Yan H, Chan WK, Zhu X, Sun T, Chang X, Xia M, Sun X, Hu X, Gao X, Jia W, Bian H, Chen T, Xie G.	5.093	5.185
The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research. *Front Immunol.* 2021 Feb 25;12:602330. doi: 10.3389/fimmu.2021.602330.	Sun M, Chen Z, Wu X, Yu Y, Wang L, Lu A, Zhang G, Li F.	7.561	7.624
Animal models of cathartic colon. *World J Clin Cases.* 2021 Feb 26;9(6):1251-1258. doi: 10.12998/wjcc.v9.i6.1251.	Meng YY, Li QD, Feng Y, Liu J, Wang EK, Zhong L, Sun QL, Yuan JY.	1.337	1.742
Isolation of an acidic polysaccharide from the flowers of Leucosceptrum canum Smith and its immunomodulatory activity evaluation. *Int J Biol Macromol.* 2021 Feb 28;171:177-184. doi: 10.1016/j.ijbiomac.2021.01.009.	Ma F, Liu H, Xu S, Cheng Y, Fei Q, Chen H.	6.953	6.737
Amyloid-β oligomer targeted theranostic probes for in vivo NIR imaging and inhibition of self-aggregation and amyloid-β induced ROS generation. *Talanta.* 2021 Mar 1;224:121830. doi: 10.1016/j.talanta.2020.121830.	Wang X, Wang C, Chan HN, Ashok I, Krishnamoorthi SK, Li M, Li HW, Wong MS.	6.057	5.386
Structure of a laminarin-type β-(1→3)-glucan from brown algae Sargassum henslowianum and its potential on regulating gut microbiota. *Carbohydr Polym.* 2021 Mar 1;255:117389. doi: 10.1016/j.carbpol.2020.117389.	Cui Y, Zhu L, Li Y, Jiang S, Sun Q, Xie E, Chen H, Zhao Z, Qiao W, Xu J, Dong C.	9.381	8.678
Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer. *Life Sci.* 2021 Mar 1;268:118999. doi: 10.1016/j.lfs.2020.118999.	Aziz MA, Sarwar MS, Akter T, Uddin MS, Song X, Zhu Yu, Islam MS, Zhang HJ.	5.037	4.690
Hyocholic acid species as novel biomarkers for metabolic disorders. *Nat Commun.* 2021 Mar 5;12(1):1487. doi: 10.1038/s41467-021-21744-w.	Zheng X, Chen T, Zhao A, Ning Z, Kuang J, Wang S, You Y, Bao Y, Ma X, Yu H, Zhou J, Jiang M, Li M, Wang J, Ma X, Zhou S, Li Y, Ge K, Rajani C, Xie G, Hu C, Guo Y, Lu A, Jia W, Jia W.	14.919	15.805
Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach. *AAPS J.* 2021 Mar 4;23(2):38. doi: 10.1208/s12248-021-00559-z.	Zhang Y, Liu H, Tang MJ, Ho NJ, Shek TL, Yang Z, Zuo Z.	4.009	4.743

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
A Comparative Study for License Application Regulations on Proprietary Chinese Medicines in Hong Kong and Canada. *Front Med (Lausanne).* 2021 Mar 9;8:617625. doi: 10.3389/fmed.2021.617625.	Zhong LLD, Lam WC, Lu F, Tang XD, Lyu A, Bian Z, Boon H.	5.093	5.185
Factors Affecting Extracellular Vesicles Based Drug Delivery Systems. *Molecules.* 2021 Mar 11;26(6):1544. doi: 10.3390/molecules26061544.	Gaurav I, Thakur A, Iyaswamy A, Wang X, Chen X, Yang Z.	4.412	4.588
PySmash: Python package and individual executable program for representative substructure generation and application. *Brief Bioinform.* 2021 Mar 12:bbab017. doi: 10.1093/bib/bbab017.	Yang ZY, Yang ZJ, Zhao Y, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS.	11.622	10.288
Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. *EBioMedicine.* 2021 Mar 19;66:103290. doi: 10.1016/j.ebiom.2021.103290.	Xie G, Jiang R, Wang X, Liu P, Zhao A, Wu Y, Huang F, Liu Z, Rajani C, Zheng X, Qiu J, Zhang X, Zhao S, Bian H, Gao X, Sun B, Jia W.	8.143	8.333
Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease. *J Proteome Res.* 2021 Mar 23. doi: 10.1021/acs.jproteome.0c00852.	Sang C, Wang X, Zhou K, Sun T, Bian H, Gao X, Wang Y, Zhang H, Jia W, Liu P, Xie G, Chen T.	4.466	4.352
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy. *Front Cell Dev Biol.* 2021 Mar 29;9:626910. doi: 10.3389/fcell.2021.626910.	Ma Y, Yu S, Ni S, Zhang B, Kung ACF, Gao J, Lu A, Zhang G.	6.684	7.219
Airborne fine particulate matter induces cognitive and emotional disorders in offspring mice exposed during pregnancy. *Sci Bull.* 2021 Mar 30;66(6):578-591. doi. 10.1016/j.scib.2020.08.036.	Zhao C, Xie PS, Yong T, Huang W, Liu JJ, Wu DS, Ji FF, Li M, Zhang DD, Li RJ, Dong C, Ma J, Dong Z, Liu SJ, Cai ZW.	11.780	7.658
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. *Front Immunol.* 2021 Mar 30;12:658753. doi: 10.3389/fimmu.2021.658753.	Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, Wu X, Du F, Li M, Cho CH, Li J, Wen Q, Liu T, Yi T, Xiao Z.	7.561	7.624
Artificial Intelligence in Aptamer-Target Binding Prediction. *Int J Mol Sci.* 2021 Mar 30;22(7):3605. doi: 10.3390/ijms22073605.	Chen Z, Hu L, Zhang BT, Lu A, Wang Y, Yu Y, Zhang G.	5.923	6.132
Targeting long noncoding RNA PMIF facilitates osteoprogenitor cells migrating to bone formation surface to promote bone formation during aging. *Theranostics.* 2021 Mar 20;11(11):5585-5604. doi: 10.7150/thno.54477.	Li D, Liu J, Yang C, Tian Y, Yin C, Hu L, Chen Z, Zhao F, Zhang R, Lu A, Zhang G, Qian A.	11.556	11.629
A two-herb formula inhibits STAT3 signaling and exerts anti-melanoma effects in cell and animal models. *J Ethnopharmacol.* 2021 Mar 25;268:113671. doi: 10.1016/j.jep.2020.113671.	Li JK, Chou JY, Yin CL, Fu XQ, Wu Y, Chen YJ, Bai JX, Wu JY, Liang C, Yu ZL.	4.360	4.489
Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy. *Int J Biol Markers.* 2021 Mar 31:17246008211005473. doi: 10.1177/17246008211005473.	Zhang H, Li M, Kaboli PJ, Ji H, Du F, Wu X, Zhao Y, Shen J, Wan L, Yi T, Wen Q, Li X, Cho CH, Li J, Xiao Z.	2.659	2.309
Interaction of nobiletin with methotrexate ameliorates 7-OH methotrexate-induced nephrotoxicity through endoplasmic reticulum stress-dependent PERK/CHOP signaling pathway. *Pharmacol Res.* 2021 Mar;165:105371. doi: 10.1016/j.phrs.2020.105371.	Song Y, Liu L, Liu B, Liu R, Chen Y, Li C, Liu G, Song Z, Lu C, Lu A, Liu Y.	7.658	7.377
Triptolide delivery: Nanotechnology-based carrier systems to enhance efficacy and limit toxicity. *Pharmacol Res.* 2021 Mar;165:105377. doi: 10.1016/j.phrs.2020.105377.	Ren Q, Li M, Deng Y, Lu A, Lu J.	7.658	7.377
The advantages of using Scutellaria baicalensis and its flavonoids for the management of non-viral hepatocellular carcinoma. *J Funct Foods.* 2021 Mar;78(7):104389. doi: 10.1016/j.jff.2021.104389.	Chen MT, Xiao HT, Chen BS, Bian ZX, Kwan HY.	4.451	4.908
Ecological Study on Differences in COVID-19 Fatality among Wuhan, Rest of Hubei, and Rest of China. *J Epidemiol Glob Health.* 2021 Mar;11(1):42-45. doi: 10.2991/jegh.k.200902.001.	Ke Y, Cui J, Wong Y.	1.719	2.922

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Sensitization of Melanoma Cells to Nitrosourea Treatment by Orchestrating Oxidative Stress and IKK β inhibition. *Free Radic Biol Med.* 2021 Mar;65 (Supplement1):NC98. doi: 10.1016/j.freeradbiomed.2020.12.416.	Chen YJ, Tse AK, Fu XQ, Su T, Yu ZL.	7.376	7.934
Use of NAD tagSeq II to identify growth phase-dependent alterations in E. coli RNA NAD+ capping. *Proc Natl Acad Sci U S A.* 2021 Apr 6;118(14):e2026183118. doi: 10.1073/pnas.2026183118.	Zhang H, Zhong H, Wang X, Zhang S, Shao X, Hu H, Yu Z, Cai Z, Chen X, Xia Y.	11.205	12.291
Analysis of historical changes in traditional Chinese medicine based on an Indonesian collection of Chinese materia medica from c. 1870. *J Ethnopharmacol*. 2021 Apr 6;269:113714. doi: 10.1016/j.jep.2020.113714.	Jia Y, Lei L, Luo X, Zhao Z, Wang M, van Andel T.	4.360	4.489
Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma. *Front Immunol.* 2021 Apr 7;12:653836. doi: 10.3389/fimmu.2021.653836.	Xiang S, Li J, Shen J, Zhao Y, Wu X, Li M, Yang X, Kaboli PJ, Du F, Zheng Y, Wen Q, Cho CH, Yi T, Xiao Z.	7.561	7.624
Compensatory Transition of Bile Acid Metabolism from Fecal Disposition of Secondary Bile Acids to Urinary Excretion of Primary Bile Acids Underlies Rifampicin-Induced Cholestasis in Beagle Dogs. *ACS Pharmacol Transl Sci.* 2021 Apr 9;4(2):1001-1013. doi: 10.1021/acsptsci.1c00052.	Gui L, Wu Q, Hu Y, Zeng W, Tan X, Zhu P, Li X, Yang L, Jia W, Liu C, Lan K.	--	--
Natural Cyclopeptides as Anticancer Agents in the Last 20 Years. *Int J Mol Sci.* 2021 Apr 12;22(8):3973. doi: 10.3390/ijms22083973.	Zhang JN, Xia YX, Zhang HJ.	5.923	6.132
Transcriptomics-based analysis of the mechanism by which Wang-Bi capsule alleviates joint destruction in rats with collagen-induced arthritis. *Chin Med.* 2021 Apr 12;16(1):31. doi: 10.1186/s13020-021-00439-w.	Shu H, Zhao H, Shi Y, Lu C, Li L, Zhao N, Lu A, He X.	5.455	4.426
Corynoxine Protects Dopaminergic Neurons Through Inducing Autophagy and Diminishing Neuroinflammation in Rotenone-Induced Animal Models of Parkinson's Disease. *Front Pharmacol*. 2021 Apr 13;12:642900. doi: 10.3389/fphar.2021.642900.	Chen L, Huang Y, Yu X, Lu J, Jia W, Song J, Liu L, Wang Y, Huang Y, Xie J, Li M.	5.811	6.006
A Metabolite Array Technology for Precision Medicine. *Anal Chem.* 2021 Apr 13;93(14):5709-5717. doi: 10.1021/acs.analchem.0c04686.	Xie G, Wang L, Chen T, Zhou K, Zhang Z, Li J, Sun B, Guo Y, Wang X, Wang Y, Zhang H, Liu P, Nicholson JK, Ge W, Jia W.	6.986	6.755
Structural Biology for the Molecular Insight between Aptamers and Target Proteins. *Int J Mol Sci.* 2021 Apr 15;22(8):4093. doi: 10.3390/ijms22084093.	Zhang N, Chen Z, Liu D, Jiang H, Zhang ZK, Lu A, Zhang BT, Yu Y, Zhang G.	5.923	6.132
Exosomal transfer of osteoclast-derived miRNAs to chondrocytes contributes to osteoarthritis progression. *Nature Aging.* 2021 Apr 15;1(4):368-384. doi: 10.1038/s43587-021-00050-6.	Liu J, Wu X, Lu J, Huang G, Dang L, Zhang H, Zhong C, Zhang Z, Li D, Li F, Liang C, Yu Y, Zhang B, Chen L, Lu A, Zhang G	--	--
Stable Axially Chiral Isomers of Arylnaphthalene Lignan Glycosides with Antiviral Potential Discovered from Justicia procumbens. *J Org Chem.* 2021 Apr 16;86(8):5568-5583. doi: 10.1021/acs.joc.1c00068.	Zhao Y, Ku CF, Xu XY, Tsang NY, Zhu Y, Zhao CL, Liu KL, Li CC, Rong L, Zhang HJ.	4.354	4.082
Serum metabolic signatures of subclinical atherosclerosis in patients with type 2 diabetes mellitus: a preliminary study. *Acta Diabetol.* 2021 Apr 19. doi: 10.1007/s00592-021-01717-7.	Su J, Zhao Q, Zhao A, Jia W, Zhu W, Lu J, Ma X.	4.280	3.770
Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies. *Front Pharmacol.* 2021 Apr 22;12:644219. doi: 10.3389/fphar.2021.644219.	Su CF, Jiang L, Zhang XW, Iyaswamy A, Li M.	5.811	6.006
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. *Nucleic Acids Res.* 2021 Jul 2;49(W1):W5-W14. doi: 10.1093/nar/gkab255.	Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D.	16.971	15.542
Massage therapy in infants and children under 5 years of age: protocol for an overview of systematic reviews. *Syst Rev.* 2021 Apr 28;10(1):127. doi: 10.1186/s13643-021-01681-x.	Chen SC, Yu J, Yuen SC, Lam JC, Suen LK, Yeung WF.	2.522	5.039

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Hyocholic acid and glycemic regulation: comments on 'Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism'. *J Mol Cell Biol.* 2021 Apr 30:mjab027. doi: 10.1093/jmcb/mjab027.	Jia W, Rajani C, Zheng X, Jia W.	6.216	6.688
A missense mutation sheds light on a novel structure-function relationship of RANKL. *J Cell Physiol.* 2021 Apr;236(4):2800-2816. doi: 10.1002/jcp.30045.	Qiu H, Qin A, Cheng T, Chim SM, Smithers L, Chen K, Song D, Liu Q, Zhao J, Wang C, Teguh D, Zhang G, Tickner J, Vrielink A, Pavlos NJ, Xu J.	6.384	5.988
The Complete Mitochondrial Genome of Lepidotrigona flavibasis (Hymenoptera: Meliponini) and High Gene Rearrangement in Lepidotrigona Mitogenomes. *J Insect Sci.* 2021 May 1;21(3):10. doi: 10.1093/jisesa/ieab038.	Wang CY, Zhao M, Wang SJ, Xu HL, Yang YM, Liu LN, Feng Y.	1.857	1.904
Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors. *Brief Bioinform.* 2021 May 3:bbab135. doi: 10.1093/bib/bbab135.	Zhao Y, Wang XG, Ma ZY, Xiong GL, Yang ZJ, Cheng Y, Lu AP, Huang ZJ, Cao DS.	11.622	10.288
Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis. *Front Pharmacol.* 2021 May 5;12:657080. doi: 10.3389/fphar.2021.657080.	Chen M, Wu HL, Wong TS, Chen B, Gong RH, Wong HLX, Xiao H, Bian Z, Kwan HY.	5.811	6.006
Cytotoxic tigliane diterpenoids from Euphorbia neorubella. *Nat Prod Res.* 2021 May 7:1-5. doi: 10.1080/14786419.2021.1924712.	Chen S, Tsang NY, Jiang H, Zhang H, Ge X, Wu Y, Shen Y, Xie W, Li J.	2.862	2.572
Mouse Spexin: (III) Differential Regulation by Glucose and Insulin in Glandular Stomach and Functional Implication in Feeding Control. *Front Endocrinol (Lausanne).* 2021 May 7;12:681648. doi: 10.3389/fendo.2021.681648.	Chen Y, He M, Lei MML, Ko WKW, Lin C, Bian Z, Wong AOL.	5.555	5.456
A hybrid platform featuring nanomagnetic ligand fishing for discovering COX-2 selective inhibitors from aerial part of Saussurea laniceps Hand.-Mazz. *J Ethnopharmacol.* 2021 May 10;271:113849. doi: 10.1016/j.jep.2021.113849.	Chen Q, Zhu L, Yip KM, Tang Y, Liu Y, Jiang T, Zhang J, Zhao Z, Yi T, Chen H.	4.360	4.489
Structural analogues in herbal medicine ginseng hit a shared target to achieve cumulative bioactivity. *Commun Biol.* 2021 May 10;4(1):549. doi: 10.1038/s42003-021-02084-3.	Zhang W, Tao WW, Zhou J, Wu CY, Long F, Shen H, Zhu H, Mao Q, Xu J, Li SL, Wu QN.	6.268	6.268
Ginseng ameliorates exercise-induced fatigue potentially by regulating the gut microbiota. *Food Funct.* 2021 May 11;12(9):3954-3964. doi: 10.1039/d0fo03384g.	Zhou SS, Zhou J, Xu JD, Shen H, Kong M, Yip KM, Han QB, Zhao ZZ, Xu J, Chen HB, Li SL.	5.396	5.536
Ubiquitination Regulators Discovered by Virtual Screening for the Treatment of Cancer. *Front Cell Dev Biol.* 2021 May 12;9:665646. doi: 10.3389/fcell.2021.665646.	Song YQ, Wu C, Wu KJ, Han QB, Miao XM, Ma DL, Leung CH.	6.684	7.219
Tertiary Oxidation of Deoxycholate Is Predictive of CYP3A Activity in Dogs. *Drug Metab Dispos.* 2021 May;49(5):369-378. doi: 10.1124/dmd.121.000385.	Zeng W, Gui L, Tan X, Zhu P, Hu Y, Wu Q, Li X, Yang L, Jia W, Liu C, Lan K.	3.922	4.237
Hierarchical drug release designed Au @PDA-PEG-MTX NPs for targeted delivery to breast cancer with combined photothermal-chemotherapy. *J Nanobiotechnology.* 2021 May 17;19(1):143. doi: 10.1186/s12951-021-00883-8.	Li W, Cao Z, Yu L, Huang Q, Zhu D, Lu C, Lu A, Liu Y.	10.435	9.151
A network meta-analysis on the effectiveness and safety of acupuncture in treating patients with major depressive disorder. *Sci Rep.* 2021 May 17;11(1):10384. doi: 10.1038/s41598-021-88263-y.	Hu ZC, Lam WC, Li HJ, Yao L, Wang ZY, Huang WY, Bian ZX, Zhong LD.	4.380	5.134
Dickkopf-1: A Promising Target for Cancer Immunotherapy. *Front Immunol.* 2021 May 20;12:658097. doi: 10.3389/fimmu.2021.658097.	Chu HY, Chen Z, Wang L, Zhang ZK, Tan X, Liu S, Zhang BT, Lu A, Yu Y, Zhang G.	7.561	7.624
A Cross-sectional literature survey showed the reporting quality of multicenter randomized controlled trials should be improved. *J Clin Epidemiol.* 2021 May 21;137:250-261. doi: 10.1016/j.jclinepi.2021.05.008.	Zhang X, Lam WC, Liu F, Li M, Zhang L, Xiong W, Zhou X, Tian R, Dong C, Yao C, Moher D, Bian Z.	6.437	7.302

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Investigation of the Mechanism of Complement System in Diabetic Nephropathy via Bioinformatics Analysis. *J Diabetes Res.* 2021 May 24;2021:5546199. doi: 10.1155/2021/5546199.	Xu B, Wang L, Zhan H, Zhao L, Wang Y, Shen M, Xu K, Li L, Luo X, Zhou S, Tang A, Liu G, Song L, Li Y.	4.011	4.369
Radix Astragali polysaccharide RAP directly protects hematopoietic stem cells from chemotherapy-induced myelosuppression by increasing FOS expression. *Int J Biol Macromol.* 2021 Jul 31;183:1715-1722. doi: 10.1016/j.ijbiomac.2021.05.120.	Bao W, Zhang Q, Zheng H, Li L, Liu M, Cheng H, Wong T, Zhang G, Lu A, Bian Z, Ma D, Leung C, Han Q.	6.953	6.737
COVID-19 Rehabilitation With Herbal Medicine and Cardiorespiratory Exercise: Protocol for a Clinical Study. *JMIR Res Protoc.* 2021 May 26;10(5):e25556. doi: 10.2196/25556.	Gao Y, Zhong LLD, Quach B, Davies B, Ash GI, Lin ZX, Feng Y, Lau BWM, Wagner PD, Yang X, Guo Y, Jia W, Bian Z, Baker JS.	--	--
Plant-derived lignans as potential antiviral agents: a systematic review. *Phytochem Rev.* 2021 May 31:1-51. doi: 10.1007/s11101-021-09758-0.	Xu XY, Wang DY, Li YP, Deyrup ST, Zhang HJ.	5.374	6.048
Sustaining Healthy Staying Communities in University Residential Halls amid Unprecedented Pandemic. *Sustainability.* 2021 Jun; 13(11). doi: 10.3390/su13116176.	Cheng MWT, Leung ML, Yu CWM, Yue KKM, Liu ESC, Chu SKW.	3.251	3.473
Clinical reasoning in traditional medicine exemplified by the clinical encounter of Korean medicine: a narrative review. *Integr Med Res.* 2021 Jun;10(2):100641. doi: 10.1016/j.imr.2020.100641.	Kim TH, Alraek T, Bian ZX, Birch S, Bovey M, Lee J, Lee MS, Robinson N, Zaslawski C.	2.379	3.114
Lung microbiome alterations in NSCLC patients. *Sci Rep.* 2021 Jun 3;11(1):11736. doi: 10.1038/s41598-021-91195-2.	Zheng L, Sun R, Zhu Y, Li Z, She X, Jian X, Yu F, Deng X, Sai B, Wang L, Zhou W, Wu M, Li G, Tang J, Jia W, Xiang J.	4.380	5.134
Computational Bioactivity Fingerprint Similarities To Navigate the Discovery of Novel Scaffolds. *J Med Chem.* 2021 Jun 10;64(11):7544-7554. doi: 10.1021/acs.jmedchem.1c00234.	Xiong GL, Zhao Y, Liu L, Ma ZY, Lu AP, Cheng Y, Hou TJ, Cao DS.	7.446	7.319
Inflammatory properties of ribosome-inactivating protein momorcharin derived from bitter melon: abridged secondary publication. *Hong Kong Med J.* 2021 Jun;27 Suppl 2(3):14-17.	Chen YJ, Yu ZL, Tse AKW.	2.070	2.189
Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. *Gut Microbes.* 2021 Jun 14;13(1):1-20. doi: 10.1080/19490976.2021.1930874.	Hong Y, Sheng L, Zhong J, Tao X, Zhu W, Ma J, Yan J, Zhao A, Zheng X, Wu G, Li B, Han B, Ding K, Zheng N, Jia W, Li H.	10.245	12.117
Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes. *BMJ Open Diabetes Res Care.* 2021 Jun;9(1):e002199. doi: 10.1136/bmjdrc-2021-002199.	Ying L, Jian C, Ma X, Ge K, Zhu W, Wang Y, Zhao A, Zhou J, Jia W, Bao Y.	3.388	3.980
MUC1: Structure, Function, and Clinic Application in Epithelial Cancers. *Int J Mol Sci.* 2021 Jun 18;22(12):6567. doi: 10.3390/ijms22126567.	Chen W, Zhang Z, Zhang S, Zhu P, Ko JK, Yung KK.	5.923	6.132
Natural Products for Neurodegeneration: Regulating Neurotrophic Signals. *Oxid Med Cell Longev.* 2021 Jun 21;2021:8820406. doi: 10.1155/2021/8820406.	Uddin MS, Mamun AA, Rahman MM, Jeandet P, Alexiou A, Behl T, Sarwar MS, Sobarzo-Sánchez E, Ashraf GM, Sayed AA, Albadrani GM, Peluso I, Abdel-Daim MM.	6.543	7.454
Regulatory effect of volatile compounds in fermented alcoholic beverages on gut microbiota and serum metabolism in a mouse model. *Food Funct.* 2021 Jun 21;12(12):5576-5590. doi: 10.1039/d0fo03028g.	Ji M, Fang C, Jia W, Du H, Xu Y.	5.396	5.536
Rubesanolides F and G: Two Novel Lactone-Type Norditerpenoids from Isodon rubescens. *Molecules.* 2021 Jun 24;26(13):3865. doi: 10.3390/molecules26133865.	He K, Zou J, Wang YX, Zhao CL, Ye JH, Zhang JJ, Pan LT, Zhang HJ.	4.412	4.588
Trustworthiness assessment for industrial IoT as multilayer networks with von Neumann entropy. *Appl Soft Comput.* 2020 Jul; 106:107342. doi: 10.1016/j.asoc.2021.107342.	Wu X, Wang JJ, Wang P, Bian ZX, Huang T, Guo YK, Fujita H.	6.725	6.607

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Ensemble machine learning to evaluate the in vivo acute oral toxicity and in vitro human acetylcholinesterase inhibitory activity of organophosphates. *Arch Toxicol.* 2021 Jul;95(7):2443-2457. doi: 10.1007/s00204-021-03056-6.	Wang L, Ding J, Shi P, Fu L, Pan L, Tian J, Cao D, Jiang H, Ding X.	5.153	6.352
Application of Nanotechnology in Analysis and Removal of Heavy Metals in Food and Water Resources. *Nanomaterials (Basel).* 2021 Jul 9;11(7):1792. doi: 10.3390/nano11071792.	Gong Z, Chan HT, Chen Q, Chen H.	5.076	5.346
Mouse Spexin: (I) NMR Solution Structure, Docking Models for Receptor Binding, and Histological Expression at Tissue Level. *Front Endocrinol (Lausanne).* 2021 Jul 2;12:681646. doi: 10.3389/fendo.2021.681646.	Wong MKH, He M, Sze KH, Huang T, Ko WKW, Bian ZX, Wong AOL.	5.555	5.456
Mouse Spexin: (II) Functional Role as a Satiety Factor inhibiting Food Intake by Regulatory Actions Within the Hypothalamus. *Front Endocrinol (Lausanne).* 2021 Jul 2;12:681647. doi: 10.3389/fendo.2021.681647.	Wong MKH, Chen Y, He M, Lin C, Bian Z, Wong AOL.	5.555	5.456
Weight changes in hypertensive patients with phlegm-dampness syndrome: an integrated proteomics and metabolomics approach. *Chin Med.* 2021 Jul 7;16(1):54. doi: 10.1186/s13020-021-00462-x.	Zhang C, Li L, Cheng S, Chowdhury D, Tan Y, Liu X, Zhao N, He X, Jiang M, Lu C, Lyu A.	5.455	4.426
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. *Front Immunol.* 2021 Jul 9;12:686155. doi: 10.3389/fimmu.2021.686155.	Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C.	7.561	7.624
A proprietary herbal drug Young Yum Pill ameliorates chronic fatigue syndrome in mice. *Phytomedicine.* 2021 Jul 15;88:153602. doi: 10.1016/j.phymed.2021.153602.	Yin C, Fu X, Chou J, Li J, Chen Y, Bai J, Wu J, Wu Y, Wang X, Yu ZL.	5.340	5.161
Potential Role of Traditional Chinese Medicines by Wnt/β-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy. *Front Pharmacol.* 2021 Jul 26;12:690501. doi: 10.3389/fphar.2021.690501.	Chang J, Wong XHL, Chen D, Liu Y, Li H, Bian Z.	5.811	6.006
Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease. *Autophagy.* 2021 Jul 27:1-19. doi: 10.1080/15548627.2021.1945220.	Tong BC, Wu AJ, Huang AS, Dong R, Malampati S, Iyaswamy A, Krishnamoorthi S, Sreenivasmurthy SG, Zhu Z, Su C, Liu J, Song J, Lu JH, Tan J, Pan W, Li M, Cheung KH.	16.016	16.586
A Scoping Review of Cross-Sectional Studies on Traditional Chinese Medicine. *Am J Chin Med.* 2021;49(6):1275-1296. doi: 10.1142/S0192415X21500610.	Duan Y, Xu Z, Lin Y, Miao J, Chen J, Guo H, Zheng Y, Deng J, Tang X, Lee HC, Zhang X, Zhao L, Bian Z.	4.667	4.135
Assessment of the reporting quality of randomised controlled trials of massage. *Chin Med.* 2021 Jul 28;16(1):64. doi: 10.1186/s13020-021-00475-6.	Zhang X, Zhang L, Xiong W, Wang X, Zhou X, Zhao C, Tian G, Shang H, Wu T, Miao J, Bian Z.	5.455	4.426
Phytochemicals as regulators of Th17/Treg balance in inflammatory bowel diseases. *Biomed Pharmacother.* 2021 Jul 20;141:111931. doi: 10.1016/j.biopha.2021.111931.	Chang Y, Zhai L, Peng J, Wu H, Bian Z, Xiao H.	6.530	5.980
Qingyangshen mitigates amyloid-β and Tau aggregate defects involving PPARα-TFEB activation in transgenic mice of Alzheimer's disease. *Phytomedicine.* 2021 Jul 12;91:153648. doi: 10.1016/j.phymed.2021.153648.	Iyaswamy A, Krishnamoorthi SK, Zhang H, Sreenivasmurthy SG, Zhu Z, Liu J, Su CF, Guan XJ, Wang ZY, Cheung KH, Song JX, Durairajan SSK, Li M.	5.340	5.161
Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. *Am J Cancer Res.* 2021 Jul 15;11(7):3445-3460.	Chen Y, Liu R, Li C, Song Y, Liu G, Huang Q, Yu L, Zhu D, Lu C, Lu A, Li L, Liu Y.	6.166	5.863
An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells. *Bioorg Chem.* 2021 Jul 9;114:105158. doi: 10.1016/j.bioorg.2021.105158.	Yang GJ, Song YQ, Wang W, Han QB, Ma DL, Leung CH.	5.275	5.252

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
Clinical Evidence-Guided Anti-rheumatoid Arthritis Study of Shuji Tablet in Adjuvant-Induced Arthritis Rats and Mechanism Exploration via Network Pharmacological Approach. *Front Pharmacol.* 2021 Jul 29;12:694507. doi: 10.3389/fphar.2021.694507.	Dai W, Yang J, Cao H, Wang Z, Li G, Zhong X, Peng W, Chen C, Liu X, Zeng C, Hu X.	5.811	6.006
The current understanding on the impact of KRAS on colorectal cancer. *Biomed Pharmacother.* 2021 Aug;140:111717. doi: 10.1016/j.biopha.2021.111717.	Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T.	6.530	5.980
Role of Autophagy in the Maintenance of Stemness in Adult Stem Cells: A Disease-Relevant Mechanism of Action. *Front Cell Dev Biol.* 2021 Aug 3;9:715200. doi: 10.3389/fcell.2021.715200.	Chen S, Wang W, Tan HY, Lu Y, Li Z, Qu Y, Wang N, Wang D.	6.684	7.219
Featurization strategies for protein-ligand interactions and their applications in scoring function development. *Wiley Interdiscip Rev Comput Mol Sci.* 2021 Aug 3. doi: 10.1002/wcms.1567.	Xiong GL, Shen C, Yang ZY, Jiang DJ, Liu S, Lu AP, Chen X, Hou TJ, Cao DS.	25.113	16.743
Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism. *Cell Death Dis.* 2021 Aug 12;12(8):791. doi: 10.1038/s41419-021-04076-x.	Hu X, Fatima S, Chen M, Xu K, Huang C, Gong RH, Su T, Wong HLX, Bian Z, Kwan HY.	8.469	8.713
Developing urinary pyrrole-amino acid adducts as non-invasive biomarkers for identifying pyrrolizidine alkaloids-induced liver injury in human. *Arch Toxicol.* 2021 Aug 14:1-14. doi: 10.1007/s00204-021-03129-6.	Zhu L, Zhang C, Zhang W, Xia Q, Ma J, He X, He Y, Fu PP, Jia W, Zhuge Y, Lin G.	5.153	6.352
Activation of PPARα-catalase pathway reverses alcoholic liver injury via upregulating NAD synthesis and accelerating alcohol clearance. *Free Radic Biol Med.* 2021 Aug 11:S0891-5849(21)00464-0. doi: 10.1016/j.freeradbiomed.2021.08.005.	Yue R, Chen GY, Xie G, Hao L, Guo W, Sun X, Jia W, Zhang Q, Zhou Z, Zhong W.	7.376	7.934
Neolignans and Diarylheptanoids with Anti-Inflammatory Activity from the Rhizomes of Alpinia zerumbet. *J Agric Food Chem.* 2021 Aug 18;69(32):9229-9237. doi: 10.1021/acs.jafc.1c02271.	Zhang Y, Yu YY, Peng F, Duan WT, Wu CH, Li HT, Zhang XF, Shi YS.	5.279	5.269
How Perturbated Metabolites in Diabetes Mellitus Affect the Pathogenesis of Hypertension? *Front Physiol.* 2021 Aug 18;12:705588. doi: 10.3389/fphys.2021.705588.	Ning Z, Song Z, Wang C, Peng S, Wan X, Liu Z, Lu A.	4.566	4.805
Editorial: Predicting High-Risk Individuals for Common Diseases Using Multi-Omics and Epidemiological Data. *Front Genet.* 2021 Aug 18;12:737598. doi: 10.3389/fgene.2021.737598.	Chowdhury D, Zhou X, Li B, Zhang Y, Cheung WK, Lu A, Zhang L.	4.599	4.888
Current Pharmacological Strategies for Duchenne Muscular Dystrophy. *Front Cell Dev Biol.* 2021 Aug 19;9:689533. doi: 10.3389/fcell.2021.689533.	Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G, Zhang Z, Zhang B.	6.684	7.219
TFEB, a master regulator of autophagy and biogenesis, unexpectedly promotes apoptosis in response to the cyclopentenone prostaglandin 15d-PGJ2. *Acta Pharmacol Sin.* 2021 Aug 20. doi: 10.1038/s41401-021-00711-7.	Yang CB, Liu J, Tong BC, Wang ZY, Zhu Z, Su CF, Sreenivasmurthy SG, Wu JX, Iyaswamy A, Krishnamoorthi S, Huang SY, Cheung KH, Song JX, Tan JQ, Lu JH, Li M.	6.150	6.124

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
DeepDRIM: a deep neural network to reconstruct cell-type-specific gene regulatory network using single-cell RNA-seq data. *Brief Bioinform.* 2021 Aug 23:bbab325. doi: 10.1093/bib/bbab325.	Chen J, Cheong C, Lan L, Zhou X, Liu J, Lyu A, Cheung WK, Zhang L.	11.622	10.288
Learning to SMILES: BAN-based strategies to improve latent representation learning from molecules. *Brief Bioinform.* 2021 Aug 24:bbab327. doi: 10.1093/bib/bbab327.	Wu CK, Zhang XC, Yang ZJ, Lu AP, Hou TJ, Cao DS.	11.622	10.288
Would integrated Western and traditional Chinese medicine have more benefits for stroke rehabilitation? A systematic review and meta-analysis. *Stroke Vasc Neurol.* 2021 Aug 26:svn-2020-000781. doi: 10.1136/svn-2020-000781.	Zhong LL, Zheng Y, Lau AY, Wong N, Yao L, Wu X, Shao T, Lu Z, Li H, Yuen CS, Guo J, Lo S, Chau J, Chan KW, Ng BFL, Bian Z, Yu EC.	4.081	6.174
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). *Am J Chin Med.* 2020;48(6):1279-1313. doi: 10.1142/S0192415X20500639.	Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z.	4.667	4.135
*〈雪蓮的化學成分及藥理作用研究進展〉，載《藥學學報》，第55卷第(7)期，頁 1466-1477。	楊璐銘，陳虎彪，郭喬如，波拉提，周雯敏，黃佩敏，吳增寶，張建業	--	--
*〈CONSORT 2010聲明：針對隨機先導性和可行性試驗的擴展〉，載《中國循證醫學雜誌》，第21卷第(3)期。	蔣寅，劉岩，商洪才，張弛，段玉婷，卞兆祥	--	--
*〈CONSORT-SPI 2018的解釋與說明：社會和心理干預措施試驗報告規範〉，載《中國循證醫學雜誌》，第20卷第(2)期。	黃耀連，劉凡，段玉婷，卞兆祥，張弛，陳耀龍	--	--
*〈CONSORT聲明：在牙科矯正臨床試驗中的擴展與應用〉，載《中國循證醫學雜誌》，第21卷第(2)期	趙晨，付姝菲，段玉婷，張弛，商洪才，卞兆祥	--	--
*〈中醫藥單病例隨機對照試驗報告規範(中醫藥CENT)：CENT聲明的擴展、說明與詳述〉，載《中國循證醫學雜誌》，第21卷第(3)期。	胡嘉元，李江，翟靜波，李博，田金徽，馬彬，楊克虎，代敏，田貴華，商洪才，張弛，段玉婷，卞兆祥	--	--
*〈中醫藥單病例隨機對照試驗報告規範(中醫藥CENT)：CENT聲明的擴展、說明與詳述〉，載《中國循證醫學雜誌》，第21卷第(3)期。	胡嘉元，李江，翟靜波，李博，田金徽，馬彬，楊克虎，代敏，田貴華，商洪才，張弛，段玉婷，卞兆祥	--	--
*〈中醫藥防治新冠肺炎臨床證據質量的提升〉，載《科學通報》。	卞兆祥	--	--
*〈衛生保健模擬研究報告規範：基於CONSORT和STROBE聲明的擴展〉，載《中國循證醫學雜誌》，第21卷第(2)期。	王家瑩，付姝菲，段玉婷，張弛，商洪才，卞兆祥	--	--
*〈基於麻子仁丸治療功能性便秘複方研究的整合醫學模式探討〉，載《中醫雜誌》。	卞兆祥，鄭頌華，趙晨，張軒，黃韜，林成源，商洪才，鐘麗丹	--	--
*〈多臂平行對照隨機臨床試驗報告規範：CONSORT 2010聲明擴展版〉，載《中國循證醫學雜誌》，第21卷第(2)期。	魏旭煦，劉岩，胡嘉元，蔣寅，商洪才，張弛，段玉婷，卞兆祥	--	--
*〈報告草藥干預措施隨機對照試驗的建議：解釋和說明〉，載《中國循證醫學雜誌》，第2卷。	田然，林偉青，段玉婷，商洪才，張弛，卞兆祥	--	--
*〈更好地報告干預措施：描述干預措施的範本和報告規範〉，載《中國循證醫學雜誌》，第20卷第(12)期，頁 1439-1448。	陳玨璇，段玉婷，卞兆祥，張弛，陳耀龍	--	--
*〈社會及心理干預措施隨機試驗報告規範：CONSORT-SPI 2018擴展版〉，載《中國循證醫學雜誌》，第20卷第(12)期，頁 1449-1457。	黃耀連，劉凡，段玉婷，卞兆祥，張弛，陳耀龍	--	--
*〈系統評價報告規範：PRISMA 2020與PRISMA 2009的對比分析與實例解讀〉，載《中國循證醫學雜誌》，第21卷第(5)期，頁 606-616。	高亞，劉明，楊珂璐，葛龍，李倫，李江，孫鳳，楊智榮，武珊珊，董聖傑，張天嵩，肖月，吳嘉瑞，張俊華，卞兆祥，田金徽	--	--
*〈肺病患者先天運氣稟賦與後天發病運氣之關聯研究〉，載《中華中醫藥雜誌》，第35卷第(11)期，頁 5436-5442。	張軒，劉忠第，賀娟	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2020-2021 Research Papers			
*〈草藥干預措施隨機對照試驗報告：CONSORT擴展聲明〉，載《中國循證醫學雜誌》，第21卷第(1)期，頁 97-99。	田然，林偉青，段玉婷，卞兆祥，張弛，商洪才	--	--
*〈進一步提升中國臨床研究的報告質量〉，載《中國循證醫學雜誌》，第20卷第(12)期，頁 1365-1366。	卞兆祥，李幼平，DAVID MOHER	--	--
*〈隨機對照試驗中的患者報告結局：CONSORT PRO擴展版〉，載《中國循證醫學雜誌》，第21卷第(3)期，頁 347-354。	陳澤，陳玨璇，段玉婷，張弛，陳耀龍，卞兆祥	--	--
*〈黃帝內經運氣思想在疾病發生與藥物治療的應用研究〉，載《中華中醫藥雜誌》，第36卷第(6)期，頁 29-32。	張軒，劉忠第，賀娟	--	--
*〈基於"三年化疫"理論探討香港地區痢疾發病與氣象因素的相關性〉，載《中華中醫藥雜誌》，第37卷第(1)期，頁 333-336。	黃涵婧，劉忠第，梁峰，張軒	--	--
*〈基於"三年化疫"理論探討香港地區水痘發病與不同時期氣象變化的關聯性〉，載《中醫藥導報》，第27卷第(7)期，頁 190-195。	王喜紅，周小涵，黃涵婧，張林，陳夢琳，劉忠第，梁峰，張軒	--	--
*〈基於運氣理論探討香港呼吸道傳染病與氣象因素的相關性〉，載《中醫藥學報》，第49卷第(7)期，頁1-6。	張林，陳子穎，劉忠第，梁峰，張軒	--	--
*〈疫病流行與六氣之少陰、少陽的關聯探析〉，載《中醫藥學報》，第49卷第(9)期，頁43-49。	周小涵，陳夢琳，熊為鋒，劉忠第，張軒，賀娟	--	--
*〈基於加權基因共表達網絡分析槲皮素抗胃癌的基因模塊和分子標誌物研究〉，載《世界中醫藥》，2021年16卷(4)期，頁 546-552。	張林，歐祥琴，張濤，鐘凱，吳學會，李睿思，李青璿，梁峰，張軒	--	--
2020-2021 Books			
《中華醫學百科全書 • 中西醫結合醫學》，中國協和醫科大學出版社，ISBN：978-7567-915121。	主編：呂愛平 副主編：卞兆祥	--	--
《百藥鑑別》(韓文版)，ISBN：979-11-88847-89-1 93510。	主編：趙中振 (與李應生)	--	--
《中國中成藥名方藥效與應用叢書—內分泌代謝、風濕免疫、泌尿男生殖卷》，科學出版社，ISBN: 978-7-03-066635-2。	風濕免疫冊主編：呂愛平 (與劉孟宇)	--	--
《中藥材鑒定圖典》(德文版 Pflanzen und Minerale der Chinesischen Medizin)，ISBN: 978-3-926936-20-2。	主編：趙中振、陳虎彪	--	--
《ISO中醫藥國際標準理論研究與實踐》，上海遠東出版社，ISBN: 978-7-5478-5079-4。	副主編：呂愛平 (與桑珍)	--	--
《域外本草記》，北京科學技術出版社，ISBN: 978-7-5714-0551-9。	趙中振	--	--
《中藥原植物鑒定圖典》，福建科學技術出版社，ISBN：987-7-5335-6203-8。	陳虎彪、趙中振	--	--
Novel Drug Delivery Systems for Chinese Medicines, Springer, ISBN: 978-981-16-3443-7.	Yang Zhijun (with Feng Nianping)	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Roles of Glutamate Receptors in Parkinson's Disease. *Int J Mol Sci.* 2019 Sep 6;20(18):4391. doi: 10.3390/ijms20184391.	Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK, Yung KK.	5.924	6.132
The use of pattern differentiation in WHO-registered traditional Chinese medicine trials - A systematic review. *Eur J Integr Med.* 2019 Sep; 30:100945. doi: 10.1016/j.eujim.2019.100945. Review.	Zhang X, Tian R, Zhao C, Birch S, Lee JA, Alreak T, Bovey M, Zaslawski C, Robinson N, Kim TH, Lee MS, Bian ZX.	1.314	1.491
Reporting quality of 2014-2018 clinical practice guidelines on diabetes according to the RIGHT checklist. *Endocrine.* 2019 Sep;65(3):531-541. doi: 10.1007/s12020-019-02005-9.	Wang Q, Duan Y, Liang J, Chen Z, Chen J, Zheng Y, Chen Y, Tang C.	3.633	3.613
Signal transducer and activator of transcription-3 drives the high-fat diet-associated prostate cancer growth. *Cell Death Dis.* 2019 Sep 2;10(9):637. doi: 10.1038/s41419-019-1842-4.	Kwan HY, Liu B, Huang C, Fatima S, Su T, Zhao X, Ho AHM, Han Q, Hu X, Gong RH, Chen M, Wong HLX, Bian Z.	8.469	8.713
Safety and antifatigue effect of Korean Red Ginseng: a randomized, double-blind, and placebo-controlled clinical trial. *J Ginseng Res.* 2019 Oct;43(4):676-683. doi: 10.1016/j.jgr.2019.05.006.	Zhang L, Chen X, Cheng Y, Chen Q, Tan H, Son D, Chang D, Bian Z, Fang H, Xu H.	6.060	5.711
Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice. *Biomed Pharmacother.* 2019 Oct;118:109206. doi: 10.1016/j.biopha.2019.109206	Hou Q, Zhu S, Zhang C, Huang Y, Guo Y, Li P, Chen X, Wen Y, Han Q, Liu F.	6.530	5.980
Investigation of the molecular state of 4-aminosalicylic acid in matrix formulations for dry powder inhalers using solid-state fluorescence spectroscopy of 4-dimethylaminobenzonitrile. *Adv Powder Technol.* 2019 Oct, 30(10):2422-2429. doi: 10.1016/j.apt.2019.07.027.	Tse JY, Kadota K, Yang ZJ, Uchiyama H, Tozuka Y	4.833	4.650
m1A Regulated Genes Modulate PI3K/AKT/mTOR and ErbB Pathways in Gastrointestinal Cancer. *Transl Oncol.* 2019 Oct;12(10):1323-1333. doi: 10.1016/j.tranon.2019.06.007.	Zhao Y, Zhao Q, Kaboli PJ, Shen J, Li M, Wu X, Yin J, Zhang H, Wu Y, Lin L, Zhang L, Wan L, Wen Q, Li X, Cho CH, Yi T, Li J, Xiao Z.	4.243	4.183
ICD-11: Impact on Traditional Chinese Medicine and World Healthcare Systems. *Pharmaceut Med.* 2019 Oct;33(5):373-377. doi: 10.1007/s40290-019-00295-y.	Lam WC, Lyu A, Bian Z.	--	--
Young Yum pill inhibits inflammatory mediators and nuclear factor-kappa B signaling in lipopolysaccharide-stimulated RAW 264.7 macrophages. *J Tradit Chin Med.* 2019 Oct;39(5):624-631.	Yin C, Muhammad JH, Anfernee Kai-Wing T, Su T, Fu X, Li T, Guo H, Zhu P, Li J, Chou J, Wang Y, Yu Z.	0.848	1.320
The dataset of methylglyoxal activating p38 and p44/42 pathway in osteoclast. *Data Brief.* 2019 Sep 17;26:104500. doi: 10.1016/j.dib.2019.104500.	Lee KM, Lee CY, Zhang G, Lyu A, Yue KKM.	--	--
The Effects of Vinegar Processing on the Changes in the Physical Properties of Frankincense Related to the Absorption of the Main Boswellic Acids. *Molecules.* 2019 Sep 23;24(19):3453.doi: 10.3390/molecules24193453.	Liang D, Ning Z, Song Z, Wang C, Liu Y, Wan X, Peng S, Liu Z, Lu A.	4.412	4.588
Mechanisms of white mustard seed (Sinapis alba L.) volatile oils as transdermal penetration enhancers. *Fitoterapia.* 2019 Oct;138:104195. doi: 10.1016/j.fitote.2019.104195.	Ruan S, Wang Z, Xiang S, Chen H, Shen Q, Liu L, Wu W, Cao S, Wang Z, Yang Z, Weng L, Zhu H, Liu Q.	2.882	3.203
Danshensu, a novel indoleamine 2,3-dioxygenase1 inhibitor, exerts anti-hepatic fibrosis effects via inhibition of JAK2-STAT3 signaling. *Phytomedicine.* 2019 Oct;63:153055. doi: 10.1016/j.phymed.2019.153055.	Cao G, Zhu R, Jiang T, Tang D, Kwan HY, Su T.	5.340	5.161
Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia. *Dose-Response.* 2019 Dec 11;17(4):1559325819887048. doi: 10.1177/1559325819887048. Review.	Huang X, Lin H, Huang F, Xie Y, Wong KH, Chen X, Wu D, Lu A, Yang Z.	2.658	3.210
Comparisons of carbohydrate-utilizing enzymes inhibitory effects and chemical profiles of five deeply colored food extracts. *J Food Biochem*. 2019 Dec;43(12):e13069. doi: 10.1111/jfbc.13069.	Wu Y, Zhou Q, Wang Y, Zhang S, Zhang JL.	2.720	2.543

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. *Nat Commun.* 2019 Oct 8;10(1):4579. doi: 10.1038/s41467-019-12163-z.	Liang C, Li J, Lu C, Xie D, Liu J, Zhong C, Wu X, Dai R, Zhang H, Guan D, Guo B, He B, Li F, He X, Zhang W, Zhang BT, Zhang G, Lu A.	14.919	15.805
Indigo Naturalis Suppresses Colonic Oxidative Stress and Th1/Th17 Responses of DSS-Induced Colitis in Mice. *Oxid Med Cell Longev.* 2019 Oct 13;2019:9480945. doi: 10.1155/2019/9480945.	Xiao HT, Peng J, Wen B, Hu DD, Hu XP, Shen XC, Liu ZG, He ZD, Bian ZX.	6.543	7.454
Systems Pharmacology-Based Method to Assess the Mechanism of Action of Weight-Loss Herbal Intervention Therapy for Obesity. *Front Pharmacol.* 2019 Oct 14;10:1165. doi: 10.3389/fphar.2019.01165.	Zhou W, Chen Z, Wang Y, Li X, Lu A, Sun X, Liu Z.	5.811	6.006
Study of BDE-47 induced Parkinson's disease-like metabolic changes in C57BL/6 mice by integrated metabolomic, lipidomic and proteomic analysis. *J Hazard Mater.* 2019 Oct 15;378:120738. doi: 10.1016/j.jhazmat.2019.06.015.	Ji F, Sreenivasmurthy SG, Wei J, Shao X, Luan H, Zhu L, Song J, Liu L, Li M, Cai Z.	10.588	10.129
Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. *Nat Commun.* 2019 Oct 31;10(1):4971. doi: 10.1038/s41467-019-12896-x.	Huang F, Zheng X, Ma X, Jiang R, Zhou W, Zhou S, Zhang Y, Lei S, Wang S, Kuang J, Han X, Wei M, You Y, Li M, Li Y, Liang D, Liu J, Chen T, Yan C, Wei R, Rajani C, Shen C, Xie G, Bian Z, Li H, Zhao A, Jia W.	14.919	15.805
DRAM1 deficiency affects the organization and function of the Golgi apparatus. *Cell Signal.* 2019 Nov;63:109375. doi: 10.1016/j.cellsig.2019.109375.	Wei M, Zhu Z, Wu J, Wang Y, Geng J, Qin ZH.	4.315	4.206
Arnicolide D exerts anti-melanoma effects and inhibits the NF-κB pathway. *Phytomedicine.* 2019 Nov;64:153065. doi: 10.1016/j.phymed.2019.153065.	Zhu P, Zheng Z, Fu X, Li J, Yin C, Chou J, Wang Y, Liu Y, Chen Y, Bai J, Wu J, Chen S, Yu ZL.	5.340	5.161
MiR-let-7a/f-CCR7 signaling is involved in the anti-metastatic effects of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos in melanoma. *Phytomedicine.* 2019 Nov;64:153084. doi: 10.1016/j.phymed.2019.153084.	Liu YX, Bai JX, Li T, Fu XQ, Chen YJ, Zhu PL, Chou JY, Yin CL, Li JK, Wang YP, Wu JY, Yu ZL.	5.340	5.161
Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease. *Planta Med.* 2019 Nov;85(17):1316-1325. doi: 10.1055/a-1019-9819.	Naushad M, Durairajan SSK, Bera AK, Senapati S, Li M.	3.356	3.401
Placebo design in WHO-registered trials of Chinese herbal medicine need improvements. *BMC Complement Altern Med.* 2019 Nov 6;19(1):299. doi: 10.1186/s12906-019-2722-2.	Zhang X, Tian R, Zhao C, Tang X, Lu A, Bian Z.	3.659	3.767
Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review. *World J Clin Cases.* 2019 Nov 6;7(21):3486-3504. doi: 10.12998/wjcc.v7.i21.3486.	Dai L, Zhong LL, Ji G.	1.337	1.742
Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma. *Biochem Biophys Res Commun.* 2019 Nov 12;519(3):533-539. doi: 10.1016/j.bbrc.2019.09.023.	Wang N, Zeng GZ, Yin JL, Bian ZX.	3.575	3.381
Type III-C rotaxane dendrimers: synthesis, dual size modulation and in vivo evaluation. *Chem Commun (Camb).* 2019 Nov 18;55(89):13426-13429. doi: 10.1039/c9cc06200a.	Kwan CS, Wang T, Li M, Chan ASC, Cai Z, Leung KC.	6.222	6.008
Strategy for Intercorrelation Identification between Metabolome and Microbiome. *Anal Chem.* 2019 Nov 19;91(22):14424-14432. doi: 10.1021/acs.analchem.9b02948.	Liang D, Li M, Wei R, Wang J, Li Y, Jia W, Chen T.	6.986	6.755
An analytical strategy for accurate, rapid and sensitive quantitative analysis of isoflavones in traditional Chinese medicines using ultra-high performance supercritical fluid chromatography: Take Radix Puerariae as an example. *J Chromatogr A.* 2019 Nov 22;1606:460385. doi: 10.1016/j.chroma.2019.460385.	Wu W, Zhang Y, Zhang F, Liu J, Ren Z, Xu Y, Liu T, Zhou W, Li H, Zhang C.	4.759	4.302

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways. *BMC Complement Altern Med.* 2019 Nov 27;19(1):337. doi: 10.1186/s12906-019-2749-4.	Hou Q, Huang Y, Zhu Z, Liao L, Chen X, Han Q, Liu F.	3.659	3.767
Engineering High-Resolution Micropatterns Directly onto Titanium with Optimized Contact Guidance to Promote Osteogenic Differentiation and Bone Regeneration. *ACS Appl Mater Interfaces.* 2019 Nov 27;11(47):43888-43901. doi: 10.1021/acsami.9b16050.	Zhu M, Ye H, Fang J, Zhong C, Yao J, Park J, Lu X, Ren F.	9.229	9.570
Study of metabolic disorders associated with BDE-47 exposure in Drosophila model by MS-based metabolomics. *Ecotox Environ Safe.* 2019 Nov 30;184:109606. doi: 10.1016/j.ecoenv.2019.109606.	Ji F, Wei J, Luan H, Li M, Cai Z.	6.291	6.393
Exploration of the antibiotic potentiating activity of indolglyoxylpolyamines. *Eur J Med Chem.* 2019 Dec 1;183:111708. doi: 10.1016/j.ejmech.2019.111708.	Cadelis MM, Pike EIW, Kang W, Wu Z, Bourguet-Kondracki ML, Blanchet M, Vidal N, Brunel JM, Copp BR.	6.514	6.099
XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy. *Biomed Pharmacother.* 2019 Dec;120: 109519. doi: 10.1016/j.biopha.2019.109519.	Wang N, Yang B, Muhetaer G, Wang S, Zheng Y, Lu J, Li M, Zhang F, Situ H, Lin Y, Wang Z.	6.530	5.980
How do acupuncture practitioners use pattern identification - An international web-based survey? *Eur J Integr Med.* 2019 Dec; 32:100997. doi: 0.1016/j.eujim.2019.100997.	Robinson N, Bovey M, Lee JA , Zaslawski C, Tian P, Kim TH, Alraek T, Bian ZX, Lee MS, Birch S	1.314	1.491
Anti-HIV lignans from Justicia procumbens. *Chin J Nat Med.* 2019 Dec;17(12):945-952. doi: 10.1016/S1875-5364(19)30117-7.	Xu XY, Wang DY, Ku CF, Zhao Y, Cheng H, Liu KL, Rong LJ, Zhang HJ.	3.000	2.869
Difficulties in research of Chinese medicine polysaccharides. *Chin J Nat Med.* 2019 Dec;17(12):883-886. doi: 10.1016/S1875-5364(19)30107-4.	Li LF, Wong TL, Han QB.	3.000	2.869
Mitochondrial calcium signaling as a therapeutic target for Alzheimer's disease. *Curr Alzheimer Res.* 2019 Dec 9. doi: 10.2174/1567205016666191210091302.	Wu AJ, Tong BC, Huang AS, Li M, Cheung KH.	3.498	4.083
Silencing of lncRNA AK045490 Promotes Osteoblast Differentiation and Bone Formation via β-Catenin/TCF1/Runx2 Signaling Axis. *Int J Mol Sci.* 2019 Dec 10;20(24):6229. doi: 10.3390/ijms20246229.	Li D, Tian Y, Yin C, Huai Y, Zhao Y, Su P, Wang X, Pei J, Zhang K, Yang C, Dang K, Jiang S, Miao Z, Li M, Hao Q, Zhang G, Qian A.	5.924	6.132
Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant Momordica charantia Induces Inflammatory Responses by Activating the NF-kappaB and JNK Pathways. *Toxins (Basel).* 2019 Nov 26;11(12):694. doi: 10.3390/toxins11120694.	Chen YJ, Zhu JQ, Fu XQ, Su T, Li T, Guo H, Zhu PL, Lee SK, Yu H, Tse AK, Yu ZL.	4.546	4.800
Systems-Based Interactome Analysis for Hematopoiesis Effect of Angelicae sinensis Radix: Regulated Network of Cell Proliferation towards Hemopoiesis. *Chin J Integr Med.* 2019 Dec;25(12):939-947. doi: 10.1007/s11655-018-3003-5.	Zheng G, Zhang H, Yang Y, Sun YL, Zhang YJ, Chen JP, Hao T, Lu C, Guo HT, Zhang G, Fan DP, He XJ, Lu AP.	1.978	2.047
Correlation Analysis of Rubella Incidence and Meteorological Variables Based on Chinese Medicine Theory of Yunqi. *Chin J Integr Med.* 2019 Dec;25(12):911-916. doi: 10.1007/s11655-018-3016-0.	Zhang X, Ma SL, Liu ZD, He J.	1.978	2.047
Long-term osteoblast-specific Plekho1 silencing by RNA interference prevents bone formation reduction during aging in safety in both genders. *J Bone Miner Res.* 2019 Dec; 34:370-370. Supplement: 1. Meeting Abstract: MON-889.	Zhang ZK, Zhuo ZJ, Zhang BT, Liu J, Liang C, Lu AP, Zhang G	6.741	6.893
Targeting a newly identified lncRNA and its interaction ith HuR to promote osteogenic cells migration to bone formation surface for reversing established age-related osteoporosis. *J Bone Miner Res.* 2019 Dec; 34:333-334. Supplement: 1. Meeting Abstract: MON-495.	Li DJ, Yang CF, Chen ZH, Zhao F, Qian AR, Liu J, Liang C , Guan DG, Ni SJ, Ren Q, Tang Y, Wu XH , Lu AP, Zhang G	6.741	6.893

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Toward a novel muscle anabolic strategy for sarcopenia: targeting the interaction between long noncoding RNA lncRNA-3 and MyoD1 promoter to promote myogenesis. *J Bone Miner Res.* 2019 Dec; 34:278-278. Supplement: 1. Meeting Abstract: SUN-963.	Zhang ZK, Zhuo ZJ, Zhang BT, Guan DG, Lu AP, Zhang G	6.741	6.893
A Potential Next Generation Sclerostin Inhibitor Specifically Targets Sclerostin Monomer for Bone Anabolic Therapy with Low Cardiovascular Risk to Reverse Established Osteoporosis in Ovariectomized Rats. *J Bone Miner Res*. 2019 Dec; 34:264-264. Supplement: 1. Meeting Abstract: SUN-801.	Yu YY, Ren Q, Ni SJ, Liu J, Zhong CX, Lu J, Tang Y, Li DJ, Xie DL, Dai, Zhang HR, Dang L, Lyu AP, Zhang G, Zhuo ZJ, Zhang ZK, Zhang BT, Wang LY, Li YS, Wong KK, Zhai J	6.741	6.893
A potential next generation sclerostin inhibitor specifically targets sclerostin monomer for bone anabolic therapy with low cardiovascular risk in osteogenesis imperfecta mice. *J Bone Miner Res.* 2019 Dec; 34:47-48. Supplement: 1. Meeting Abstract: 1138.	Ren Q, Xie DL, Yu YY, Tang Y, Ni SJ, Lu J, Lu AP, Zhang G, Chan SY, Zhang BT	6.741	6.893
FA-97, a New Synthetic Caffeic Acid Phenethyl Ester Derivative, Protects against Oxidative Stress-Mediated Neuronal Cell Apoptosis and Scopolamine-Induced Cognitive Impairment by Activating Nrf2/HO-1 Signaling. *Oxid Med Cell Longev.* 2019 Dec 3;2019:8239642. doi: 10.1155/2019/8239642. eCollection 2019.	Wan T, Wang Z, Luo Y, Zhang Y, He W, Mei Y, Xue J, Li M, Pan H, Li W, Wang Q, Huang Y.	6.543	7.454
Reporting quality of Cochrane systematic reviews with Chinese herbal medicines. *Syst Rev.* 2019 Dec 3;8(1):302. doi: 10.1186/s13643-019-1218-y.	Zhang X, Aixinjueluo QY, Li SY, Song LL, Lau CT, Tan R, Bian ZX.	2.522	5.039
Oligosaccharide-marker approach for qualitative and quantitative analysis of specific polysaccharide in herb formula by ultra-high-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry: Dendrobium officinale, a case study. *J Chromatogr A.* 2019 Dec 6;1607:460388. doi: 10.1016/j.chroma.2019.460388.	Wong TL, Li LF, Zhang JX, Bai SP, Zhou LS, Fung HY, Zhang QW, Ma DL, Leung CH, Zhao ZZ, Han QB.	4.759	4.302
Glyoxalase 1 gene improves the antistress capacity and reduces the immune inflammatory response. *BMC Genet.* 2019 Dec 10;20(1):95. doi: 10.1186/s12863-019-0795-z.	Du F, Li Y, Shen J, Zhao Y, Kaboli PJ, Xiang S, Wu X, Li M, Zhou J, Zheng Y, Yi T, Li X, Li J, Xiao Z, Wen Q.	2.797	3.263
Fish Oil Is More Potent than Flaxseed Oil in Modulating Gut Microbiota and Reducing Trimethylamine-N-oxide-Exacerbated Atherogenesis. *J Agric Food Chem.* 2019 Dec 11;67(49):13635-13647. doi: 10.1021/acs.jafc.9b06753.	He Z, Hao W, Kwek E, Lei L, Liu J, Zhu H, Ma KY, Zhao Y, Ho HM, He WS, Chen ZY.	5.279	5.269
Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review. *BMC Complement Altern Med.* 2019 Dec 12;19(1):366. doi: 10.1186/s12906-019-2779-y.	Zhou X, Liu M, Ren Q, Zhu W, Wang Y, Chen H, Chen J.	3.659	3.767
Enterochromaffin cell hyperplasia in the gut: Factors, mechanism and therapeutic clues. *Life Sci.* 2019 Dec 15;239:116886. doi: 10.1016/j.lfs.2019.116886. Review.	Qin HY, Wong XHL, Zang KH, Li X, Bian ZX.	5.037	4.690
Targeting Aggrephagy for the Treatment of Alzheimer's Disease. *Cells.* 2020 Jan 28;9(2):311. doi: 10.3390/cells9020311. Review.	Malampati S, Song JX, Tong CK, Nalluri A, Yang CB, Wang Z, Sreenivasmurthy G S, Zhu Z, Liu J, Su C, Krishnamoorthi S, Iyaswamy A, Cheung KH, Lu JH, Li M.	6.600	6.663
A small molecule transcription factor EB activator ameliorates beta-amyloid precursor protein and Tau pathology in Alzheimer's disease models. *Aging Cell.* 2020 Feb;19(2):e13069. doi: 10.1111/acel.13069.	Song JX, Malampati S, Zeng Y, Durairajan SSK, Yang CB, Tong BC, Iyaswamy A, Shang WB, Sreenivasmurthy SG, Zhu Z, Cheung KH, Lu JH, Tang C, Xu N, Li M.	9.304	9.951
Autophagy modulator scoring system: a user-friendly tool for quantitative analysis of methodological integrity of chemical autophagy modulator studies. *Autophagy.* 2020 Feb;16(2):195-202. doi: 10.1080/15548627.2019.1704119.	Dong Y, Hu Y, Sarkar S, Zong WX, Li M, Feng D, Song JX, Li M, Medina DL, Tan J, Zhang Z, Yue Z, Lu JH.	16.016	16.586

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Reactivation of Epstein-Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn2+-chelating function. *Proc Natl Acad Sci U S A.* 2019 Dec 10;116(52):26614-26624. doi: 10.1073/pnas.1915372116.	Jiang L, Lung HL, Huang T, Lan R, Zha S, Chan LS, Thor W, Tsoi TH, Chau HF, Boreström C, Cobb SL, Tsao SW, Bian ZX, Law GL, Wong WT, Tai WC, Chau WY, Du Y, Tang LHX, Chiang AKS, Middeldorp JM, Lo KW, Mak NK, Long NJ, Wong KL.	11.205	12.291
Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. *Cell Death Differ.* 2020 Jan;27(1):242-254. doi: 10.1038/s41418-019-0352-3.	Chen GQ, Benthani FA, Wu J, Liang D, Bian ZX, Jiang X.	15.828	12.774
Post-translational Modifications of Key Machinery in the Control of Mitophagy. *Trends Biochem Sci.* 2020 Jan;45(1):58-75. doi: 10.1016/j.tibs.2019.08.002. Review.	Wang L, Qi H, Tang Y, Shen HM.	13.807	19.788
NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models. *J Food Drug Anal.* 2020 Jan;28(1):132-146. doi: 10.1016/j.jfda.2019.09.004.	Iyaswamy A, Krishnamoorthi SK, Song JX, Yang CB, Kaliyamoorthy V, Zhang H, Sreenivasmurthy SG, Malampati S, Wang ZY, Zhu Z, Tong BC, Cheung KH, Lu JH, Durairajan SSK, Li M.	6.079	6.360
A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. *J Clin Invest.* 2020 Jan 2;130(1):438-450. doi: 10.1172/JCI130976.	Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, Huang T, Ning Z, Zhai L, Zhong LL, Lam W, Yang Z, Zhang X, Cheng C, Han L, Qiu Q, Shang X, Huang R, Xiao H, Ren Z, Chen D, Sun S, El-Nezami H, Cai Z, Lu A, Fang X, Jia W, Bian Z.	14.808	16.792
LncRNA, Important Player in Bone Development and Disease. *Endocr Metab Immune Disord Drug Targets.* 2020;20(1):50-66. doi: 10.2174/1871530319666190904161707.	Li D, Yang C, Yin C, Zhao F, Chen Z, Tian Y, Dang K, Jiang S, Zhang W, Zhang G, Qian A.	2.895	3.037
Two new bioactive diterpenes identified from Isodon interruptus. *Bioorg Chem.* 2020 Jan;95:103512. doi: 10.1016/j.bioorg.2019.103512.	Li QJ, Zhao CL, Ku CF, Zhu Y, Zhu XJ, Zhang JJ, Deyrup ST, Pan LT, Zhang HJ.	5.275	5.252
Mechanistic Pathways and Molecular Targets of Plant-Derived Anticancer ent-Kaurane Diterpenes. *Biomolecules.* 2020 Jan 16;10(1):144. doi: 10.3390/biom10010144. Review.	Sarwar MS, Xia YX, Liang ZM, Tsang SW, Zhang HJ.	4.879	5.362
FA-97, a New Synthetic Caffeic Acid Phenethyl Ester Derivative, Ameliorates DSS-Induced Colitis Against Oxidative Stress by Activating Nrf2/HO-1 Pathway. *Front Immunol.* 2020 Jan 8;10:2969. doi: 10.3389/fimmu.2019.02969	Mei Y, Wang Z, Zhang Y, Wan T, Xue J, He W, Luo Y, Xu Y, Bai X, Wang Q, Huang Y.	7.561	7.624
The efficacy and safety of electro-acupuncture for alleviating chemotherapy-induced peripheral neuropathy in patients with coloreactal cancer: study protocol for a single-blinded, randomized sham-controlled trial. *Trials.* 2020 Jan 9;21(1):58. doi: 10.1186/s13063-019-3972-5.	Chan K, Lui L, Yu K, Lau K, Lai M, Lau W, Ng B, Zhong LLD, Bian ZX.	2.279	2.606
The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin A. *Life Sci.* 2020 Jan 15;241:117169. doi: 10.1016/j.lfs.2019.117169.	Su T, Wang YP, Wang XN, Li CY, Zhu PL, Huang YM, Yang ZY, Chen SB, Yu ZL.	5.037	4.690
Chinese Herbal Medicine (MaZiRenWan) Improves Bowel Movement in Functional Constipation Through Down-Regulating Oleamide. *Front Pharmacol.* 2020 Jan 23;10:1570. doi: 10.3389/fphar.2019.01570.	Huang T, Zhao L, Lin CY, Lu L, Ning ZW, Hu DD, Zhong LLD, Yang ZJ, Bian ZX.	5.811	6.006
Bone marrow stromal cell-derived growth inhibitor serves as a stress sensor to induce autophagy. *FEBS Lett.* 2020 Jan 16. doi: 10.1002/1873-3468.13732.	Zhang J, Wang L, Xu J, Tang Y, Huang B, Chen Z, Zhang T, Shen HM, Wu Y, Xia D.	4.124	3.814
Metabolomics of the Protective Effect of Ampelopsis grossedentata and Its Major Active Compound Dihydromyricetin on the Liver of High-Fat Diet Hamster. *Evid Based Complement Alternat Med.* 2020 Jan 28;2020:3472578. doi: 10.1155/2020/3472578.	Fan L, Qu X, Yi T, Peng Y, Jiang M, Miao J, Xiao P.	2.630	2.846

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
A stress response p38 MAP kinase inhibitor SB202190 promoted TFEB/TFE3-dependent autophagy and lysosomal biogenesis independent of p38. *Redox Biol*. 2020 Jan 28:101445. doi: 10.1016/j.redox.2020.101445.	Yang C, Zhu Z, Tong BC, Iyaswamy A, Xie WJ, Zhu Y, Sreenivasmurthy SG, Senthilkumar K, Cheung KH, Song JX, Zhang HJ, Li M.	11.799	12.038
Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. *Chin Med.* 2020 Jan 31;15:10. doi: 10.1186/s13020-020-0293-2.	Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z.	5.455	4.426
Diethyl Aminoethyl Hexanoate Increases Chicoric Acid Accumulation in Purple Coneflower (Echinacea purpurea L.). *Basic Clin Pharmacol Toxicol*. 2020 Feb; 126:16-17. Supplement: 1. Special Issue: SI. Meeting Abstract: 012.	Chen XL, Li DL, Chen HB, Chen YY , Yang YS, Wu H.	4.084	3.457
A Self-Assembled α-Synuclein Nanoscavenger for Parkinson's Disease. *ACS Nano.* 2020 Feb 25;14(2):1533-1549. doi: 10.1021/acsnano.9b06453.	Liu J, Liu C, Zhang J, Zhang Y, Liu K, Song JX, Sreenivasmurthy SG, Wang Z, Shi Y, Chu C, Zhang Y, Wu C, Deng X, Liu X, Song J, Zhuang R, Huang S, Zhang P, Li M, Wen L, Zhang YW, Liu G.	15.881	16.207
Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity. *Pharmacol Res.* 2020 Feb;152:104586. doi: 10.1016/j.phrs.2019.104586.	Su T, Huang C, Yang C, Jiang T, Su J, Chen M, Fatima S, Gong R, Hu X, Bian Z, Liu Z, Kwan HY.	7.658	7.377
Qualitative and quantitative characterization of carbohydrate profiles in three different parts of Poria cocos. *J Pharm Biomed Anal.* 2020 Feb 5;179:113009. doi: 10.1016/j.jpba.2019.113009.	Zhu L, Wang X, Li S, Qi ER, Meng J, Ching Lam KY, Dong X, Xu J, Chen H, Zhao Z.	3.935	3.564
Leocarpinolide B attenuates LPS-induced inflammation on RAW264.7 macrophages by mediating NF-κB and Nrf2 pathways. *Eur J Pharmacol.* 2020 Feb 5;868:172854. doi: 10.1016/j.ejphar.2019.172854.	Linghu KG, Ma QS, Zhao GD, Xiong W, Lin L, Zhang QW, Bian Z, Wang Y, Yu H.	4.432	4.014
Naturally Occurring TPE-CA Maintains Gut Microbiota and Bile Acids Homeostasis via FXR Signaling Modulation of the Liver-Gut Axis. *Front Pharmacol.* 2020 Feb 6;11:12. doi: 10.3389/fphar.2020.00012.	Liu L, Liu Z, Li H, Cao Z, Li W, Song Z, Li X, Lu A, Lu C, Liu Y.	5.811	6.006
RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. *Front Cell Dev Biol.* 2020 Feb 11;8:76. doi: 10.3389/fcell.2020.00076. Review.	Wu X, Li F, Dang L, Liang C, Lu A, Zhang G.	6.684	7.219
Targeted silencing of miRNA-132-3p expression rescues disuse osteopenia by promoting mesenchymal stem cell osteogenic differentiation and osteogenesis in mice. *Stem Cell Res Ther.* 2020 Feb 13;11(1):58. doi: 10.1186/s13287-020-1581-6.	Hu Z, Zhang L, Wang H, Wang Y, Tan Y, Dang L, Wang K, Sun Z, Li G, Cao X, Zhang S, Shi F, Zhang G.	6.832	7.153
Pharmacological enhancement of TFEB-mediated autophagy alleviated neuronal death in oxidative stress-induced Parkinson's disease models. *Cell Death Dis.* 2020 Feb 18;11(2):128. doi: 10.1038/s41419-020-2322-6.	Zhuang XX, Wang SF, Tan Y, Song JX, Zhu Z, Wang ZY, Wu MY, Cai CZ, Huang ZJ, Tan JQ, Su HX, Li M, Lu JH.	8.469	8.713
Targeted overexpression of the long noncoding RNA ODSM can regulate osteoblast function in vitro and in vivo. *Cell Death Dis.* 2020 Feb 18;11(2):133. doi: 10.1038/s41419-020-2325-3.	Wang Y, Wang K, Zhang L, Tan Y, Hu Z, Dang L, Zhou H, Li G, Wang H, Zhang S, Shi F, Cao X, Zhang G.	8.469	8.713
Determination of 14 heterocyclic aromatic amines in meat products using solid-phase extraction and supercritical fluid chromatography coupled to triple quadrupole mass spectrometry. *J Sep Sci.* 2020 Jan 16. doi: 10.1002/jssc.201900816.	Zhang Y, Wu WJ, Zhou WE, Ren ZQ, Feng XS, Zhang F.	3.645	2.943
A Curcumin Derivative Activates TFEB and Protects Against Parkinsonian Neurotoxicity in Vitro. *Int J Mol Sci.* 2020 Feb 22;21(4):1515. doi: 10.3390/ijms21041515.	Wang Z, Yang C, Liu J, Chun-Kit Tong B, Zhu Z, Malampati S, Gopalkrishnashetty Sreenivasmurthy S, Cheung KH, Iyaswamy A, Su C, Lu J, Song J, Li M.	5.924	6.132

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Comparative proteomic analysis of the brain and colon in three rat models of irritable bowel syndrome. *Proteome Sci.* 2020 Feb 24;18:1. doi: 10.1186/s12953-020-0157-9.	Zhang B, Xue H, Wang W, Chen T, Su M, Kang N, Yang J, Bian Z, Wang F, Tang X.	2.480	2.619
Dietary phytochemical approaches to stem cell regulation. *J Funct Food.* 2020 Mar; 66:103822. doi: 10.1016/j.jff.2020.103822.	Zhang S, Lam KKH, Wan JH, Yip CW, Liu HKH, Lau QMN, Man AHY, Cheung CH, Wong LH, Chen HB, Shi J, Leung GPH, Lee CKF, Shi YG, Tang SCW, Zhang KYB	4.451	4.908
The dual roles of calycosin in growth inhibition and metastatic progression during pancreatic cancer development: A "TGF-β paradox". *Phytomedicine.* 2020 Mar;68:153177. doi: 10.1016/j.phymed.2020.153177.	Zhang Z, Auyeung KK, Sze SC, Zhang S, Yung KK, Ko JK.	5.340	5.161
Inhibiting the Src/STAT3 signaling pathway contributes to the anti-melanoma mechanisms of dioscin. *Oncol Lett.* 2020 Mar;19(3):2508-2514. doi: 10.3892/ol.2020.11315.	Liu YX, Xu BW, Chen YJ, Fu XQ, Zhu PL, Bai JX, Chou JY, Yin CL, Li JK, Wang YP, Wu JY, Wu Y, Chan KK, Liang C, Yu ZL.	2.967	2.575
Chrysoeriol ameliorates TPA-induced acute skin inflammation in mice and inhibits NF-κB and STAT3 pathways. *Phytomedicine.* 2020 Mar;68:153173. doi: 10.1016/j.phymed.2020.153173.	Wu JY, Chen YJ, Bai L, Liu YX, Fu XQ, Zhu PL, Li JK, Chou JY, Yin CL, Wang YP, Bai JX, Wu Y, Wu ZZ, Yu ZL.	5.340	5.161
Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer's disease mouse model. *Mol Psychiatry.* 2020 Mar 4. doi: 10.1038/s41380-020-0701-0.	Ng RC, Jian M, Ma OK, Bunting M, Kwan JS, Zhou GJ, Senthilkumar K, Iyaswamy A, Chan PK, Li M, Leung KM, Kumar Durairajan SS, Lam KS, Chu LW, Festenstein R, Chung SK, Chan KH.	15.992	14.806
Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. *BMC Complement Med Ther.* 2020 Mar 6;20(1):73. doi: 10.1186/s12906-020-2849-1.	Ardah MT, Ghanem SS, Abdulla SA, Lv G, Emara MM, Paleologou KE, Vaikath NN, Lu JH, Li M, Vekrellis K, Eliezer D, El-Agnaf OMA.	3.659	3.767
An Essential and Cell-Cycle-Dependent ORC Dimerization Cycle Regulates Eukaryotic Chromosomal DNA Replication. *Cell Rep.* 2020 Mar 10;30(10):3323-3338.e6. doi: 10.1016/j.celrep.2020.02.046.	Amin A, Wu R, Cheung MH, Scott JF, Wang Z, Zhou Z, Liu C, Zhu G, Wong CK, Yu Z, Liang C.	9.423	10.394
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation. *Autophagy.* 2020 Mar 19:1-16. doi: 10.1080/15548627.2020.1741332.	Wu MY, Liu L, Wang EJ, Xiao HT, Cai CZ, Wang J, Su H, Wang Y, Tan J, Zhang Z, Wang J, Yao M, Ouyang DF, Yue Z, Li M, Chen Y, Bian ZX, Lu JH.	16.016	16.586
Comprehensive comparison on the anti-inflammatory effects of three species of Sigesbeckia plants based on NF-κB and MAPKs signal pathways in vitro. *J Ethnopharmacol.* 2020 Mar 25;250:112530. doi: 10.1016/j.jep.2019.112530.	Linghu KG, Zhao GD, Xiong W, Sang W, Xiong SH, Tse AKW, Hu Y, Bian Z, Wang Y, Yu H.	4.360	4.489
6-OH-BDE-47 exposure-induced Parkinson's disease pathology in Sprague Dawley rat. *Sci Total Environ.* 2020 Apr 1;711:135184. doi: 10.1016/j.scitotenv.2019.135184.	Ji F, Zhu Z, Zhang M, Zhang H, Zhu L, Cai X, Liu W, Song J, Li M, Cai Z.	7.963	7.842
A two-herb formula inhibits osteoclastogenesis and suppresses NF-kB and MAPK pathways. *J Ethnopharmacol.* 2020 Apr 24;252:112625. doi: 10.1016/j.jep.2020.112625	Chen YJ, Bai L, Wu JY, Liu YX, Fu XQ, Zhu PL, Li JK, Yin CL, Chou JY, Wang YP, Wu Y, Bai JX, Yu ZL.	4.360	4.489
Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease. *Front Pharmacol.* 2020 Feb 27;11:195. doi: 10.3389/fphar.2020.00195.	Zhang Y, Zhao H, Liu B, Li L, Zhang L, Bao M, Ji X, He X, Yi J, Chen P, Lu C, Lu A.	5.811	6.006
Mesenchymal MACF1 Facilitates SMAD7 Nuclear Translocation to Drive Bone Formation. *Cells.* 2020 Mar 4;9(3):616. doi: 10.3390/cells9030616.	Zhao F, Ma X, Qiu W, Wang P, Zhang R, Chen Z, Su P, Zhang Y, Li D, Ma J, Yang C, Chen L, Yin C, Tian Y, Hu L, Li Y, Zhang G, Wu X, Qian A.	6.600	6.663

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer. *Front Pharmacol.* 2020 Mar 12;11:271. doi: 10.3389/fphar.2020.00271.	You Y, He Q, Lu H, Zhou X, Chen L, Liu H, Lu Z, Liu D, Liu Y, Zuo D, Fu X, Kwan H, Zhao X.	5.811	6.006
Wang-Bi Capsule Alleviates the Joint Inflammation and Bone Destruction in Mice with Collagen-Induced Arthritis. *Evid Based Complement Alternat Med.* 2020 Mar 19;2020:1015083. doi: 10.1155/2020/1015083.	Cui H, Shu H, Fan D, Wang X, Zhao N, Lu C, Lu A, He X.	2.630	2.846
XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling. *Cell Commun Signal.* 2020 Mar 26;18(1):48. doi: 10.1186/s12964-020-0520-6.	Zheng Y, Wang N, Wang S, Yang B, Situ H, Zhong L, Lin Y, Wang Z.	5.712	6.153
Pien Tze Huang alleviate the joint inflammation in collagen-induced arthritis mice. *Chin Med*. 2020 Mar 30;15:30. doi: 10.1186/s13020-020-00311-3.	Deng Y, Luo H, Shu J, Shu H, Lu C, Zhao N, Geng Y, He X, Lu A.	5.455	4.426
Target triggered fluorescence "turn-off" of silicon nanoparticles for cobalt detection and cell imaging with high sensitivity and selectivity. *Talanta.* 2020 Apr 1;210:120636. doi: 10.1016/j.talanta.2019.120636.	Nsanzamahoro S, Cheng W, Mutuyimana FP, Li L, Wang W, Ren C, Yi T, Chen H, Chen X.	6.057	5.386
Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development. *Eur J Med Chem.* 2020 Apr 1;191:112134. doi: 10.1016/j.ejmech.2020.112134.	Zhong C, Wang S, Dang L, Xie D , Liu J, Ren F, Lu A , Zhang G.	6.514	6.099
Frequent hitters: nuisance artifacts in high-throughput screening. *Drug Discov Today.* 2020 Apr;25(4):657-667. doi: 10.1016/j.drudis.2020.01.014.	Yang ZY, He JH, Lu AP, Hou TJ, Cao DS.	7.851	8.458
Cross-Sectional Study of SARS-CoV-2 Epidemic in China and Implications for the World. *Iran Red Crescent Med J.* 2020 Apr;22(4). doi: 10.5812/ircmj.102685.	Ke YF, Chen ZM, Peng B.	0.611	1.152
Rhodium-Catalyzed Enantioselective Hydroselenation of Heterobicyclic Alkenes. *Org Lett.* 2020 Apr 3;22(7):2781-2785. doi: 10.1021/acs.orglett.0c00762.	Li S, Yang Q, Bian Z, Wang J.	6.005	5.551
Tojapride Reverses Esophageal Epithelial Inflammatory Responses on Reflux Esophagitis Model Rats. *Chin J Integr Med.* 2020 Apr 4. doi: 10.1007/s11655-019-3027-5.	Yin XL, Zhong L, Lin CY, Shi XS, Zhang J, Chen ZY, Che H, Ma XX, Tian YX, Duan YZ, Lu L, Ji HJ, Zhao YP, Tang XD, Wang FY.	1.978	2.047
The Role of Exosomal microRNA in Cancer Drug Resistance. *Front Oncol.* 2020 Apr 7;10:472. doi: 10.3389/fonc.2020.00472.	Guo QR, Wang H, Yan YD, Liu Y, Su CY, Chen HB, Yan YY, Adhikari R, Wu Q, Zhang JY.	6.244	6.264
A multi-center international study of acupuncture for lateral elbow pain - Results of a randomized controlled trial. *Eur J Pain.* 2020 Apr 17. doi: 10.1002/ejp.1574.	Gadau M, Zhang SP, Wang FC, Liguori S, Li WH, Liu WH, Bangrazi S, Berle C, Razavy S, Bian ZX, Filomena P, Hao Y, Jiang HL, Lei L, Li T, Zaslawski C, Liguori A, Liu YS, Lu AP, Tan YS, Yim WW, Xie CL.	3.934	4.068
Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression. *Cell Death Dis.* 2020 Apr 20;11(4):246. doi: 10.1038/s41419-020-2440-1.	Fu XQ, Liu B, Wang YP, Li JK, Zhu PL, Li T, Tse KW, Chou JY, Yin CL, Bai JX, Liu YX, Chen YJ, Yu ZL.	8.469	8.713
Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1. *Signal Transduct Target Ther.* 2020 Apr 22;5(1):39. doi: 10.1038/s41392-020-0133-y.	Huang W, Yan Y, Liu Y, Lin M, Ma J, Zhang W, Dai J, Li J, Guo Q, Chen H, Makabel B, Liu H, Su C, Bi H, Zhang J.	18.187	21.177
Structural Analysis and Identification of False Positive Hits in Luciferase-Based Assays. *J Chem Inf Model.* 2020 Apr 27;60(4):2031-2043. doi: 10.1021/acs.jcim.9b01188.	Yang ZY, Dong J, Yang ZJ, Lu AP, Hou TJ, Cao DS.	4.956	5.390

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Spexin as an anxiety regulator in mouse hippocampus: Mechanisms for transcriptional regulation of spexin gene expression by corticotropin releasing factor. *Biochem Biophys Res Commun.* 2020 Apr 30; 525(2):326-333. doi: 10.1016/j.bbrc.2020.02.023.	Zhuang M, Lai Q, Yang C, Ma Y, Fan B, Bian Z, Lin C, Bai J, Zeng G.	3.575	3.381
Amelioration of experimental autoimmune encephalomyelitis by Rhodiola rosea, a natural adaptogen. *Biomed Pharmacother.* 2020 May;125:109960. doi: 10.1016/j.biopha.2020.109960.	Lin X, Liu Y, Ma L, Ma X, Chen Z, Chen H, Si L, Ma X, Yu Z, Chen X.	6.530	5.980
A new peptide-based chemosensor for selective imaging of copper ion and hydrogen sulfide in living cells. *Microchem J.* 2020 May; 154. doi: 10.1016/j.microc.2020.104658.	Hao CW, Li YX, Fan BM, Zeng GZ, Zhang DN, Bian ZX, Wu J.	4.821	4.364
20(S)-protopanaxadiol promotes the migration, proliferation, and differentiation of neural stem cells by targeting GSK-3β in the Wnt/GSK-3β/β-catenin pathway. *J Ginseng Res.* 2020 May;44(3):475-482. doi: 10.1016/j.jgr.2019.03.001.	Lin K, Liu B, Lim SL, Fu X, Sze SC, Yung KK, Zhang S.	6.060	5.711
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. *EBioMedicine.* 2020 May;55:102766. doi: 10.1016/j.ebiom.2020.102766.	Wei M, Huang F, Zhao L, Zhang Y, Yang W, Wang S, Li M, Han X, Ge K, Qu C, Rajani C, Xie G, Zheng X, Zhao A, Bian Z, Jia W.	8.143	8.333
Anti-inflammatory properties of uvaol on DSS-induced colitis and LPS-stimulated macrophages. *Chin Med.* 2020 May 7;15:43. doi: 10.1186/s13020-020-00322-0.	Du SY, Huang HF, Li XQ, Zhai LX, Zhu QC, Zheng K, Song X, Xu CS, Li CY, Li Y, He ZD, Xiao HT.	5.455	4.426
Imperatorin and β-sitosterol have synergistic activities in alleviating collagen-induced arthritis. *J Leukoc Biol.* 2020 Aug;108(2):509-517. doi: 10.1002/JLB.3MA0320-440RR.	Guo Q, Li L, Zheng K, Zheng G, Shu H, Shi Y, Lu C, Shu J, Guan D, Lu A, He X.	4.962	5.275
Suitability evaluation on material specifications and edible methods of Dendrobii Officinalis Caulis based on holistic polysaccharide marker. *Chin Med.* 2020 May 13;15:46. doi: 10.1186/s13020-020-0300-7.	Cao ZJ, Yip KM, Jiang YG, Ji SL, Ruan JQ, Wang C, Chen HB.	5.455	4.426
Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. *Front Cell Dev Biol.* 2020 May 14;8:325. doi: 10.3389/fcell.2020.00325.	Zhang N, Zhang ZK, Yu Y, Zhuo Z, Zhang G, Zhang BT.	6.684	7.219
Application of Negative Design To Design a More Desirable Virtual Screening Library. *J Med Chem.* 2020 May 14;63(9):4411-4429. doi: 10.1021/acs.jmedchem.9b01476.	Yang ZY, He JH, Lu AP, Hou TJ, Cao DS.	7.446	7.319
Simultaneous determination of formononetin, biochanin A and their active metabolites in human breast milk, saliva and urine using salting-out assisted liquid-liquid extraction and ultra high performance liquid chromatography-electrospray ionization tandem mass spectrum. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2020 May 15;1145:122108. doi: 10.1016/j.jchromb.2020.122108.	Zhou W, Wu H, Wang Q, Zhou X, Zhang Y, Wu W, Wang Y, Ren Z, Li H, Ling Y, Zhang F, Li P.	3.205	3.068
Bone-targeted lncRNA OGRU alleviates unloading-induced bone loss via miR-320-3p/Hoxa10 axis. *Cell Death Dis.* 2020 May 19;11(5):382. doi: 10.1038/s41419-020-2574-1.	Wang K, Wang Y, Hu Z, Zhang L, Li G, Dang L, Tan Y, Cao X, Shi F, Zhang S, Zhang G.	8.469	8.713
A Loop-Based and AGO-Incorporated Virtual Screening Model Targeting AGO-Mediated miRNA-mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice. *Adv Sci.* 2020 May; 1903451. doi: 10.1002/advs.201903451.	Zhuo ZJ, Wan YY, Guan DG, Ni SJ, Wang LY, Zhang ZK, Liu J, Liang C, Yu YY, Lu AP, Zhang G, Zhang BT	16.806	17.835
Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. *Microbiome.* 2020 May 28;8(1):74. doi: 10.1186/s40168-020-00854-5.	Jian X, Zhu Y, Ouyang J, Wang Y, Lei Q, Xia J, Guan Y, Zhang J, Guo J, He Y, Wang J, Li J, Lin J, Su M, Li G, Wu M, Qiu L, Xiang J, Xie L, Jia W, Zhou W.	14.652	15.679
The Effect of Abnormal Iron Metabolism on Osteoporosis. *Biol Trace Elem Res.* 2020 Jun;195(2):353-365. doi: 10.1007/s12011-019-01867-4.	Che J, Yang J, Zhao B, Zhang G, Wang L, Peng S, Shang P.	3.738	3.440

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
The relationship between atherosclerosis and bone mineral density in patients with type 2 diabetes depends on vascular calcifications and sex. *Osteoporos Int.* 2020 Jun;31(6):1135-1143. doi: 10.1007/s00198-020-05374-4.	Cui R, Sun SQ, Zhong N, Xu MX, Cai HD, Zhang G, Qu S, Sheng H.	4.507	4.802
Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the P2rx3/P2rx7 axis in mouse hippocampal neuronal cells. *Am J Physiol Cell Physiol.* 2020 Jun 1;318(6):C1123-C1135. doi: 10.1152/ajpcell.00070.2019.	Gong M, Ye S, Li WX, Zhang J, Liu Y, Zhu J, Lv W, Zhang H, Wang J, Lu A, He K.	4.249	4.627
An oligosaccharide-marker approach to quantify specific polysaccharides in herbal formula by LC-qTOF-MS: Danggui Buxue Tang, a case study. *J Pharm Biomed Anal.* 2020 Jun 5;185:113235. doi: 10.1016/j.jpba.2020.113235.	Li LF, Wong TL, Zhang JX, Zhou LS, Bai SP, Fung HY, Cheng HY, Zhang QW, Zheng HM, Bao WR, Ma DL, Leung CH, Zhang G, Bian ZX, Lyu AP, Han QB.	3.935	3.564
Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. *BMC Med.* 2020 Jun 5;18(1):144. doi: 10.1186/s12916-020-01595-w.	Xie G, Wang X, Wei R, Wang J, Zhao A, Chen T, Wang Y, Zhang H, Xiao Z, Liu X, Deng Y, Wong L, Rajani C, Kwee S, Bian H, Gao X, Liu P, Jia W.	8.775	10.250
NRBF2 is a RAB7 effector required for autophagosome maturation and mediates the association of APP-CTFs with active form of RAB7 for degradation. *Autophagy*. 2020 Jun 16:1-19. doi: 10.1080/15548627.2020.1760623.	Cai CZ, Yang C, Zhuang XX, Yuan NN, Wu MY, Tan JQ, Song JX, Cheung KH, Su H, Wang YT, Tang BS, Behrends C, Durairajan SSK, Yue Z, Li M, Lu JH.	16.016	16.586
Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming. *Cell Death Dis*. 2020 Jun 11;11(6):450. doi: 10.1038/s41419-020-2667-x.	Wang S, Wang N, Zheng Y, Yang B, Liu P, Zhang F, Li M, Song J, Chang X, Wang Z.	8.469	8.713
Advances in the discovery of exosome inhibitors in cancer. *J Enzyme Inhib Med Chem.* 2020 Jun 16;35(1):1322-1330. doi: 10.1080/14756366.2020.1754814.	Zhang H, Lu J, Liu J, Zhang G, Lu A.	5.051	4.598
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. *Med Sci Monit.* 2020 Jun 23;26:e925583. doi: 10.12659/MSM.925583.	Wu X, Li F, Li Y, Yu Y, Liang C, Zhang B, Zhao C, Lu A, Zhang G.	2.649	2.637
Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models. *J Nat Prod.* 2020 Jun 26;83(6):1939-1949. doi: 10.1021/acs.jnatprod.0c00175.	Han Q, Tang HZ, Zou M, Zhao J, Wang L, Bian ZX, Li YH.	4.050	4.603
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. *ACS Appl Mater Interfaces.* 2020 Jun 30. doi: 10.1021/acsami.0c05750.	Ni S, Zhuo Z, Pan Y, Yu Y, Li F, Liu J, Wang L, Wu X, Li D, Wan Y, Zhang L, Yang Z, Zhang BT, Lu A, Zhang G.	9.229	9.570
Characterization of Maca (Lepidium meyenii/Lepidium peruvianum) Using a Mass Spectral Fingerprinting, Metabolomic Analysis, and Genetic Sequencing Approach. *Planta Med.* 2020 Jul;86(10):674-685. doi: 10.1055/a-1161-0372.	Geng P, Sun J, Chen P, Brand E, Frame J, Meissner H, Stewart J, Gafner S, Clark S, Miller J, Harnly J.	3.356	3.401
Bioactive natural compounds against human coronaviruses: a review and perspective. *Acta Pharm Sin B.* 2020 Jul;10(7):1163-1174. doi: 10.1016/j.apsb.2020.06.002.	Xian Y, Zhang J, Bian Z, Zhou H, Zhang Z, Lin Z, Xu H.	11.614	10.891
Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. *Am J Chin Med.* 2020;48(5):1179-1202. doi: 10.1142/S0192415X20500585.	Wang Y, Zhang Z, Auyeung KK, Cho CH, Yung KK, Ko JK.	4.667	4.135
Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and Its Major Herbs. *Am J Chin Med.* 2020;48(5):1051-1071. doi: 10.1142/S0192415X20500512.	Zhong LLD, Lam WC, Yang W, Chan KW, Sze SCW, Miao J, Yung KKL, Bian Z, Wong VT.	4.667	4.135
Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study. *JMIR Mhealth Uhealth.* 2020 Jul 9;8(7):e16018. doi: 10.2196/16018.	Wang ZC, Zhang SP, Yuen PC, Chan KW, Chan YY, Cheung CH, Chow CH, Chua KK, Hu J, Hu Z, Lao B, Leung CC, Li H, Zhong L, Liu X, Liu Y, Liu Z, Lun X, Mo W, Siu SY, Xiong Z, Yeung WF, Zhang RY, Zhang X.	4.773	6.111

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Enantioselective synthesis of indole derivatives by Rh/Pd relay catalysis and their anti-inflammatory evaluation. *Chem Commun (Camb).* 2020 Jul 9;56(55):7573-7576. doi: 10.1039/d0cc03158e.	Li S, Wang Z, Xiao H, Bian Z, Wang JJ.	6.222	6.008
A Mechanistic Review on Medicinal Mushrooms-Derived Bioactive Compounds: Potential Mycotherapy Candidates for Alleviating Neurological Disorders. *Planta Med.* 2020 Jul 14. doi: 10.1055/a-1177-4834.	Yadav SK, Ir R, Jeewon R, Doble M, Hyde KD, Kaliappan I, Jeyaraman R, Reddi RN, Krishnan J, Li M, Durairajan SSK.	3.356	3.401
WHO Trial Registration Data Set (TRDS) extension for traditional Chinese medicine 2020: recommendations, explanation, and elaboration. *BMC Med Res Methodol.* 2020 Jul 17;20(1):192. doi: 10.1186/s12874-020-01077-w.	Zhang X, Lan L, Chan JCP, Zhong LLD, Cheng CW, Lam WC, Tian R, Zhao C, Wu TX, Shang HC, Lyu AP, Bian ZX.	4.615	5.260
Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. *Chin Med.* 2020 Jul 25;15:75. doi: 10.1186/s13020-020-00356-4.	Lam CS, Cheng LP, Zhou LM, Cheung YT, Zuo Z.	5.455	4.426
PlaMoM: a comprehensive database compiles plant mobile macromolecules. *Nucleic Acids Res.* 2020 Jul 27;48(13):7607. doi: 10.1093/nar/gkaa538.	Guan D, Yan B, Thieme C, Hua J, Zhu H, Boheler KR, Zhao Z, Kragler F, Xia Y, Zhang S.	16.971	15.542
Stronger anti-obesity effect of white ginseng over red ginseng and the potential mechanisms involving chemically structural/compositional specificity to gut microbiota. *Phytomedicine.* 2020 Aug;74:152761. doi: 10.1016/j.phymed.2018.11.021.	Zhou SS, Auyeung KK, Yip KM, Ye R, Zhao ZZ, Mao Q, Xu J, Chen HB, Li SL.	5.340	5.161
Acupuncture and related techniques for obesity and cardiovascular risk factors: a systematic review and meta-regression analysis. *Acupunct Med.* 2020 Aug;38(4):227-234. doi: 10.1136/acupmed-2018-011646.	Chen J, Chen D, Ren Q, Zhu W, Xu S, Lu L, Chen X, Yan D, Nie H, Zhou X.	2.267	2.561
Managing Chronic Diarrhea From a Gut Microbiota-Bile Acid Perspective. *Clin Transl Gastroenterol.* 2020 Aug;11(8):e00208. doi: 10.14309/ctg.0000000000000208.	Zhao L, Fang XD, Jia W, Bian ZX.	4.488	5.551
Food-Derived Nanoscopic Drug Delivery Systems for Treatment of Rheumatoid Arthritis. *Molecules.* 2020 Jul 31;25(15):3506. doi: 10.3390/molecules25153506.	Han D, Chen Q, Chen H.	4.412	4.588
Gomisin N Exerts Anti-liver Cancer Effects and Regulates PI3K-Akt and mTOR-ULK1 Pathways in Vitro. *Biol Pharm Bull.* 2020;43(8):1267-1271. doi: 10.1248/bpb.b20-00030.	Zhu PL, Lam DF, Li JK, Fu XQ, Yin CL, Chou JY, Wang YP, Liu YX, Chen YJ, Wu JY, Wu Y, Bai JX, Liang C, Yu ZL.	2.233	2.309
Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment. *Molecules.* 2020 Aug 9;25(16):3620. doi: 10.3390/molecules25163620.	Wong KH, Lu A, Chen X, Yang Z.	4.412	3.589
The Effect of Conduction Exercise and Self-Acupressure in Treatment of Parkinson's Disease: A Pilot Study. *Evid Based Complement Alternat Med.* 2020 Aug 11;2020:7950131. doi: 10.1155/2020/7950131.	Yuen CS, Chua KK, Lau WH, Zhuang ZY, Chow HY, Li M.	2.630	2.846
Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. *Protein Cell.* 2020 Aug 14. doi: 10.1007/s13238-020-00748-0.	Jia W, Rajani C, Xu H, Zheng X.	14.870	11.279
Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. *Mol Psychiatry.* 2020 Aug 20. doi: 10.1038/s41380-020-00865-6.	Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, Zhang J, Lin Y, Wang Z.	15.992	14.806
Sigesbeckia orientalis L. Extract Alleviated the Collagen Type II-Induced Arthritis Through Inhibiting Multi-Target-Mediated Synovial Hyperplasia and Inflammation. *Front Pharmacol.* 2020 Aug 28;11:547913. doi: 10.3389/fphar.2020.547913.	Linghu KG, Xiong SH, Zhao GD, Zhang T, Xiong W, Zhao M, Shen XC, Xu W, Bian Z, Wang Y, Yu H.	5.811	6.006

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2020	5-year Impact Factor
2019-2020 Research Papers			
Network Pharmacology Analysis and Molecular Characterization of the Herbal Medicine Formulation Qi-Fu-Yin for the Inhibition of the Neuroinflammatory Biomarker iNOS in Microglial BV-2 Cells: Implication for the Treatment of Alzheimer's Disease. *Oxid Med Cell Longev.* 2020 Aug 31;2020:5780703. doi: 10.1155/2020/5780703.	Ngo FY, Wang W, Chen Q, Zhao J, Chen H, Gao JM, Rong J.	6.543	7.454
An herbal formula inhibits STAT3 signaling and attenuates bone erosion in collagen-induced arthritis rats. *Phytomedicine.* 2020 May 30;76:153254. doi: 10.1016/j.phymed.2020.153254.	Chen YJ, Wu JY, Leung WC, Liu YX, Fu XQ, Zhu JQ, Wu Y, Chou JY, Yin CL, Wang YP, Wang XQ, Bai JX, Wu ZZ, Yu ZL.	5.340	5.161
*〈五臟病患者出生期運氣相合特點的臨床研究〉，載《中華中醫藥雜誌》，第34卷第(8)期，頁72-76。	張軒，劉忠第，賀娟	--	--
2019-2020 Books			
《血液病的中醫治療經驗》，三聯出版，ISBN：978-988-8573-83-7。	董汝玲	--	--
《800種中草藥彩色圖鑒(精選版)》，福建科學技術出版社，ISBN 978-7-5335-5933-5。	陳虎彪(與楊全)	--	--
《藥用植物學精解圖典》，福建科學技術出版社，ISBN: 978-7-5335-5895-6。	陳虎彪(與鄔家林)	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Dingchuan tang essential oil inhibits the production of inflammatory mediators via suppressing the IRAK/NF-κB, IRAK/AP-1, and TBK1/IRF3 pathways in lipopolysaccharide-stimulated RAW264.7 cells. *Drug Des Devel Ther.* 2018 Sep 4;12:2731-2748. doi: 10.2147/DDDT.S160645.	Zhang Y, Guo H, Cheng BCY, Su T, Fu XQ, Li T, Zhu PL, Tse KW, Pan SY, Yu ZL	3.216	3.270
The Use of Naphthoquinones and Furano-naphthoquinones as Antiinvasive Agents. *Curr Med Chem.* 2018;25(38):5007-5056. doi: 10.2174/0929867324666171006131927. Review.	Tsang NY, Chik WI, Sze LP, Wang MZ, Tsang SW, Zhang HJ	4.184	3.797
Perspectives of Plant Natural Products in Inhibition of Cancer Invasion and Metastasis by Regulating Multiple Signaling Pathways. *Curr Med Chem*. 2018;25(38):5057-5087. doi: 10.2174/0929867324666170918123413. Review.	Sarwar MS, Zhang HJ, Tsang SW	4.184	3.797
Oolong tea: A critical review of processing methods, chemical composition, health effects, and risk. *Crit Rev Food Sci Nutr.* 2018;58(17):2957-2980. doi: 10.1080/10408398.2017.1347556.	Ng KW, Cao ZJ, Chen HB, Zhao ZZ, Zhu L, Yi T	7.862	7.808
Intracellular signaling pathways of inflammation modulated by dietary flavonoids: The most recent evidence. *Crit Rev Food Sci Nutr.* 2018;58(17):2908-2924. doi: 10.1080/10408398.2017.1345853.	Chen L, Teng H, Jia Z, Battino M, Miron A, Yu Z, Cao H, Xiao J	7.862	7.808
Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI. *J Bone Miner Metab.* 2018 Sep;36(5):609-619. doi: 10.1007/s00774-017-0877-9 .	Xu M, Su J, Hao J, Zhong N, Zhang Z, Cui R, Li F, Sheng C, Zhang G, Sheng H, Qu S	2.297	2.294
Herbal medicine (Gancao Xiexin decoction) for Behcet disease: A systematic review protocol. *Medicine (Baltimore).* 2018 Sep;97(37):e12324. doi: 10.1097/MD.0000000000012324.	Wu D, Lin W, Wong KW	1.552	1.998
Discrimination of three Siegesbeckiae Herba species using UPLC-QTOF/MS-based metabolomics approach. *Food Chem Toxicol.* 2018 Sep;119:400-406. doi: 10.1016/j.fct.2017.12.068.	Tao HX, Xiong W, Zhao GD, Peng Y, Zhong ZF, Xu L, Duan R, Tsim KWK, Yu H, Wang YT	4.679	4.550
Determination and regulation of hepatotoxic pyrrolizidine alkaloids in food: A critical review of recent research. *Food Chem Toxicol.* 2018 Sep;119:50-60. doi: 10.1016/j.fct.2018.05.037.	Ma C, Liu Y, Zhu L, Ji H, Song X, Guo H, Yi T	4.679	4.550
Microangiopathy is associated with bone loss in female type 2 diabetes mellitus patients. *Diab Vasc Dis Res.* 2018 Sep;15(5):433-441. doi: 10.1177/1479164118779386	Zhong N, Zhang Y, Pu X, Xu B, Xu M, Cai H, Zhang G, Cui R, Sheng H, Qu S	2.707	3.045
PTEN-L puts a brake on mitophagy. *Autophagy.* 2018 Sep 2:1-3. doi: 10.1080/15548627.2018.1502565.	Wang L, Wang J, Tang Y, Shen HM	9.770	11.966
Text Mining of Rheumatoid Arthritis and Diabetes Mellitus to Understand the Mechanisms of Chinese Medicine in Different Diseases with Same Treatment. *Chin J Integr Med.* 2018 Oct;24(10):777-784. doi: 10.1007/s11655-018-2825-x.	Zhao N, Zheng G, Li J, Zhao HY, Lu C, Jiang M, Zhang C, Guo HT, Lu AP	1.545	1.571
Exploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles. *J Tradit Chin Med.* 2018 Oct;38(5):773-780.	Tan Y, Shen SS, Guan FL, He B, Lu C, Xiao C, Jiang M, Zhao N, Li L, Cheng SP, Zu XP, Zhang WD, Liu XR, Lu AP	0.676	1.146
Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis. *Medicine (Baltimore).* 2018 Oct;97(41):e12657. doi: 10.1097/MD.0000000000012657.	Wu D, Yang Z, Zhao C, Yao L	1.552	1.998
Oleanolic acid enhances neural stem cell migration, proliferation, and differentiation in vitro by inhibiting GSK3β activity. *Cell Death Discov.* 2018 Oct 15;4:48. doi: 10.1038/s41420-018-0111-0.	Zhang SQ, Lin KL, Law CY, Liu B, Fu XQ, Tse WS, Wong SSM, Sze SCW, Yung KKL	4.114	3.977
Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma. *Cells.* 2018 Oct 22;7(10):177. doi: 10.3390/cells7100177.	Chung PY, Lam PL, Zhou YY, Gasparello J, Finotti A, Chilin A, Marzaro G, Gambari R, Bian ZX, Kwok WM, Wong WY, Wang X, Lam AK, Chan AS, Li X, Ma JY, Chui CH, Lam KH, Tang JC	4.366	5.276

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Systems-Mapping of Herbal Effects on Complex Diseases Using the Network-Perturbation Signatures. *Front Pharmacol.* 2018 Oct 18;9:1174. doi: 10.3389/fphar.2018.01174.	Chen X, Zheng C, Wang C, Guo Z, Gao S, Ning Z, Huang C, Lu C, Fu Y, Guan D, Lu A, Wang Y	4.225	4.604
Stronger Anti-obesity Effect of White Ginseng over Red Ginseng and the Potential Mechanisms Involving Chemically Structural. *Phytomedicine.* 2018 Nov. doi: 10.1016/j.phymed.2018.11.021.	Zhou S, Auyeung KK, Yip K, Ye R, Zhao Z, Mao Q, Xu J, Chen H, Li S	4.268	4.152
A bone-targeting delivery system carrying osteogenic phytomolecule icaritin prevents osteoporosis in mice. *Biomaterials.* 2018 Nov;182:58-71. doi: 10.1016/j.biomaterials.2018.07.046.	Huang L, Wang X, Cao H, Li L, Chow DH, Tian L, Wu H, Zhang J, Wang N, Zheng L, Yao X, Yang Z, Qin L	10.317	9.656
Calcium signaling in Alzheimer's disease & therapies. *Biochim Biophys Acta Mol Cell Res.* 2018 Nov;1865(11 Pt B):1745-1760. doi: 10.1016/j.bbamcr.2018.07.018.	Tong BC, Wu AJ, Li M, Cheung KH	4.105	5.246
Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota. *Pharmacol Res.* 2018 Nov;137:34-46. doi: 10.1016/j.phrs.2018.09.010.	Zhang XJ, Yuan ZW, Qu C, Yu XT, Huang T, Chen PV, Su ZR, Dou YX, Wu JZ, Zeng HF, Xie Y, Chen JN	5.893	5.631
Acupressure for insomnia: A protocol for systematic review and meta-analysis. *Medicine (Baltimore).* 2018 Nov;97(45):e13180. doi: 10.1097/MD.0000000000013180.	Wu DJ, Dong HC, Tang TN, Zhu SF	1.552	1.998
Quality assessment of cancer cachexia clinical practice guidelines. *Cancer Treat Rev.* 2018 Nov;70:9-15. doi: 10.1016/j.ctrv.2018.07.008. Review.	Shen WQ, Yao L, Wang XQ, Hu Y, Bian ZX	8.885	8.547
Anti-inflammatory and antiproliferative prenylated chalcones from Hedysarum gmelinii. *J Asian Nat Prod Res.* 2018 Nov;20(11):1009-1018. doi: 10.1080/10286020.2018.1450390.	Liu Y, Zhang J, Wen R, Tu GZ, Chen HB, Liang H, Zhao YY	1.345	1.237
Long Noncoding RNA lncMUMA Reverses Established Skeletal Muscle Atrophy following Mechanical Unloading. *Mol Ther.* 2018 Nov 7;26(11):2669-2680. doi: 10.1016/j.ymthe.2018.09.014.	Zhang ZK, Li J, Guan D, Liang C, Zhuo Z, Liu J, Lu A, Zhang G, Zhang BT	8.986	7.885
Comparative pharmacognostical and UHPLC-QTOF MS analysis of two species of Lilium. *World Journal of Pharmacy and Pharmaceutical Sciences.* 2018 Nov 14;7(12):159-167. doi: 10.20959/wjpps201812-12769.	Jaiswal Y, Liang Z, Ho A, Chen H, Williams L, Zhao Z	--	--
Anti-inflammatory effects of Zhishi and Zhiqiao revealed by network pharmacology integrated with molecular mechanism and metabolomics studies. *Phytomedicine.* 2018 Nov 15;50:61-72. doi: 10.1016/j.phymed.2018.09.184.	Zhao S, Liu Z, Wang M, He D, Liu L, Shu Y, Song Z, Li H, Liu Y, Lu A	4.268	4.152
The preparation of poly-levodopa coated capillary column for capillary electrochromatography enantioseparation. *J Chromatogr A.* 2018 Nov 30;1578:91-98. doi: 10.1016/j.chroma.2018.10.007.	Guo H, Sun Y, Niu X, Wei N, Pan C, Wang G, Zhang H, Chen H, Yi T, Chen X	4.049	3.861
Chemoselective detection of alkyl halides via an iridium(III) luminescent probe. *Dyes Pigment.* 2018 Dec; 159: 479-482. doi: 10.1016/j.dyepig.2018.07.029.	Wu C, Liu JB, Li GD, Wong SY, Han QB, Leung CH, Ma DL	4.613	3.881
Oxidative stability of sunflower oil flavored by essential oil from Coriandrum sativum L. during accelerated storage. *LWT-Food Sci Technol.* 2018 Dec; 98: 268-275. doi: 10.1016/j.lwt.2018.08.055.	Wang DY, Fan WC , Guan YF, Huang HN, Yi T, Ji JM	4.006	4.385
In vivo antifungal activity of dipyrithione against Trichophyton rubrum on guinea pig dermatophytosis models. *Biomed Pharmacother.* 2018 Dec;108:558-564. doi: 10.1016/j.biopha.2018.09.045.	Song X, Wei YX, Lai KM, He ZD, Zhang HJ	4.545	4.392
Rhodiola rosea L. Improves Learning and Memory Function: Preclinical Evidence and Possible Mechanisms. *Front Pharmacol.* 2018 Dec 4;9:1415. doi: 10.3389/fphar.2018.01415.	Ma GP, Zheng Q, Xu MB, Zhou XL, Lu L, Li ZX, Zheng GQ	4.225	4.604
Schisandra Chinensis Lignans Suppresses the Production of Inflammatory Mediators Regulated by NF-κB, AP-1, and IRF3 in Lipopolysaccharide-Stimulated RAW264.7 Cells. *Molecules.* 2018 Dec 14;23(12):3319. doi: 10.3390/molecules23123319.	Luo G, Cheng BC, Zhao H, Fu XQ, Xie R, Zhang SF, Pan SY, Zhang Y	3.267	3.589

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Siegesbeckia Orientalis L. Extract Attenuates Postoperative Cognitive Dysfunction, Systemic Inflammation, and Neuroinflammation. *Exp Neurobiol.* 2018 Dec;27(6):564-573. doi: 10.5607/en.2018.27.6.564.	Chu JMT, Xiong W, Linghu KG, Liu Y, Zhang Y, Zhao GD, Irwin MG, Wong GTC, Yu H	2.370	--
Antrodia camphorata Mycelia Exert Anti-liver Cancer Effects and Inhibit STAT3 Signaling in vitro and in vivo. *Front Pharmacol.* 2018 Dec 17;9:1449. doi: 10.3389/fphar.2018.01449.	Zhu PL, Fu XQ, Li JK, Tse AK, Guo H, Yin CL, Chou JY, Wang YP, Liu YX, Chen YJ, Hossen MJ, Zhang Y, Pan SY, Zhao ZJ, Yu ZL	4.225	4.604
Integrating Strategies of Herbal Metabolomics, Network Pharmacology, and Experiment Validation to Investigate Frankincense Processing Effects. *Front Pharmacol.* 2018 Dec 18;9:1482. doi: 10.3389/fphar.2018.01482.	Ning Z, Wang C, Liu Y, Song Z, Ma X, Liang D, Liu Z, Lu A	4.225	4.604
Synthesis of javanicunines A and B, 9-deoxy-PF1233s A and B, and absolute configuration establishment of javanicunine B. *J Org Chem.* 2018 Dec 18. doi: 10.1021/acs.joc.8b02650.	Wang MZ, Si TX, Ku CF, Zhang HJ, Li ZM, Chan ASC	4.335	4.072
Palladium-catalyzed borylation of aryl (pseudo)halides and its applications in biaryl synthesis. *Chem Cent J.* 2018 Dec 19;12(1):136. doi: 10.1186/s13065-018-0510-6.	Ji H, Cai J, Gan N, Wang Z, Wu L, Li G, Yi T	2.493	2.837
Time segment scanning-based quasi-multiple reaction monitoring mode by ultra-performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry for quantitative determination of herbal medicines: Moutan Cortex, a case study. *J Chromatogr A.* 2018 Dec 21;1581-1582:33-42. doi: 10.1016/j.chroma.2018.10.047.	Li XY, Xu JD, Zhou SS, Kong M, Xu YY, Zou YT, Tang Y, Zhou L, Xu MZ, Xu J, Li SL	4.049	3.861
Ginger attenuates trimethylamine-N-oxide (TMAO)-exacerbated disturbance in cholesterol metabolism and vascular inflammation. *J Funct Food.* 2019 Jan; 52: 25-33.doi: 10.1016/j.jff.2018.10.022.	He ZY, Lei L, Kwek E, Zhao YM, Liu JH, Hao WJ, Zhu HY, Liang N, Ma KY, Ho HM, He WS, Chen ZY	3.701	4.178
Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). *Chin J Integr Med.* 2019 Jan;25(1):71-79. doi: 10.1007/s11655-018-2999-x.	Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX	1.545	1.571
Comparative comprehension on the anti-rheumatic Chinese herbal medicine Siegesbeckiae Herba: Combined computational predictions and experimental investigations. *J Ethnopharmacol*. 2019 Jan 10;228:200-209. doi: 10.1016/j.jep.2018.09.023.	Zhang QR, Zhong ZF, Sang W, Xiong W, Tao HX, Zhao GD, Li ZX, Ma QS, Tse AKW, Hu YJ, Yu H, Wang YT	3.690	3.908
An ethanol extract of the rhizome of Atractylodes chinensis exerts anti-gastritis activities and inhibits Akt/NF-κB signaling. *J Ethnopharmacol.* 2019 Jan 10;228:18-25. doi: 10.1016/j.jep.2018.09.015.	Hossen MJ, Chou JY, Li SM, Fu XQ, Yin C, Guo H, Amin A, Chou GX, Yu ZL	3.690	3.908
Brij-grafted-chitosan copolymers with function of P-glycoprotein modulation: Synthesis, characterization and in vitro investigations. *Carbohydr Polym.* 2019 Jan 15;204:89-96. doi: 10.1016/j.carbpol.2018.10.007.	Xiong W, Zhao GD, Yin X, Linghu KG, Chu JMT, Wong GTC, Li H, Yu H, Wang YT	7.182	6.890
Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies. *Int J Mol Sci.* 2019 Jan 15;20(2):341. doi: 10.3390/ijms20020341. Review.	Ma DL, Wu C, Cheng SS, Lee FW, Han QB, Leung CH	4.556	4.653
Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. *Int J Mol Sci.* 2019 Jan 17;20(2):381. doi: 10.3390/ijms20020381. Review.	Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H, Bian Z, Chen X, Lu A, Yang Z	4.556	4.653
Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative Care: Pain, Constipation, and Insomnia. *Evid Based Complement Alternat Med.* 2019 Jan 22;2019:1038206. doi: 10.1155/2019/1038206.	Lam WC, Zhong L, Liu Y, Shi N, Ng B, Ziea E, Bian Z, Lu A.	1.813	2.179
In Vitro and in Vivo Antitumor Effects of Plant-Derived Miliusanes and Their Induction of Cellular Senescence. *J Med Chem.* 2019 Feb 14;62(3):1541-1561. doi: 10.1021/acs.jmedchem.8b01742.	Xu XY, Tsang SW, Guan YF, Liu KL, Pan WH, Lam CS, Lee KM, Xia YX, Xie WJ, Wong WY, Lee MML, Tai WCS, Zhang HJ	6.205	6.521

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway. *Phytomedicine.* 2019 Jan 28;61:152843. doi: 10.1016/j.phymed.2019.152843.	Liu JS, Huo CY, Cao HH, Fan CL, Hu JY, Deng LJ, Lu ZB, Yang HY, Yu LZ, Mo ZX, Yu ZL	4.268	4.152
Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology. *Front Pharmacol.* 2019 Jan 28;10:16. doi: 10.3389/fphar.2019.00016.	Yuan NN, Cai CZ, Wu MY, Zhu Q, Su H, Li M, Ren J, Tan JQ, Lu JH	4.225	4.604
Chinese herb pair Paeoniae Radix Alba and Atractylodis Macrocephalae Rhizoma suppresses LPS-induced inflammatory response through inhibiting MAPK and NF-κB pathway. *Chin Med.* 2019 Jan 29;14:2. doi: 10.1186/s13020-019-0224-2.	Zhou Y, Tao H, Wang A, Zhong Z, Wu X, Wang M, Bian Z, Wang S, Wang Y	2.960	2.878
Comprehensive profiling of JMJD3 in gastric cancer and its influence on patient survival. *Sci Rep.* 2019 Jan 29;9(1):868. doi: 10.1038/s41598-018-37340-w.	Xu Z, Xia Y, Xiao Z, Jia Y, Li L, Jin Y, Zhao Q, Wan L, Yi T, Yu Y, Wen Q, Zhu Y, Qin B, Zhang F, Shen J	3.998	4.576
Enhancing the mechanical and thermal properties of polypropylene composite by encapsulating styrene acrylonitrile with ammonium polyphosphate. *BMC Chemistry.* 2019 Jan 30; 13(9). doi: 10.1186/s13065-019-0534-6.	Liao YJ, Wu XL, Peng X, Zhou Z, Wu JZ, Wu F, Jiang T, Chen JX, Zhu L, Yi T	#	--
Electroacupuncture for tapering off long-term benzodiazepine use: A randomized controlled trial. *J Psychiatr Res.* 2019 Feb;109:59-67. doi: 10.1016/j.jpsychires.2018.11.015.	Yeung WF, Chung KF, Zhang ZJ, Zhang SP, Chan WC, Ng RM, Chan CL, Ho LM, Yu BY, Chau JC, Lau NC, Lao LX	3.745	4.360
Massage therapy for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents: A systematic review and meta-analysis. *Complement Ther Med.* 2019 Feb;42:389-399. doi: 10.1016/j.ctim.2018.12.011. Review.	Chen SC, Yu BY, Suen LK, Yu J, Ho FY, Yang JJ, Yeung WF	2.063	2.615
Synthesis of 2,6-dimethoxy-9-phenyl-1H-phenalen-1-one and structural revision of the benzoindenone from Eichhornia crassipes. *Zeitschrift für Naturforschung B.* 2019 Feb; 74(2): 183-189. doi: 10.1515/znb-2018-0181.	Li XW, Si TX, Ku CF, Zhang HJ, Wang MZ, Chan ASC	0.839	0.718
Dendrobine targeting JNK stress signaling to sensitize chemotoxicity of cisplatin against non-small cell lung cancer cells in vitro and in vivo. *Phytomedicine.* 2019 Feb;53:18-27. doi: 10.1016/j.phymed.2018.06.018.	Song TH, Chen XX, Lee CK, Sze SC, Feng YB, Yang ZJ, Chen HY, Li ST, Zhang LY, Wei G, Shi J, Xu K, Ng TB, Zhu LL, Zhang KY	4.268	4.152
Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases. *Drug Discov Today.* 2019 Feb;24(2):595-605. doi: 10.1016/j.drudis.2018.11.001. Review.	Wang ZY, Sreenivasmurthy SG, Song JX, Liu JY, Li M	7.321	7.006
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson's Disease. *Int J Mol Sci.* 2019 Feb 8;20(3). pii: E728. doi: 10.3390/ijms20030728. Review.	Zhu Z, Yang C, Iyaswamy A, Krishnamoorthi S, Sreenivasmurthy SG, Liu J, Wang Z, Tong BC, Song J, Lu J, Cheung KH, Li M	4.556	4.653
Astragalus Polysaccharide RAP Selectively Attenuates Paclitaxel-Induced Cytotoxicity Toward RAW 264.7 Cells by Reversing Cell Cycle Arrest and Apoptosis. *Front Pharmacol.* 2019 Feb 11;9:1580. doi: 10.3389/fphar.2018.01580.	Bao WR, Li ZP, Zhang QW, Li LF, Liu HB, Ma DL, Leung CH, Lu AP, Bian ZX, Han QB	4.225	4.604
Bushen Yijing Fang Reduces Fall Risk in Late Postmenopausal Women with Osteopenia: A Randomized Double-blind and Placebo-controlled Trial. *Sci Rep.* 2019 Feb 14;9(1):2089. doi: 10.1038/s41598-018-38335-3.	Zheng Y, Wang X, Zhang ZK, Guo B, Dang L, He B, Zhang C, Zhou J, Shi W, Zhao Y, Zhan H, Xu Y, Liang C, Liu J, Guan D, Wang L, Wu X, Li J, Zhuo Z, Lin Z, Qiu H, Zhong L, Bian Z, Shi Y, Zhang BT, Zhang G, Lu A	3.998	4.576
Plant Natural Products for Human Health. *Int J Mol Sci.* 2019 Feb 15;20(4):830. doi: 10.3390/ijms20040830.	Che CT, Zhang H	4.556	4.653
Less SO2 residue may not indicate higher quality, better efficacy and weaker toxicity of sulfur-fumigated herbs: Ginseng, a pilot study. *J Hazard Mater.* 2019 Feb 15;364:376-387. doi: 10.1016/j.jhazmat.2018.10.038.	Zhou SS, Hu JW, Kong M, Xu JD, Shen H, Chen HB, Shen MQ, Xu J, Li SL	9.038	8.512

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Quality assessment of clinical trial registration with traditional Chinese medicine in WHO registries. *BMJ Open.* 2019 Feb 19;9(2):e025218. doi: 10.1136/bmjopen-2018-025218.	Zhang X, Tian R, Yang Z, Zhao C, Yao L, Lau C, Wu T, Shang H, Zhang X, Lu A, Bian Z	2.496	2.992
Independent or integrative processing approach of metabolite datasets from different biospecimens potentially affects metabolic pathway recognition in metabolomics. *J Chromatogr A.* 2019 Feb 22;1587:146-154. doi: 10.1016/j.chroma.2018.12.024.	Zhou L, Xu JD, Zhou SS, Zhu H, Kong M, Shen H, Zou YT, Cong LJ, Xu J, Li SL	4.049	3.861
High content screening for drug discovery from traditional Chinese medicine. *Chin Med.* 2019 Feb 28;14:5. doi: 10.1186/s13020-019-0228-y. Review.	Wang J, Wu MY, Tan JQ, Li M, Lu JH	2.960	2.878
Whether Syndrome Differentiation Affects Treatment Result: Study Protocol of MaZiRenWan (麻子仁丸) for Functional Constipation in A Randomized Controlled Trial. *Chin J Integr Med.* 2019 Mar;25(3):175-181. doi: 10.1007/s11655-018-2848-y.	Cheng CW, Zhang L, Zhao C, Zhong LL, Shi LJ, Dai L, Zheng R, Chen J, Li G, Zhai JB, Kun W, Lu AP, Shang HC, Bian ZX	1.545	1.571
RNA-Sequencing Analysis Reveals Critical Roles of Hormone Metabolism and Signaling Transduction in Seed Germination of Andrographis paniculata. *J Plant Growth Regul.* 2019 Mar;38(1):273-282. doi: 10.1007/s00344-018-9839-2.	Tong JY, He R, Tang XT, Li MZ, Yi T	2.672	2.962
Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis. *EBioMedicine.* 2019 Mar;41:538-555. doi: 10.1016/j.ebiom.2019.02.009.	He X, Liu J, Liang C, Badshah SA, Zheng K, Dang L, Guo B, Li D, Lu C, Guo Q, Fan D, Bian Y, Feng H, Xiao L, Pan X, Xiao C, Zhang B, Zhang G, Lu A	5.736	6.292
Human NOC3 is essential for DNA replication licensing in human cells. *Cell Cycle.* 2019 Mar;18(5):605-620. doi: 10.1080/15384101.2019.1578522.	Cheung MH, Amin A, Wu R, Qin Y, Zou L, Yu Z, Liang C	3.699	3.645
Recent Updates on Mouse Models for Human Immunodeficiency, Influenza, and Dengue Viral Infections. *Viruses.* 2019 Mar 13;11(3):252. doi: 10.3390/v11030252. Review.	Krishnakumar V, Durairajan SSK, Alagarasu K, Li M, Dash AP	3.816	4.001
Recent progress in nanomaterial-based assay for the detection of phytotoxins in foods. *Food Chem.* 2019 Mar 30;277:162-178. doi: 10.1016/j.foodchem.2018.10.075.	Chen Q, Zhu L, Chen J, Jiang T, Ye H, Ji H, Tsang S, Zhao Z, Yi T, Chen H	6.306	6.219
The interaction networks of the budding yeast and human DNA replication-initiation proteins. *Cell Cycle.* 2019 Mar - Apr;18(6-7):723-741. doi: 10.1080/15384101.2019.1586509.	Wu R, Amin A, Wang Z, Huang Y, Man-Hei Cheung M, Yu Z, Yang W, Liang C	3.699	3.645
Synergistic enhancement and hepatoprotective effect of combination of total phenolic extracts of Citrus aurantium L. and methotrexate for treatment of rheumatoid arthritis. *Phytother Res.* 2019 Apr;33(4):1122-1133. doi: 10.1002/ptr.6306.	He D, Liu Z, Wang M, Shu Y, Zhao S, Song Z, Li H, Liu L, Liang W, Li W, Cao Z, Lu C, Lu A, Liu Y	4.087	3.971
Anti-tumor effects and 3D-quantitative structure-activity relationship analysis of bufadienolides from toad venom. *Fitoterapia.* 2019 Apr;134:362-371. doi: 10.1016/j.fitote.2019.03.006.	Liu JS, Deng LJ, Tian HY, Ruan ZX, Cao HH, Ye WC, Zhang DM, Yu ZL	2.527	2.906
Network-pharmacology-based identification of caveolin-1 as a key target of Oldenlandia diffusa to suppress breast cancer metastasis. *Biomed Pharmacother.* 2019 Apr;112:108607. doi: 10.1016/j.biopha.2019.108607.	Yang B, Wang N, Wang S, Li X, Zheng Y, Li M, Song J, Zhang F, Mei W, Lin Y, Wang Z	4.545	4.392
A TCM formula comprising Sophorae Flos and Lonicerae Japonicae Flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment. *Pharmacol Res.* 2019 Apr;142:115-126. doi: 10.1016/j.phrs.2019.02.020.	Liu YX, Bai JX, Li T, Fu XQ, Guo H, Zhu PL, Chan YC, Chou JY, Yin CL, Li JK, Wang YP, Chen YJ, Yu ZL	5.893	5.631
Isobavachalcone attenuates Sephadex-induced lung injury via activation of A20 and NRF2/HO-1 in rats. *Eur J Pharmacol.* 2019 Apr 5;848:49-54. doi: 10.1016/j.ejphar.2019.01.034.	Gao D, Liu F, Li Z, Guan Y	3.263	3.266

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
An External CAM Therapy (Tian Jiu) versus Placebo in Treatment of Allergic Rhinitis: A Pilot Single-Blinded, Three-Arm, Randomized Controlled Study. *Evid Based Complement Alternat Med.* 2019 Apr 14;2019:6369754. doi: 10.1155/2019/6369754.	Dai L, Zhong LLD, Kun W, Lam WC, Yang Z, Huang T, Mu H, Bian ZX	1.813	2.179
Early life stress disrupts intestinal homeostasis via NGF-TrkA signaling. *Nat Commun.* 2019 Apr 15;10(1):1745. doi: 10.1038/s41467-019-09744-3.	Wong HLX, Qin H, Tsang SW, Zuo X, Che S, Chow CFW, Li X, Xiao H, Zhao L, Lin CY, Kwan HY, Yang T, Longo F, Lu A, Bian ZX	12.121	13.611
The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis. *Gastroenterol Res Pract.* 2019 Apr 15;2019:1287493. doi: 10.1155/2019/1287493. Review.	Lam WC, Zhao C, Ma WJ, Yao L	1.806	1.870
Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. *Front Oncol.* 2019 Apr 16;9:263. doi: 10.3389/fonc.2019.00263.	Jin J, Wu X, Yin J, Li M, Shen J, Li J, Zhao Y, Zhao Q, Wu J, Wen Q, Cho CH, Yi T, Xiao Z, Qu L	4.848	--
Identification of α-glucosidase inhibitors from cyclocarya paliurus tea leaves using UF-UPLC-Q/TOF-MS/MS and molecular docking. *Food Funct.* 2019 Apr 17;10(4):1893-1902. doi: 10.1039/c8fo01845f.	Ning ZW, Zhai LX, Huang T, Peng J, Hu D, Xiao HT, Wen B, Lin CY, Zhao L, Bian ZX	4.171	4.364
Flexicaulin A, An ent-Kaurane Diterpenoid, Activates p21 and Inhibits the Proliferation of Colorectal Carcinoma Cells through a Non-Apoptotic Mechanism. *Int J Mol Sci.* 2019 Apr 18;20(8):1917. doi: 10.3390/ijms20081917.	Xia Y, Lam CS, Li W, Sarwar MS, Liu K, Lee KM, Zhang HJ, Tsang SW	4.556	4.653
8-Hydroxyquinoline-2-Carboxanilides as Antiviral Agents Against Avian Influenza Virus. *Chemistryselect.* 2019 Apr 24; 4(15):4582-4587. doi: 10.1002/slct.201900873.	Kos J, Ku CF, Kapustikova I, Oravec M, Zhang HJ, Jampilek J	1.811	1.835
Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy. *Int J Nanomedicine.* 2019 Apr 24;14:2879-2902. doi: 10.2147/IJN.S192219.	Riaz MK, Zhang X, Wong KH, Chen H, Liu Q, Chen X, Zhang G, Lu A, Yang Z	5.115	5.166
Xiao Qing Long Tang essential oil exhibits inhibitory effects on the release of pro-inflammatory mediators by suppressing NF-κB, AP-1, and IRF3 signalling in the lipopolysaccharide-stimulated RAW264.7 cells. *RSC Adv.* 2019 Apr 26; 9(23):12977-12989. doi: 10.1039/c9ra01448a.	Luo G, Kong J, Cheng BCY, Zhao H, Fu XQ, Yan LS, Ding Y, Liu YL, Pan SY, Zhang SF, Zhang Y	3.119	3.098
The activity of transient receptor potential channel C-6 modulates the differentiation of fat cells. *FASEB J.* 2019 May;33(5):6526-6538. doi: 10.1096/fj.201801518RR.	Tan YQ, Kwan HY, Yao X, Leung LK	4.966	5.394
iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis. *Eur J Pharmacol.* 2019 May 5;850:167-179. doi: 10.1016/j.ejphar.2019.02.021.	Li YH, Sun W, Zhou BJ, Rosenstein A, Zhao J, Wang J, Bian ZX	3.263	3.266
Time series analysis of mumps and meteorological factors in Beijing, China. *BMC Infect Dis.* 2019 May 17;19(1):435. doi: 10.1186/s12879-019-4011-6.	Hao Y, Wang RR, Han L, Wang H, Zhang X, Tang QL, Yan L, He J	2.688	2.960
Sea bass (Lateolabrax maculatus) accelerates wound healing: A transition from inflammation to proliferation. *J Ethnopharmacol.* 2019 May 23;236:263-276. doi: 10.1016/j.jep.2019.03.012.	Chen J, Jayachandran M, Xu B, Yu Z	3.690	3.908
A patent herbal drug Yi-Shen-Hua-Shi granule ameliorates C-BSA-induced chronic glomerulonephritis and inhabits TGFβ signaling in rats. *J Ethnopharmacol.* 2019 May 23;236:258-262. doi: 10.1016/j.jep.2019.02.044.	Zhao J, Chan YC, He B, Duan TT, Yu ZL	3.690	3.908
Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies. *BMC Complement Altern Med.* 2019 May 23;19(1):109. doi: 10.1186/s12906-019-2510-z.	Yuan NN, Cai CZ, Wu MY, Su HX, Li M, Lu JH	2.833	2.986
Astragalus Polysaccharide RAP Induces Macrophage Phenotype Polarization to M1 via the Notch Signaling Pathway. *Molecules.* 2019 May 27;24(10):2016. doi: 10.3390/molecules24102016.	Wei W, Li ZP, Bian ZX, Han QB	3.267	3.589

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Destiny of Dendrobium officinale Polysaccharide after Oral Administration: Indigestible and Nonabsorbing, Ends in Modulating Gut Microbiota. *J Agric Food Chem.* 2019 May 29;67(21):5968-5977. doi: 10.1021/acs.jafc.9b01489.	Li L, Yao H, Li X, Zhang Q, Wu X, Wong T, Zheng H, Fung H, Yang B, Ma D, Leung C, Zhang G, Bian Z, Lu A, Han Q	4.192	4.290
Efficacy of MaZiRenWan, a Chinese Herbal Medicine, in Patients With Functional Constipation in a Randomized Controlled Trial. *Clin Gastroenterol Hepatol.* 2019 Jun;17(7):1303-1310.e18. doi: 10.1016/j.cgh.2018.04.005.	Zhong LLD, Cheng CW, Kun W, Dai L, Hu DD, Ning ZW, Xiao HT, Lin CY, Zhao L, Huang T, Tian K, Chan KH, Lam TW, Chen XR, Wong CT, Li M, Lu AP, Wu JCY, Bian ZX	8.549	7.505
Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism. *J Clin Neurosci.* 2019 Jun;64:242-251. doi: 10.1016/j.jocn.2019.02.005.	Zheng ZV, Cheung CY, Lyu H, Chan HY, Li Y, Bian ZX, Wang KKW, Poon WS	1.760	1.749
A clostridia-rich enterotype contributes to increased excretion of bile acids in diarrhea-predominant irritable bowel syndrome. *Gut.* 2019 Jun; 68:A18-A19 Supplement: 1. Meeting Abstract: IDDF2019-A. doi: 10.1136/gutjnl-2019-IDDFabstracts.34.	Zhao L	19.819	17.751
An ethanolic extract of Bailian (Radix Ampelopsis Japonicae): demonstration of colorectal cancer treatment efficacy via inhibition of beta-catenin signaling in vitro. *J Tradit Chin Med.* 2019 Jun; 39(3):339-345.	Tao S ,Wang XN, Li CY, Bai JX, Cheng CY, Fu XQ, Ting L, Yu ZL	0.676	1.146
New 4,5-seco-20(10→5)-abeo-Abietane Diterpenoids with Anti-Inflammatory Activity from Isodon lophanthoides var. graciliflorus (Benth.) H.Hara. *Chem Biodivers.* 2019 Jun;16(6):e1900206. doi: 10.1002/cbdv.201900206.	Chen WF, Wong LL, Zhang X, Zhou FX, Xia F, Tang LP, Li X.	2.039	1.879
Schisandra fruits for the management of drug-induced liver injury in China: A review. *Phytomedicine.* 2019 Jun;59:152760. doi: 10.1016/j.phymed.2018.11.020. Review.	Zhu P, Li J, Fu X, Yu Z	4.268	4.152
Antidiabetic Activity and Potential Mechanism of Amentoflavone in Diabetic Mice. *Molecules.* 2019 Jun 11;24(11):2184. doi: 10.3390/molecules24112184.	Su C, Yang C, Gong M, Ke Y, Yuan P, Wang X, Li M, Zheng X, Feng W	3.267	3.589
Dietary Supplementation with Sea Bass (Lateolabrax maculatus) Ameliorates Ulcerative Colitis and Inflammation in Macrophages through Inhibiting Toll-Like Receptor 4-Linked Pathways. *Int J Mol Sci.* 2019 Jun 14;20(12):2907. doi: 10.3390/ijms20122907.	Chen J, Jayachandran M, Zhang W, Chen L, Du B, Yu Z, Xu B	4.556	4.653
Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease. *Chin Med.* 2019 Jun 17;14:23. doi: 10.1186/s13020-019-0245-x. Review.	Gao C, Liu L, Zhou Y, Bian Z, Wang S, Wang Y	2.960	2.878
An electro-osmotic microfluidic system to characterize cancer cell migration under confinement. *J R Soc Interface.* 2019 Jun 28;16(155):20190062. doi: 10.1098/rsif.2019.0062.	Hui TH, Cho WC, Fong HW, Yu M, Kwan KW, Ngan KC, Wong KH, Tan Y, Yao S, Jiang H, Gu Z, Lin Y	3.748	4.251
Quercetin Attenuates Visceral Hypersensitivity and 5-Hydroxytryptamine Availability in Postinflammatory Irritable Bowel Syndrome Rats: Role of Enterochromaffin Cells in the Colon. *J Med Food.* 2019 Jul;22(7):663-671. doi: 10.1089/jmf.2018.4264.	Qin HY, Zang KH, Zuo X, Wu XA, Bian ZX	2.040	2.313
Regulatory network reconstruction of five essential microRNAs for survival analysis in breast cancer by integrating miRNA and mRNA expression datasets. *Funct Integr Genomics.* 2019 Jul;19(4):645-658. doi: 10.1007/s10142-019-00670-7.	He K, Li WX, Guan D, Gong M, Ye S, Fang Z, Huang JF, Lu A	3.058	3.449
Palmitic acid is an intracellular signaling molecule involved in disease development. *Cell Mol Life Sci.* 2019 Jul;76(13):2547-2557. doi: 10.1007/s00018-019-03092-7.	Fatima S, Hu X, Gong RH, Huang C, Chen M, Wong HLX, Bian Z, Kwan HY	6.496	6.769
Potential Drug-Drug Interactions and Strategies for Their Detection and Prevention. *Farmacia.* 2019 Jul-Aug; 67(4):572-579. doi: 10.31925/farmacia.2019.4.3.	Riaz MK	1.607	1.326

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Comparative quality of the forms of decoction pieces evaluated by multidimensional chemical analysis and chemometrics: Poria cocos, a pilot study. *J Food Drug Anal.* 2019 Jul;27(3):766-777. doi: 10.1016/j.jfda.2019.03.002.	Zhu LX, Xu J, Wu Y, Su LF, Ching Lam KY, Qi ER, Dong XP, Chen HB, Liu YD, Zhao ZZ	4.727	5.316
A Biocompatible Free Radical Nanogenerator with Real-Time Monitoring Capability for High Performance Sequential Hypoxic Tumor Therapy. *Adv Funct Mater.* 2019 Jul. doi: 10.1002/adfm.201903436.	Wan YP, Lu GH, Zhang JF, Wang ZY, Li XZ, Chen R, Cui X, Huang ZM, Xiao YF, Chelora J, Zhang WJ , Liu YH, Li M, Xie HY, Lee CS	16.836	15.722
Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Front Pharmacol.* 2019 Jul 3;10:703. doi: 10.3389/fphar.2019.00703.	Zhong L, Yan P, Lam WC, Yao L, Bian Z	4.225	4.604
Characterization of Chemical Component Variations in Different Growth Years and Tissues of Morindae Officinalis Radix by Integrating Metabolomics and Glycomics. *J Agric Food Chem.* 2019 Jul 3;67(26):7304-7314. doi: 10.1021/acs.jafc.9b01910.	Yip KM, Xu J, Zhou SS, Lau YM, Chen QL, Tang YC, Yang ZJ, Yao ZP, Ding P, Chen HB, Zhao ZZ	4.192	4.290
Identification of Characteristic Autoantibodies Associated With Deficiency Pattern in Traditional Chinese Medicine of Rheumatoid Arthritis Using Protein Chips. *Front Pharmacol.* 2019 Jul 10;10:755. doi: 10.3389/fphar.2019.00755.	Zhao H, Zhang Y, Liu B, Li L, Zhang L, Bao M, Guo H, Xu H, Feng H, Xiao L, Yi W, Yi J, Chen P, Lu C, Lu A	4.225	4.604
Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review. *Front Pharmacol.* 2019 Jul 12;10:746. doi: 10.3389/fphar.2019.00746. Review.	Li JJ, Yan YY, Sun HM, Liu Y, Su CY, Chen HB, Zhang JY	4.225	4.604
Hypoglycemic and hypolipidemic effects of a polysaccharide from Fructus Corni in streptozotocin-induced diabetic rats. *Int J Biol Macromol.* 2019 Jul 15;133:420-427. doi: 10.1016/j.ijbiomac.2019.04.160.	Wang D, Li C, Fan W, Yi T, Wei A, Ma Y	5.162	5.137
The effect of conduction exercise and self-acupressure in treatment of Parkinson's disease: Protocol for a pilot study. *Journal of Traditional Chinese Medical Sciences.* 2019 Jul;6(3):270-276. doi: 10.1016/j.jtcms.2019.07.001.	Yuen CS, Chua KK, Lau WH, Zhuang ZY, Chow HY, Li M	--	--
LncRNA HOTAIR-mediated Wnt/β-catenin network modeling to predict and validate therapeutic targets for cartilage damage. *BMC Bioinformatics.* 2019 Jul 31;20(1):412. doi: 10.1186/s12859-019-2981-4.	Zhou W, He X, Chen Z, Fan D, Wang Y, Feng H, Zhang G, Lu A, Xiao L	3.242	3.213
Sunflower oil flavored by essential oil from Punica granatum cv. Heyinshiliu peels improved its oxidative stability and sensory properties. *LWT-Food Sci Technol.* 2019 Aug;111:55-61. doi:10.1016/j.lwt.2019.05.005.	Wang DY; Meng YD; Zhao XM; Fan WC; Yi T; Wang XD	4.006	4.385
Delivery of patient-centered care in complementary medicine: Insights and evidence from the Chinese medical practitioners and patients in primary care consultations in Hong Kong. *Complement Ther Med.* 2019 Aug;45:198-204. doi: 10.1016/j.ctim.2019.06.013.	Pun J, Chor W, Zhong L	2.063	2.615
From psychology to physicality: how nerve growth factor transduces early life stress into gastrointestinal motility disorders later in life. *Cell Cycle.* 2019 Aug;18(16):1824-1829. doi: 10.1080/15384101.2019.1637203.	Chow CFW, Che S, Qin HY, Kwan HY, Bian ZX, Wong HLX	3.699	3.645
Methylglyoxal activates osteoclasts through JNK pathway leading to osteoporosis. *Chem Biol Interact.* 2019 Aug 1;308:147-154. doi: 10.1016/j.cbi.2019.05.026.	Lee KM, Lee CY, Zhang G, Lyu A, Yue KKM	3.723	3.629
Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial. *Chin Med.* 2019 Aug 2;14:26. doi: 10.1186/s13020-019-0247-8.	Zhang C, Guan D, Jiang M, Liang C, Li L, Zhao N, Zha Q, Zhang W, Lu C, Zhang G, Liu J, Lu A	2.960	2.878
Simultaneous UPLC-TQ-MS/MS determination of six active components in rat plasma: application in the pharmacokinetic study of Cyclocarya paliurus leaves. *Chin Med.* 2019 Aug 6;14:28. doi: 10.1186/s13020-019-0248-7.	Ning ZW, Zhai LX, Peng J, Zhao L, Huang T, Lin CY, Chen WH, Luo Z, Xiao HT, Bian ZX	2.960	2.878

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2019	5-year Impact Factor
2018-2019 Research Papers			
Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. *BMC Complement Altern Med*. 2019 Aug 12;19(1):208. doi: 10.1186/s12906-019-2624-3.	Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K	2.833	2.986
Understanding Quantitative Circadian Regulations Are Crucial Towards Advancing Chronotherapy. *Cells.* 2019 Aug 13;8(8):883. doi: 10.3390/cells8080883. Review.	Chowdhury D, Wang C, Lu AP, Zhu HL	4.366	5.276
Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway. *Oxid Med Cell Longev.* 2019 Aug 19;2019:8781690. doi: 10.1155/2019/8781690.	Zheng Y, Liu P, Wang N, Wang S, Yang B, Li M, Chen J, Situ H, Xie M, Lin Y, Wang Z	5.076	5.608
GSP-2, a polysaccharide extracted from Ganoderma sinense, is a novel toll-like receptor 4 agonist. *PLoS One.* 2019 Aug 23;14(8):e0221636. doi: 10.1371/journal.pone.0221636.	Liu KS, Zhang C, Dong HL, Li KK, Han QB, Wan Y, Chen R, Yang F, Li HL, Ko CH, Han XQ	2.740	3.227
2018-2019 Books			
《當代藥用植物典(第二版)》，世界圖書出版公司，ISBN：978-7519-245375, 978-7519-245382, 978-7519-245399, 978-7519-245412。	主編：趙中振(與肖培根)	--	--
《浸大中醫經典系列——中醫經典與臨床應用2》，中華書局，ISBN: 978-988-8571-73-4。	主編：呂愛平與卞兆祥 副主編：李敏(與黃霏莉) 編輯：馬劍穎與陶志廣	--	--
New Horizon on Treatment of Autism, LAP LAMBERT Academic Publishing, ISBN: 978-3-659-81110-4.	Yau Chuen-heung and Ip Cheuk-long (with Chau Yuk-yin)	--	--
《本草精華系列叢書》(共9個分冊)，中國中醫藥出版社，	主編：趙中振	--	--
《香港行山植物探賞徑——增訂版》，萬里機構，ISBN：978-9621-470379。	陳虎彪及楊永平	--	--
《果療——水果保健養生食療》，萬里機構，ISBN：978-9621-470256。	陳虎彪教授(與党毅博士)	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
NRBF2 is involved in the autophagic degradation process of APP-CTFs in Alzheimer disease models. *Autophagy.* 2017;13(12):2028-2040. doi: 10.1080/15548627.2017.1379633.	Yang C, Cai CZ, Song JX, Tan JQ, Durairajan SSK, Iyaswamy A, Wu MY, Chen LL, Yue Z, Li M, Lu JH.	11.059	11.227
Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy. *Autophagy.* 2017;13(11):1969-1980. doi: 10.1080/15548627.2017.1371393.	Chen LL, Wang YB, Song JX, Deng WK, Lu JH, Ma LL, Yang CB, Li M, Xue Y.	11.059	11.227
MS Based Metabolomics for the Investigation of Neuro Metabolic Changes Associated with BDE 47 Exposure in C57BL/6 Mice. *J Anal Test.* 2017; 1:233–244. doi: 10.1007/s41664-017-0026-4.	Ji FF, Luan HM, Huang YY, Cai ZW, Li M	--	--
Biotransformation of Dioscorea nipponica by Rat Intestinal Microflora and Cardioprotective Effects of Diosgenin. *Oxid Med Cell Longev.* 2017;2017: 4176518. doi: 10.1155/2017/4176518.	Feng JF, Tang YN, Ji H, Xiao ZG, Zhu L, Yi T.	4.868	5.317
Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota. *Med Res Rev.* 2017 Sep;37(5):1140-1185. doi: 10.1002/med.21431. Review.	Xu J, Chen HB, Li SL	9.791	8.949
Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. *Ann N Y Acad Sci.* 2017 Sep 11;1401(1):37-48. doi: 10.1111/nyas.13414.	Guo BJ, Bian ZX, Qiu HC, Wang YT, Wang Y.	4.295	4.788
Molecular weight and helix conformation determine intestinal anti-inflammatory effects of exopolysaccharide from Schizophyllum commune. *Carbohydr Polym.* 2017 Sep 15;172:68-77. doi: 10.1016/j.carbpol.2017.05.032.	Du B, Yang Y, Bian Z, Xu B	6.044	5.975
A review of drug-induced liver injury databases. *Arch Toxicol.* 2017 Sep;91(9):3039-3049. doi: 10.1007/s00204-017-2024-8.	Luo G, Shen Y, Yang L, Lu A, Xiang Z.	5.741	6.044
The Potential Impact of Radix Paeoniae Alba in Embryonic Development of Mice. *Phytother Res.* 2017 Sep;31(9):1376-1383. doi: 10.1002/ptr.5864.	Xu W, Xu L, Deng B, Leng J, Tang N, Zhao LC, Zhou HH, Zhao ZZ, Yang ZJ, Xiao TT, Tian XY, Ho AHM, Chan NWK, Chow YL, Chow CY, Xu M.	3.766	3.437
MACF1, versatility in tissue-specific function and in human disease. *Semin Cell Dev Biol.* 2017 Sep;69:3-8. doi: 10.1016/j.semcdb.2017.05.017.	Hu L, Xiao Y, Xiong Z, Zhao F, Yin C, Zhang Y, Su P, Li D, Chen Z, Ma X, Zhang G, Qian A.	5.460	6.170
Multiconstituent identification in root, branch, and leaf extracts of Juglans mandshurica using ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry. *J Sep Sci.* 2017 Sep;40(17): 3440-3452. doi: 10.1002/jssc.201700521.	Wang TM, Liu J, Yi T, Zhai YJ, Zhang H, Chen HB, Cai SQ, Kang TG, Zhao ZZ.	2.516	2.209
Identification of Polar Constituents in the Decoction of Juglans mandshurica and in the Medicated Egg Prepared with the Decoction by HPLC-Q-TOF MS^2. *Molecules.* 2017 Sep 1;22(9):1452. doi: 10.3390/molecules22091452.	Wang TM, Fu Y, Yu WJ, Chen C, Di X, Zhang H, Zhai YJ, Chu ZY, Kang TG, Chen HB.	3.060	3.380
Natural autophagy blockers, dauricine (DAC) and daurisoline (DAS), sensitize cancer cells to camptothecin-induced toxicity. *Oncotarget.* 2017 Sep 8;8(44):77673-77684. doi: 10.18632/oncotarget.20767. eCollection 2017 Sep 29.	Wu MY, Wang SF, Cai CZ, Tan JQ, Li M, Lu JJ, Chen XP, Wang YT, Zheng W, Lu JH.	5.168	5.312
Bringing Abstract Academic Integrity and Ethical Concepts into Real-Life Situations. *Technol Knowl Learn,* 2017 Oct; 22(3):353-368. doi:10.1007/s10758-017-9315-2.	Kwong T, Wong E, Yue K.	--	--
Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing the osteoclast differentiation in collagen-induced arthritis. *Int Immunopharmacol.* 2017 Oct;51:114-123. doi: 10.1016/j.intimp.2017.08.013.	Zhao H, Xu H, Qiao S, Lu C, Wang G, Liu M, Guo B, Tan Y, Ju D, Xiao C.	3.361	3.229
Luteolin exerted less inhibitory effect on macrophage activation induced by Astragalus polysaccharide than by lipopolysaccharide. *J Funct Food.* 2017 Oct; 37: 618-623. doi: 10.1016/j.jff.2017.08.023.	Li ZP, Zhang QW, Wei W, Li LF, Ma DL, Leung CH, Lu AP, Bian ZX, Han QB.	3.197	3.833

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
Qualitative and quantitative characterization of secondary metabolites and carbohydrates in Bai-Hu-Tang using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and ultraperformance liquid chromatography coupled with photodiode array detector. *J Food Drug Anal.* 2017 Oct;25(4):946-959. doi: 10.1016/j.jfda.2016.12.007	Zhong WF, Tong WS, Zhou SS, Yip KM, Li SL, Zhao ZZ, Xu J, Chen HB.	4.176	4.565
Phytochemical and phytopharmacological review of Perilla frutescens L. (Labiatae), a traditional edible-medicinal herb in China. *Food Chem Toxicol.* 2017 Oct;108(Pt B):375-391. doi: 10.1016/j.fct.2016.11.023. Review.	Yu H, Qiu JF, Ma LJ, Hu YJ, Li P, Wan JB.	3.775	4.248
Evidence-based Chinese medicine clinical practice guideline for stomach pain in Hong Kong. *Chin J Integr Med*. 2017 Oct;23(10):793-800. doi: 10.1007/s11655-016-2586-y.	Zhong LLD, Shi NN, Dai L, Ziea TC, Ng B, Tang XD, Bian ZX, Lu AP.	1.445	1.388
Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine. *Int J Mol Sci.* 2017 Oct 14;18(10):2142. doi: 10.3390/ijms18102142. Review.	Zhuo Z, Yu Y, Wang M, Li J, Zhang Z, Liu J, Wu X, Lu A, Zhang G, Zhang B.	4.183	4.331
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. I*nt J Mol Sci.* 2017 Oct 8;18(10):2111. doi: 10.3390/ijms18102111. Review.	Wang L, Liang C, Li F, Guan D, Wu X, Fu X, Lu A, Zhang G.	4.183	4.331
Potential of plant-sourced phenols for inflammatory bowel disease. *Curr Med Chem.* 2017 Oct 9. doi: 10.2174/0929867324666171009100900.	Xiao HT, Wen B, Shen XC, Bian ZX.	3.894	3.693
Chemotaxonomic Classification Applied to the Identification of Two Closely-Related Citrus TCMs Using UPLC-Q-TOF-MS-Based Metabolomics. *Molecules.* 2017 Oct 13;22(10):1721. doi: 10.3390/molecules22101721.	Zhao SY, Liu ZL, Shu YS, Wang ML, He D, Song ZQ, Zeng HL, Ning ZC, Lu C, Lu AP, Liu YY.	3.060	3.380
Investigation of the Phenomenon of Propagated Sensation along the Channels in the Upper Limb Following Administration of Acupuncture and Mock Laser. *J Acupunct Meridian Stud.* 2017 Oct;10(5):307-316. doi: 10.1016/j.jams.2017.06.007.	Razavy S, Gadau M, Zhang SP, Wang FC, Bangrazi S, Berle C, Harahap M, Li T, Li WH, Zaslawski C.	--	--
Ginsenoside Rb1 prevents homocysteine-induced EPC dysfunction via VEGF/p38MAPK and SDF-1/CXCR4 activation. Sci Rep. 2017 Oct 12;7(1):13061. doi: 10.1038/s41598-017-13436-7.	Lan TH, Xu DP, Huang MT, Song JX, Wu HL, Li M.	4.011	4.525
An integrative method to decode regulatory logics in gene transcription. *Nat Commun.* 2017 Oct 19;8(1):1044. doi: 10.1038/s41467-017-01193-0	Yan B, Guan D, Wang C, Wang J, He B, Qin J, Boheler KR, Lu A, Zhang G, Zhu H.	11.878	13.811
Metabolic profiling of the traditional Chinese medicine formulation Yu Ping Feng San for the identification of constituents relevant for effects on expression of TNF-α, IFN-γ, IL-1β and IL-4 in U937 cells. *J Pharm Biomed Anal.* 2017 Oct 25;145:219-229. doi: 10.1016/j.jpba.2017.03.049.	Stefanie N, Marlene M, Zou HQ, Liu Y, He XJ, Fan DP, Lu AP, Kate Y, Giorgis I, Rudolf B.	2.983	3.054
Synchronous characterization of carbohydrates and ginsenosides yields deeper insights into the processing chemistry of ginseng. *J Pharm Biomed Anal.* 2017 Oct 25;145:59-70. doi: 10.1016/j.jpba.2017.06.042.	Zhou SS, Xu J, Kong M, Yip KM, Xu JD, Shen H, Zhao ZZ, Li SL, Chen HB.	2.983	3.054
A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. *Nat Commun.* 2017 Nov 9;8(1):1390. doi: 10.1038/s41467-017-01565-6.	Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang BT, Lu A, Zhang G.	11.878	13.811
A transcriptomic study of myogenic differentiation under the overexpression of PPARγ by RNA-Seq. *Sci Rep*. 2017 Nov 10;7(1):15308. doi: 10.1038/s41598-017-14275-2.	He K, Wu G, Li WX, Guan D, Lv W, Gong M, Ye S, Lu A.	4.011	4.525
ADME properties evaluation in drug discovery: Prediction of plasma protein binding using NSGA-II combining PLS and consensus modeling. *Chemometrics Intell Lab Syst.* 2017 Nov; 170; 84-95. doi: 10.1016/j.chemolab.2017.09.005.	Wang NN, Deng ZK, Huang C, Dong J, Zhu MF, Yao ZJ, Chen AF, Lu AP, Mi Q, Cao DS.	2.786	2.991

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. *Oncotarget.* 2017 Jun 7;8(61):104615-104637. doi: 10.18632/oncotarget.18403. Review.	Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX.	5.168	5.312
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. *Biomaterials.* 2017 Dec;147:68-85. doi: 10.1016/j.biomaterials.2017.09.015.	Liang C, Li F, Wang L, Zhang ZK, Wang C, He B, Li J, Chen Z, Shaikh AB, Liu J, Wu X, Peng S, Dang L, Guo B, He X, Au DWT, Lu C, Zhu H, Zhang BT, Lu A, Zhang G.	10.273	9.550
Akt downstream of NFκB, MAPKs and IRF3 pathway involved in macrophage activation induced by Astragalus polysaccharide RAP. *J Funct Food.* 2017 Dec; 39:152-159. doi: 10.1016/j.jff.2017.10.004.	Li ZP, Li LF, Zhang QW, Wei W, Liu HB, Sao WR, Ma DL, Leung CH, Bian ZX, Lu AP, Han QB.	3.197	3.833
Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing the osteoclast differentiation in collagen-induced arthritis. *Int Immunopharmacol.* 2017 Oct;51:114-123. doi: 10.1016/j.intimp.2017.08.013.	Zhao H, Xu H, Qiao S, Lu C, Wang G, Liu M, Guo B, Tan Y, Ju D, Xiao C.	3.361	3.229
Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice. *Front Pharmacol.* 2017 Dec 22;8:944. doi: 10.3389/fphar.2017.00944.	Liu X, Shen J, Fan D, Qiu X, Guo Q, Zheng K, Luo H, Shu J, Lu C, Zhang G, Lu A, Ma C, He X.	3.845	4.469
Real-time detection of oxalyl chloride based on a long-lived iridium(iii) probe. *Dalton Trans.* 2017 Dec 12;46(48):17074-17079. doi: 10.1039/c7dt04054g.	Wu C, Li G, Han QB, Pei RJ, Liu JB, Ma DL, Leung CH.	4.052	3.813
Chemomics-based marker compounds mining and mimetic processing for exploring chemical mechanisms in traditional processing of herbal medicines, a continuous study on Rehmanniae Radix. *J Chromatogr A.* 2017 Dec 29;1530:232-240. doi: 10.1016/j.chroma.2017.11.036.	Zhou L, Xu JD, Zhou SS, Shen H, Mao Q, Kong M, Zou YT, Xu YY, Xu J, Li SL.	3.858	3.741
A novel bone targeting delivery system carrying phytomolecule icaritin for prevention of steroid-associated osteonecrosis in rats. *Bone.* 2018 Jan;106:52-60. doi: 10.1016/j.bone.2017.09.011.	Chen S, Zheng L, Zhang J, Wu H, Wang N, Tong W, Xu J, Huang L, Zhang Y, Yang Z, Lin G, Wang X, Qin L.	4.360	4.334
Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. *Neurogastroenterol Motil.* 2018 Jan;30(1). doi: 10.1111/nmo.13192. Review.	Bashashati M, Moossavi S, Cremon C, Barbaro MR, Moraveji S, Talmon G, Rezaei N, Hughes PA, Bian ZX, Choi CH, Lee OY, Coëffier M, Chang L, Ohman L, Schmulson MJ, McCallum RW, Simren M, Sharkey KA, Barbara G.	3.803	4.109
The Effect of Triptolide in Rheumatoid Arthritis: From Basic Research towards Clinical Translation. *Int J Mol Sci.* 2018 Jan 26;19(2):376 doi: 10.3390/ijms19020376. Review.	Fan D, Guo Q, Shen J, Zheng K, Lu C, Zhang G, Lu A, He X.	4.183	4.331
Recent advances on topical antimicrobials for skin and soft tissue infections and their safety concerns. *Crit Rev Microbiol.* 2018 Feb;44(1):40-78. doi: 10.1080/1040841X.2017.1313811.	Lam PL, Lee KKH, Wong RSM, Cheng GYM, Bian ZX, Chui CH, Gambari R.	5.697	6.269
Design, synthesis and evaluation of novel dihydrostilbene derivatives as potential anti-melanogenic skin-protecting agents. *Eur J Med Chem.* 2018 Jan 1;143:1254-1260. doi: 10.1016/j.ejmech.2017.10.014.	Zhu Y, Pan WH, Ku CF, Zhang HJ, Tsang SW.	4.833	4.666
Concise Synthesis of Natural Phenylphenalenone Phytoalexins and a Regioisomer. *J Nat Prod.* 2018 Jan 26;81(1):98-105. doi: 10.1021/acs.jnatprod.7b00709.	Wang MZ, Ku CF, Si TX, Tsang SW, Lv XM, Li XW, Li ZM, Zhang HJ, Chan ASC.	4.257	3.938
A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system. *Int J Nanomedicine.* 2018 Jan 31;13:617-631. doi: 10.2147/IJN.S142797.	Wang S, Wei X, Sun X, Chen C, Zhou J, Zhang G, Wu H, Guo B, Wei L.	4.471	5.029
Molecular modeling reveals the inhibition mechanism and binding mode of ursolic acid to TLR4-MD2. *Comput Theor Chem.* 2018 Jan 1;1123:73-78. doi: 10.1016/j.comptc.2017.11.016.	Niu XD, Yu YD, Guo H, Yang YA, Wang GZ, Sun L, Gao YW, Yu ZL, Wang HS.	1.344	1.363

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review. *Int J Mol Sci.* 2018 Jan 9;19(1):195. doi: 10.3390/ijms19010195. Review.	Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, Zhang G, Lu A, Yang Z.	4.183	4.331
Impact of sulphur fumigation on the chemistry of ginger. *Food Chem.* 2018 Jan 15;239:953-963. doi: 10.1016/j.foodchem.2017.07.033.	Wu CY, Kong M, Zhang W, Long F, Zhou J, Zhou SS, Xu JD, Xu J, Li SL.	5.399	5.488
Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. *Drug Deliv.* 2018 Nov;25(1):256-266. doi: 10.1080/10717544.2018.1425777.	Lin C, Zhang X, Chen H, Bian Z, Zhang G, Riaz MK, Tyagi D, Lin G, Zhang Y, Wang J, Lu A, Yang Z.	3.829	3.798
Nano-functionalized long-period fiber grating probe for disease-specific protein detection. *J Mat Chem B.* 2018 Jan 21; 6(3):386-392. doi: 10.1039/c7tb02406a.	Tyagi D, Mishra SK, Zou B, Lin CC, Hao T, Zhang G, Lu AP, Chiang KS, Yang ZJ.	5.047	5.003
A dual-functional luminescent probe for imaging H2S in living zebrafish and discrimination hypoxic cells from normoxic cells. *Sens Actuator B-Chem.* 2018 Feb;255:1953-1959. doi: 10.1016/j.snb.2017.08.222.	Wang WH, Wu C, Yang C, Li GD, Han QB, Li SN, Lee SMY, Leung CH, Ma DL.	6.393	5.773
Coupling factors and exosomal packaging microRNAs involved in the regulation of bone remodelling. *Biol Rev Camb Philos Soc.* 2018 Feb;93(1):469-480. doi: 10.1111/brv.12353.	Zhu S, Yao F, Qiu H, Zhang G, Xu H, Xu J.	10.288	11.516
The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. *Exp Dermatol.* 2018 Feb;27(2):201-204. doi: 10.1111/exd.13454.	Fu XQ, Chou JY, Li T, Zhu PL, Li JK, Yin CL, Su T, Guo H, Lee KW, Hossen MJ, Chou GX, Yu ZL.	2.868	2.680
Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage. *Aging Dis.* 2018 Feb 1;9(1):51-65. doi: 10.14336/AD.2017.0416.	Zou J, Chen Z, Liang C, Fu Y, Wei X, Lu J, Pan M, Guo Y, Liao X, Xie H, Wu D, Li M, Liang L, Wang P, Wang Q.	4.232	4.512
Laser microdissection hyphenated with high performance gel permeation chromatography-charged aerosol detector and ultra performance liquid chromatography-triple quadrupole mass spectrometry for histochemical analysis of polysaccharides in herbal medicine: Ginseng, a case study. *Int J Biol Macromol.* 2018 Feb;107(Pt A):332-342. doi: 10.1016/j.ijbiomac.2017.08.	Chen QL, Chen YJ, Zhou SS, Yip KM, Xu J, Chen HB, Zhao ZZ.	4.784	4.731
Systematic Reviews/Meta-Analyses of Integrative Medicine in Chinese Need Regulation and Monitoring Urgently and Some Suggestions for Its Solutions. *Chin J Integr Med.* 2018 Feb;24(2):83-86. doi: 10.1007/s11655-017-2427-7.	Wang JY, Tian GH, Li YP, Wu TX, Bian ZX, Du L, Shang HC.	1.445	1.388
Acupuncture with or without combined auricular acupuncture for insomnia: a randomised, waitlist-controlled trial. *Acupunct Med.* 2018 Feb;36(1):2-13. doi: 10.1136/acupmed-2017-011371	Chung KF, Yeung WF, Yu BY, Leung FC, Zhang SP, Zhang ZJ, Ng RM, Yiu GC.	2.637	2.083
Tissue-based metabolite profiling and qualitative comparison of two species of Achyranthes roots by use of UHPLC-QTOF MS and laser micro-dissection. *J Pharm Anal.* 2018 Feb; 8(1):10-19. doi: 10.1016/j.jpha.2017.06.006.	Jaiswal Y, Liang ZT, Ho A, Chen HB, Williams L, Zhao ZZ.	4.440	--
The role of CKIP-1 in osteoporosis development and treatment. *Bone Joint Res.* 2018 Feb; 7(2):173-178. doi: 10.1302/2046-3758.72.BJR-2017-0172.R1.	Peng X, Wu X, Zhang J, Zhang G, Li G, Pan X.	3.652	3.350
Efficacy of Chinese herbal medicine Zengru Gao to promote breastfeeding: a multicenter randomized controlled trial. *BMC Complement Altern Med.* 2018 Feb 6;18(1):53. doi: 10.1186/s12906-018-2121-0.	Wang S, Zhang C, Li C, Li D, He P, Su Z, Li Y, Ding Y, Lu A.	2.479	2.820
Cell imaging of dopamine receptor using agonist labeling iridium(III) complex. *Chemical Science.* 2018 Feb; 9(5):1119-1125. doi:10.1039/c7sc04798c.	Vellaisamy K, Li GD, Ko CN, Zhong HJ, Fatima S, Kwan HY, Wong CY, Kwong WJ, Tan WH, Leung CH, Ma DL.	9.556	8.921
Authenticity analyses of Rhizoma Paridis using barcoding coupled with high resolution melting (Bar-HRM) analysis to control its quality for medicinal plant product. *Chin Med.* 2018 Feb 8;13:8. doi: 10.1186/s13020-018-0162-4. eCollection 2018.	Duan BZ, Wang YP, Fang HL, Xiong C, Li XW, Wang P, Chen SL.	2.265	2.433

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
Qualitatively and quantitatively comparing secondary metabolites in three medicinal parts derived from Poria cocos (Schw.) Wolf using UHPLC-QTOF-MS/MS-based chemical profiling. *J Pharm Biomed Anal.* 2018 Feb 20;150:278-286. doi: 10.1016/j.jpba.2017.11.066.	Zhu L, Xu J, Zhang S, Wang R, Huang Q, Chen H, Dong X, Zhao Z.	2.983	3.054
Contamination of hepatotoxic pyrrolizidine alkaloids in retail honey in China. *Food Control.* 2018 Mar; 85:484-494. doi:10.1016/j.foodcont.2017.10.026.	Zhu L, Wang ZT, Wong LL, He YS, Zhao ZZ, Ye Y, Fu PP, Lin G.	4.248	4.391
Selective autophagy: The new player in the fight against neurodegenerative diseases? *Brain Res Bull.* 2018 Mar;137:79-90. doi: 10.1016/j.brainresbull.2017.11.009. Review.	Wu MY, Song JX, Wang SF, Cai CZ, Li M, Lu JH.	3.103	2.939
Toward Evidence-Based Chinese Medicine: Status Quo, Opportunities and Challenges. *Chin J Integr Med.* 2018 Mar;24(3):163-170. doi: 10.1007/s11655-017-2795-2.	Chen YL, Zhao C, Zhang L, Li B, Wu CH, Mu W, Wang JY, Yang KH, Li YP, Chen C, Wang YY, Wang C, Bian ZX, Shang HC.	1.445	1.388
Grass Carp Prolactin Gene: Structural Characterization and Signal Transduction for PACAP-induced Prolactin Promoter Activity. *Sci Rep.* 2018 Mar;8(1):4655. doi: 10.1038/s41598-018-23092-0.	Lin C, Bai J, He M, Wong AOL.	4.011	4.525
PyBioMed: a python library for various molecular representations of chemicals, proteins and DNAs and their interactions. *J Cheminform.* 2018 Mar;10(1):16. doi: 10.1186/s13321-018-0270-2.	Dong J, Yao ZJ, Zhang L, Luo F, Lin Q, Lu AP, Chen AF, Cao DS.	4.154	4.619
Total synthesis and absolute configuration reassignment of mollenines A and B. *Org Chem Front.* 2018 Mar;5(6):954-957.doi:10.1039/c7qo00985b.	Wang MZ, Si TX, Ku CF, Li XW, Li ZM, Zhang HJ, Chan ASC.	5.076	4.999
Approaches in studying the pharmacology of Chinese Medicine formulas: bottom-up, top-down-and meeting in the middle. *Chin Med.* 2018 Mar 21;13:15. doi: 10.1186/s13020-018-0170-4. Review.	Huang T, Zhong LLD, Lin CY, Zhao L, Ning ZW, Hu DD, Zhang M, Tian K, Cheng CW, Bian ZX; for MZRW Research Group.	2.265	2.433
Uncovering the Mechanisms of Chinese Herbal Medicine (MaZiRenWan) for Functional Constipation by Focused Network Pharmacology Approach. *Front Pharmacol.* 2018 Mar 26;9:270. doi: 10.3389/fphar.2018.00270.	Huang T, Ning Z, Hu D, Zhang M, Zhao L, Lin C, Zhong LLD, Yang Z, Xu H, Bian Z.	3.845	4.469
Spexin Acts as Novel Regulator for Bile Acid Synthesis. *Front Physiol.* 2018 Apr 10;9:378. doi: 10.3389/fphys.2018.00378.	Lin CY, Zhao L, Huang T, Lu L, Khan M, Liu J, Zhong LLD, Cai ZW, Fan BM, Wong AOL, Bian ZX.	3.201	3.921
A concise classification of bencao (materia medica). *Chin Med.* 2018 Apr 10;13:18. doi: 10.1186/s13020-018-0176-y. Review.	Zhao Z, Guo P, Brand E.	2.265	2.433
The antipsychotics sulpiride induces fatty liver in rats via phosphorylation of insulin receptor substrate-1 at Serine 307-mediated adipose tissue insulin resistance. *Toxicol Appl Pharmacol.* 2018 Apr 15;345:66-74. doi: 10.1016/j.taap.2018.02.023.	Zhou X, Ren L, Yu Z, Huang X, Li Y, Wang C.	3.585	3.876
Comprehensive comparison of polysaccharides from Ganoderma lucidum and G. sinense: chemical, antitumor, immunomodulating and gut-microbiota modulatory properties. *Sci Rep.* 2018 Apr 18;8(1):6172. doi: 10.1038/s41598-018-22885-7.	Li LF, Liu HB, Zhang QW, Li ZP, Wong TL, Fung HY, Zhang JX, Bai SP, Lu AP, Han QB.	4.011	4.525
UPLC-QTOF-MS/MS-guided isolation and purification of sulfur-containing derivatives from sulfur-fumigated edible herbs, a case study on ginseng. *Food Chem.* 2018 Apr 25;246:202-210. doi: 10.1016/j.foodchem.2017.10.151.	Zhang L, Shen H, Xu J, Xu JD, Li ZL, Wu J, Zou YT, Liu LF, Li SL.	5.399	5.488
InsP3R-SEC5 interaction on phagosomes modulates innate immunity to Candida albicans by promoting cytosolic Ca2+ elevation and TBK1 activity. *BMC Biol.* 2018 Apr 27;16(1):46. doi: 10.1186/s12915-018-0507-6.	Yang L, Gu W, Cheung KH, Yan L, Tong BC, Jiang Y, Yang J.	6.723	7.508
Isolation, evaluation of bioactivity and structure determination of amethinol A, a prototypic amethane diterpene from Isodon amethystoides bearing a six/five/seven-membered carbon-ring system. *Acta Crystallogr C Struct Chem.* 2018 May 1;74(Pt 5):635-640. doi: 10.1107/S2053229618005740.	Zhao CL, Sarwar MS, Ye JH, Ku CF, Li WF, Luo GY, Zhang JJ, Xu J, Huang ZF, Tsang SW, Pan LT, Zhang HJ.	0.930	4.360

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
Integrated transcriptomic and regulatory network analyses identify microRNA-200c as a novel repressor of human pluripotent stem cell-derived cardiomyocyte differentiation and maturation. *Cardiovasc Res.* 2018 May 1;114(6):894-906. doi: 10.1093/cvr/cvy019.	Poon EN, Hao B, Guan D, Jun Li M, Lu J, Yang Y, Wu B, Wu SC, Webb SE, Liang Y, Miller AL, Yao X, Wang J, Yan B, Boheler KR.	7.014	6.233
Antimalarial Activity of Plant Metabolites. *Int J Mol Sci.* 2018 May 6;19(5). pii: E1382. doi: 10.3390/ijms19051382. Review.	Pan WH, Xu XY, Shi N, Tsang SW, Zhang HJ.	4.183	4.331
The Rules and Functions of Nucleocytoplasmic Shuttling Proteins. *Int J Mol Sci.* 2018 May 12;19(5):1445. doi: 10.3390/ijms19051445. Review.	Fu X, Liang C, Li F, Wang L, Wu X, Lu A, Xiao G, Zhang G.	4.183	4.331
Tissue-Specific Analysis of Secondary Metabolites Creates a Reliable Morphological Criterion for Quality Grading of Polygoni Multiflori Radix. *Molecules.* 2018 May 8;23(5):1115. doi: 10.3390/molecules23051115.	Liang L, Xu J, Liang ZT, Dong XP, Chen HB, Zhao ZZ.	3.060	3.380
Circulating Spexin Levels Negatively Correlate With Age, BMI, Fasting Glucose, and Triglycerides in Healthy Adult Women. *J Endocr Soc.* 2018 Apr 3;2(5):409-419. doi: 10.1210/js.2018-00020.	Lin CY, Huang T, Zhao L, Zhong LLD, Lam WC, Fan BM, Bian ZX.	--	--
Comparison of the chemical profiles and inflammatory mediator-inhibitory effects of three Siegesbeckia herbs used as Herba Siegesbeckiae (Xixiancao). *BMC Complement Altern Med.* 2018 May 2;18(1):141. doi: 10.1186/s12906-018-2205-x.	Guo H, Zhang Y, Cheng BC, Lau MY, Fu XQ, Li T, Su T, Zhu PL, Chan YC, Tse AK, Yi T, Chen HB, Yu ZL.	2.479	2.820
Clarifying the origin of Houzao. *Chin Med.* 2018 May 3;13:25. doi: 10.1186/s13020-018-0182-0.	Zhao Z, Brand E, Kwan HY, Han Q, Zhou M.	2.265	2.433
Critical Problems Stalling Progress in Natural Bioactive Polysaccharide Research and Development. *J Agric Food Chem.* 2018 May ;66(18):4581-4583. doi: 10.1021/acs.jafc.8b00493.	Han QB.	3.571	3.911
Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer. *Phytomedicine.* 2018 May 15;44:56-64. doi: 10.1016/j.phymed.2018.03.055.	Li L, Zhao SL, Yue GGL, Wong TP, Pu JX, Sun HD, Fung KP, Leung PC, Han QB, Lau CBS, Leung PS.	4.180	3.928
A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. *J Cachexia Sarcopenia Muscle.* 2018 Jun;9(3):613-626. doi: 10.1002/jcsm.12281.	Zhang ZK, Li J, Guan D, Liang C, Zhuo Z, Liu J, Lu A, Zhang G, Zhang BT.	10.754	9.374
An ethanolic extract of the aerial part of Siegesbeckia orientalis L. inhibits the production of inflammatory mediators regulated by AP-1, NF-κB and IRF3 in LPS-stimulated RAW 264.7 cells. *Biosci Trends.* 2018;12(3):330-337. doi: 10.5582/bst.2018.01103.	Guo H, Zhang Y, Cheng BC, Fu X, Zhu P, Chen J, Chan Y, Yin C, Wang Y, Hossen M, Amin A, Tse AK, Yu ZL.	1.686	1.705
Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats. *Microbiome.* 2018 Jun 14;6(1):107. doi: 10.1186/s40168-018-0492-6.	Zhao L, Huang Y, Lu L, Yang W, Huang T, Lin Z, Lin C, Kwan H, Wong HLX, Chen Y, Sun S, Xie X, Fang X, Yang H, Wang J, Zhu L, Bian Z.	10.465	11.356
Panax ginseng Polysaccharide Protected H9c2 Cardiomyocyte From Hypoxia/Reoxygenation Injury Through Regulating Mitochondrial Metabolism and RISK Pathway. *Front Physiol.* 2018 Jun 15;9:699. doi: 10.3389/fphys.2018.00699.	Zuo YH, Han QB, Dong GT, Yue RQ, Ren XC, Liu JX, Liu L, Luo P, Zhou H.	3.201	3.921
The therapeutic effect of scalp acupuncture on natal autism and regressive autism. *Chin Med.* 2018 Jun 15;13:30. doi: 10.1186/s13020-018-0189-6.	Yau CH, Ip CL, Chau YY.	2.265	2.433
Corni Fructus: a review of chemical constituents and pharmacological activities. *Chin Med.* 2018 Jun;13:34. doi: 10.1186/s13020-018-0191-z.	Dong Y, Feng ZL, Chen HB, Wang FS, Lu JH.	2.265	2.433
Tissue-specific chemical profiling and quantitative analysis of bioactive components of Cinnamomum cassia by combining laser-microdissection with UPLC-Q/TOF-MS. *Chem Cent J.* 2018 Jun 21;12(1):71. doi: 10.1186/s13065-018-0438-x.	Zhou W, Liang Z, Li P, Zhao Z, Chen J.	2.094	2.871

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. *J Cheminform.* 2018 Jun 26;10(1):29. doi: 10.1186/s13321-018-0283-x.	Dong J, Wang NN, Yao ZJ, Zhang L, Cheng Y, Ouyang D, Lu AP, Cao DS.	4.154	4.619
Quality Control of the Fuzi Lizhong Pill Through Simultaneous Determination of 16 Major Bioactive Constituents by RRLC-MS-MS. *J Chromatogr Sci.* 2018 Jul 1;56(6):541-554. doi: 10.1093/chromsci/bmy029.	Dong YZ, Liu ZL, Liu YY, Song ZQ, Guo N, Wang C, Ning ZC, Ma XL, Lu AP.	1.216	1.265
A characterization of pro-inflammatory cytokines in dextran sulfate sodium-induced chronic relapsing colitis mice model. Int Immunopharmacol. 2018 Jul;60:194-201. doi: 10.1016/j.intimp.2018.05.001.	Li YH, Adam R, Colombel JF, Bian ZX.	3.361	3.229
Comprehensive quality evaluation and comparison of Angelica sinensis radix and Angelica acutiloba radix by integrated metabolomics and glycomics. *J Food Drug Anal.* 2018 Jul;26(3):1122-1137. doi: 10.1016/j.jfda.2018.01.015.	Zhou SS, Xu J, Tsang CK, Yip KM, Yeung WP, Zhao ZZ, Zhu S, Fushimi H, Chang HY, Chen HB.	4.176	4.565
A feasible and practical 1H NMR analytical method for the quality control and quantification of bioactive principles in Lycii Fructus. *J Food Drug Anal.* 2018 Jul;26(3):1105-1112. doi: 10.1016/j.jfda.2018.01.001.	Hsieh LY, Chan HH, Kuo PC, Hung HY, Li YC, Kuo CL, Peng Y, Zhao ZZ, Kuo DH, Sun IW, Wu TS.	4.176	4.565
The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells. *Front Immunol.* 2018 Jul 9; 9: 1556. doi: 10.3389/fimmu.2018.01556.	He TZ, Liu SY, Chen SK, Ye JY, Wu XQ, Bian ZX, Chen X.	4.716	5.789
Synthesis and properties of novel styrene acrylonitrile/polypropylene blends with enhanced toughness. *Chem Cent J.* 2018 Jul 9;12(1):78. doi: 10.1186/s13065-018-0447-9.	Liao YJ, Wu XL, Zhu L, Yi T.	2.094	2.871
Network Intervention, a Method to Address Complex Therapeutic Strategies. *Front Pharmacol.* 2018 Jul;9:754. doi: 10.3389/fphar.2018.00754.	Zhang C, Zhou W, Guan DG, Wang YH, Lu AP.	3.845	4.469
HAMdb: a database of human autophagy modulators with specific pathway and disease information. *J Cheminform.* 2018 Jul 31;10(1):34. doi: 10.1186/s13321-018-0289-4.	Wang NN, Dong J, Zhang L, Ouyang D, Cheng Y, Chen AF, Lu AP, Cao DS.	4.154	4.619
Impact of meteorological factors on the incidence of influenza in Beijing: A 35-year retrospective study based on Yunqi theory. *J Tradit Chin Med Sci.* 2018 Jul;5(3):264-270. doi: 10.1016/j.jtcms.2018.06.003.	Wang H, Zhang X, Gao ZL, Han L, Liu ZD, Yan L, Li MY, He J.	--	--
System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of Zhi-zhu Wan for Functional Dyspepsia. *Front Pharmacol.* 2018 Aug 6. doi: 10.3389/fphar.2018.00841.	Wang C, Ren Q, Chen XT, Song ZQ, Ning ZC, Gan JH, Ma XL, Liang DR, Guan DG, Liu ZL, Lu AP.	3.845	4.469
Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. *Nat Commun.* 2018 Aug 24;9(1):3428. doi: 10.1038/s41467-018-05974-z.	Liang C, Peng S, Li J, Lu J, Guan D, Jiang F, Lu C, Li F, He X, Zhu H, Au DWT, Yang D, Zhang BT, Lu A, Zhang G.	11.878	13.811
Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study. *Front Pharmacol.* 2018 Aug 28;9. doi: 10.3389/fphar.2018.00973.	Zhai LX, Ning ZW, Huang T, Wen B, Liao CH, Lin CY, Zhao L, Xiao HT, Bian ZX.	3.845	4.469
Integrating Targeted and Untargeted Metabolomics to Investigate the Processing Chemistry of Polygoni Multiflori Radix. *Front Pharmacol.* 2018 Aug 28;9. doi: 10.3389/fphar.2018.00934.	Liang L, Xu J, Zhou WW, Brand E, Chen HB, Zhao ZZ.	3.845	4.469
CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling. *Cell Death Dis.* 2018 Aug 29;9(9):880. doi: 10.1038/s41419-018-0876-3.	Wang N, Liu W, Zheng Y, Wang S, Yang B, Li M, Song J, Zhang F, Zhang X, Wang Q, Wang Z.	5.959	6.211
Correlation between Quality and Geographical Origins of Poria cocos Revealed by Qualitative Fingerprint Profiling and Quantitative Determination of Triterpenoid Acids. *Molecules.* 2018 Aug 31;23(9):2200. doi: 10.3390/molecules23092200.	Zhu LX, Xu J, Wang RJ, Li HX, Tan YZ, Chen HB, Dong XP, Zhao ZZ.	3.060	3.380

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2018	5-year Impact Factor
2017-2018 Research Papers			
Resveratrol Ameliorates the Severity of Fibrogenesis in Mice with Experimental Chronic Pancreatitis. *Mol Nutr Food Res.* 2018 Aug;62(16):e1700561. doi: 10.1002/mnfr.201700561.	Xia Y, Xiao HT, Liu K, Zhang HJ, Tsang SW.	4.653	4.976
*〈腎病罹患者的胚胎期六氣特徵研究〉，載《中華中醫藥雜誌》，第37卷第(1)期，頁 333-336。	張軒，王鴻，顏隆，賀娟	--	--
*〈肝病患者先天運氣與發病運氣的關係探析〉，載《中醫藥學報》，第45卷第(1)期， 頁 9-15。	張軒，顏隆，王鴻，劉忠第，賀娟	--	--
2017-2018 Books			
《中醫診療指南評價方法與應用》，中國中醫藥出版社，ISBN：978-7513-243650。	主編：呂愛平（與王燕平）	--	--
《針灸臨床精要》，學術專業圖書中心出版，ISBN: 978-988-16080-6-2。	主編：呂愛平與張世平（與劉保延、楊金生）	--	--
《戰勝更年期綜合症》，萬里機構，ISBN: 978-962-14-6559-7。	梁浩榮	--	--
《中草藥全真圖鑒》，福建科學技術出版社，ISBN: 978-7-5335-5467-5。	主編：陳虎彪 (與楊全) 副主編：趙中振	--	--
《指壓自療》，明窗出版社，ISBN：978-9888-525881。	倫新	--	--
《浸大中醫醫案系列：壺天擷英（上&下）》，中華書局，ISBN：978-988-85-1245-4。	呂愛平與卞兆祥	--	--
《世說本草》，萬里機構，ISBN：978-962-14-6634-1。	趙中振	--	--
《百毒不侵》，萬里機構，ISBN：978-962-14-6418-7。	趙中振與梁之桃	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
Seed-mediated growth approach for rapid synthesis of high-performance red-emitting CdTe quantum dots in aqueous phase and their application in detection of highly reactive oxygen species. *Chem Eng J.* 2016 Sep 1; 299:201-208. doi: 10.1016/j.cej.2016.04.008.	Xu YL, Hao JJ, Niu XY, Qi SD, Chen HL, Wang K, Chen XG, Yi T.	6.735	6.496
Standardization and future directions in pattern identification research: International brainstorming session. *Chin J Integr Med.* 2016 Sep;22(9):714-20. doi: 10.1007/s11655-014-1989-x.	Jung J, Park B, Lee JA, You S, Alraek T, Bian ZX, Birch S, Kim TH, Xu H, Zaslawski C, Kang BK, Lee MS	1.346	1.379
Protective effects of Semiaquilegia adoxoides n-butanol extract against hydrogen peroxide-induced oxidative stress in human lens epithelial cells. *Pharm Biol.* 2016 Sep;54(9):1656-63. doi: 10.3109/13880209.2015.1113993.	Liang B, Wei W, Wang J, Zhang M, Xu R, Wu F, Xiao H, Tang L	1.918	1.823
Protective Effect of Bioactivity Guided Fractions of Ziziphus jujuba Mill. Root Bark against Hepatic Injury and Chronic Inflammation via Inhibiting Inflammatory Markers and Oxidative Stress. *Front Pharmacol.* 2016 Sep 7;7:298. doi: 10.3389/fphar.2016.00298.	Kandimalla R, Dash S, Kalita S, Choudhury B, Malampati S, Kalita K, Kalita B, Devi R, Kotoky J	3.831	4.439
TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. *Sci Rep.* 2016 Sep 7;6:32834. doi: 10.1038/srep32834.	Chen X, Nie Y, Xiao H, Bian Z, Scarzello AJ, Song NY, Anna TL, Yang D, Oppenheim JJ	4.122	4.609
HSCCC-based strategy for preparative separation of in vivo metabolites after administration of an herbal medicine: Saussurea laniceps, a case study. *Sci Rep.* 2016 Sep 13;6:33036. doi: 10.1038/srep33036.	Yi T, Zhu L, Zhu GY, Tang YN, Xu J, Fan JY, Zhao ZZ, Chen HB	4.122	4.609
Discovery of antifungal constituents from the Miao medicinal plant Isodon flavidus. *J Ethnopharmacol.* 2016 Sep 15;191:372-8. doi: 10.1016/j.jep.2016.06.046.	Li JX, Li QJ, Guan YF, Song X, Liu YH, Zhang JJ, Li WF, Du J, Zhu M, Banas JA, Li XN, Pan LT, Zhang HJ	3.115	3.493
Authentication of Acori Tatarinowii Rhizoma (Shi Chang Pu) and its adulterants by morphological distinction, chemical composition and ITS sequencing. *Chin Med.* 2016 Sep 26;11:41.	Lam KY, Ku CF, Wang HY, Chan GK, Yao P, Lin HQ, Dong TT, Zhang HJ, Tsim KW	1.802	1.915
Full component analysis of Tianma-Gouteng-Yin. *Chin Med.* 2016 Sep 29;11:44. doi: 10.1186/s13020-016-0115-8.	Huang YY, Liu LF, Yue RQ, Xu J, Ho A, Li M, Han QB	1.802	1.915
Anti-inflammatory activity of polysaccharide from Schizophyllum commune as affected by ultrasonication. *Int J Biol Macromol.* 2016 Oct;91:100-5. doi: 10.1016/j.ijbiomac.2016.05.052.	Du B, Zeng H, Yang Y, Bian Z, Xu B	3.909	3.929
Pi (Spleen)-deficiency syndrome in tumor microenvironment is the pivotal pathogenesis of colorectal cancer immune escape. *Chin J Integr Med.* 2016 Oct;22(10):789-94. doi: 10.1007/s11655-015-2086-5.	Sun XG, Lin XC, Diao JX, Yu ZL, Li K.	1.346	1.379
The critical roles of mitophagy in cerebral ischemia. *Protein Cell.* 2016 Oct;7(10):699-713. doi: 10.1007/s13238-016-0307-0.	Tang YC, Tian HX, Yi T, Chen HB	6.228	4.326
Methylglyoxal-induced neuroinflammatory response in vitro astrocytic cultures and hippocampus of experimental animals. *Metab Brain Dis.* 2016 Oct;31(5):1055-64. doi: 10.1007/s11011-016-9849-3.	Chu JM, Lee DK, Wong DP, Wong GT, Yue KK	2.441	2.481
Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis. *Medicine (Baltimore).* 2016 Oct;95(40):e4904. doi: 10.1097/MD.0000000000004904.	Li JH, Chen ZX, Zhang XG, Li Y, Yang WT, Zheng XW, Chen S, Lu L, Gu Y, Zheng GQ	2.028	2.193
Soluble N-ethylmaleimide-sensitive Factor Attachment Receptor (SNARE) Protein Involved in the Remission of Depression by Acupuncture in Rats. *J Acupunct Meridian Stud.* 2016 Oct;9(5):242-249. doi: 10.1016/j.jams.2016.04.002.	Fan L, Chen Z, Fu W, Xu N, Liu J, Lu A, Li Z, Su S, Wu T, Ou A.	--	--
Hong Kong Lead Burden: Poisoning in the Former Years. *HK J Paediatr (New Series).* 2016;21:273-279.	ECL Yu	0.070	0.128

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
Preparation and quantification of the total phenolic products in Citrus fruit using solid-phase extraction coupled with high-performance liquid chromatography with diode array and UV detection. *J Sep Sci.* 2016 Oct;39(19):3806-3817. doi: 10.1002/jssc.201600547.	Zeng H, Liu Z, Zhao S, Shu Y, Song Z, Wang C, Dong Y, Ning Z, He D, Wang M, Lu C, Liu Y, Lu A	2.415	2.337
Rapid Fingerprint Analysis of Flos Carthami by Ultra-Performance Liquid Chromatography and Similarity Evaluation. *J Chromatogr Sci.* 2016 Oct 17;54(9):1619-1624. doi: 10.1093/chromsci/bmw115.	Yu S, Zhu L, Xiao Z, Shen J, Li J, Lai H, Li J, Chen H, Zhao Z, Yi T	1.037	1.169
Attitudes to personalised versus standardised practice in traditional Chinese medicine: a national cross-sectional survey of practitioners in China. *Lancet (Special Issue).* 2016 Oct; Volume 388, Meeting Abstract:S59. doi: 10.1016/S0140-6736(16)31986-9.	Liu MY, Zhang C, Zha QL, Yang W, Ya YW, Zhong LD, Bian ZX, Han XJ, Lu AP	53.254	52.665
Traditional Chinese medicine diagnosis and response to acupuncture for insomnia: An analysis of two randomized placebo-controlled trials. *Eur J Integr Med.* 2016 Oct; 8(5):797-801. doi: 10.1016/j.eujim.2016.06.021	Chung KF, Yeung WF, Leung FCY, Zhang SP.	0.698	0.834
Jolkinolide B induces apoptosis and inhibits tumor growth in mouse melanoma B16F10 cells by altering glycolysis. *Sci Rep.* 2016 Oct 31;6:36114. doi: 10.1038/srep36114.	Gao C, Yan X, Wang B, Yu L, Han J, Li D, Zheng Q.	4.122	4.609
Pre-clinical toxicity of a combination of berberine and 5-aminosalicylic acid in mice. *Food Chem Toxicol.* 2016 Nov;97:150-158. doi: 10.1016/j.fct.2016.08.031.	Li YH, Zhang M, Fu HB, Xiao HT, Bian ZX.	3.977	3.900
Pattern Differentiation of Lateral Elbow Pain in Traditional Chinese Medicine: A Systematic Review. *J Altern Complement Med.* 2016 Nov;22(11):921-935. doi: 10.1089/acm.2016.0098.	Gadau M, Zhang SP, Yip HY, Yeung WF, Bian ZX, Lu AP, Zaslawski C.	1.498	1.799
Discovery of Bioactive Compounds by the UIC-ICBG Drug Discovery Program in the 18 Years Since 1998. *Molecules.* 2016 Oct 31;21(11):1448. doi: 10.3390/molecules21111448.	Zhang HJ, Li WF, Fong HH, Soejarto DD.	3.098	3.268
Ultrasound-Assisted Extraction May Not Be a Better Alternative Approach than Conventional Boiling for Extracting Polysaccharides from Herbal Medicines. *Molecules.* 2016 Nov 18;21(11):1569. doi: 10.3390/molecules21111569.	Yip KM, Xu J, Tong WS, Zhou SS, Yi T, Zhao ZZ, Chen HB.	3.098	3.268
Neuroprotective effect of a novel Chinese herbal decoction on cultured neurons and cerebral ischemic rats. *BMC Complement Altern Med.* 2016 Nov 4;16(1):437. doi: 10.1186/s12906-016-1417-1.	Ip FC, Zhao YM, Chan KW, Cheng EY, Tong EP, Chandrashekar O, Fu GM, Zhao ZZ, Ip NY.	2.109	2.732
Safety Profiles of Tripterygium wilfordii Hook F: A Systematic Review and Meta-Analysis. *Front Pharmacol.* 2016 Nov 8;7:402. doi: 10.3389/fphar.2016.00402.	Zhang C, Sun PP, Guo HT, Liu Y, Li J, He XJ, Lu AP.	3.831	4.439
Integrating targeted glycomics and untargeted metabolomics to investigate the processing chemistry of herbal medicines, a case study on Rehmanniae Radix. *J Chromatogr A.* 2016 Nov 11;1472:74-87. doi: 10.1016/j.chroma.2016.10.043.	Zhou L, Xu JD, Zhou SS, Mao Q, Kong M, Shen H, Li XY, Duan SM, Xu J, Li SL	3.716	3.713
Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis. *Front Pharmacol.* 2016 Nov 25;7:455. doi: 10.3389/fphar.2016.00455.	Zhao HM, Xu R, Huang XY, Cheng SM, Huang MF, Yue HY, Wang X, Zou Y, Lu AP, Liu DY.	3.831	4.439
Synthesis of platinum(II) and palladium(II) complexes with 9,9-dihexyl-4,5-diazafluorene and their in vivo antitumour activity against Hep3B xenografted mice. *Eur J Med Chem.* 2016 Nov 29;124:537-543. doi: 10.1016/j.ejmech.2016.08.033.	Wang QW, Lam PL, Wong RS, Cheng GY, Lam KH, Bian ZX, Ho CL, Feng YH, Gambari R, Lo YH, Wong WY, Chui CH.	4.816	4.527
Current research and future directions in pattern identification: Results of an international symposium. *Chin J Integr Med.* 2016 Dec;22(12):947-955. doi: 10.1007/s11655-014-1833-3.	Lee MS, Lee JA, Alraek T, Bian ZX, Birch S, Goto H, Jung J, Kao ST, Moon SK, Park B, Park KM, You S, Yun KJ, Zaslawski C.	1.346	1.379
Combination therapeutics in complex diseases. *J Cell Mol Med.* 2016 Dec;20(12):2231-2240. doi: 10.1111/jcmm.12930.	He B, Lu C, Zheng G, He X, Wang M, Chen G, Zhang G, Lu A	4.302	4.252

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
The genus Rosa and arthritis: Overview on pharmacological perspectives. *Pharmacol Res.* 2016 Dec;114:219-234. doi: 10.1016/j.phrs.2016.10.029. Review.	Cheng BC, Fu XQ, Guo H, Li T, Wu ZZ, Chan K, Yu ZL.	4.897	5.048
Metabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis Research. *Int J Mol Sci.* 2016 Dec 2;17(12):2018. doi: 10.3390/ijms17122018. Review.	Lv H, Jiang F, Guan D, Lu C, Guo B, Chan C, Peng S, Liu B, Guo W, Zhu H, Xu X, Lu A, Zhang G.	3.687	3.878
Developing clinical practice guidelines for the integration of Chinese medicine and biomedicine: A new process. *Eur J Integr Med.* 2016 Dec;8(6):916-920. doi: 10.1016/j.eujim.2016.11.013.	Shi N, Zhong LLD, Zhang C, Han X, Wang Y, Liu Y, Wang L, Liu M, Lu A.	0.698	0.834
Standardization of the manufacturing procedure for Pinelliae Rhizoma Praeparatum cum Zingibere et Alumine. *J Ethnopharmacol.* 2016 Dec 4;193:663-669. doi: 10.1016/j.jep.2016.09.038.	Su T, Zhang WW, Zhang YM, Cheng BC, Fu XQ, Li T, Guo H, Li YX, Zhu PL, Cao H, Yu ZL.	3.115	3.493
Rapid differentiation of Xihuangcao from the three Isodon species by UPLC-ESI-QTOF-MS/MS and chemometrics analysis. *Chin Med.* 2016 Dec 15;11:48. doi: 10.1186/s13020-016-0120-y.	Wong LL, Liang Z, Chen H, Zhao Z.	1.802	1.915
Autophagy modulators from traditional Chinese medicine: Mechanisms and therapeutic potentials for cancer and neurodegenerative diseases. *J Ethnopharmacol.* 2016 Dec 24;194:861-876. doi: 10.1016/j.jep.2016.10.069. Review.	Wang SF, Wu MY, Cai CZ, Li M, Lu JH.	3.115	3.493
Botanical drugs in Ayurveda and Traditional Chinese Medicine. *J Ethnopharmacol.* 2016 Dec 24;194:245-259. doi: 10.1016/j.jep.2016.06.052. Review.	Jaiswal Y, Liang Z, Zhao Z.	3.115	3.493
In vitro assays suggest Shenqi Fuzheng Injection has the potential to alter melanoma immune microenvironment. *J Ethnopharmacol.* 2016 Dec 24;194:15-19. doi: 10.1016/j.jep.2016.08.038.	Du J, Cheng BC, Fu XQ, Su T, Li T, Guo H, Li SM, Wu JF, Yu H, Huang WH, Cao H, Yu ZL	3.115	3.493
The anticancer and antiobesity effects of Mediterranean diet. *Crit Rev Food Sci Nutr.* 2017 Jan 2;57(1):82-94. doi: 10.1080/10408398.2013.852510. Review.	Kwan HY, Chao X, Su T, Fu X, Tse AK, Fong WF, Yu ZL	6.202	6.776
Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells. *J Cell Mol Med.* 2017 Jan;21(1):46-57. doi: 10.1111/jcmm.12937.	Luo M, Liu Q, He M, Yu Z, Pi R, Li M, Yang X, Wang S, Liu A.	4.302	4.252
Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE(2). *Cancer Res Treat.* 2017 Jan;49(1):219-229. doi: 10.4143/crt.2016.190.	Pun IH, Chan D, Chan SH, Chung PY, Zhou YY, Law S, Lam AK, Chui CH, Chan AS, Lam KH, Tang JC.	3.230	3.192
Strategies to identify natural antisense transcripts. *Biochimie.* 2017 Jan;132:131-151. doi: 10.1016/j.biochi.2016.11.006. Review.	Sun Y, Li D, Zhang R, Peng S, Zhang G, Yang T, Qian A	3.188	3.058
Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis. *Mediators Inflamm.* 2017;2017:2405291. doi: 10.1155/2017/2405291.	Tan Y, Qi Q, Lu C, Niu X, Bai Y, Jiang C, Wang Y, Zhou Y, Lu A, Xiao C.	3.549	4.033
Determination of ginsenosides in Asian and American ginsengs by liquid chromatography-quadrupole/time-of-flight MS: assessing variations based on morphological characteristics. *J Ginseng Res.* 2017 Jan;41(1):10-22. doi: 10.1016/j.jgr.2015.12.004.	Chen Y, Zhao Z, Chen H, Brand E, Yi T, Qin M, Liang Z.	4.053	4.026
Utilization of G-Quadruplex-Forming Aptamers for the Construction of Luminescence Sensing Platforms. *ChemPlusChem.* 2017 Jan;82(1):8-17. doi: 10.1002/cplu.201600036.	Ma DL, Wang WH, Mao ZF, Kang TS, Han QB, Chan PWH, Leung CH.	3.205	2.867
Anti-Fatigue Effects of the Unique Polysaccharide Marker of Dendrobium officinale on BALB/c Mice. *Molecules.* 2017 Jan 18;22(1):155. doi: 10.3390/molecules22010155.	Wei W, Li ZP, Zhu T, Fung HY, Wong TL, Wen X, Ma DL, Leung CH, Han QB.	3.098	3.268
Comprehensive Quantitative Analysis of 32 Chemical Ingredients of a Chinese Patented Drug Sanhuang Tablet. *Molecules.* 2017 Jan 12;22(1):111. doi: 10.3390/molecules22010111.	Fung HY, Lang Y, Ho HM, Wong TL, Ma DL, Leung CH, Han QB.	3.098	3.268

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
Euphorbia factor L2 induces apoptosis in A549 cells through the mitochondrial pathway. *Acta Pharm Sin B.* 2017 Jan;7(1):59-64. doi: 10.1016/j.apsb.2016.06.008.	Lin M, Tang S, Zhang C, Chen H, Huang W, Liu Y, Zhang J.	6.014	--
Evaluation of clinical safety and beneficial effects of stachyose-enriched alpha-galacto-oligosaccharides on gut microbiota and bowel function in humans. *Food Funct.* 2017 Jan 25;8(1):262-269. doi: 10.1039/c6fo01290f.	Li T, Lu X, Yang X.	3.289	3.685
Effects of boiling duration in processing of White Paeony Root on its overall quality evaluated by ultra-high performance liquid chromatography quadrupole/ time-of-flight mass spectrometry based metabolomics analysis and high performance liquid chromatography quantification. *Chin J Nat Med.* 2017 Jan;15(1):62-70. doi: 10.1016/S1875-5364(17)30009-2.	Ming K, Xu J, Liu HH, Xu JD, Li XY, Lu M, Wang CR, Chen HB, Li SL.	1.991	1.791
Predicting human intestinal absorption with modified random forest approach: a comprehensive evaluation of molecular representation, unbalanced data, and applicability domain issues. *RSC Adv.* 2017; 7(31):19007-19018. doi: 10.1039/ c6ra28442f.	Wang NN, Huang C, Dong J, Yao ZJ, Zhu MF, Deng ZK, Lv B, Lu AP, Chen AF, Cao DS.	2.936	3.096
A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinson's Disease. *Parkinsons Dis.* 2017;2017:1902708. doi: 10.1155/2017/1902708.	Chua KK, Wong A, Chan KW, Lau YK, Bian ZX, Lu JH, Liu LF, Chen LL, Chan KH, Tse KP, Chan A, Song JX, Wu J, Zhu LX, Mok V, Li M.	2.117	2.480
Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis. *Curr Drug Targets.* 2017;18(9):1051-1068. doi: 10.2174/1389450118666170321105425.	Wang T, Liu Q, Tjhioe W, Zhao J, Lu A, Zhang G, Tan RX, Zhou M, Xu J, Feng HT.	3.112	3.110
PlaMoM: a comprehensive database compiles plant mobile macromolecules. *Nucleic Acids Res.* 2017 Jan 4;45(D1):D1021-D1028. doi: 10.1093/nar/gkw988.	Guan D, Yan B, Thieme C, Hua J, Zhu H, Boheler KR, Zhao Z, Kragler F, Xia Y, Zhang S.	11.561	10.235
Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. *Sci Rep.* 2017 Jan 10;7:40487. doi: 10.1038/srep40487.	Liu J, Li D, Dang L, Liang C, Guo B, Lu C, He X, Cheung HY, He B, Liu B, Li F, Lu J, Wang L, Shaikh AB, Jiang F, Lu C, Peng S, Zhang Z, Zhang BT, Pan X, Xiao L, Lu A, Zhang G.	4.122	4.609
Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/ hepatomegaly induced by acute schisandrin B treatment in mice. *Lipids Health Dis.* 2017 Jan 13;16(1):8. doi: 10.1186/s12944-017-0406-9.	Zhang Y, Zhao J, Zhou SF, Yu ZL, Wang XY, Zhu PL, Chu ZS, Pan SY, Xie M, Ko KM.	2.663	2.707
Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis. *Sci Rep.* 2017 Jan 27;7:41295. doi: 10.1038/srep41295.	Liu J, Lu C, Wu X, Zhang Z, Li J, Guo B, Li D, Liang C, Dang L, Pan X, Peng S, Lu A, Zhang B, Zhang G.	4.122	4.609
Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice. *Oncotarget.* 2017 Jan 31;8(5):8264-8282. doi: 10.18632/oncotarget.14160.	Li J, Huang S, Huang W, Wang W, Wen G, Gao L, Fu X, Wang M, Liang W, Kwan HY, Zhao X, Lv Z.	5.168	5.312
Zika: How safe is India? Infect Dis Poverty. 2017 Jan 31;6(1):37. doi: 10.1186/s40249-016-0234-6.	Doss CG, Siva R, Christopher BP, Chakraborty C, Zhu H.	2.708	3.126
Neurogenic Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer's Disease. *Int J Mol Sci.* 2017 Jan 28;18(2):272. doi: 10.3390/ijms18020272. Review.	Sreenivasmurthy SG, Liu JY, Song JX, Yang CB, Malampati S, Wang ZY, Huang YY, Li M.	3.687	3.878
Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern. *Nanomedicine (Lond).* 2017 Feb;12(4):357-385. doi: 10.2217/nnm-2016-0305.	Lam PL, Wong WY, Bian Z, Chui CH, Gambari R.	5.005	5.519

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
Ancestral benzo[a]pyrene exposure affects bone integrity in F3 adult fish (Oryzias latipes). *Aquat Toxicol.* 2017 Feb;183:127-134. doi: 10.1016/j.aquatox.2016.12.018. Epub 2016 Dec 23.	Seemann F, Jeong CB, Zhang G, Wan MT, Guo B, Peterson DR, Lee JS, Au DW.	3.884	4.143
The effects of short-term high-fat feeding on exercise capacity: multi-tissue transcriptome changes by RNA sequencing analysis. *Lipids Health Dis.* 2017 Feb 2;16(1):28. doi: 10.1186/s12944-017-0424-7.	Xiao Y, Wang W, Chen L, Chen J, Jiang P, Fu X, Nie X, Kwan H, Liu Y, Zhao X.	2.663	2.707
Efficient Semisynthesis of (-)-Pseudoirroratin A from (-)-Flexicaulin A and Assessment of Their Antitumor Activities. *ACS Med Chem Lett.* 2017 Feb 28;8(3):372-376. doi: 10.1021/acsmedchemlett.7b00033.	Guo L, Tsang SW, Zhang TX, Liu KL, Guan YF, Wang B, Sun HD, Zhang HJ, Wong MS.	3.794	3.591
Cannabis in Chinese Medicine: Are Some Traditional Indications Referenced in Ancient Literature Related to Cannabinoids? *Front Pharmacol.* 2017 Mar 10;8:108. doi: 10.3389/fphar.2017.00108. Review.	Brand EJ, Zhao Z.	3.831	4.439
MOST: most-similar ligand based approach to target prediction. *BMC Bioinformatics.* 2017 Mar 11;18(1):165. doi: 10.1186/s12859-017-1586-z.	Huang T, Mi H, Lin CY, Zhao L, Zhong LL, Liu FB, Zhang G, Lu AP, Bian ZX & for MZRW Group	2.213	3.114
Tissue-specific metabolite profiling of benzylisoquinoline alkaloids in the root of Macleaya cordata by combining laser microdissection with ultra-high-performance liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom.* 2017 Mar 15;31(5):397-410. doi: 10.1002/rcm.7804.	Zuo Z, Zheng Y, Liang Z, Liu Y, Tang Q, Liu X, Zhao Z, Zeng J.	1.970	1.989
Bioactive Fraction of Annona reticulata Bark (or) Ziziphus jujuba Root Bark along with Insulin Attenuates Painful Diabetic Neuropathy through Inhibiting NF-κB Inflammatory Cascade. *Front Cell Neurosci.* 2017 Mar 22;11:73. doi: 10.3389/fncel.2017.00073. eCollection 2017.	Kandimalla R, Dash S, Kalita S, Choudhury B, Malampati S, Devi R, Ramanathan M, Talukdar NC, Kotoky J.	4.300	4.915
Economic botany collections: A source of material evidence for exploring historical changes in Chinese medicinal materials. *J Ethnopharmacol.* 2017 Mar 22;200:209-227. doi: 10.1016/j.jep.2017.02.028.	Brand E, Leon C, Nesbitt M, Guo P, Huang R, Chen H, Liang L, Zhao Z.	3.115	3.369
Electroacupuncture for tapering off long-term benzodiazepine use: study protocol of randomized controlled trial. *BMC Complement Altern Med.* 2017 Mar 31;17(1):183. doi: 10.1186/s12906-017-1692-5.	Yeung WF, Chung KF, Zhang ZJ, Chan WC, Zhang SP, Ng RM, Chan CL, Ho LM, Yu YM, Lao LX.	2.109	2.732
Mixed epithelial and stromal tumor of kidney with renal vein extension: an unusual case report and review of literature. *Histol Histopathol.* 2017 Apr;32(4):361-369. doi: 10.14670/HH-11-800.	Xie WL, Lian JY, Li B, Tian XY, Li Z.	2.015	1.793
Anti-HIV diphyllin glycosides from Justicia gendarussa. *Phytochemistry.* 2017 Apr;136:94-100. doi: 10.1016/j.phytochem.2017.01.005.	Zhang HJ, Rumschlag-Booms E, Guan YF, Liu KL, Wang DY, Li WF, Nguyen VH, Cuong NM, Soejarto DD, Fong HH, Rong L.	3.186	3.041
Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro. *Oncol Rep.* 2017 Apr;37(4):2016-2024. doi: 10.3892/or.2017.5435.	Zhong ZF, Tan W, Tian K, Yu H, Qiang WA, Wang YT.	2.976	2.804
Mechanisms for PACAP-induced prolactin gene expression in grass carp pituitary cells. *J Endocrinol.* 2017 Apr;233(1):37-51. doi: 10.1530/JOE-16-0433.	Lin C, Jiang X, He M, Zhao L, Huang T, Bian Z, Wong AO.	4.012	4.276
Mechanism of herbal pairs with the properties of Qi-tonifying, blood activation, blood-stasis breaking in treating coronary heart disease. *J Tradit Chin Med.* 2017 Apr;37(2):269-78. doi: 10.1016/s0254-6272(17)30054-7.	Yang J, Li J, Li L, Zhao N, Niu XY, He XJ, Jiang M, Lu AP, Lei Y.	0.857	1.076
Application of Traditional Chinese Medicine in medical practice: a survey of community residents in Beijing, China. *J Tradit Chin Med.* 2017 Apr;37(2):261-8. doi: 10.1016/s0254-6272(17)30053-5.	Liu ZD, Huang YY, Cui ZL, Tan Y, Yang J, Lü AP, Wang YX, Jiang M.	0.857	1.076
An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling In Vitro. *Front Pharmacol.* 2017 Apr 28;8:227. doi: 10.3389/fphar.2017.00227.	Su T, Bai JX, Chen YJ, Wang XN, Fu XQ, Li T, Guo H, Zhu PL, Wang Y, Yu ZL.	3.831	4.439

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. *Redox Biol.* 2017 Apr;11:562-576. doi: 10.1016/j.redox.2017.01.010.	Tse AK, Chen YJ, Fu XQ, Su T, Li T, Guo H, Zhu PL, Kwan HY, Cheng BC, Cao HH, Lee SK, Fong WF, Yu ZL.	7.126	7.613
Exploring beta-Tubulin Inhibitors from Plant Origin using Computational Approach. *Phytochem Anal.* 2017 May;28(3):230-241. doi: 10.1002/pca.2665.	Kanika Verma, Kaavya Kannan, Shanthi V,Sethumadhavan R, Karthick V, Ramanathan K.	2.337	2.433
Halofuginone dually regulates autophagic flux through nutrient-sensing pathways in colorectal cancer. *Cell Death Dis.* 2017 May 11;8(5):e2789. doi: 10.1038/cddis.2017.203.	Chen GQ, Gong RH, Yang DJ, Zhang G, Lu AP, Yan SC, Lin SH, Bian ZX.	5.638	6.187
Characterization and quantitation of aristolochic acid analogs in different parts of Aristolochiae Fructus, using UHPLCQ/TOF-MS and UHPLC-QqQ-MS. *Chin J Nat Med.* 2017 May;15(5):392-400. doi: 10.1016/S1875-5364(17)30060-2.	Mao WW, Gao W, Liang ZT, Li P, Zhao ZZ, Li HJ.	1.991	1.791
Wu-Tou Decoction in Rheumatoid Arthritis: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation. *Front Pharmacol.* 2017 May 3;8:230. doi: 10.3389/fphar.2017.00230.	Guo Q, Zheng K, Fan D, Zhao Y, Li L, Bian Y, Qiu X, Liu X, Zhang G, Ma C, He X, Lu A.	3.831	4.439
Application of a strategy based on metabolomics guided promoting blood circulation bioactivity compounds screening of vinegar. *Chem Cent J.* 2017; 11: 38. doi: 10.1186/s13065-017-0265-5.	Ning ZC, Liu ZL, Song ZQ, Wang C, Liu YY, Gan JH, Ma XL, Lu AP.	2.284	3.066
Characterization and Anti-Inflammatory Potential of an Exopolysaccharide from Submerged Mycelial Culture of Schizophyllum commune. *Front Pharmacol.* 2017 May 15;8:252. doi: 10.3389/fphar.2017.00252.	Du B, Yang Y, Bian Z, Xu B.	3.831	4.439
Azoxystrobin Induces Apoptosis of Human Esophageal Squamous Cell Carcinoma KYSE-150 Cells through Triggering of the Mitochondrial Pathway. *Front Pharmacol.* 2017 May 17;8:277. doi: 10.3389/fphar.2017.00277.	Shi XK, Bian XB, Huang T, Wen B, Zhao L, Mu HX, Fatima S, Fan BM, Bian ZX, Huang LF, Lin CY.	3.831	4.439
Two new prenylated isoflavones from Hedysarum multijugum. *J Asian Nat Prod Res.* 2017 May;19(5):444-447. doi: 10.1080/10286020.2016.1231672.	Wang W, Zhao YY, Chen H, Zhang QY, Liang H.	1.091	1.125
Cinnamon induces browning in subcutaneous adipocytes. *Sci Rep.* 2017 May 26;7(1):2447. doi: 10.1038/s41598-017-02263-5.	Kwan HY, Wu J, Su T, Chao XJ, Liu B, Fu X, Chan CL, Lau RHY, Tse AKW, Han QB, Fong WF, Yu ZL.	4.122	4.609
Bioactivity, toxicity and detoxification assessment of Dioscorea bulbifera L.: a comprehensive review. *Phytochem Rev.* 2017 Jun; 16(3):573–601. doi: 10.1007/s11101-017-9505-5.	Guan XR, Zhu L, Xiao ZG, Zhang YL, Chen HB, Yi T.	3.875	3.710
A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. *PLoS One.* 2017 Jun 1;12(6):e0177123. doi: 10.1371/journal.pone.0177123.	Wu KJ, Huang JM, Zhong HJ, Dong ZZ, Vellaisamy K, Lu JJ, Chen XP, Chiu P, Kwong DWJ, Han QB, Ma DL, Leung CH.	2.766	3.352
A novel in situ strategy for the preparation of a β-cyclodextrin/polydopamine-coated capillary column for capillary electrochromatography enantioseparations. *J Sep Sci.* 2017 Jun;40(12):2645-2653. doi: 10.1002/jssc.201700152.	Guo H, Niu X, Pan C, Yi T, Chen H, Chen X.	2.415	2.337
Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa. *J Nat Prod.* 2017 Jun 23;80(6):1798-1807. doi: 10.1021/acs.jnatprod.7b00004.	Zhang HJ, Rumschlag-Booms E, Guan YF, Wang DY, Liu KL, Li WF, Nguyen VH, Cuong NM, Soejarto DD, Fong HHS, Rong L.	3.885	3.904
Pharmaceutical prospects of naturally occurring quinazolinone and its derivatives. *Fitoterapia.* 2017 Jun;119:136-149. doi: 10.1016/j.fitote.2017.05.001.	He D, Wang M, Zhao S, Shu Y, Zeng H, Xiao C, Lu C, Liu Y.	2.642	2.867
Inhibiting STAT3 signaling is involved in the anti-melanoma effects of a herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos. *Sci Rep.* 2017 Jun 8;7(1):3097. doi: 10.1038/s41598-017-03351-2.	Li T, Fu X, Tse AK, Guo H, Lee KW, Liu B, Su T, Wang X, Yu Z.	4.122	4.609

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

PUBLICATIONS

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
Comparison of chemical profiles between the root and aerial parts from three Bupleurum species based on a UHPLC-QTOF-MS metabolomics approach. *BMC Complement Altern Med*. 2017 Jun 12;17(1):305. doi: 10.1186/s12906-017-1816-y.	Zhu L, Liang ZT, Yi T, Ma Y, Zhao ZZ, Guo BL, Zhang JY, Chen HB.	2.109	2.732
Differential gene expression profile of Buyanghuanwu decoction in rats with ventricular remodeling post-myocardial infarction. *J Tradit Chin Med.* 2017 Jun;37(3):341-354.	Zhang T, Hua Y, Luo H, Chen HM, Shao M, Fu XQ, JMT Chu, Huang GQ, Liu B, Zhou YC.	0.857	1.076
Luminescent detection of nicking endonuclease Nb.BsmI activity by using a G-quadruplex-selective iridium(III) complex in aqueous solution. *Sensors and Actuators B: Chemical.* 2017 Jul; 246:826-832. doi: 10.1016/j.snb.2017.02.156.	Dong ZZ, Lu LH, Wang WH, Li GD, Kang TS, Han QB, Leung CH, Ma DL	5.667	5.118
Psychophysical responses in patients receiving a mock laser within context of an acupuncture clinical trial: an interoceptive perspective. *BMC Complement Altern Med.* 2017 Jul 3;17(1):348. doi: 10.1186/s12906-017-1859-0.	Razavy S, Gadau M, Zhang SP, Wang FC, Bangrazi S, Berle C, Harahap M, Li T, Li WH, Zaslawski C	2.109	2.732
Integrated and global pseudotargeted metabolomics strategy applied to screening for quality control markers of Citrus TCMs. *Anal Bioanal Chem.* 2017 Aug;409(20):4849-4865. doi: 10.1007/s00216-017-0428-1.	Shu Y, Liu Z, Zhao S, Song Z, He D, Wang M, Zeng H, Lu C, Lu A, Liu Y	3.307	3.222
Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy-Lysosome Pathway: A Systematic Review. *Phytother Res.* 2017 Aug;31(8):1119-1127. doi: 10.1002/ptr.5834. Review.	Wang ZY, Liu JY, Yang CB, Malampati S, Huang YY, Li MX, Li M, Song JX	3.349	3.112
Comparative evaluation of chemical profiles of three representative 'snow lotus' herbs by UPLC-DAD-QTOF-MS combined with principal component and hierarchical cluster analyses. *Drug Test Anal.* 2017 Aug;9(8):1105-1115. doi: 10.1002/dta.2123.	Chen QL, Zhu L, Tang YN, Kwan HY, Zhao ZZ, Chen HB, Yi T	2.993	2.649
Morbidity pattern of traditional Chinese medicine primary care in the Hong Kong population. *Sci Rep.* 2017 Aug 8;7(1):7513. doi: 10.1038/s41598-017-07538-5.	Wong WD, Lam CLK, Bian XZ, Zhang ZJ, Ng ST, Tung S	4.122	4.609
Impact of meteorological factors on the incidence of bacillary dysentery in Beijing, China: A time series analysis (1970-2012). *PLoS One.* 2017 Aug 10;12(8):e0182937. doi: 10.1371/journal.pone.0182937.	Yan L, Wang H, Zhang X, Li MY, He J.	2.766	3.352
Baicalein prevents 6-OHDA/ascorbic acid-induced calcium-dependent dopaminergic neuronal cell death. *Sci Rep.* 2017 Aug 21;7(1):8398. doi: 10.1038/s41598-017-07142-7.	Wang SF, Liu LF, Wu MY, Cai CZ, Su H, Tan J, Lu JH, Li M	4.122	4.609
Cyclocarya paliurus tea leaves enhances pancreatic β cell preservation through inhibition of apoptosis. *Sci Rep.* 2017 Aug 22;7(1):9155. doi: 10.1038/s41598-017-09641-z.	Xiao HT, Wen B, Ning ZW, Zhai LX, Liao CH, Lin CY, Mu HX, Bian ZX	4.122	4.609
Effect of the Natural Product Triptolide on Pancreatic Cancer: A Systematic Review of Preclinical Studies. *Front Pharmacol.* 2017 Aug 25;8:490. doi: 10.3389/fphar.2017.00490.	Zhang C, He XJ, Li L, Lu C, Lu AP	3.831	4.439
Schisandrin B regulates lipid metabolism in subcutaneous adipocytes. *Sci Rep*. 2017 Aug 31;7(1):10266. doi: 10.1038/s41598-017-10385-z.	Kwan HY, Wu J, Su T, Chao XJ, Yu H, Liu B, Fu X, Tse AKW, Chan CL, Fong WF, Yu ZL	4.122	4.609
Magnolol, a Natural Polyphenol, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice. *Molecules.* 2017 Jul 20;22(7). doi: 10.3390/molecules22071218.	Zhao L, Xiao HT, Mu HX, Huang T, Lin ZS, Zhong LLD, Zeng GZ, Fan BM, Lin CY, Bian ZX.	3.098	3.268
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. *Ann Intern Med.* 2017 Jul 18. doi: 10.7326/M16-2977.	Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group.	19.384	18.726
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Traditional Chinese Version). *Ann Intern Med.* 2017 Jul 18; 167(2):W7-W20.doi: 10.7326/IsTranslatedFrom_M17-2977_1.	Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group.	19.384	18.726

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2017	5-year Impact Factor
2016-2017 Research Papers			
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Simplified Chinese Version). *Ann Intern Med.* 2017 Jul 18; 167 (2):W21-W34.doi:10.7326/IsTranslatedFrom_M17-2977_2.	Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group.	19.384	18.726
Protocol for Acupuncture Treatment of Lateral Elbow Pain: A Multisite Randomised Controlled Trial in China, Hong Kong, Australia, and Italy. *Evid Based Complement Alternat Med.* 2016;2016:1868659. doi: 10.1155/2016/1868659.	Zaslawski C, Berle C, Gadau M, Li WH, Li T, Wang FC, Bangrazi S, Li L, Liguori S, Liu YS, Tan YS, Zhang SP	2.064	2.482
Development of Chinese medicine research in Hong Kong, China in last decade. *Chin J Integr Med.* 2017 Jul;23(7):483-485. doi: 10.1007/s11655-017-2816-y.	Lu AP, Cheng SP, Liu B	1.346	1.379
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. *Int J Mol Sci.* 2017 Aug 25;18(9):1851.doi: 10.3390/ijms18091851. Review.	Wu X, Shaikh AB, Yu Y, Li Y, Ni S, Lu A, Zhang G.	3.687	3.878
Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine. *J Ethnopharmacol.* 2017 Aug 17;208:225-235. doi: 10.1016/j.jep.2017.07.023.	Liu B, Fu XQ, Li T, Su T, Guo H, Zhu PL, Tse AK, Liu SM, Yu ZL.	3.115	3.493
Structure Identification and In Vitro Anticancer Activity of Lathyrol-3-phenylacetate-5,15-diacetate. *Molecules.* 2017 Aug 25;22(9):1412. doi: 10.3390/molecules22091412.	Zhang JY, Huang WJ, Sun HM, Liu Y, Zhao XQ, Tang SL, Sun MN, Wang S, Li JJ, Zhang LL, Zhou JH, Pan QR, Chen HB.	3.098	3.268
Chinese medicine practice and research in Hong Kong, China: Current status and future direction. *Chin J Integr Med.* 2017 Jul; 23(7):490-493. doi: 10.1007/s11655-017-2817-x.	Bian ZX	1.346	1.379
2016-2017 Books			
《中藥藥效研究方法學》，人民衛生出版社，ISBN: 978-7117-220521。	執行主編：呂愛平	--	--
《朱良春益腎蠲痹法治療風濕病》，科學出版社，ISBN: 978-7030-465078。	副主編：呂愛平	--	--
《香港中藥材圖鑑》，香港浸會大學，ISBN: 978-988-97448-4-7。	主編：趙中振	--	--
《中藥顯微鑒定圖典》，福建科學技術出版社，ISBN: 978-7-5335-4974-9。	趙中振與陳虎彪	--	--
《當代藥用植物典》1，2冊 (韓文版)，ISBN：978-8926-876268、978-8926-876275。	趙中振（與蕭培根）	--	--
《浸大中醫經典系列——中醫經典與臨床應用1》，中華書局(香港)有限公司，ISBN：978-9888-420766。	主編：呂愛平與卞兆祥	--	--
《戰勝失眠——中醫治療與生活調養》，萬里機構・萬里書店，ISBN：978-9621-462558。	倫新	--	--
《中振說本草》，萬里機構・萬里書店，ISBN:978-9621-463258 。	主編：趙中振	--	--

Notes

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI paper, Impact Factor is not available yet.

School of Chinese Medicine

Jockey Club School of Chinese Medicine Building,
7 Baptist University Road, Kowloon Tong, Hong Kong.

Tel (852) 3411 5387
Fax (852) 3411 2902
scm@hkbu.edu.hk

scm.hkbu.edu.hk

@scm.hkbu

@hkbuscm